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Abstract 
Renal replacement therapy, in the form of dialysis or transplantation, is the 
cornerstone of management for end-stage renal disease. UK renal registry shows 
nearly half of those needing renal replacement therapy are treated by dialysis – 
predominantly by haemodialysis. Patients on renal replacement therapy have 
increased mortality risk compared to age matched general population. Moreover, 
some specific subgroups of patients on haemodialysis have increased risk of 
mortality than expected. The survival benefit seen in women in the general 
population is attenuated resulting in similar survival for men and women on 
haemodialysis therapy. In addition, obese individuals and those of non-Caucasian 
origin have better survival outcome. Though the underlying reason for these findings 
is not clear and is likely to be multi-factorial, it has been hypothesised that this 
paradox could be due to the current practice of normalising dialysis dose to total 
body water. A number of metabolic factors – body surface area, resting energy 
expenditure and total energy expenditure – have been proposed as alternative to 
total body water for scaling dialysis dose. 
There were two overarching aims of this work – one was to study the effect of 
declining renal function on resting and total energy expenditure and to study the 
influence of various energy expenditure measures on uraemic toxin generation. The 
second was to study the impact on survival outcome of using these alternate 
parameters for normalising dialysis dose and to derive dialysis dose adjustments 
based on these metabolic parameters. In order to study these aims, studies were 
designed to explore different aspects of energy expenditure measures along with a 
longitudinal study to examine the impact of these parameters on survival outcome. 
The relationship between energy metabolism, body composition and uraemic toxin 
generation was studied with a retrospective analysis of 166 haemodialysis patients in 
whom urea generation rate was used as surrogate marker of uraemic toxin 
generation. It was found that total energy expenditure and fat-free mass predicted 
uraemic toxin generation after adjustment for other relevant variables. This study 
provided the preliminary data which was useful in designing further studies for this 
work. 
 ix 
The effect of renal function on resting and total energy expenditure was studied in 80 
patients with varying stages of chronic kidney disease who were not on renal 
replacement therapy. Resting and total energy expenditures were measured directly 
using gold-standard methods. It was found that declining renal function did not have 
a significant influence on either of these measures. This supports the hypothesis that 
metabolic rate is the driving force for glomerular filtration rate and not vice-versa. 
The directly measured energy expenditure measures were also found to have a 
moderately strong relationship with urea generation rate in these patients not on 
renal replacement therapy. 
The impact of physical activity on uraemic toxin generation, and thereby dialysis 
requirement, was studied in a prospective cross-sectional study of 120 
haemodialysis patients in whom the physical activity was measured by an 
accelerometer device. Results from the study showed physical activity level to be a 
significant predictor of uraemic toxin generation after adjustment for gender and 
body size differences. This study results stressed the importance of adjusting 
dialysis dose based on individual’s physical activity level. 
To study the impact of using metabolic factors as normalising parameter for scaling 
dialysis dose on survival outcome, a large-scale longitudinal study was conducted 
with 1500 maintenance haemodialysis patients recruited for the study. Dialysis dose-
related parameters and survival outcomes were collected at baseline and at various 
time points during the follow-up period of 18 months. Study results were analysed in 
two parts - the theoretical basis for using these metabolic factors as scaling 
parameters was explored which showed that current minimum target dialysis dose 
risks under-dialysis in certain subgroups of patients and using these alternative 
parameters may provide a more equivalent dialysis dose across individuals of 
different body sizes and gender. 
With these results arguing for potential use of the alternative parameters, the impact 
on survival of using them were examined. It was found that all three parameters 
performed better than the current parameter (total body water) with regards to 
predicting mortality. Total energy expenditure was found to be the best parameter 
with the lowest hazard ratio for risk of death. The study data was also analysed to 
derive an algorithm for adjustment of minimum target dialysis dose based on body 
 x 
size and physical activity level. This newly derived minimum dose target was also 
shown to impact on survival with those underdialysed based on this criteria having 
poorer survival outcomes. 
To understand the impact of whole body protein turnover on resting energy 
expenditure and uraemic toxin generation, a cross-sectional study was conducted on 
12 patients with advanced CKD – 6 each in pre-dialysis CKD and haemodialysis 
group. It was found that haemodialysis patients had higher rate of protein turnover 
compared to pre-dialysis patients. Whole body protein turnover was found to 
contribute significantly to resting energy expenditure and had a moderately strong 
relationship with urea generation rate. 
In the course of these studies, two questionnaire tools have been validated for use 
for clinical and research purposes – one is a self-report comorbidity questionnaire 
and the other, the Recent Physical Activity Questionnaire. The comorbidity 
questionnaire was developed as part of this work and was validated against 
Charlson Comorbidity Index. The Recent Physical Activity Questionnaire was 
validated for physical activity data collection and energy expenditure calculation 
against the gold-standard doubly labelled water method. 
In conclusion, it has been demonstrated that metabolic factors such as body surface 
area, resting energy expenditure and total energy expenditure are more closely 
related to uraemic toxin generation compared to total body water. It has also been 
demonstrated that physical activity contributes to metabolic waste production and 
may necessitate changes in dialysis requirement. It has been shown that these 
metabolic factors, when used as scaling parameter for dialysis dosing, may predict 
survival better than the current parameter in use. The algorithm for dialysis dose 
adjustment and the questionnaires validated in this work have provided novel tools 
for further research studies and clinical practice. 
The central hypothesis of this work is that some metabolic factors may be better 
markers of uraemic toxin generation compared to total body water. It is hypothesised 
that modifications in dialysis practice based on these factors may improve the quality 
of haemodialysis and favourably impact on survival outcome for patients with end-
stage renal disease. The work presented here largely supports this hypothesis. 
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Thesis Structure and Prelude 
 
This work is organised into four main sections to defend the thesis offered. 
Following the introductory chapter on kidneys and kidney failure, the first section 
provides a detailed review of relevant literature on dialysis dosing. The section 
focuses specifically on inadequacies of current dialysis dosing practice and 
examines the potential role of metabolic factors in haemodialysis therapy. 
The second section describes general methodology relevant to all the studies 
presented in this work and provides information on calculation of various parameters 
used in the studies. 
The third section describes the clinical studies used in defence of the thesis offered. 
These empirical studies could be broadly divided into those focusing on the 
relationship of metabolic factors to uraemic toxin generation and those examining the 
impact of the metabolic factors on survival outcome. 
The fourth section focuses on overall conclusions derived from the studies reported 
in this work and suggests recommendations for future work. 
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 Chapter 1 
1. Introduction: End Stage Renal Disease 
 
1.1  The Kidneys and Kidney failure 
This introductory chapter has been divided into two sections. The first section will 
provide an overview of functions of the kidneys and about chronic kidney disease, its 
measurement and consequences on various organ systems. The second section will 
discuss the options for replacement of kidney function in patients with kidney failure. 
1.1.1 Functions of the Kidney 
Humans normally have two kidneys which are located in the posterior part of the 
abdomen. The size of the kidneys is dependant on body size with the typical range 
being 10 to 13 cm. Healthy kidneys weigh approximately 150g each. The kidneys are 
highly vascular and receive nearly 25% of the cardiac output (approximately 
1250ml/minute of blood) (Marieb & Hoehn, 2014). This high proportion of cardiac 
output delivery is needed for the kidneys to perform its functions effectively. The 
primary functions of the kidneys are excretion of metabolic waste products, 
regulation of body water and maintaining electrolyte and acid-base balance. They 
also perform a number of secondary, albeit essential, functions. The kidneys play an 
important role in regulation of blood pressure through secretion of a hormone called 
renin. They also secrete erythropoietin, a hormone which regulates red blood cell 
production. Kidneys produce metabolically active form of Vitamin-D (1,25-dihydroxy 
cholecalciferol) which regulates bone mineral metabolism in conjunction with 
parathyroid hormone. Kidneys also play a major role in protein and amino acid 
metabolism through the synthesis, degradation, filtration, reabsorption and urinary 
excretion of various amino acids. 
Each kidney has two sections - an outer cortex and a deeper medulla. The functional 
unit of the kidney is a nephron and each kidney has approximately a million of them. 
Each nephron is comprised of a renal corpuscle located in the cortex of the kidney 
and a tubular segment that occupies both cortex and medullary portions of the 
kidney. The renal tubules consist of primary convoluted tubule, loop of Henle and 
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distal convoluted tubule and drains into collecting ducts. The renal corpuscle is the 
initial filtering unit and consists of glomerulus within Bowman’s capsule. Glomerulus 
consists of a tuft of capillaries from which the blood is filtered through different 
barriers before the final glomerular filtrate reaches the Bowman’s space. These 
capillaries have fenestrations in their walls which measure approximately 200-500 Å. 
These fenestrae allow many of the metabolic waste products to be filtered. The 
filtrate from the capillary fenestrae passes through the glomerular basement 
membrane surrounding the capillary walls. The other side of the basement 
membrane is surrounded by cells called podocytes. These podocytes have foot 
processes with filtration slits through which the filtrate has to pass through to reach 
Bowman’s space. These 3 layers – capillary wall, basement membrane and 
podocyte foot processes form an effective barrier and prevent filtration of red blood 
cells, leucocytes and platelets and also the serum proteins such as albumin and 
globulin into the urinary space. 
The driving force of this filtration (ultrafiltration) process is the hydrostatic pressure 
within the glomerulus. The filtrate entering the Bowman’s space is thereby termed 
ultrafiltrate. Glomerular filtration rate (GFR) is the volume of ultrafiltrate filtered 
through the glomerular capillaries into Bowman’s space per unit of time and is 
commonly used as a marker of renal function. The normal GFR is approximately 
100-125 ml/min/1.73 m2 body surface area in adult men and women (Marieb & 
Hoehn, 2014). This means around 150 Litres of ultrafiltrate is generated daily. This 
high volume of ultrafiltration necessitates significant reabsorption in the various 
tubular segments. The proximal convoluted tubule reabsorbs nearly 60-70% of the 
filtrate by active reabsorption of sodium ions and passive chloride ion transport along 
with a number of other substances such as glucose and amino acids. The remainder 
of the filtrate passes down the loop of Henle. 
Loop of Henle, with its descending and ascending limbs, extends between cortex 
and medulla. The filtrate passing into the loop of Henle is processed by a 
countercurrent multiplier mechanism which enables the kidneys to recirculate 
electrolytes and trap it in the medulla surrounding the loop of Henle. The descending 
loop is permeable to water but impermeable to solutes which makes the filtrate 
hypertonic as it passes through this segment. The ascending loop is impermeable to 
water but sodium, chloride and potassium ions are actively transported in this 
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segment from the tubular lumen into the surrounding medulla. This in turn provides a 
positive feedback loop and the consequence of this is that the osmolality is much 
higher in the renal medulla compared to the cortex. This osmotic gradient is vital to 
enable reabsorption of water in the collecting ducts. 
Filtrate from the loop of Henle passes into the distal convoluted tubule where further 
reabsorption of sodium and chloride ions occurs. Parathyroid hormone (PTH) acts on 
this segment to increase calcium reabsorption through the tubules. Aldosterone is a 
mineralocorticoid hormone secreted in the adrenal cortex in response to a number of 
factors including increase in serum potassium and renin concentration. Aldosterone 
acts on the distal segment to increase active reabsorption of sodium and with it, the 
passive diffusion of water. There is also active secretion of potassium and hydrogen 
ions in the distal part of distal convoluted tubule along with reabsorption of 
bicarbonate which is essential for maintaining acid-base balance. The filtrate finally 
passes into the collecting ducts where further active reabsorption of water occurs 
through the influence of Antidiuretic hormone (ADH). The final outcome of these 
complex processes is not only the formation of urine containing the waste products 
of metabolism but also maintenance of fluid, acid-base and electrolyte balance. 
The kidneys also perform important endocrine functions through secretion of various 
hormones. Renin is secreted from the juxtaglomerulus apparatus in the kidneys, 
which plays an important role in regulation of blood pressure and salt and water 
retention. Kidneys secrete erythropoietin which acts on the bone marrow to stimulate 
red blood cell production. Erythropoietin production is stimulated by reduced levels of 
oxygen. Kidneys also perform an essential final step in the production of active 
metabolite of Vitamin D (1,25-dihydroxy vitamin D) by hydroxylating the circulating 
form of vitamin D (25-hydroxy vitamin D). This active metabolite acts in conjunction 
with PTH to regulate bone mineral metabolism and to maintain serum calcium and 
phosphorus levels. 
1.1.2  Chronic Kidney Disease and its measurement 
Chronic kidney disease (CKD) is a general term for heterogeneous disorders where 
there is kidney damage and reduction in kidney function. CKD is a worldwide health 
problem and has got wide ranging health and financial implications in the long term. 
Guidelines to diagnose, investigate and manage CKD have been published by the 
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United States National Kidney Foundation in 2002 ("K/DOQI clinical practice 
guidelines for chronic kidney disease: evaluation, classification, and stratification," 
2002) and more recently by KDIGO in 2013 ("KDIGO Clinical Practice Guideline for 
the Evaluation and Management of Chronic Kidney Disease," 2013). These 
guidelines define CKD as structural or functional abnormality of kidney function 
persisting for ≥ 3 months with or without reduced GFR. The K/DOQI stages of CKD 
are shown in Error! Reference source not found.. 
Table 1-1: K/DOQI Stages of Chronic Kidney Disease 
Stages Description GFR (ml/min/1.73 m
2 
BSA) 
1 Kidney damage with normal or increased GFR ≥90 
2 Kidney damage with mild reduction in GFR 60-89 
3 Moderate reduction in GFR 30-59 
4 Severe reduction in GFR 15-29 
5 Kidney failure <15 (or dialysis) 
 
Though patients with stage 1 kidney disease have normal GFR, they ought to have 
other markers of structural or functional kidney damage such as proteinuria to be 
included in the CKD classification. Further stages of CKD are defined by 
progressively reduced levels of GFR. 
The markers of kidney damage include pathological abnormalities detected by 
histology, structural abnormalities detected by imaging, electrolyte abnormalities due 
to tubular disorders, abnormalities in blood such as raised urea and creatinine and 
abnormalities in urine such as presence of blood and protein. Proteinuria is presence 
of significant amounts of protein such as albumin in urine (albuminuria). Proteinuria 
is regarded as key marker of kidney damage and has been shown to be a significant 
prognostic indicator for progression of CKD and cardiovascular mortality (Jafar et al., 
2001; Keane & Eknoyan, 1999; Ruggenenti, Perna, Mosconi, Pisoni, & Remuzzi, 
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1998). Traditionally, the amount of proteinuria has been calculated through a 24-hour 
urine collection. In current clinical practice, this is calculated from a spot urine 
sample by the comparison of urine protein concentration to creatinine level and is 
termed protein:creatinine ratio (PCR). Proteinuria is generally due to glomerular 
injury although it could be due to excessive synthesis of specific proteins in 
conditions such as myeloma. Increased levels of proteinuria are associated with 
increased risk of progression of CKD and when conditions such as hypertension co-
exist, the risk is even higher (Jafar et al., 2003). Proteinuria is predominantly 
albuminuria and hence, the potential of albuminuria as an early marker of kidney 
damage is being explored in clinical studies. Microalbuminuria has been shown to be 
an indicator of incipient diabetic nephropathy (Chiarelli, Verrotti, Mohn, & Morgese, 
1997; Mogensen, 1987) and there is considerable focus on initiating treatment in 
early stages of microalbuminuria detection. 
Glomerular Filtration Rate (GFR) is the measure that is used to define level of kidney 
function. GFR is dependant on several factors such as age, sex, body size and 
metabolic rate. The most accurate method of measuring GFR is through Inulin 
clearance. Inulin is a polysaccharide that is freely filtered at the glomerulus and is 
neither reabsorbed nor secreted by the tubules. Because of the expensive and 
cumbersome nature of studies involving Inulin, alternative reliable methods have 
been devised for GFR measurement using markers such as iohexol (Brändström et 
al., 1998; Olsson, Aulie, Sveen, & Andrew, 1983) and radioactive isotopes such as 
125I-iothalamate and 99mTc-DTPA (Perrone et al., 1990). These methods are time-
consuming and are not routinely used in clinical practice. 
Creatinine clearance is the method that can be used in clinical practice for 
measurement of GFR. This method entails 24-hour urine collection along with a 
blood test to measure creatinine levels in urine and serum. Creatinine clearance is 
then calculated using the following formula: 
𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒  𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =    𝑈𝑟𝑖𝑛𝑒  𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒  𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛  ×  𝑈𝑟𝑖𝑛𝑒  𝑣𝑜𝑙𝑢𝑚𝑒𝑆𝑒𝑟𝑢𝑚  𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒  𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛  ×  𝑡𝑖𝑚𝑒𝑝𝑒𝑟𝑖𝑜𝑑  𝑜𝑓  𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑖𝑜𝑛 
 
Creatinine is an endogenous substance generated as a result of muscle metabolism 
and as such, is dependant on muscle mass of the individual. Hence, for results to be 
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comparable between individuals of different body size, creatinine clearance is 
usually corrected to body surface area of 1.73 m2 (Stevens, Coresh, Greene, & 
Levey, 2006). Creatinine is freely filtered in the glomerulus but is also actively 
secreted by the proximal tubules into the tubular lumen (van Olden, Krediet, Struijk, 
& Arisz, 1996). As a result, it overestimates GFR by around 20% (van Olden et al., 
1996). An alternative method is to measure urinary urea clearance in a similar 
fashion. Urea clearance underestimates GFR by 20% and hence, some authors 
suggest calculating the average of urea and creatinine clearance as a measure of 
GFR (Traynor, Mactier, Geddes, & Fox, 2006). The variations in the assays used for 
creatinine estimation and the problem of inaccurate 24-hour urine collection 
complicate this methodology further. 
In view of the practical difficulties with the methods described above, there is a need 
for simpler methods to estimate GFR in clinical practice. Serum creatinine alone can 
be used as a measure of renal function but the serum level is affected by a number 
of factors such as age, sex, diet, ethnicity and muscle mass (Stevens et al., 2006; 
Jones et al., 1998; Levey, 1990). In order to relate serum creatinine to GFR, two 
predictive equations are in common use – Cockcroft–Gault equation (Cockcroft & 
Gault, 1976) and the Modification of Diet in Renal Disease (MDRD) study equation 
(Levey et al., 1999) which are shown below. 
Cockcroft-Gault equation: 
𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒  𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒  (𝑚𝑙/𝑚𝑖𝑛)   =    140 − 𝑎𝑔𝑒 ×  𝑤𝑒𝑖𝑔ℎ𝑡   𝑘𝑔 ×  (1.23  𝑖𝑓  𝑚𝑎𝑙𝑒, 1.04  𝑖𝑓  𝑓𝑒𝑚𝑎𝑙𝑒)𝑆𝑒𝑟𝑢𝑚  𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒  (𝜇𝑚𝑜𝑙/𝐿)  
  
Abbreviated 4-variable MDRD equation: 
𝑒𝐺𝐹𝑅 = 186  ×    𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒88.4 !!.!"#   ×   𝑎𝑔𝑒 !!.!"#  ×   0.742  𝑖𝑓  𝑓𝑒𝑚𝑎𝑙𝑒   ×  (1.210  𝑖𝑓  𝑏𝑙𝑎𝑐𝑘) 
 where creatinine is measured in µmol/L. 
It is worth noting that the former equation measures creatinine clearance while the 
latter measures estimated GFR (eGFR). Also, there is no correction for body weight 
in MDRD formula. Both these formulae have been shown to be less accurate for 
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individuals without CKD (Stevens et al., 2006; Poggio, Wang, Greene, Van Lente, & 
Hall, 2005). Nevertheless, MDRD formula is now commonly used in routine clinical 
practice to aid recognition of chronic kidney disease in combination with the K/DOQI 
stages of CKD mentioned above. 
1.1.3  Progression of Chronic Kidney Disease 
The rate of CKD progression varies widely on the basis of population studied. The 
rate of decline of GFR has been found to be associated with a number of factors in 
many clinical studies – these include hypertension, presence of proteinuria, 
glycaemic control in those with diabetes and use of medications such as Angiotensin 
Converting Enzyme inhibitors (ACEI) or Angiotensin receptor blockers (ARB) to 
control proteinuria. 
Diabetes Mellitus is the single most common cause of end-stage renal disease 
(ESRD) in UK ("UK Renal Registry - The Sixteenth Annual Report," 2013) with 
nearly 26% of incident ESRD patients having diabetic renal disease. There is strong 
evidence to suggest that tight glycaemic control in patients with diabetes mellitus can 
prevent or slow down the progression of kidney disease ("The effect of intensive 
treatment of diabetes on the development and progression of long-term 
complications in insulin-dependent diabetes mellitus. The Diabetes Control and 
Complications Trial Research Group," 1993). The Diabetes Control and 
Complications Trial was a randomised controlled study in which type 1 diabetics 
were randomised to either conventional or intensive glucose control group (Newman 
et al., 2005). The study showed that intensive glucose control reduced the 
occurrence of microalbuminuria by 39% and that of albuminuria by 54%. Similarly, 
United Kingdom Prospective Diabetes Study (UKPDS) also showed a reduction in 
the incidence of microalbuminuria and of decline in renal function with intensive 
glycaemic control ("Intensive blood-glucose control with sulphonylureas or insulin 
compared with conventional treatment and risk of complications in patients with type 
2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group," 1998). 
Presence of proteinuria is a significant factor in the progression of renal disease 
irrespective of the underlying aetiology. A systematic review conducted by Newman 
et al (2005) showed that in the presence of microalbuminuria, the relative risk (RR) 
of developing ESRD was 4.8 for patients with type 1 Diabetes Mellitus and 3.6 for 
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those with type 2 diabetes (Newman et al., 2005). RR of developing clinical 
proteinuria was also higher at 7.5 for patients with either types of diabetes. The 
Irbesartan Diabetic Nephropathy Trial randomised hypertensive patients with 
diabetic nephropathy to receive either irbesartan, amlodipine or placebo with primary 
composite outcome as doubling of serum creatinine, development of ESRD or death 
(Lewis et al., 2001). This study showed that irbesartan was effective in slowing the 
progression of the renal disease with 33% reduction in the risk of CKD progression. 
ACEIs have also been shown to have similar effects on progression of renal disease 
and proteinuria (Lewis & Lewis, 2003; Brenner et al., 2001; Laffel, McGill, & Gans, 
1995). Subsequent clinical studies also confirmed the reno-protective effects of 
ARBs and ACEIs in hypertensive and diabetic patients (Izuhara et al., 2005; Wright 
et al., 2002; "Tight blood pressure control and risk of macrovascular and 
microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective 
Diabetes Study Group," 1998). It is now common practise that ARBs and ACEIs are 
routinely prescribed for patients with diabetic nephropathy to reduce proteinuria and 
limit the progression of renal disease. Hypertension is another important factor 
contributing to the progression of renal disease. Several studies in patients with and 
without diabetes have clearly shown that better blood pressure control is associated 
with reduced incidence of microalbuminuria and reduced rate of renal function 
decline ("Randomised placebo-controlled trial of effect of ramipril on decline in 
glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic 
nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in 
Nefrologia)," 1997; Hunsicker et al., 1997; Klahr et al., 1994; Lewis, Hunsicker, Bain, 
& Rohde, 1993). 
1.1.4  Effects of CKD on Organ Systems 
Progressive renal impairment has adverse effects on many organ systems. Early 
stages of CKD are usually asymptomatic with little biochemical abnormalities. As 
CKD progresses, the serum concentrations of various metabolites, collectively 
termed “uraemic solutes”, increase progressively. Whilst many of the adverse effects 
of CKD are due to the loss of various endocrine and excretory functions of the kidney 
itself, an increasing number of uraemic solutes are being identified as potential 
causes of various cardiovascular and immune system defects seen in advanced 
CKD. The prevalence of various complications according to CKD stages are shown 
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in Table 1-2 ("KDIGO Clinical Practice Guideline for the Evaluation and Management 
of Chronic Kidney Disease," 2013). 
Table 1-2: Prevalence of complications of CKD 
Complication 
GFR Category (ml/min/1.73m2) 
60-89 45-59 30-44 <30 
Anaemia 4.7% 12.3% 22.7% 51.5% 
Hypertension 41.0% 71.8% 78.3% 82.1% 
25(OH) Vit D deficiency 9.1% 10.7% 27.2% 
Acidosis 8.4% 9.4% 18.1% 31.5% 
Hyperphosphataemia 7.4% 9.2% 9.3% 23.0% 
Hyperparathyroidism 9.4% 23.0% 44.0% 72.5% 
Reproduced with permission from Macmillan Publishers Ltd: Kidney International Supplements, 2013; 
3: 73-90, copyright 2013 
Hypertension is a common complication of CKD and has also an adverse effect on 
the progression of CKD as discussed above. This is generally managed by a 
combination of dietary salt restriction and anti-hypertensive medications. Secondary 
hyperparathyroidism is another complication of CKD. Kidneys convert 1α-hydroxy 
Vitamin D to its active form 1,25-dihydroxy Vitamin-D, which plays a vital role in 
regulation of phosphorus and calcium in the blood and in bones. In addition, 
progression of CKD leads to hyperphosphataemia and hypocalcaemia due to 
deranged excretory function. All these combine to cause hyperparathyroidism. 
Secondary hyperparathyroidism has low prevalence in early stages of CKD and is 
initially asymptomatic. However, its prevalence increases with progression of CKD 
(Figure 1-1) (Levin et al., 2006) and has various adverse effects on bone mineral 
metabolism finally culminating in renal osteodystrophy in untreated cases. 
Secondary hyperparathyroidism is usually treated with 1,25-dihydroxy Vitamin-D 
replacement, dietary phosphate restriction and oral phosphate-binding medications. 
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Figure 1-1: Prevalence of abnormal serum calcium, phosphorus and PTH by 
GFR levels 
Reproduced by permission from Macmillan Publishers Ltd: Kidney International, Levin et al, 
2006; 71: 31-38, copyright 2007 
 
Anaemia is a common complication of CKD. Although symptomatic anaemia is seen 
only in CKD stages 4 and 5, the prevalence of anaemia starts increasing even in 
earlier stages of CKD. Whilst anaemia prevalence is around 4.7% in CKD stage 2, it 
increases steadily to around 51.5% in CKD stage 5 (Inker, Coresh, Levey, Tonelli, & 
Muntner, 2011). This is due to progressive reduction in secretion of erythropoietin by 
the kidneys. The effects of anaemia are quite varied ranging from fatigue and 
reduction in quality of life to cardiovascular effects such as left ventricular 
hypertrophy in the long-term. Anaemia has been shown to be associated with 
increased mortality risk, hospitalisation and reduced quality of life (Foley et al., 2000; 
Collins, Ma, Xia, & Ebben, 1998). Renal anaemia is treated with recombinant human 
erythropoietin injections. 
Metabolic acidosis is also a complication of advanced CKD with nearly 31% of 
patients in CKD stage 5 having acidosis. Acidosis is one of the causes for protein 
energy wasting commonly seen in patients with renal failure. Acidosis has also been 
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shown to contribute to the progression of CKD and increased mortality risk in CKD 
patients (Kanda, Ai, Yoshida, Kuriyama, & Shiigai, 2013; Raphael et al., 2013). 
Acidosis is treated by oral sodium bicarbonate supplementation. 
In addition to the above complications due to the direct effect of loss of kidney 
functions, many other adverse effects are also being increasingly identified due to 
the actions of accumulated uraemic solutes. The database of uraemic retention 
solutes continues to increase with nearly 25 new retention solutes added to the initial 
reported list of 90 solutes (Vanholder et al., 2008; Vanholder et al., 2001) some of 
which are shown to exert toxic effects on various organ systems. For example, 
Guanidino compounds have been implicated in neurotoxicity and stimulation of 
leucocytes to produce pro-inflammatory cytokines leading to atherogenesis 
(Glorieux, Dhondt, et al., 2004; D'Hooge et al., 2003). Advanced glycation end-
products (AGEs), p-cresylsulphate and homocysteine have been shown to stimulate 
various lymphocyte cells leading to increased oxidative stress and atherogenesis 
(Schepers et al., 2007; Au-Yeung, Yip, Siow, & O, 2006; Glorieux, Helling, et al., 
2004; Vanholder et al., 1995). Moreover, uraemic solutes such as AGE (Rashid, 
Benchetrit, Fishman, & Bernheim, 2004), asymmetric dimethylarginine (Vallance, 
Leone, Calver, Collier, & Moncada, 1992), homocysteine (Abahji et al., 2007) and 
indoxyl sulphate (Dou et al., 2007; Dou et al., 2004) have been shown to cause 
endothelial dysfunction and inhibition of endothelial proliferation which may 
precipitate development of atherosclerotic vascular disease. The increasing 
recognition of the in-vivo effects of these retention solutes help us understand better 
the mechanisms behind various complications of CKD. 
1.2 Treatment of End-Stage Renal Disease 
Management of End-stage renal disease is focused on preventing and treating the 
consequences of renal failure.  Many of the complications discussed above are 
common by the time ESRD is established. Appropriate dietary restrictions are an 
important part of managing ESRD to prevent hyperkalaemia and 
hyperphosphataemia. Anaemia, acidosis and hypertension are managed usually by 
medications. Nevertheless, renal replacement therapy becomes a necessary 
addition to these treatments. 
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Renal replacement therapy (RRT) aims to replace the excretory functions of the 
kidney including excretion of metabolic wastes, maintenance of acid-base and fluid 
balance. RRT is offered in the form of dialysis or kidney transplantation. The ideal 
RRT modality for an individual patient is decided based on many clinical and social 
factors. Clinical factors such as comorbid conditions, frailty and age need to be 
considered in the decision-making process. A detailed assessment of social factors 
needs to be carried out to determine suitability for home-based therapies. A subset 
of patients will not be suitable for dialysis or transplantation and the choice of 
treatment in those individuals is conservative management. Conservative 
management involves continuing support to ESRD patients and aims to provide a 
good quality of life by means of medical and psychological interventions. 
Dialysis is the most commonly used renal replacement therapy (Grassmann, 
Gioberge, Moeller, & Brown, 2005). Broadly, there are two dialysis modalities – 
haemodialysis and peritoneal dialysis. Although the principles are similar in these 
modalities, their clinical application and patient selection are different. 
1.2.1  Haemodialysis 
Haemodialysis (HD) is administered commonly as a hospital-based therapy although 
home haemodialysis is now increasingly being made available in many centres. HD 
involves routing the blood from the patient through the HD circuit and returning it to 
the patient. The dialyser in the HD circuit is the artificial kidney where removal of fluid 
and uraemic solutes takes place. The uraemic solutes are removed from patient’s 
blood through diffusion and osmosis in the dialyser. Dialyser is a synthetic semi-
permeable membrane with separate compartments for flow of blood and dialysis 
fluid. A schematic representation of HD circuit is shown in Figure 1-2. 
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Figure 1-2: Haemodialysis Circuit 
Reproduced with permission from Elsevier Ltd: Sivalingam M, Farrington K. Haemodialysis. 
Medicine 2007; 35(8): 461-465. 
The preferred access for HD is an arterio-venous fistula (AVF) which is fashioned 
surgically either near the wrist or the elbow by joining a superficial vein to an artery. 
Two needles are inserted into the AVF – one to draw the blood away from the patient 
(“A-needle”) and the other to return it to the patient (“V-needle”). Blood from the A-
needle flows through the blood compartment of the dialyser where it interacts with 
the dialysate compartment through minute pores in the dialyser membrane. It is 
through these pores the exchange of solutes and fluid take place. The composition 
of the dialysate fluid is devised for optimal removal of uraemic solutes and correction 
of acidosis. Solutes such as urea, creatinine, potassium and phosphate that are high 
in patient’s blood move to the dialysate compartment as bicarbonate moves from the 
dialysate into patient’s blood. A schematic representation of solute movement within 
the dialyser is shown in Figure 1-3. 
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Figure 1-3: Solute and fluid movement within the dialyser 
Reproduced with permission from Elsevier Ltd: Sivalingam M, Farrington K. Haemodialysis. 
Medicine 2007; 35(8): 461-465. 
 
While small molecules such as urea and creatinine are removed easily by 
conventional “low-flux” HD, much larger uraemic solutes (i.e. middle molecules) such 
as β2-microglobulin and Cystatin C are not removed by this method. To enhance 
removal of these middle molecules, the pore size of the dialyser needs to be 
increased thereby providing a “high-flux” haemodialysis. HD is predominantly a 
diffusive treatment. Haemofiltration is a convective form of treatment and has been 
combined with haemodialysis to develop Haemodiafiltration (HDF). HDF using a 
high-flux dialyser provides better middle molecule clearance and causes less 
haemodynamic instability in patients. 
Haemodialysis is commonly provided in hospital setting, typically for 3 days a week 
for 3-4 hours per session. There has been a surging interest in home haemodialysis 
in the recent years. Typically, a home HD patient will dialyse 4-5 times a week for 
shorter times per session. The technological advancement in home HD delivery has 
led to portable dialysis machines which provide reliable dialysis to patients. Home 
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HD patients have less dietary restrictions compared to those having in-centre HD 
and may provide better quality of life. 
1.2.2  Peritoneal Dialysis 
Peritoneal dialysis (PD) employs the same principles of diffusion and osmosis but 
the dialysis is not performed outside the body like HD. Instead, the peritoneal 
membrane in the abdomen is used as the semi-permeable membrane for dialysis. A 
peritoneal dialysis catheter is inserted in between the two layers of the peritoneal 
membrane. An external connecting tube is used to fill in and drain the dialysis fluid 
from the peritoneal cavity. The patients fills the peritoneal cavity with the dialysis fluid 
which is different in composition to that used in HD and leave it to ‘dwell’ in the cavity 
for a few hours before draining it out and exchanging it with another bag of dialysis 
fluid. Similar to HD, the process of diffusion and convection takes place between the 
dialysate in the peritoneal cavity and the blood flowing in the capillaries of the 
peritoneal membrane. 
The advantage of PD is that it is home-based and causes less intrusion to patient’s 
everyday activities compared to HD. Patients could choose to dialyse in one of the 
two ways - Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated 
Peritoneal dialysis (APD). CAPD is typically carried out during the day in which the 
patient does the fluid exchanges manually. APD is usually carried out at night with 
the help of an automated machine which performs the fluid exchanges at specified 
intervals. As it is a home-based therapy, it is imperative that patients opting to do PD 
have appropriate provisions at home and have a reasonable level of physical and 
mental functioning capacity. 
Two potentially fatal complications of PD are PD peritonitis and Encapsulating 
Peritoneal Sclerosis (EPS). PD peritonitis is an infection of the peritoneal membrane. 
This is usually precipitated by failing to follow sterile precautions before doing a PD 
fluid exchange. Rarely, this could also be caused by contaminated PD fluid. Most PD 
peritonitis can be treated successfully with antibiotics if diagnosed early. In non-
responsive cases, PD catheter is removed and the patient is required to do HD. In a 
minority of patients, a severe PD peritonitis may be fatal. EPS is widespread 
thickening of peritoneal membrane leading to frequent episodes of bowel obstruction 
due to adhesions. This is mostly seen in patients who have been on PD for many 
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years or in those who have had multiple episodes of PD peritonitis. EPS is a 
progressive condition in majority of patients leading to multiple abdominal surgeries 
and poor nutrition with high mortality risk. 
1.2.3  Transplantation 
Renal transplantation is the preferred form of RRT. A well functioning transplant 
replaces the lost kidney function and reverses many of the complications associated 
with ESRD. Transplantation involves a kidney donor – either a living donor or a 
cadaveric donor. Cadaveric kidney donation could be from a “non-heart beating” 
donor or a “heart-beating, brain-dead donor”. In order to maximise the benefit of a 
transplant and to minimise the risks associated with immunosuppression post-
transplant, most centres employ rigorous criteria before accepting a CKD patient for 
transplant. A potential transplant recipient is expected to have good cardiac and 
functional status. Many ESRD patients are elderly and frail and hence, are not 
suitable for transplantation. Traditionally, transplant is only carried out between ABO-
compatible and HLA-matched individuals. With the advent of very effective 
immunosuppressants, HLA-mismatch and even ABO-incompatibility are not seen as 
absolute barriers to transplantation at present. 
Following a transplant, patients are required to take immunosuppressive medications 
to avoid episodes of transplant rejection. Infective complications due to 
immunosuppression are common in post-transplant period and have to be diagnosed 
early and treated aggressively. Nevertheless, the benefits of transplantation, which 
include increased survival and better quality of life, outweigh the risks as long as the 
transplant recipients are appropriately selected. 
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 Chapter 2 
2. A Review on Haemodialysis Dose 
 
2.1 Haemodialysis dose 
Kidneys play a central role in maintaining the body’s internal milieu. Excretion of 
metabolic waste products, generated as a result of a myriad of metabolic processes, 
is a primary function. In kidney failure, metabolic waste products accumulate and 
exert pathological effects on many organ systems. Many such uraemic toxins are 
end-products of body protein metabolism. To maintain life in advanced kidney failure, 
these uraemic toxins must be removed by dialysis. Judging minimal requirements for 
dialysis is difficult. It might be expected that requirements should be related to the 
rate of metabolic waste production i.e. metabolic rate. Current practice however, 
adjusts dialysis requirement to body water volume. This may have a number of 
unintended consequences. This chapter discusses the basis and disadvantages of 
the current dialysis practice along with evidence base for potential alternative scaling 
measures for dialysis dosing. 
2.1.1  Dialysis dose based on urea clearance 
Urea was identified in early days as one of the many uraemic toxins whose serum 
levels are significantly elevated in renal failure. It was also recognised as a useful 
marker of dialysis clearance. As it is a small molecule, it is easily cleared by the 
kidneys and through dialysis. It is also an end-product of protein metabolism and 
could be used as a marker of whole body protein turnover. Moreover, it is 
inexpensive and easy to quantify in laboratory settings. 
The current practice of deciding dialysis dose is based on urea clearance, a concept 
that was developed through a number of clinical studies. Teschan and colleagues 
conducted a study to examine the adequacy of dialysis (Teschan, Ginn, Bourne, & 
Ward, 1977). They proposed a minimum dialysis urea nitrogen clearance of 
3000ml/week/litre of body water (equivalent to a Kt/V of 1). During an experimental 
period lasting for 6 months, patients were underdialysed with a total dialytic urea 
nitrogen clearance of 2000ml/week/litre of body water (equivalent to a Kt/V of 0.66). 
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The researchers found that patients exhibited subclinical EEG abnormalities and 
behavioural test scores, when they were underdialysed and these changes 
normalised on returning to baseline dialysis dose. 
Subsequently, the National Cooperative Dialysis Study (NCDS) was conducted in an 
attempt to define adequate dose of dialysis. NCDS was the first randomised 
controlled trial examining the effect of dialysis dose on clinical outcomes (Lowrie, 
Laird, Parker, & Sargent, 1981). The study was designed to evaluate the clinical 
effects of different dialysis prescriptions. It was a 2x2 factorial design with 151 
patients randomised to be included in one of the four study groups. The treatment 
groups were based on time-averaged concentration of urea (TACurea) – high or low 
concentration (pre-dialysis Blood Urea Nitrogen of 60-80 or 110-130 mg/dL) and on 
the duration of dialysis – long or short duration (4.5-5 hr or 2.5-3.5 hr). Outcome 
measures studied were hospitalisation rates and withdrawal from the study which 
included death (treatment failure). The follow-up was for less than a year. The study 
was stopped as the treatment failure rates were significantly higher in groups with 
high TACurea (groups II and IV in Figure 2-1) compared to groups with low TACurea 
(groups I and III in Figure 2-1). Although dialysis time was not a predictor of 
treatment failure, hospitalisation rates were higher in the group with high TACurea 
receiving short dialysis. It is worth noting that the dialysis dose received by patients 
in the high TACurea group were very low (average Kt/V 0.45) and this may have 
contributed to poor outcomes. Nevertheless, this study demonstrated the important 
association between urea clearance and short-term survival for haemodialysis 
patients. 
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Figure 2-1: Proportion of Patients Not Withdrawn for Medical Reasons or Death 
in NCDS 
Reproduced with permission from Lowrie et al. N Engl J Med 1981; 305:1176-1181, 
Copyright Massachusetts Medical Society. 
Gotch and Sargent (1985) followed this up with a mechanistic analysis of the NCDS 
study (Gotch & Sargent, 1985). They introduced the concept of measuring dialysis 
dose by the dimensionless parameter Kt/V, where K is the dialyser urea clearance, t 
is the treatment time and V is the total body water volume which is the volume of 
distribution of urea. The mechanistic analysis showed that Kt/V < 0.8 was associated 
with higher risk of treatment failure irrespective of the nutritional status of the 
patients. The authors concluded that a fully adequate dialysis can be provided with a 
Kt/V of 1.0. 
A number of studies carried out subsequently showed a consistent relationship 
between reduced mortality and higher Kt/V values. Marshall et al (2006) suggested 
that a combination of higher Kt/V dose (≥1.3) and longer dialysis duration (≥4.5 
hours) will provide maximal survival benefit (Marshall, Byrne, Kerr, & McDonald, 
2006). Other studies have also demonstrated survival benefits with Kt/V of greater 
than 1.0 (Shinzato et al., 1997; Charra et al., 1992).  However, there were practical 
difficulties in calculation of Kt/V. As in-vivo dialyser clearance of urea was lower than 
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in-vitro clearance, the calculation of K (conventionally done using in-vitro clearance) 
resulted in overestimation of Kt/V by around 15-20% (Hakim, 1990). Also, the 
documentation of the dialysis duration and estimation of V are prone to clerical errors 
which may result in inaccurate Kt/V calculation. 
In light of the benefits shown with higher doses of Kt/V from observational and 
prospective studies, the HEMO study was designed to test whether increasing 
dialysis dose will affect survival. The HEMO study was a randomised controlled trial 
to examine the effect of increasing dialysis dose or using a high-flux dialyser on 
survival (Eknoyan et al., 2002). This study randomised patients in a 2x2 factorial 
design to receive low- or high-flux haemodialysis and standard (urea-reduction ratio 
of 65% or a single-pool Kt/V of 1.25) or high dose dialysis (urea-reduction ratio of 
75% or a single-pool Kt/V of 1.65). Patients who died or transplanted during the 
study were replaced with new recruits, thereby increasing the power of the study. 
The primary outcome was death from any cause and the main secondary outcome 
was rate of hospitalisation not related to vascular access. There was no difference in 
all-cause mortality between the different dose or membrane-flux groups. This study 
concluded that increasing the sessional dialysis dose beyond a single-pool Kt/V of 
1.25 did not confer survival benefit in haemodialysis patients which forms the basis 
for many of the current guidelines for minimum dialysis dose requirements. 
2.1.2  Inclusion of residual renal function to dialysis dose 
The dialysis dose measurement discussed above relates only to the urea clearance 
achieved by dialysis. Most patients have reasonable amount of urine output at the 
time of dialysis initiation and have considerable urea clearance through the residual 
renal function (RRF). Although most centres prescribe and measure dialysis dose 
solely based on dialysis urea clearance, there is an alternative approach termed 
“incremental haemodialysis”. In this approach, total target urea clearance is 
calculated as the sum of dialysis clearance and clearance from residual renal 
function. As RRF declines with time, dialysis dose is titrated up to achieve target 
urea clearance value.  
Incremental haemodialysis was first introduced in 1985 by Bonomini et al (Bonomini, 
Feletti, Scolari, & Stefoni, 1985). The researchers compared 82 patients dialysing 
twice weekly but had early initiation of dialysis (at a mean creatinine clearance of 11 
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ml/min) to 308 patients who started dialysis at a mean creatinine clearance of 2-5 
ml/min. They showed that patients who had incremental haemodialysis had better 
12-year crude mortality and tended to preserve RRF better. Preserving RRF through 
incremental haemodialysis has been shown to be associated with reduced mortality 
(Vilar, Wellsted, Chandna, Greenwood, & Farrington, 2009) and better phosphate 
and anaemia control (Penne et al., 2011). Though the mechanisms underlying the 
survival benefit associated with preserving RRF are not clear, it is likely that it may 
be due to better clearance of middle molecule and protein-bound uraemic solutes by 
the native kidneys. 
The urea clearance from RRF is continuous but this is not the case with 
haemodialysis which is intermittent. Hence, to measure total urea clearance, either 
the dialysis clearance (Kd) needs to be converted to an equivalent continuous 
measure or the residual renal function (Kr) needs to be changed to an equivalent 
intermittent clearance. Different approaches have been proposed for this conversion. 
The NKF-K/DOQI guideline recommends using standardised Kt/V developed by 
Frank Gotch (Gotch, 1998) in which the sessional Kt/V is converted to an equivalent 
weekly urea clearance. The European Best Practice Guidelines recommend using 
the Casino-Lopez equivalent renal urea clearance ("Measurement of renal function. 
European Best Practice Guidelines for Haemodialysis," 2002; Casino & Lopez, 
1996). A simpler approach is to inflate Kr by a factor to add it to Kd. As renal 
clearance is continuous, it is more efficient than dialysis clearance and this inflating 
factor will adjust for the higher efficiency of the renal clearance. 
There are some practical difficulties in measuring residual renal function. RRF is 
measured through timed urine collection. As RRF declines with time, it has to be 
measured at regular intervals so that appropriate adjustments can be made to 
dialysis prescription. Due to the low-volume of urine output in ESRD patients, the 
timed urine collection has to be carried out through the entire inter-dialytic period. 
This can be inconvenient to patients and may lead to incomplete urine collection 
resulting in inaccurate RRF calculation. Alternative novel methods to measure RRF 
using markers such as Cystatin C are being explored by many researchers (Lindsay, 
Huang, & Filler, 2010; Hoek, Korevaar, Dekker, Boeschoten, & Krediet, 2007). 
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2.2 Deficiencies in haemodialysis dose quantification methods 
2.2.1  Is Urea Clearance the correct marker for dialysis adequacy? 
The two randomised controlled trials on dialysis dosing – NCDS and HEMO study – 
used small molecule clearance (Kt/Vurea) to define the study outcomes. Both these 
studies did not show survival benefit for longer dialysis treatment time. Knowledge 
about the kinetics of uraemic toxins of various molecular weights has expanded over 
the last decade. Urea was considered a surrogate marker of small molecule 
clearance in the above studies. It has now been shown that the kinetics of small 
molecule toxins such as guanidine compounds and methylamine are different to urea 
(Ponda et al., 2010; Eloot et al., 2007; Eloot et al., 2005) and hence, the clearance of 
these substances may not be similar to urea during standard haemodialysis. It has 
also been acknowledged by other authors that urea is a poor surrogate marker of 
removal of other toxic uraemic compounds(Depner, 2001). 
There has been growing interest in middle molecule clearance as a measure of 
dialysis dose. HEMO study did not show overall survival benefit with the use of high-
flux membranes which augment middle-molecule clearance as measured by β2-
microglobulin clearance in the study. The HEMO study data was subsequently re-
analysed to examine whether there was survival benefit in sub-groups of patients in 
different groups. The sub-group of patients whose dialysis duration was >3.7 years 
at the time of recruitment had 32% reduction in all-cause mortality on high-flux 
haemodialysis (Cheung et al., 2003). The researchers also noted 37% reduction in 
cardiac deaths in the same long duration dialysis group on high-flux therapy, 
although none of the secondary outcomes reached statistical significance after 
adjustment for multiple comparisons. This may be due to the inadequate power of 
the study to detect such small differences. Although, no obvious reason was 
identified to explain the interaction between dialysis vintage and flux, it is likely that 
this may be due to better clearance of middle molecules. This suggestion is 
supported by the study finding that patients on long-term dialysis who had been 
receiving low-flux dialysis previously had a 41% reduction in all-cause mortality when 
dialysed using high-flux dialysers. This sub-group analysis, therefore, suggested 
there might be potential long-term survival benefit from enhanced middle molecule 
clearance through high-flux dialysis. 
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The Membrane Permeability Outcome (MPO) Study was a prospective randomised 
controlled trial to compare the impact of dialyser membrane permeability, and 
thereby the middle molecule clearance, on survival in HD patients with normal or low 
albumin with a minimum dialysis dose (single-pool Kt/V) of 1.2 (Locatelli et al., 1999). 
Although there was no significant survival benefit associated with use of dialysers 
with high membrane permeability in the study population as a whole, the sub-group 
of patients with low albumin had significant survival benefit with 37% reduction in 
mortality risk with use of high-flux membranes (Locatelli et al., 2009). 
Evidence from observational studies had also shown other benefits associated with 
middle-molecule clearance such as reduction in the risk of dialysis-related 
amyloidosis (Küchle, Fricke, Held, & Schiffl, 1996; van Ypersele de Strihou, Jadoul, 
Malghem, Maldague, & Jamart, 1991). These data suggest there is potentially a role 
for middle molecule clearance in defining the minimum dialysis requirements 
alongside urea clearance. Nevertheless, the kinetics and metabolism of many of 
these molecules have not been mapped and urea remains the best possible 
surrogate marker of uraemic toxins at least in the small molecular weight category. 
2.2.2  The Denominator Problem: Body Water 
The above mentioned disadvantages of using urea clearance to define minimum 
dialysis requirement is also compounded by other problems. Dialysis adequacy as 
expressed by Kt/Vurea normalises the urea clearance to the volume of distribution of 
urea (V). This method is based on the assumption that uraemic toxin production is a 
function of distribution volume. Hence, the dialysis dose here is normalised not on 
the basis of the rate of production of the toxin (urea in this instance) but on the 
distribution volume of the toxin. Such use of distribution volume to normalise dialysis 
dose poses certain problems. 
V, sometimes referred to as Watson volume, is normally estimated using Watson 
formula (Watson, Watson, & Batt, 1980). This volume is derived from anthropometric 
measures of weight, height and age. For any given age, weight and height, the 
estimated V is lower in women than men. Similarly, patients with low body mass will 
be estimated to have low V values. Hence, if the dialysis dose is scaled based on V, 
this may result in the prescribed standard dialysis dose being inadequate in relation 
to the rate of uraemic toxin production in females and males with low body mass 
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index. Needless to say, this sub-optimal dialysis will impact on the survival of these 
patient groups and indeed, several studies have shown mortality differences in 
women and patients with low body mass index on haemodialysis. These studies are 
discussed in the following section. 
2.2.3  Survival Differences in ESRD patients on Haemodialysis 
Since the publication of HEMO study, a number of researchers have investigated 
dialysis dose as a predictor of survival in different groups of haemodialysis patients. 
Survival differences among patients of different gender, body size and body 
composition have been explored in various studies. A post-hoc analysis of the 
HEMO study showed that women randomised to the higher dialysis dose group had 
lower risk of death (Figure 2-2) compared to those receiving standard dialysis dose 
with a 19% reduction in mortality (Depner et al., 2004). Also in the high dose group, 
patients with larger body size had 10% reduction in mortality when body size was 
expressed as body mass index (BMI) and 12% reduction in mortality risk when 
expressed as body surface area (BSA) compared to those in the standard dose 
group. These mortality differences persisted even after adjustment for gender 
differences. The study concluded that there were significant gender and body size 
interactions with regards to dialysis dose and further studies were needed to explore 
the benefit of higher dialysis dose in specific groups of patients. 
 
Figure 2-2: Kaplan Meier curve showing time to death in women by 
randomised treatment group in HEMO study 
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These gender and body size differences suggest that using V as the denominator to 
scale dialysis dose may disadvantage specific groups of patients. In fact, analysis of 
distribution of Watson volume (V) ranges of the study participants showed 
significantly lower V values for women compared to men (Figure 2-3). A large 
observational study of 74,120 US haemodialysis patients and data from Dialysis 
Outcomes and Practice Patterns Study (DOPPS) showed a 15% lower mortality risk 
in women who achieved urea reduction ratio (URR) of >75% on dialysis compared to 
those who received less dialysis dose but similar effect was not seen in men (Port et 
al., 2004) further strengthening the findings from HEMO study about gender 
differences in survival among haemodialysis patients. 
 
 
 
Figure 2-3: Distribution of body water volumes (V) by gender in HEMO study 
Reproduced by permission from Macmillan Publishers Ltd: Kidney International, Depner et al, 2004; 
65: 1386-1394, copyright 2004 
 
The problem of using V as a normalising factor for dialysis dose becomes clear when 
the delivered dose is compared with other variables as normalising factor. A study 
was conducted by Spalding et al (Spalding, Chandna, Davenport, & Farrington, 
2008) to compare the delivered dialysis dose by substituting V for other parameters 
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such as body surface area (BSA) or as a power function of body weight (W0.67). This 
study demonstrated that for any given Kt/V, equivalent dialysis dose using BSA or 
W0.67 would deliver significantly lower doses to women and small men. The 
researchers showed that the current delivered dose using Kt/V needed to be 16% 
higher in women and 6% higher in small men compared to larger men. 
Apart from the gender differences in delivered dialysis dose and mortality with the 
use of Kt/V, the relationship between body size measures and mortality in dialysis 
population was also explored by many investigators. A number of retrospective and 
prospective observational studies showed that haemodialysis patients with high body 
mass index (BMI) had a survival advantage and both short-term and long-term 
mortality risk was significantly lower in this patient group (Port, Ashby, Dhingra, 
Roys, & Wolfe, 2002; Wolfe et al., 2000; Fleischmann et al., 1999; Leavey, 
Strawderman, Jones, Port, & Held, 1998). This interaction between BMI and 
mortality was observed even in patients with extremely high BMI (BMI ≥37) and the 
survival advantage was significant even after adjustment for serum creatinine and 
estimated lean body mass (Johansen, Young, Kaysen, & Chertow, 2004). This 
suggests that there is a survival advantage for obese haemodialysis patients 
irrespective of their body muscle mass content.  
The above findings are in stark contrast to those found in the general population 
where females have higher life expectancy compared to males. The mortality risk 
also increases progressively in individuals with higher BMI levels in the general 
population as shown in Figure 2-4 (Calle, Thun, Petrelli, Rodriguez, & Heath, 1999). 
The reduced mortality risk noted in haemodialysis patients with regards to gender 
and body size is strongly suggestive that Kt/Vurea underestimates dialysis 
requirements in women and small men. 
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Figure 2-4: Multivariate Relative Risk of death from All Causes among Men and 
Women 
Reproduced with permission from Calle et al. N Engl J Med 1999; 341:1097-1105, Copyright 
Massachusetts Medical Society. 
 
This phenomenon of reduced mortality risk noted in obese dialysis patients, termed 
“reverse epidemiology”, led many investigators to explore the mechanisms 
underlying these differences. As people with higher BMI may receive relatively larger 
dialysis dose, could dialysis dose be a confounding variable in these analyses? In 
order to answer this, Levey et al (Leavey et al., 2001) used DOPPS data and 
showed that the reduced mortality risk persisted in haemodialysis patients with high 
BMI even after adjustment for dialysis dose, dialysis time and associated comorbid 
conditions (Figure 2-5). Other studies have also shown that the interaction between 
BMI and mortality risk was maintained for any given dialysis dose as measured by 
URR or Kt/V (Port et al., 2002). These studies demonstrated that there may be a 
partial interaction in survival analyses between dialysis dose and BMI but this alone 
does not explain the reduced mortality risk in this patient population. 
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Figure 2-5: Relative mortality risk vs. BMI in Haemodialysis patients in Europe 
and USA 
Leavey et al. Nephrol Dial Transplant 2001; 16: 2386-2394, by permission from European 
Renal Association-European Dialysis and Transplant Association. 
The disadvantage of using BMI as a body size measure is that it does not 
differentiate between fat mass and muscle mass. Could the phenomenon of reverse 
epidemiology be related to their body composition? It may be that the survival 
advantage seen in these patients is limited to those with relatively less fat mass and 
more muscle mass. The evidence to support this is somewhat conflicting. A 
retrospective study (Beddhu, Pappas, Ramkumar, & Samore, 2003) conducted to 
explore the interaction between muscle mass and survival in high BMI patients 
showed the mortality risk to be higher in patients with low muscle mass (and inferred 
high fat mass). In this study of more than 70,000 patients with the study data 
collected through the Medical Evidence Form from the Centers of Medicare and 
Medicaid, patients with BMI ≥ 25 with low muscle mass (defined by Urine creatinine 
excretion of >0.55 g/day) had higher risk of all-cause death (Hazard ratio of 1.14) 
and cardiovascular death (HR 1.19) compared to those with normal BMI. However, 
analysis of the HEMO study data showed both low muscle mass and low fat mass to 
be independently associated with higher mortality risk in dialysis patients (Huang et 
al., 2010). It is worth noting that neither of these studies measured whole body 
muscle and fat mass directly. Whilst the former study used urine creatinine 
concentration as a surrogate marker of muscle mass, the latter used anthropometric 
measurements such as triceps skin-fold thickness and mid-arm muscle 
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circumference. However, in a study conducted by Kalantar-Zadeh et al in which the 
fat mass was measured by near infrared interactance, high baseline fat percentage 
and maintenance of fat mass over time was associated with better survival in dialysis 
patients with individuals with low body fat having four-fold increase in the Hazard 
ratio for death compared to those with normal body fat percentage (Kalantar-Zadeh 
et al., 2006). Nevertheless, the above-mentioned studies did not provide conclusive 
answers to explain the phenomenon of reverse epidemiology observed in dialysis 
patients. 
2.3 Alternative Measures of Dialysis Dose Quantification 
The survival disadvantage, noted in women and small men with the use of urea 
distribution volume (V) as the scaling parameter, led many authors to suggest that 
Kt/V is not the best measure of dialysis dose. A number of alternative scaling 
parameters, instead of V, have been suggested. These include resting energy 
expenditure (basal metabolic rate), body surface area, high metabolic rate organ 
mass and liver size (Daugirdas, Levin, et al., 2008). Using total dialysis clearance 
(Kt) alone without any scaling factor has also been suggested as an alternative 
(Lowrie, 2000). 
Kt, the product of dialyser clearance of the solute and dialysis time, represents the 
total dialysis dose and is not normalised to V. In 1999, Lowrie et al proposed ‘Kt’ as a 
measurement index for dialysis dose (Lowrie, Chertow, Lew, Lazarus, & Owen, 
1999). The argument in favour of using Kt is that the relationship between Kt and 
survival is somewhat linear and increasing doses of dialysis as expressed by Kt is 
always associated with better survival. This is in contrast to the finding that there is a 
trend toward reduced survival at higher doses of URR or Kt/V demonstrated by some 
previous studies (Chertow, Owen, Lazarus, Lew, & Lowrie, 1999; McClellan, Soucie, 
& Flanders, 1998). Also, Kt, unlike Kt/V, is not confounded by nutritional factors. 
However, there are some factors that argue against applying Kt in the wider clinical 
practice. Direct calculation of Kt is difficult due to complexities associated with 
calculation of in-vivo clearance (K). Although initial studies derived Kt by multiplying 
Kt/V with V, this calculation needs prior determination of Kt/V and V through different 
equations and increases the workload of dialysis unit staff and as such, is difficult to 
apply in clinical practice. 
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The emergence of ionic dialysance measurement resolved this problem. Ionic 
dialysance measurement entails calculation of conductivity across the dialyser 
membrane and is similar to the urea clearance (K). Kt obtained by ionic dialysance 
also has a direct relationship with survival (Lowrie, Li, Ofsthun, & Lazarus, 2004). 
The ionic dialysance monitors automatically provide Kt values for each dialysis 
session. The problem in using these monitors is that there are considerable 
variations in the calculated Kt values depending on the type of monitor that is used 
(Maduell et al., 2008). This means that dialysis units should be equipped with similar 
ionic dialysance measuring monitors for the results to be comparable. In addition, as 
the dialysis dose is not scaled to any body size measure, patients across a wide 
range of body weights will receive similar dialysis doses irrespective of their 
nutritional status. Although a method has been described to correct Kt by BSA 
(Lowrie, Li, Ofsthun, & Lazarus, 2005), there are still no recommended target levels 
for quantifying dialysis dose using this method. These practical difficulties 
surrounding the use of Kt as a dialysis dose remains a barrier to its wider application 
to clinical practice. 
As a result of the above issues, there is a need to explore an appropriate normalising 
factor for dialysis dose scaling. Scaling dialysis dose to body surface area (BSA) is a 
promising alternative. The advantage in using BSA is that the GFR is routinely 
adjusted to this parameter in clinical practice and normalising dialysis dose to the 
same parameter will allow comparison between dialysis dose and residual renal 
function. In a study carried out in healthy kidney donors, GFR estimated from 125I-
iothalamate clearance was scaled to various parameters including BSA, V, metabolic 
rate and liver size (Daugirdas, Meyer, Greene, Butler, & Poggio, 2009). This study 
demonstrated that GFR scaled to BSA was similar in men and women whereas the 
difference in measured GFR between sexes was approximately 14% when scaled to 
V and 7% with metabolic rate. The authors concluded that BSA was the best 
parameter for scaling GFR and possibly, for scaling dialysis dose as well. 
There is evidence from observational studies that this approach of normalising 
dialysis dose by BSA would deliver higher dialysis dose to women and small men 
and may favourably impact on survival in this subgroup of dialysis population. A 
study of 328 HD patients showed that women and small men will indeed receive 
higher dialysis doses if the target levels were decided according to Kt/BSA or 
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Kt/Weight0.67 (Spalding et al., 2008). This study showed that to provide similar 
dialysis dose across all patients with current dialysis dosing practices, the dose for 
women should be 16% higher compared to large men and at least 6% higher in 
small men. A retrospective analysis of the HEMO study also found that the BSA 
adjusted dialysis dose in the HEMO study was significantly lower in women than 
men which may explain in part the survival benefit observed in women in the high-
flux dialysis group (Daugirdas, Greene, Chertow, & Depner, 2010). A study exploring 
the implications of BSA-based dialysis dose scaling – expressed as surface area 
normalised Standard Kt/V – showed that this approach will mandate more dialysis for 
women and small men and slightly lower doses for large men (Daugirdas, Depner, et 
al., 2008). In a more recent study using the same BSA-based scaling parameter, 
Ramirez et al (2012) demonstrated that women had better short-term survival 
compared to men when this approach of dialysis dose scaling was followed (Ramirez 
et al., 2012). This pattern of survival is similar to that observed in general population. 
All these studies support the use of BSA as a scaling parameter and suggest that 
BSA may reflect better the dialysis requirements compared to body water volume. 
BSA is closely related to liver size and hence, has an inherent gender-related 
adjustment (Daugirdas, Levin, et al., 2008). This links BSA to the rate of metabolic 
waste production and hence, it may be an appropriate parameter for dialysis dose 
scaling. 
If a body size measure such as BSA that is linked to liver size is a better measure of 
dialysis requirement, then why not use the liver size directly as a scaling parameter? 
It has indeed been proposed by some investigators that liver mass could be used for 
scaling dialysis dose. Liver is an important site for metabolism of nitrogenous 
compounds and could be viewed along with kidney as a paired set of excretory 
organs working in tandem. High metabolic rate compartment comprises of the 
visceral organs including the gut and liver is a major component of this. It has been 
hypothesised that visceral organs generate bulk of uraemic toxins (Kotanko et al., 
2007) and hence, scaling dialysis dose to liver mass may provide dialysis based on 
the rate of uraemic toxin generation. However, there are practical difficulties in this 
approach. It is not practical to measure liver size in all dialysis patients and hence, it 
has to be estimated from equations. The problem here is that most of the available 
equations calculate liver size as a function of BSA (Yoshizumi et al., 2003; 
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Heinemann, Wischhusen, Püschel, & Rogiers, 1999) and is not gender dependent. 
Moreover, the data on liver size norms and variability in renal failure patients is scant 
which hinders the application of this approach to clinical practice at the present time. 
2.3.1  Metabolic Rate and Dialysis Dose Measurements 
Basal Metabolic Rate (BMR) represents the sum of all the metabolic activities that 
occur in an organism at rest and as such, is closely related to the rate of metabolic 
waste production. Using Kt/Vurea means that the dialysis dose is scaled to the volume 
in which the uraemic toxins are distributed rather than the generation rate of these 
toxins. Morton and Singer (2007) argued that the dialysis dose should be scaled to 
metabolic rate as it is more closely related to uraemic toxin generation than 
distribution volume (Morton & Singer, 2007). 
Nitrogenous waste products are formed as a result of amino acid and protein 
metabolism. The primary function of the kidneys is excretion of nitrogenous waste 
products at a rate proportional to its production in the body. Does this mean that 
GFR is related to metabolic rate? Singer (2001) argues that GFR increases in 
proportion to body mass and so does the BMR (Singer, 2001). Based on the review 
of body functions by White and Seymour (White & Seymour, 2005) in a wide range 
of animal species, allometric scaling applies to mammals of all sizes. Allometric 
scaling allows scaling of biological functions, such as GFR or BMR, to body mass 
according to the equation y=axb where ‘y’ is the biological function of interest, ‘a’ is 
the scaling coefficient, ‘x’ is body mass and ‘b’ is the exponent. A number of body 
functions including cardiac output, respiratory functions (minute volume, mean 
expiratory flow rate) and effective renal plasma flow are all shown to scale to body 
mass using this equation. The scaling exponent ‘b’ in the above equation is close to 
0.75 for all these parameters (Singer, 2001). Singer (2001) explains that animals of 
varying sizes adapt their metabolism to become more energy efficient in such a way 
that the energetic cost of overall metabolic activity is relatively lower in larger 
animals. Although there are inter-species variations in the scaling exponent, it 
remains constant in the same sized mammal. 
GFR increases with increase in body size due to increase in both the number of 
nephrons in each kidney and the surface area of the glomeruli. Although there is an 
absolute increase in GFR with increase in body size, GFR per unit of body mass 
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decreases. Similar effect is seen with regards to BMR. As body size increases, the 
oxygen consumption per unit body mass decreases although there is an absolute 
increase in BMR (KREBS, 1950). 
Allometric scaling shows that both GFR and BMR increase with body size with a 
scaling exponent of approximately 0.75 as shown by Singer (2001) using previously 
published data (Figure 2-6).  
 
Figure 2-6: Relationship between Body weight (BW) and BMR (•) or GFR (o) 
Reprinted from Singer MA, Am J Kidney Dis 37(1): 164-178; Copyright 2001, with 
permission from Elsevier. 
Singer (2001) hypothesised that this is because the metabolic rate is the driving 
process for renal blood flow and hence, GFR responds to changes in metabolic rate. 
He also argued that the converse is not true i.e. changes in GFR should not result in 
corresponding changes in metabolic rate. There is circumstantial evidence to 
suggest that changes in metabolic rate drive corresponding changes in GFR. In 
patients with hypothyroidism, reduction in BMR is accompanied by reduction in GFR 
(Davies, Mackinnon, & Platts, 1952; Mackay & Sherrill, 1943) and opposite 
relationship prevails in patients with hyperthyroidism (Aizawa et al., 1986; Ford, 
Owens, Curd, Moyer, & Spurr, 1961; Mackay & Sherrill, 1943). This hypothesis is 
also supported by some clinical studies in CKD patients demonstrating no change in 
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metabolic rate with the reduced GFR in this patient population (Schneeweiss et al., 
1990; Monteon, Laidlaw, Shaib, & Kopple, 1986). 
There are survival differences among dialysis patients of different ethnicity which 
may be related to metabolic rate. BMR estimated by resting energy expenditure 
(REE) has been shown to be lower in Asians and Blacks compared to Whites 
(Wouters-Adriaens & Westerterp, 2008; Gallagher et al., 2006). This means that 
these ethnic group patients may receive sufficient dialysis even at lower levels of 
Kt/V. This difference in metabolic rate may be the underlying cause for the increased 
survival observed among Asian and Black dialysis patients compared to Whites (Jain 
et al., 2009; Roderick et al., 2009). 
These findings definitely present a case in favour of using metabolic rate as a scaling 
parameter for dialysis dose. However, the counter arguments to using metabolic rate 
as the scaling parameter need to be considered. Although some studies showed 
normal REE in CKD patients, there are studies that demonstrate raised (Neyra et al., 
2003; Kuhlmann, Schwickardi, Trebst, & Lange, 2001; Ikizler et al., 1996) or lowered 
(Avesani et al., 2004; Panesar & Agarwal, 2003) metabolic rate in patients with 
kidney disease. This argues against Morton and Singer’s above mentioned 
hypothesis. Moreover, if metabolic rate is the driving process for GFR, one would 
expect GFR to rise with large amounts of physical activity. There is little evidence to 
strongly support this. Although there is some evidence that physical activity may be 
related to GFR (Finkelstein, Joshi, & Hise, 2006), this relationship may vary 
depending on the intensity of exercise and there may even be a reduction in GFR at 
higher levels of physical activity (Kachadorian & Johnson, 1970). Daugirdas et al 
(2008) used HEMO study data to quantify dialysis dose using REE-normalised 
Standard Kt/V and analysed the potential dose change that will be needed if REE is 
used as scaling parameter. The researchers showed that this approach will result in 
only trivial changes in recommended dialysis dose for both men and women 
compared to current dosing practice (Daugirdas, Levin, et al., 2008). The 
researchers argued that the lack of evidence demonstrating significantly higher GFR 
in athletes and labourers compared to office workers undermines the importance of 
BMR as a principal determinant of GFR. 
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There are some practical difficulties that could be expected in studies related to 
metabolic rate. The main barrier is the availability of resources – direct measurement 
of metabolic rate requires indirect calorimetry apparatus which is relatively 
expensive. Metabolic rate measurement with this device could take up to 30 minutes 
for each patient. Hence, it is not practical to use this in routine clinical practice and 
as such, it remains only as a research tool. As a result, studies related to metabolic 
rate in renal failure are limited leading to poor understanding of the effect of renal 
failure on metabolic rate and the determinants of metabolic rate in renal failure. 
Studies focusing on exploring these aspects of metabolic rate may shed more light 
on the reliability and applicability of metabolic rate as a normalising factor for dialysis 
dosing. 
The following sections discuss two important determinants of metabolic rate – body 
composition and protein turnover – with regards to their role in management of 
patients with renal disease. 
2.3.1.1 Body Composition and Metabolic Rate in Renal Failure 
Body composition is a major determinant of resting energy expenditure in general 
population. Body composition can be broadly classified into fat mass (FM) and fat-
free mass (FFM). FFM is a heterogeneous compartment and includes the masses of 
various organs, skeletal muscle, bone and other extracellular tissues excluding 
adipose tissue. With regards to metabolic rate, FFM comprises of two distinct tissue 
categories – high and low metabolic rate compartments. High metabolic rate 
(HMRO) compartment is principally made up of various organs such as brain, heart, 
liver, spleen and kidneys whereas the low metabolic rate compartment comprises of 
bone and other extracellular tissues. The metabolic activity of skeletal muscle (MM) 
is intermediate and has significantly higher metabolic activity compared to bone and 
other extracellular tissues. The different compartments of FFM and their relative 
energy expenditure are shown in Figure 2-7 (Müller, Bosy-Westphal, Kutzner, & 
Heller, 2002). 
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Figure 2-7: Components of Fat-free mass and their Energy Expenditure at Rest 
Reproduced with permission from Muller et al, Obes Rev 3(2): 113-122; Copyright 2002, 
John Wiley and Sons. 
The concentration of uraemic toxins in the blood is influenced by the rate of 
production of toxins, their distribution volume and their clearance through dialysis 
and/or residual renal function. It is vital to understand the relative roles of HMRO and 
MM in the metabolism of uraemic toxins in individuals of varying body sizes. HMRO 
is a highly metabolically active compartment and is responsible for the major bulk of 
nitrogenous metabolic waste production. Although comprising only about 5% of body 
weight, they contribute approximately 70-75% to the basal metabolic rate. In 
contrast, MM forms a greater proportion of body weight but contributes far less to the 
metabolic rate. Approximately 70% of muscle tissue is comprised of water. Hence, 
MM compartment may be considered a site of uraemic toxin sequestration. 
If it is assumed that the proportion of HMRO and MM as FFM remains constant 
irrespective of body size, one would expect to see a constant REE/kg of FFM across 
adults of all sizes. However, this is not the case as shown by some clinical studies 
(Wang et al., 2000; Weinsier, Schutz, & Bracco, 1992; Ravussin & Bogardus, 1989). 
Indeed, REE/FFM decreases with greater FFM. This may be due to changes in 
relative proportions of HMRO mass and MM in individuals with higher body weights. 
Heymsfield et al (2002) measured various tissue compartments using MRI and 
showed whilst the proportion of HMRO mass as FFM decreases, the MM and low 
metabolic rate compartment mass increases with increase in FFM mass (Heymsfield 
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et al., 2002). This means that in larger individuals, the metabolic rate, and thereby 
the metabolic waste production, per unit mass of metabolically active tissue is less 
compared to a smaller individual. 
If the above changes in body composition with body size holds true for patients with 
kidney disease, then this may have important implications for dosing of dialysis. 
However, studies exploring body composition differences in haemodialysis patients 
are very limited. Kotanko et al (2007) hypothesised that the concentration of uraemic 
toxins is lower in larger in dialysis patients for two reasons (Kotanko & Levin, 2007). 
Firstly, larger dialysis patients have higher muscle and fat mass providing a larger 
distribution volume and secondly, the relative mass of HMRO in relation to body 
weight is smaller in these patients (Figure 2-8). As dialysis dose is scaled to urea 
distribution volume, smaller patients may be receiving lower dialysis doses relative to 
their metabolic needs. They estimated HMRO mass using published equation and 
showed that small patients had significantly higher HMRO mass per kg of body 
weight (Kotanko & Levin, 2007). This means that the uraemic toxin concentration 
was relatively higher in smaller patients compared to larger patients. If this is true, 
does it impact on survival? The same group examined short-term survival in 
haemodialysis patients in relation to HMRO mass/body weight and found that 
patients in the lowest HMRO mass/body weight tertile group had 10% higher survival 
time compared to those in middle tertile and nearly 17% compared to those in the 
lowest tertile. 
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Figure 2-8: Relative sizes of HMRO, skeletal muscle and adipose tissue 
Larger patients have relatively larger muscle and fat mass and lower HMRO mass/body 
weight compared to smaller patients. Reproduced with permission from Kotanko et al; Blood 
Purification 25(1): 27-30, Copyright © 2007 Karger Publishers, Basel, Switzerland. 
Whilst this study was suggestive of body composition differences as a possible 
mechanism underlying the survival difference observed in women and small men on 
haemodialysis, the HMRO mass was estimated using predictive equation and was 
not measured directly. Moreover, this equation had not been previously validated in 
renal failure population. 
In order to examine the relationship between body size and body composition, 
Sarkar et al (2006) measured various tissue components using MRI and explored 
their relationship with body size and estimated REE (Sarkar et al., 2006). The 
authors demonstrated that there was a clear inverse relationship between body size 
and HMRO mass per kg of body weight and hence, smaller patients had relatively 
higher HMRO mass compared to their larger counterparts (Figure 2-9). The authors 
also showed that the relative contribution of HMRO-derived REE expressed as 
percentage of total REE was highest in the small patients (Figure 2-10). In addition, 
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there was also a strong correlation between HMRO mass and estimated protein 
catabolic rate (PCR) (r = 0.616, p < 0.001). 
 
Figure 2-9: Relationship of body weight to HMRO mass (as percentage of body 
weight) 
 
 
Figure 2-10: Relative contribution of various tissue components to metabolic 
rate in various BMI-group patients 
BMI tertile 1 is the lowest and tertile 3 is the highest tertile. Reprinted by permission from 
Macmillan Publishers Ltd: Kidney International, Sarkar et al, 2006, 70: 1832-1839, copyright 
2006 
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The main strength of the study was the direct measurement of body composition in 
haemodialysis patients, the first such study to do so. This study clearly demonstrated 
the importance of body composition differences in haemodialysis patients. Moreover, 
the observed relationship between HMRO mass and REE in smaller patients implies 
relatively higher metabolic waste production in these patients. PCR is a derivative of 
urea generation rate. Although this is an area of ongoing research (Vanholder, 
Glorieux, & Lameire, 2002), urea generation rate could be considered a surrogate 
marker for other uraemic toxin generation. The strong correlation between HMRO 
mass and PCR further strengthens the hypothesis that HMRO mass is the major 
determinant of uraemic toxin generation. 
These body composition differences may not be limited to body size alone. There 
are significant body composition differences in individuals from different ethnic 
population. African American men and women have lower REE compared to Whites 
(Weyer, Snitker, Bogardus, & Ravussin, 1999; Albu et al., 1997; Foster, Wadden, & 
Vogt, 1997; Kushner, Racette, Neil, & Schoeller, 1995). This may be due to 
significantly lower HMRO mass and relatively higher muscle mass in African 
Americans (Gallagher et al., 2006). Similarly, Asians have lower REE compared to 
Whites (Wouters-Adriaens & Westerterp, 2008; de Boer, van Es, Voorrips, Blokstra, 
& Vogt, 1988). This is likely due to differences in body composition as Asians have 
significantly lower FFM. Indeed, many studies have shown higher fat percentage in 
Asians compared to Whites with similar BMI (Deurenberg, Deurenberg-Yap, & 
Guricci, 2002; Wang et al., 1996; Wang et al., 1994) and that the differences in REE 
were not significant if adjusted to FFM (Wouters-Adriaens & Westerterp, 2008; 
Lawrence, Thongprasert, & Durnin, 1988). As Whites may have relatively higher 
HMRO mass as percentage of body weight compared to Asians and Blacks, their 
dialysis dose requirements may be higher compared to other ethnic populations. 
This may partly explain the higher mortality risk noted in Caucasian haemodialysis 
patients. 
Most of the above-mentioned studies have been carried out in healthy adults and 
there is dearth of information on relationship between body composition differences 
and metabolic rate in patients with kidney disease. This may be due to some major 
barriers in conducting studies to explore body composition in renal failure. Firstly, 
whole body MRI scans are time-consuming, cumbersome and expensive. A whole 
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body MRI scan takes up to an hour to complete and patients will be expected to lie in 
the scanner for this length of time. Patients with renal failure are likely to be elderly 
and frail and are not likely to tolerate such lengthy MRI scans. Secondly, if these 
studies are to be conducted in clinical environment in secondary and tertiary care 
centres, the availability of time on scanner and MRI personnel is a major limitation. A 
dedicated MRI facility for research is needed to facilitate these studies and it is not 
feasible to establish this on a wider scale. Thirdly, the time and costs associated with 
performing the scans and analysis of MRI images means that it cannot be carried out 
in large numbers. 
In view of the above limitations of using MRI scan, alternate methods need to be 
explored. Bioimpedance devices can be used to analyse body composition. Although 
not considered a gold standard method for body composition analysis, studies 
carried out in patients with ESRD have shown these devices to be reliable and 
accurate compared to DEXA scan (Fürstenberg & Davenport, 2011a; Fürstenberg & 
Davenport, 2011b). These devices are non-invasive and provide results in a short 
span of time, typically within a few minutes, and hence, are reliable alternatives to 
MRI scan. 
There is a need for clinical studies focusing on elucidating the complex relationship 
between body composition, REE and dialysis requirements. Such studies will 
improve our understanding of the inter-play of these various factors determining 
uraemic toxin generation and in turn, their impact on survival outcomes in renal 
failure patients. 
2.3.1.2  Protein Turnover and Metabolic Rate in Renal Failure 
Kidneys play a major role in protein and amino acid metabolism. This is achieved 
through the synthesis, degradation, filtration, reabsorption and urinary excretion of 
various amino acids. Approximately 50-70g/day of amino acids is filtered through the 
glomerulus and are almost completely reabsorbed by the tubules (Garibotto, 
Pastorino, & Dertenois, 2003). In healthy human kidneys, there is net uptake or 
release of several amino acids in the post-absorptive state (Brundin & Wahren, 
1994; Tizianello et al., 1982; Tizianello, De Ferrari, Garibotto, Gurreri, & Robaudo, 
1980). Hence, in renal failure, disturbed protein and amino acid metabolism may be 
expected. Indeed, many studies have shown reduced concentrations of several 
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amino acids and impairment of specific amino acid metabolism pathways in patients 
with kidney disease (Jones, Kopple, & Swendseid, 1978; Kopple, 1978; Gulyassy, 
Aviram, & Peters, 1970). 
Malnutrition is common in patients with renal failure with approximately 20-50% of 
dialysis patients affected (Ikizler, 2007). These patients suffer from a specific form of 
protein and energy malnutrition (Ikizler & Hakim, 1996; Bergström, 1995; Kopple, 
1994; Hakim & Levin, 1993), commonly termed as ‘uraemic wasting’ which is 
associated with increased mortality and hospitalisations in this patient population 
(Ikizler, Wingard, Harvell, Shyr, & Hakim, 1999; Goldwasser et al., 1993; Iseki, 
Kawazoe, & Fukiyama, 1993; Owen, Lew, Liu, Lowrie, & Lazarus, 1993). It was 
initially thought the uraemia per se was a catabolic state and the protein energy 
malnutrition was a result of this. But many studies have shown that this is not the 
case. Studies using nitrogen balance and whole-body amino acid kinetics in stable, 
non-acidotic pre-dialysis CKD patients have showed no significant increase in 
protein catabolism and neutral nitrogen balance albeit at a low protein turnover rate 
(Adey, Kumar, McCarthy, & Nair, 2000; Castellino et al., 1992; Goodship et al., 
1990). Novel mechanisms such as stimulation of ubiquitin-proteosome system have 
been suggested as possible underlying mechanism for uraemic wasting rather than 
malnutrition (Lecker & Mitch, 2011; Workeneh & Mitch, 2010). 
All these studies point to a derangement of protein metabolism in renal failure. 
Abnormal protein metabolism will have important consequences in the management 
of renal failure patients. In addition to the higher mortality risk associated with protein 
energy wasting, deranged protein metabolism may also influence uraemic toxin 
generation. Many of the uraemic toxins are products of cell protein metabolism and 
hence, excess protein intake may potentially lead to increased uraemic toxin 
generation (Workeneh & Mitch, 2010; Ikizler, 2007). Any increase in uraemic toxin 
generation is bound to influence morbidity and mortality of these patients and will 
impact on dialysis requirements.  Protein turnover is a major contributor to basal 
metabolic rate and thereby, influences energy requirements of patients with kidney 
disease. Moreover, protein metabolism has a direct relationship with body 
composition, in particular fat-free mass and hence, may impact on dialysis 
requirements. 
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A good understanding of the whole body protein turnover in renal failure patients is 
required to tackle the above potential problems. While many protein turnover studies 
in non-dialysis CKD patients have demonstrated neutral protein balance, there is no 
such consensus in patients on haemodialysis. Most of these studies in 
haemodialysis patients have used isotope labelled leucine (13C-leucine) to examine 
the whole body protein turnover. In a study of five haemodialysis patients, the 
nitrogen balance was found to be negative on dialysis days irrespective of the level 
of protein intake (Borah et al., 1978). Berkelhammer et al (1987) showed that the 
leucine oxidation rate was increased in HD patients compared to healthy controls 
(Berkelhammer et al., 1987) but this is likely due to the HD patients in the study 
being significantly acidotic (mean serum bicarbonate level of 18 mmol/L). 
Three studies undertaken to explore the effects of haemodialysis on protein turnover 
showed conflicting results. The study by Lim et al (1993) showed no increase in 
protein degradation during HD although there was significant amino acid loss in the 
dialysate with no concomitant increase in protein synthesis (Lim, Bier, Flanigan, & 
Sum-Ping, 1993). Ikizler et al (2002) studied whole body protein kinetics and forearm 
protein kinetics in 11 HD patients 2 hours before, during and 2 hours after dialysis 
(Ikizler et al., 2002). The average whole body proteolysis rate was 3.38mg/FFM/min 
pre-dialysis, 3.70mg/FFM/min during dialysis session and 3.77mg/FFM/min after 
dialysis. There was approximately 9% increase in proteolysis during dialysis and 
nearly 11% increase 2 hours after dialysis. In a study conducted by Raj et al (2004) 
in 6 HD patients, an average increase of 28% in protein synthesis and 58% in protein 
degradation was noted during HD but the increase in degradation rate was higher 
than synthesis rate (Raj et al., 2004). However, all 3 studies concluded that the 
dialysis is a catabolic process although there were variations in the abnormalities 
noted with individual components of the protein metabolism. 
Given that there are no definitive alterations observed in protein turnover during HD, 
is there conclusive evidence on protein metabolism in HD patients in steady-state 
conditions when they are not undergoing dialysis? There are only a limited number 
of studies which has explored this question but the answer again is not definitive. 
Whilst one study demonstrated neutral balance in HD patients (Raj et al., 2004), 
another study demonstrated negative protein balance with higher protein 
degradation rate in relation to the synthesis rate (Ikizler et al., 2002). In order to 
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minimise the inter-individual variations in protein metabolism, Lim et al (1998) 
conducted a longitudinal study in which whole body protein turnover was measured 
in the same group of CKD patients before initiation of dialysis and a few months after 
being established on dialysis therapy along with measurements in healthy adults as 
controls (Lim, Yarasheski, & Flanigan, 1998). Contrary to the above studies, they 
demonstrated that the whole body protein turnover and protein synthesis increased 
after initiation of dialysis compared to pre-dialysis CKD stage and was comparable to 
protein turnover rates in healthy controls. They did not find any evidence of higher 
protein degradation rate during pre-dialysis or dialysis stage compared to controls. 
What could be the reason behind such differences in protein turnover in renal failure 
patients across various studies? There does not seem to be a clear answer for this. 
The current recommended dietary protein intake for haemodialysis patients is 
1.1g/kg/day (Naylor et al., 2013). Protein intake in the study participants across 
these studies have been similar in the range of 0.9 – 1.2 g/kg/day and hence, this is 
unlikely to be a confounding factor. Lim et al (1998) showed increase in protein 
synthesis after dialysis initiation in spite of similar dietary protein intake in subjects 
before and after initiation of dialysis. Although no definitive explanation for this 
increased protein synthesis could be derived from the study, the dialysis patients had 
significantly higher serum pH (mean 7.43 ± 0.05) compared to the other pre-dialysis 
groups in the study and this may have contributed, at least in part, to the increased 
synthesis. Age is unlikely to be the confounding variable in these studies as there is 
no large age difference between the study cohorts. The variations in the results may 
be due to the small sample sizes of these studies. Whether the ethnic origin of the 
study subjects plays a major role in protein turnover is as yet unclear and this may 
be a confounding factor in these study results. There are body composition 
differences across various ethnic groups which will influence protein metabolism. As 
most studies did not report information on participants’ ethnicity, this issue cannot be 
explored from published literature. 
There has been no published literature exploring the relationship between protein 
turnover and metabolic rate in renal failure setting. It has been shown in healthy 
adults that whole body protein turnover contributes approximately 20% to the basal 
metabolic rate in both young and the elderly (Boirie, Beaufrère, & Ritz, 2001; Welle & 
Nair, 1990) but this relationship has not been studied in renal failure as yet. Although 
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it is not likely that the process of protein turnover is more efficient in renal failure, 
whether the energetic cost of protein turnover is higher in renal failure remains to be 
examined. 
It is worth considering the practical difficulties in conducting these studies in the renal 
failure population. The methods to study protein turnover are cumbersome and 
requires study subjects to be admitted for a considerable number of hours to a 
research facility. Most HD patients attend the hospital facility for routine dialysis at 
least 3 times a week and an additional day of hospital visit is not welcome amongst 
this patient population. Hence, recruitment to these studies is difficult. Protein 
turnover studies demand appropriate laboratory equipment to measure isotope 
enrichments of amino acids and its availability may pose a barrier to these studies 
being conducted. Lastly, a close collaboration between personnel from various 
disciplines (e.g., dieticians, pharmacist, laboratory staff etc.) is vital for successful 
conduct of the study. This may be cumbersome and lack of availability of all required 
personnel at a single site may hinder these studies from being carried out in routine 
clinical practice. 
Nevertheless, whole body protein turnover and its influence on metabolic rate in 
renal failure are poorly understood. Studies focusing on exploring these areas will 
help improve understanding of the protein and energy requirements of patients with 
renal disease as well as providing valuable information about the factors influencing 
metabolic rate in this patient population. 
2.3.2  Physical Activity and Dialysis Dose Requirements 
Physical activity is increasingly being studied at present in patients with kidney 
disease. Physical activity levels have been shown to be low in patients with kidney 
disease. In CKD patients not receiving dialysis, total physical activity levels 
progressively decrease with worsening renal function (Hawkins et al., 2011). Many 
studies have shown markedly reduced physical activity levels in haemodialysis 
patients even when compared to healthy sedentary individuals (Avesani et al., 2012; 
Zamojska, Szklarek, Niewodniczy, & Nowicki, 2006; Johansen et al., 2000). This 
reduction in physical activity is even more pronounced on dialysis days compared to 
non-dialysis days (Majchrzak et al., 2005). Dialysis patients are exposed to a number 
of factors that may predispose to low physical activity. Firstly, these patients are 
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likely to have significant comorbidities such as diabetes (and its associated vascular 
complications), protein-energy wasting, anaemia etc. which may restrict their 
activities. Uraemia per se may lead to sarcopenia thereby reducing the ability to 
perform regular exercise. Indeed, a study carried out on dialysis patients showed 
30% of incident and 39% of prevalent dialysis patients to have signs of muscle 
atrophy (Carrero et al., 2008). Moreover, renal failure is predominantly a disease of 
the elderly and factors related to aging may also contribute to reduced physical 
activity (Brown, Yore, Ham, & Macera, 2005; Johansen et al., 2000). Finally, studies 
have shown markedly diminished physical functioning capacity in CKD patients even 
in earlier stages of kidney disease (Leikis et al., 2006; Castaneda et al., 2001; Boyce 
et al., 1997). 
There are clear physical and mental health benefits associated with higher physical 
activity levels in patients with kidney disease. Physically active dialysis patients have 
reduced mortality risk compared to their sedentary counterparts (Tentori et al., 2010; 
Stack, Molony, Rives, Tyson, & Murthy, 2005; O'Hare, Tawney, Bacchetti, & 
Johansen, 2003). These studies have shown nearly 26-30% reduction in mortality 
risk in people who exercise regularly. Exercise training in CKD and dialysis patients 
has been shown to improve objective measures of physical functioning capacity and 
muscle strength in addition to a number of other anabolic effects (Mustata et al., 
2011; Cheema & Fiatarone Singh, 2005; Castaneda et al., 2004). Patients who 
perform regular exercise also report higher physical functioning scores, better quality 
of life and are less likely to suffer from anxiety and depression (Painter, 2005; Suh, 
Jung, Kim, Park, & Yang, 2002). 
However, there are some aspects of physical activity and its potential impact on 
various nutritional and metabolic factors in patients with kidney disease that have not 
been studied as yet. Individuals performing regular exercise and moderate to 
vigorous physical activity have higher rates of protein turnover and have higher 
dietary protein requirements compared to sedentary individuals. Indeed, it has been 
shown that physically active adults will be in negative nitrogen balance if their protein 
intake was similar to sedentary ones (Lemon, Dolny, & Yarasheski, 1997; 
Tarnopolsky et al., 1992). It is conceivable that a similar relationship between 
physical activity levels and protein turnover exists in patients with kidney disease 
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which may influence the nutritional management of this patient population but this 
has not been explored in any studies to date. 
Physical activity has been shown to be a significant predictor of fat-free mass in 
dialysis patients (Baria et al., 2011; Majchrzak, Pupim, Sundell, & Ikizler, 2007) and 
will induce changes in body composition in individuals who exercise regularly. If 
minimum dialysis requirements ought to consider body composition differences, then 
physical activity levels will have significant influence on dialysis dosing practices. 
Moreover, the increased muscle mass may provide a survival advantage as 
discussed in earlier sections. The mechanisms underlying reduced mortality risk in 
physically active haemodialysis patients have not been studied and may be multi-
factorial. However, it is likely that changes in body composition may play an 
important role and this relationship needs to be explored further. 
It is difficult to quantify the influence of increased physical activity on concentrations 
of individual metabolic waste products in the tissues. Physical activity is likely to 
increase uraemic toxin generation in patients with renal failure and may also 
increase mobilisation of these toxins from sequestrated tissues. In a study conducted 
by Kong et al (1999), intra-dialytic exercise increased transfer of uraemic solutes 
from peripheral tissues leading to higher dialysis clearance of these solutes with a 
resultant 14% increase in sessional Kt/V (Kong, Tattersall, Greenwood, & Farrington, 
1999). If the hypothesis that physical activity increases uraemic toxin generation is 
true, this would mean that minimum dialysis requirements will be higher in physically 
active patients. There is a knowledge gap in this area in that the influence of physical 
activity levels on dialysis dose requirements has not been explored as yet in clinical 
studies. 
2.3.2.1 Physical Activity and Total Energy Expenditure 
Physical activity is the variable component of total energy expenditure (TEE) and can 
be measured. If the goal is to normalise dialysis dose by a parameter that closely 
reflects the rate of uraemic toxin generation, it is imperative that TEE be examined 
as a scaling parameter amongst others. TEE, with its physical activity component, is 
related to body composition and uraemic toxin generation. Intuitively, TEE may seem 
a better scaling parameter as it encompasses both metabolic rate and physical 
activity, the two principal factors related to metabolic waste production. But, the 
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applicability and reliability of TEE as a scaling parameter for dialysis dosing has not 
been tested in clinical studies to date. 
The gold standard method of measuring daily energy expenditure is through the use 
of doubly labelled water technique which is time-consuming, expensive and 
cumbersome. The development of various accelerometer devices has enabled 
easier measurement of physical activity related energy expenditure and total energy 
expenditure. Although, these devices could not be used in routine clinical practice at 
present, use of these devices in large-scale physical activity studies could lead to 
generation of predictive equations to estimate TEE in clinical practice. These devices 
are now readily available and facilitate measurement of physical activity in clinical 
studies. 
Despite the myriad benefits demonstrated by many studies associated with exercise, 
the effects of physical activity on uraemic toxin production and its potential impact on 
dialysis dose requirements has not been explored. As discussed above, physical 
activity can potentially influence uraemic toxin generation in many ways and thereby, 
impact on dialysis requirements. Studies focusing on these aspects of physical 
activity will help bridge the knowledge gap and will support the development of 
holistic exercise programs for haemodialysis patients. 
2.4 Summary 
In summary, the current practise of using total body water for scaling dialysis dose 
may carry the risk of under-dialysis in women and small men. Factors that are 
closely related to uraemic toxin generation may provide more appropriate dialysis 
dose relative to individual metabolic needs. Many aspects of the proposed 
alternative scaling parameters – body surface area, resting energy expenditure and 
total energy expenditure – remain largely unexplored. Studies focusing on the 
relationship of energy expenditure measures to renal function and its impact on 
uraemic toxin generation are needed to examine the benefits of using these 
parameters in clinical practice. 
2.5 Research Aims 
The overarching aim of the thesis is of the form – “optimal management of advanced 
kidney failure should take into account metabolic factors influencing the rate of 
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uraemic toxin generation”. To this end, studies reported in this thesis have been 
designed with the following objectives. 
• To explore the relationship between energy expenditure and uraemic toxin 
generation 
• To measure basal metabolic rate and total energy expenditure and examine 
the impact of advanced kidney disease on these energy expenditure 
measures 
• To explore ways to quantify habitual physical activity levels in patients with 
advanced kidney disease 
• To study the impact of physical activity on uraemic toxin generation in patients 
with end-stage renal disease 
• To measure protein turnover rate in end-stage renal disease patients and 
evaluate its relationship with resting energy expenditure 
• To prospectively examine the influence of metabolic factors – BSA, REE and 
TEE – on survival outcome in patients with advanced kidney disease on 
dialysis 
The hypotheses related to each of the studies are mentioned in the respective 
chapters. 
 50 
 Chapter 3 
3. General Methodology 
3.1 Introduction 
This chapter explains the design rationale for all the studies in this thesis and 
describes the study population at each study site and the common methodologies 
used in the studies reported in this thesis. 
3.2 Rationale for the Studies 
There is paucity of data exploring the relationship between metabolic factors such as 
resting energy expenditure (REE), total energy expenditure (TEE) or fat-free mass 
(FFM) and a measure of uraemic toxin generation such as urea generation rate. 
Knowledge of the interaction between these factors will help inform designing further 
clinical studies. A retrospective analysis was carried out examining the relationship 
between REE, TEE and FFM to Urea generation rate to inform better the designing 
of further studies for this PhD. 
As discussed in chapter 2, various authors have proposed a number of alternative 
scaling parameters. However, there are no large-scale outcome-based studies 
exploring the use of such parameters. A prospective epidemiological study was 
therefore designed to explore the reliability of REE, TEE and BSA in predicting 
survival when used as normalising factor for dialysis dose. Haemodialysis patients 
(n=1500) were recruited from 5 different centres. REE was estimated from a 
predictive equation developed and validated in HD patients (Vilar et al., 2014). TEE 
was calculated from REE in conjunction with physical activity data collected through 
the Recent Physical Activity Questionnaire (RPAQ). 
One of the major functions of the kidneys is excretion of metabolic waste products 
and it is this function that is being replaced by dialysis. Hence, factors related to 
metabolic activity such as resting energy expenditure or total energy expenditure 
could potentially be a better scaling parameter for dialysis dosing. It is important to 
understand the determinants of these energy expenditure variables. Whole body 
protein turnover is an important contributor to REE and contributes as much as 20% 
to REE. As kidneys play a significant role in protein turnover, alterations of protein 
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metabolism are expected. It is not known whether the energetic cost of protein 
turnover in ESRD remains the same as in general population. Hence, a cross-
sectional study was designed to examine the energetic cost of whole body protein 
turnover in a group of haemodialysis patients (n = 6) and advanced CKD patients (n 
= 6). 
Physical activity is the variable component of Total energy expenditure and can be 
easily measured. In theory, increased physical activity may lead to increased 
generation and mobilisation of metabolic waste products and thereby, necessitating 
an appropriate increase in the dialysis dose. This has not been explored in studies to 
date. In order to examine the influence of physical activity on urea generation rate 
(and thereby, dialysis requirement), a cross-sectional study was conducted to 
measure physical activity levels in haemodialysis patients (n=120) through wrist-
worn accelerometers. The study also aimed to validate the Recent Physical Activity 
Questionnaire (RPAQ) in this study to facilitate physical activity data collection in 
routine clinical practice. 
Though accelerometers provide a reliable measure of physical activity and total 
energy expenditure, the gold-standard method of measuring total energy expenditure 
is by doubly labelled water technique. To examine the effect of varying levels of 
kidney function on resting and total energy expenditures, a study was designed to 
measure TEE through doubly labelled water in 40 patients with varying stages of 
CKD. REE was measured using indirect calorimetry. The relationship between the 
measured energy expenditure and urea generation rate was also explored in this 
study. 
An overview of each individual study carried out as part of this PhD is described 
below. A detailed explanation of the methodologies is provided in later relevant 
sections in this chapter. 
3.2.1 Retrospective analysis exploring the relationship between body 
composition, energy metabolism and urea generation rate 
As there was no published data available examining the relationship between 
various metabolic factors and uraemic toxin generation, a retrospective analysis of 
data from a previous study cohort was undertaken. This study was carried out on 
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166 HD patients from Lister renal unit. Adult HD patients older than 18 years and 
dialysing for more than 3 months were included. Exclusion criteria included patients 
with active infection, untreated thyroid dysfunction, hospital admission in the 
previous month, recent respiratory infection, treated tuberculosis in the previous 12 
months, a history of infection with hepatitis B, C or HIV, and those with amputated 
limbs. Demographic and anthropometric data such as height and weight were 
collected from all patients. Comorbidity data and blood test results were collected 
from medical records. REE was measured using indirect calorimeter. Physical 
activity data was collected using Stanford 7-day recall questionnaire, which was then 
used in conjunction with REE to calculate TEE. Body composition was measured 
using a bio-impedance device. HMRO mass was estimated from previous published 
literature (Gallagher et al., 2006). Urea Kinetic modelling was carried out using the 
software Solute Solver to calculate urea generation rate (Daugirdas, Depner, 
Greene, & Silisteanu, 2009). 
3.2.2 Prospective study of survival outcomes and alternative dialysis dose 
scaling parameters 
To determine the impact on survival of using alternative scaling parameters for 
dialysis dosing, a prospective, epidemiological study was designed. 1500 subjects 
on in-centre haemodialysis across 5 different sites were recruited for this study. Body 
size parameters were obtained through direct measurements. Comorbidity data was 
collected using a self-report comorbidity questionnaire and physical activity data from 
Recent Physical Activity Questionnaire. Subjects were followed up for a period of 18 
months to collect survival and dialysis adequacy data. Resting energy expenditure 
was estimated using the novel predictive equation mentioned above. Body surface 
area was calculated using Haycock formula and Total energy expenditure was 
calculated from REE and physical activity data. Data from this study was used to 
determine the impact on survival of using Kt/REE, Kt/BSA and Kt/TEE as dialysis 
dosing measures and to determine appropriate cut-off points for minimum dialysis 
requirement using these parameters. 
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3.2.3 Cross-sectional Study of Physical Activity and its influence on Urea 
Generation Rate in Haemodialysis Patients 
120 patients on in-centre haemodialysis at Lister and Royal Free hospitals were 
recruited for this study. Adult anuric HD patients older than 18 years and dialysing for 
more than 3 months were included. Exclusion criteria included patients with active 
infection or malignancy, untreated thyroid dysfunction, hospital admission in the 
previous month, those with cardiac pacemakers or defibrillators, those with 
amputated limbs and immobility due to physical ailments. Physical activity was 
measured using wrist-worn accelerometer and from Recent Physical Activity 
Questionnaire. Body size measures were obtained through direct measurements and 
body composition was measured using bio-impedance spectroscopy. All study 
subjects were asked to prospectively complete a food diary for 3 days in the study 
period. These 3 days included 1 dialysis weekday, 1 non-dialysis weekday and a 
non-dialysis weekend day. Pre- and post-dialysis blood tests were carried out during 
the study period. Urea generation rate was estimated using the software Solute 
Solver. 
3.2.4 Cross-sectional study of Whole-body Protein turnover in advanced 
chronic kidney disease 
Measurement of whole-body protein turnover by intravenous infusion of stable 
isotope of leucine is a validated and reliable method. The isotope is non-radioactive. 
This method was employed to study WBPT in 12 patients with advanced CKD 
(eGFR < 20 ml/min) – 6 of them receiving in-centre haemodialysis and 6 of them in 
pre-dialysis stage. Resting Energy expenditure was measured using indirect 
calorimetry and body composition by bio-impedance analysis. A bolus dose of stable 
isotopes of sodium bicarbonate and leucine were administered intravenously 
followed by a continuous infusion of leucine isotope for 2-3 hours. Blood tests were 
taken at regular intervals throughout the study period, which were then analysed for 
isotopic enrichment of α-ketoisocaproate (α-KIC). Breath samples were collected at 
the time of blood tests for estimation of isotopic enrichment of 13C in the expired air. 
The results were then used to estimate the energetic cost of protein turnover in 
patients with advanced CKD. 
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3.2.5 Prospective analysis of total energy expenditure in chronic kidney 
disease 
The doubly labelled water isotope-excretion technique has been used safely in 
general population and is the gold standard method for measuring Total Energy 
Expenditure. In order to explore TEE in patients with different stages of CKD, a study 
was conducted using the stable isotope of doubly labelled water in 40 patients with 
CKD. Patients were recruited from the general nephrology clinic at Lister hospital. 
REE was measured using indirect calorimetry. Physical activity data was also 
collected through two recall questionnaires – Stanford questionnaire and Recent 
Physical Activity Questionnaire. Body composition was measured using bio-
impedance analysis. Using doubly labelled water for TEE measurement in 
conjunction with physical activity measurement through questionnaires enabled 
validation of these questionnaires in CKD patients. 
3.3 Study Population 
All the above studies recruited patients registered under the care of the renal service 
at East and North Hertfordshire NHS Trust. In addition, two of the studies included 
patients from other sites. The study of survival outcomes with alternative scaling 
parameters recruited patients registered under the care of renal services at 4 
different sites – Royal Free London NHS Foundation Trust, Barts and The London 
NHS Trust, Southend University Hospital NHS Foundation Trust and Wirral 
University Teaching Hospital NHS Foundation Trust. The study of physical activity 
and urea generation rate recruited patients under the care of Royal Free London 
NHS Foundation Trust. 
3.4 Research Ethics 
All prospective studies were given NHS ethics committee approval and local 
Research & Development approval.  All study participants were given a written 
information sheet explaining the study. They were given at least 24 hours to make a 
decision regarding participation in the study. Written informed consent was obtained 
from all subjects recruited in prospective studies as per the Good Clinical Practice 
guidelines. Letter of approval for the studies are shown in the appendix. The NHS 
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Research Ethics committee and the University Ethics reference numbers for the 
studies are given below. 
Total Energy Expenditure in Chronic Kidney Disease – NHS ref: 13/EE/0388; UH ref: 
LMS/PG/NHS/00255 
Physical activity and urea generation rate – NHS ref: 13/EE/0053; UH ref: 
LMS/PG/NHS/00254 
Survival outcome using alternate scaling parameters – NHS ref: 12/WA/0060; UH 
ref: LMS/PG/NHS/00257 
Whole body protein turnover in advanced CKD – NHS ref: 13/EE/0158; UH ref: 
LMS/PG/NHS/00256 
3.5 Haemodialysis Programme at Study Sites 
3.5.1 Lister Hospital 
The haemodialysis programme at the Lister hospital renal units consists exclusively 
of high-flux haemodialysis and haemodiafiltration using predominantly polysulphone 
membranes. Nearly 60% of patients were receiving online haemodiafiltration. 
Bicarbonate was used exclusively as the buffer. Water quality was regularly 
monitored to ensure tight bacteriological standards. Dialysis was prescribed and 
monitored according to a target two-pool total Kt/V of 1.2 per dialysis session. The 
two-pool total Kt/V comprises of urea clearance from dialysis (Kt/Vdialysis) and that 
from residual renal function (Kt/Vrenal). Dialysis adequacy was monitored monthly 
through blood tests for dialysis clearance and inter-dialytic urine collection for 
estimation of residual renal function. 
3.5.2 Royal Free Centre for Nephrology 
Patients were dialysed using high flux membranes that were predominantly 
polysulphone. Majority of patients received online haemodiafiltration with the rest 
receiving high-flux haemodialysis. Water quality was regularly monitored to ensure 
tight bacteriological standards. Dialysis was prescribed and monitored according to 
target two-pool Kt/Vdialysis of 1.2. Patients with a urine output of more than 100ml/day 
had the urine volume measured on a 3-monthly basis but residual renal function was 
 56 
not included in the dialysis prescription. Dialysis adequacy was monitored on a 
monthly basis. 
3.5.3 Royal London Hospital 
Patients were dialysed using high flux membranes that were predominantly 
polysulphone. Majority of patients received high-flux haemodialysis. Water quality 
was regularly monitored to ensure tight bacteriological standards. Dialysis was 
prescribed and monitored according to target two-pool Kt/Vdialysis of 1.2 per session 
without inclusion of residual renal function. Dialysis adequacy was monitored on a 
monthly basis. 
3.5.4 Southend University Hospital 
Patients were dialysed exclusively using low flux polysulphone membranes. All 
patients received low-flux haemodialysis. Water quality was regularly monitored to 
ensure tight bacteriological standards. Dialysis was prescribed and monitored 
according to the Urea Reduction Ratio of 70% per session. Neither residual renal 
function nor Kt/Vdialysis was used to monitor the dialysis prescription. 
3.5.5 Wirral University Hospital 
Patients were dialysed using high-flux polysulphone membranes with nearly half of 
the patients on haemodiafiltration and the other half receiving high-flux 
haemodialysis. Water quality was regularly monitored to ensure tight bacteriological 
standards. Dialysis was prescribed and monitored according to target single-pool 
Kt/V of 1.2 per session. Dialysis adequacy was monitored on a monthly basis. 
3.6 Assessment of Metabolic Rate 
Basal metabolic rate (BMR) denotes the energy expenditure at sleep. As it is difficult 
to measure basal metabolic rate in practice, it is usually expressed as Resting 
Energy Expenditure (REE). REE includes the energy spent by being awake and also 
from the residual metabolic activity resulting from posture, spontaneous muscle 
activity etc. In sedentary individuals, REE contributes to around 60% of Total Energy 
Expenditure (TEE). Apart from REE, TEE also comprises of energy expenditure from 
physical activity and thermic effect of food, which is the energy expended for 
 57 
digestion and assimilation of ingested food. Thermic effect of food contributes to 
around 10% of TEE. REE measurement for studies in this thesis was carried out 
through predictive equations and direct measurement using indirect calorimetry as 
explained below. 
3.6.1 Predictive Equations 
A number of predictive equations for REE have been derived in general population. 
There are more than 190 published formulae to estimate REE (Foster, Knox, 
Dempsey, & Mullen, 1987) with the commonly used ones being Harris-Benedict 
equation (Harris & Benedict, 1918), Mifflin-St Jeor equation (Mifflin et al., 1990) and 
Schofield equation (Schofield, 1985). None of these equations were derived from 
patients with CKD. As explained in section 2.3.1, there is evidence to suggest 
metabolic rate differs in CKD patients compared to healthy individuals. A novel 
predictive equation for REE in HD patients was derived from previous research 
studies at Lister hospital through direct measurements using indirect calorimetry 
(Vilar et al., 2014). This equation was also validated in a separate cohort of HD 
patients and was found to be at least as accurate as other existing equations and 
was also associated with less bias. The equation is given below. 
(𝟏)    𝑹𝑬𝑬 = −𝟐.𝟒𝟗𝟕  ×  𝑨𝒈𝒆 𝒚𝒆𝒂𝒓𝒔   ×  𝑭𝒂𝒄𝒕𝒐𝒓𝒂𝒈𝒆   +    𝟎.𝟎𝟏𝟏  ×  𝑯𝒆𝒊𝒈𝒉𝒕𝟐.𝟎𝟐𝟑 𝒄𝒎   +   𝟖𝟑.𝟓𝟕𝟑  ×  𝑾𝒆𝒊𝒈𝒉𝒕𝟎.𝟔𝟐𝟗𝟏 𝒌𝒈   +    𝟔𝟖.𝟏𝟕𝟏  ×  𝑭𝒂𝒄𝒕𝒐𝒓𝒔𝒆𝒙    
where Factorage is 0 if age <65 and 1 if ≥65 and Factorsex is 0 if female and 1 if male. 
REE is expressed in kcal/day. 
As this is a condition-specific equation for patients on haemodialysis, this equation 
was used in studies involving estimation of REE. 
3.6.2 Indirect Calorimetry 
Indirect calorimetry was used to measure REE in some of the studies. Indirect 
calorimeter measures oxygen consumption rate (VO2) and carbon dioxide production 
rate (VCO2) by analysing the expired air. One litre of oxygen consumed generates 
3.9 kcal and one litre of carbon dioxide produced generates 1.1 kcal. This is then 
converted to energy expenditure using Weir equation (Cunningham, 1990; Weir, 
1949). The ratio of VCO2 / VO2 is called the respiratory quotient (RQ). RQ is related 
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to the diet and denotes which kind of substrate is predominantly used as a fuel for 
energy production. RQ of 1.0 denotes carbohydrate as a predominant source of 
energy whereas RQ of 0.7 denotes fat as the source. 
Indirect calorimetry was performed using a Sensormedics (CareFusion Corporation, 
San Diego, California, USA) Vmax 29n metabolic cart with an overhead canopy 
technique. The Sensormedics system is a ventilated open circuit system. The 
system collects the expired air through an overhead canopy which is then diluted 
with room air and passed through a gas analyser at a specific flow rate to analyse 
the oxygen and carbon dioxide concentrations. The specific flow rate is set as 5-6 
times the subject’s minute volume which is calculated as tidal volume multiplied by 
the respiratory rate per minute. The high flow rate ensures that almost all of the 
expired air is collected for analysis. The Sensormedics system has been shown to 
have good validity with a coefficient of variation of approximately 8% compared to 
the Deltatrac Metabolic Monitor and high reliability with no significant difference 
between REE measured from these two instruments (Cooper et al., 2009). 
The Sensormedics system is illustrated in Figure 3-1. The expired air, diluted with 
room air as per the set flow rate, is analysed in the mixing chamber of the gas 
analyser. The system also samples the room air to measure oxygen and carbon 
dioxide concentrations which are used in the analysis of the diluted expired air. The 
analyser is calibrated using two calibration gas mixtures containing different 
concentrations of oxygen, carbon dioxide and nitrogen. The mass flow sensor, 
shown in the illustration, is also calibrated manually using a 2.5 litre syringe which 
generates flow-volume loops of varying intensity. 
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Figure 3-1: Sensormedics Indirect Calorimetry System 
Reproduced with permission from Dr Enric Vilar. 
Indirect calorimetry was performed in a designated thermo-neutral room with a 
temperature range of 21-25°C. No measurements were made if the room 
temperature fell outside this range. Subjects were requested in writing to refrain from 
eating for 2 hours prior to the test and also from intense physical activity prior to the 
study. Prior to testing each subject, mass flow sensor and gas analyser calibration 
was performed. Subjects were requested to lie down on a couch for at least 15 
minutes before the REE measurement was initiated. Patients were requested to lie 
still for the duration of the test and not to speak unless necessary. The procedure 
room was kept closed during the study to prevent changes in room pressure and 
temperature. Overhead canopies were cleaned after each patient use as per the 
local Trust infection control policy for medical devices. 
Indirect calorimetry was performed until a steady-state period was achieved. The 
steady-state was defined as a 5-minute period of <5% variation in VO2 and VCO2. In 
patients whom the steady-state was not achieved by 20 minutes from the start of the 
test due to high variability of VO2 and VCO2, a threshold of <10% variation in these 
parameters were used. 
The oxygen consumption rate, carbon dioxide production rate and respiratory 
quotient were measured after the steady-state period has been achieved. REE was 
calculated using the Weir equation given below. 
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𝟐     𝑹𝑬𝑬  (𝒌𝒄𝒂𝒍/𝒅𝒂𝒚)   = 𝟏.𝟒𝟒  ×   𝟑.𝟗  ×  𝑽𝑶𝟐   +    𝟏.𝟏  ×  𝑽𝑪𝑶𝟐  
3.7 Assessment of Physical Activity 
Physical activity is the most variable part of the Total Energy Expenditure (TEE) and 
can be measured through various ways. For studies in this thesis, a number of 
methods have been used for physical activity measurement. While accelerometer 
was used in one of the studies, questionnaire-based methods were employed in all 
the studies. These methods are described below. 
3.7.1 Accelerometer-based Measurement 
Accelerometer-based physical activity measurement was employed in one of the 
studies in this thesis. Accelerometers measure movement of the body parts in 
different axes along with the speed, duration and the intensity of the movement. This 
data is recorded as vectors in the respective axes which are then downloaded onto a 
computer using specific software. The output obtained from the accelerometers 
varies with the type of accelerometer. While some accelerometers give the output as 
energy expenditure, some others express activity in terms of time spent at various 
activities depending on the intensity of the activity. 
Physical activity was measured using GENEActiv accelerometer (Activinsights 
Limited, Kimbolton, UK). GENEActiv is a wrist-worn, tri-axial accelerometer and 
measures hand movement in three axes. It is lightweight and worn just like a wrist 
watch. The splash-proof design ensures that it can be worn even during exposure to 
water such as swimming, shower/bath etc. GENEActiv has an internal memory 
capacity of 500MB. The data sampling frequency was set at 100 Hertz. With this 
sampling frequency, the accelerometer was capable of storing up to 8 days worth of 
physical activity data. 
GENEActiv has been validated as a physical activity measurement tool in adults. 
Esliger et al (2011) showed that GENEActiv had high technical reliability (intra-
instrument and inter-instrument coefficient of variation of 1.8% and 2.4% 
respectively) and validity (r = 0.97) compared with Multi-Axis Shaking Table (MAST) 
acceleration (Esliger et al., 2011). It also showed excellent concurrent validity with 
existing, widely used accelerometers such as ActiGraph (r = 0.92) and RT3 (r = 
0.97). In addition, specific cut off points for different intensities of activities were 
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defined. Welch et al used these cut off points in a different cohort of subjects and 
found them to be as accurate as the existing wrist-worn accelerometers in identifying 
different intensities of activities (Welch et al., 2013). Algorithms have also been 
developed and published to classify daily activities using GENEActiv with high 
accuracy (Zhang, Rowlands, Murray, & Hurst, 2012). Although the waist-worn 
GENEActiv units had higher classification accuracy (98.2% - 99.1%) compared to 
the wrist-worn units (95.3% - 97%), algorithms based on wrist-worn units were found 
to be robust enough for daily physical activity monitoring and these units were also 
more convenient for patients to use. 
Study participants were consented prior to the study. The accelerometers were pre-
programmed with the demographic (age and gender) and anthropometric data 
(height and weight) pertaining to each individual participant prior to the study date. 
The device was activated using an activation button in the device on the study day. 
At the start of the study, the accelerometer was strapped on the non-fistula hand. 
Subjects were asked to wear it continuously for a period of 7 days. They were 
specifically informed about the waterproof nature of the device and were advised not 
to take it off until the end of the study. After a week, the accelerometers were 
collected back. All accelerometers were thoroughly cleaned as per local Trust 
infection control policy for medical devices. The accelerometer was then connected 
to a computer and the raw data was downloaded. The devices were then recharged 
and re-programmed with the data for the next set of study subjects. 
3.7.2 Questionnaire-based methods 
It is practically difficult to design large scale studies of physical activity measurement 
using accelerometers due to its cost and time limitations. Self-report questionnaires 
are a useful alternative. The primary requirements for the questionnaires chosen for 
the studies were that it is validated against other methods of activity measurement 
and it would give a measure of Metabolic Equivalent of Task (MET) which will enable 
estimation of Total Energy Expenditure. 
Two physical activity questionnaires are used for studies in this thesis, namely, 
Recent Physical Activity Questionnaire (RPAQ) and Stanford 7-day recall 
questionnaire. RPAQ was used in all the studies while the other questionnaire was 
used only in the doubly labelled water study to measure TEE. 
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3.7.2.1 Recent Physical Activity Questionnaire 
Recent Physical Activity Questionnaire (RPAQ) was developed as a tool to measure 
physical activity in different domains of daily life. RPAQ (shown in Appendix B) 
enquires about the time spent on various activities at home, work and recreational 
activities over the preceding 4 weeks. It also enquires about time spent on 
commuting to and from work. The main advantage of the questionnaire is that the 
questions are divided into various sections such as at home, work and leisure time 
which aids recollection of the activities performed. The recreational activity section 
has a long list of commonly performed individual activities and some blank rows 
were also included for the study subjects to mention any performed activity that was 
not mentioned in the list. 
RPAQ has been validated using accelerometers in adults as a reliable tool to 
measure and categorise activity levels into different intensities (Besson, Brage, 
Jakes, Ekelund, & Wareham, 2010). In this study by Besson et al (Besson et al., 
2010), total and physical activity related energy expenditure derived from RPAQ was 
compared with the gold standard method using Doubly labelled water. The 
correlation between the questionnaire-derived and measured TEE was good (r = 
0.67) and the correlation for physical activity related energy expenditure (PAEE) was 
weak (r = 0.39). PAEE was calculated using subject’s body weight and sum total of 
activity expressed as MET-hours/day. However, a different method of estimating 
TEE was used in the studies here as explained below. This method of TEE 
calculation was validated using the doubly labelled water technique, the results of 
which are described in one of the studies (chapter 7). 
Study subjects completed RPAQ by themselves at the end of the study period. 
Subjects mentioned whether they had performed a particular activity as mentioned in 
the questionnaire over the preceding 4 weeks and if so, they were required to mark 
the frequency and the time spent on the activity. Where the time spent on the activity 
was expressed as a range, the average of the range was considered for analysis. 
The frequency of the activity over the preceding 4 weeks was converted to a daily 
frequency to enable calculation of daily physical activity time. If the total duration of 
reported activities was more than 18 hours per day, then each activity time was 
normalised to total activity duration of 18 hours/day as below. 
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𝟑     𝑨𝒅𝒋𝒖𝒔𝒕𝒆𝒅  𝑨𝒄𝒕𝒊𝒗𝒊𝒕𝒚  𝑻𝒊𝒎𝒆 =   𝑹𝒆𝒑𝒐𝒓𝒕𝒆𝒅  𝑨𝒄𝒕𝒊𝒗𝒊𝒕𝒚  𝑻𝒊𝒎𝒆𝑻𝒐𝒕𝒂𝒍  𝑨𝒄𝒕𝒊𝒗𝒊𝒕𝒚  𝑻𝒊𝒎𝒆   ×  𝟏𝟖 
 
The remaining time (RT) was calculated as the time not accounted for from the 
questionnaire assuming the Sleep time to be 6-8 hours/day. 
If total activity time was ≤16, then RT = 16 – Total activity time. 
If total activity time was >16, then RT = 0. 
Each reported activity was given a Metabolic Equivalent of Task (MET) score as per 
the Compendium of Physical Activities chart (Ainsworth et al., 2011; Ainsworth, 
Haskell, Whitt, Irwin, & et al., 2000). Subjects were assumed to be performing light 
activities during the unreported RT which was given a MET value of 1.3. A MET 
value of 1 was given for the sleep time. Total daily MET and TEE was calculated for 
each subject as below. 𝟒     𝑻𝒐𝒕𝒂𝒍  𝑫𝒂𝒊𝒍𝒚  𝑴𝑬𝑻 =    𝑨𝟏  ×  𝑻𝟏   +    𝑨𝟐  ×  𝑻𝟐   +   ⋯⋯   +    𝑨𝒏  ×  𝑻𝒏  
where A1 to An represent each activity and T1 to Tn represent the reported duration of 
the corresponding activity per day including sleep and RT. 
𝟓   𝑻𝑬𝑬  (𝒌𝒄𝒂𝒍/𝒅𝒂𝒚)   = 𝑹𝒆𝒔𝒕𝒊𝒏𝒈  𝑬𝒏𝒆𝒓𝒈𝒚  𝑬𝒙𝒑𝒆𝒏𝒅𝒊𝒕𝒖𝒓𝒆  (𝒌𝒄𝒂𝒍/𝒅𝒂𝒚)  ×    𝑻𝒐𝒕𝒂𝒍  𝑫𝒂𝒊𝒍𝒚  𝑴𝑬𝑻𝟐𝟒  
 
3.7.2.2 Stanford 7-day Recall Questionnaire 
The Stanford 7-day recall questionnaire (shown in Appendix C) was developed for 
the Stanford Five City Project (Blair et al., 1985). The questionnaire is based on the 
principle that recall of vigorous physical activity is more accurate than lighter 
activities. The questionnaire enquires about time spent in sleep and at moderate, 
hard and very hard activities over the preceding 7 days. Any time not accounted for 
was considered to be spent in light activity. 
The questionnaire has been validated and used in many studies for physical activity 
measurement. Taylor et al (1984) showed the 7-day recall questionnaire had 
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excellent correlation (r = 0.81) compared with a prospectively recorded physical 
activity log (Taylor et al., 1984). The questionnaire has also been shown to have high 
test-retest reliability and convergent validity compared with a daily activity diary 
(Williams, Klesges, Hanson, & Eck, 1989) which was better than that observed 
between Caltrac accelerometer and daily log. A study comparing the energy 
expenditure measured using doubly labelled water and that estimated using the 7-
day recall questionnaire showed poor correlation (r2 = 0.14) between them (Conway, 
Seale, Jacobs, Irwin, & Ainsworth, 2002). Moreover, the questionnaire data 
overestimated physical activity in a significant proportion of study subjects. However, 
this level of correlation is similar to that obtained for other activity questionnaires. 
Although there are few studies examining the validity of the questionnaire in CKD 
population, a small study by Johansen et al showed the 7-day recall questionnaire to 
have a significant correlation with accelerometer measured physical activity (r2 = 
0.34) (Johansen et al., 2001). 
Stanford 7-day recall questionnaire was used alongside RPAQ in the study 
measuring TEE using doubly labelled water. Subjects were asked to complete the 
questionnaire at the end of the study period. Using the questionnaire along with 
other activity questionnaires allowed comparison of the usefulness of these 
questionnaires in predicting total energy expenditure. A MET value was assigned to 
each activity depending on its intensity as per Table 3-1. 
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Table 3-1: Assigned MET value for activity categories in the Stanford 7-day 
recall questionnaire 
Physical Activity Intensity MET value assigned to the activity level 
Sleep 1 
Light activity 1.5 
Moderate intensity activity 4 
Hard activity 6 
Very hard activity 10 
 
 
Mean daily MET was calculated using the following formula. 
𝟔     𝑴𝒆𝒂𝒏  𝑫𝒂𝒊𝒍𝒚  𝑴𝑬𝑻 =    𝑺  ×  𝟏 +    𝑳  ×  𝟏.𝟓 +    𝑴  ×  𝟒 +    𝑯  ×  𝟔 +    𝑽𝑯  ×  𝟏𝟎𝟐𝟒  𝒉𝒐𝒖𝒓𝒔  
where S, L, M, H and VH are the time spent in sleep, light, moderate, hard and very 
hard activities respectively 
TEE was calculated using the above equation (5). 
3.8 Assessment of Total Energy Expenditure 
3.8.1 Doubly Labelled Water Isotope Excretion Technique 
Doubly labelled water technique was used for measurement of Total Energy 
Expenditure (TEE). The technique involves use of a stable, non-radioactive isotope 
of oxygen (18O) and hydrogen (2H) to estimate the production rates of water and 
carbon dioxide from which TEE is calculated. These isotopes are normally present in 
tap water but at a lower concentration. A measured dose of these isotope-enriched 
samples are given orally. The isotopes will equilibrate in the body water pool within a 
few hours which will raise the enrichment level of these molecules in body water. 
Over a period of 7-14 days, the excretion rates of these molecules are measured 
from urine samples. 2H (also known as deuterium) leaves the body primarily as water 
(2H2O) in urine and sweat. 18O, on the other hand, leaves the body as both water 
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(H218O) and carbon dioxide (C18O2). By measuring the difference between the 
elimination rates of both these isotopes, production rate of carbon dioxide can be 
calculated as explained in the section below. If the respiratory quotient (RQ) of the 
individual in the steady state is known, then TEE can be calculated with the above 
measurements. RQ can either be measured directly using indirect calorimetry or a 
population based estimate can be used instead. 
Two different methods can be employed to measure TEE using these isotopes. One 
approach is the ‘Two-point’ method where only two samples are collected – one at 
the start and at the end of the study and the rate of elimination of isotopes between 
these two time points is used to calculate TEE. Whilst this may be convenient for the 
conduct of the study, the main disadvantage is that a single erroneous result will lead 
to major errors in energy expenditure calculation. The other approach is the 
‘Multipoint’ method where multiple samples are collected during the study period for 
analysis. The principal disadvantage in this method is the cost associated with 
analysis of the samples. Although the multipoint method confers some advantage 
over the two-point method (Speakman, 1997), a study comparing them did not show 
significant difference in measured energy expenditure between the methods (Welle, 
1990). As the excretion of water may be altered in CKD and also, since there was 
previous experience of using multipoint method at Lister Hospital, this method was 
chosen for this study. The assumptions and general theory of the doubly labelled 
water technique are discussed further in the relevant chapter. 
3.8.1.1 Isotope administration and sampling 
The isotopes – 99% deuterium oxide (2H2O) and 10% oxygen-18 (H218O) – were 
sourced from Iso-Analytical Limited (Crewe, UK). The samples were analysed for 
water quality and safety at the Quality Control laboratory at Lister hospital prior to 
study use. The multipoint method of sample analysis was followed with the study 
conducted over a 14-day period. 
On the study day (day zero), subjects’ body weight was measured and the dose of 
the isotopes was calculated accordingly. Isotope samples were weighed using a 
Sartorius scale with an accuracy of >0.0001g. Calibration of the scale was carried 
out before every subject. The administered doses were 1.375g/kg body weight of 
10% oxygen-18 and 0.083g/kg body weight of 99% deuterium oxide. 1ml of this 
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sample was retained for analysis and the remaining was ingested. The actual 
administered dose was calculated from the ingested volume. The flask was washed 
out with 2-3 chasers of tap water to ensure that the entire isotope sample was 
ingested. 
Participants were asked to provide a baseline urine sample before the ingestion of 
the isotope. They were provided verbal and written instructions on urine sample 
collection during the 14-day period. They were asked to collect daily urine samples, 
beginning 24 hours after the sample administration, in a sterile universal sample pot 
and were asked to write the date and time of urine collection on the sample bottle. 
Subjects were asked to store the samples in the fridge or freezer for the duration of 
the study period. At the end of the 14-day period, all the samples were collected and 
frozen at -20°C in the research facility at Lister hospital until analysis. 
3.8.1.2 Sample Analysis 
The urine samples were analysed by Iso-Analytical Limited using a continuous flow 
isotope ratio mass spectrometry. Samples from days 1, 8 and 14 were used for 
analysis. If there was no sample collected on these days, then the closest sample to 
the missed sample was used. Standard laboratory water – calibrated against Vienna 
Standard Mean Oxygen Water and Standard Light Atlantic Precipitation – was used 
as the reference for analysis. Table 3-2 shows the list of standard notation as 
recommended by the International Atomic Energy Agency (Prentice, 1990). This 
notation has been used in the analysis of the samples. 
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Table 3-2: Standard Nomenclature recommended by IAEA 
Group Name Standard Notation 
Isotopes 
Oxygen O or 16O and 18O 
Hydrogen H or 1H 
Deuterium 2H 
Dosing Variables 
Dose of 18O administered AO 
Dose of 2H administered AD 
Dose diluted for analysis (18O) aO 
Dose diluted for analysis (2H) aD 
Pool sizes 
Pool size measured using 18O NO 
Pool size measured using 2H ND 
Removal rate constants 
Rate constant for 18O KO 
Rate constant for 2H KD 
Production rate 
Uncorrected production rate r 
Corrected production rate r’ 
Production rate of CO2 rCO2 
Enrichment 
Parts per million ppm 
Atom percent excess ‰ 
Isotope enrichment relative to a 
standard 
δ 
International standard 
isotope reference waters 
Vienna-Standard Mean Oxygen 
Water 
V-SMOW 
Standard Light Antarctic 
Precipitation 
SLAP 
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3.8.1.3 Calculation of Total Energy Expenditure 
TEE calculation was carried out as set out in the report by the International Atomic 
Energy Agency (Prentice, 1990) and published literature by Speakman (Speakman, 
1997). The isotopic enrichment in the sample was expressed as a fraction of the 
initial dose facilitating further calculation for TEE. As the administered dose was 
diluted in 100ml of water, the following formula was used to calculate fractional 
enrichment. 
𝟕     𝑭𝒓𝒂𝒄𝒕𝒊𝒐𝒏𝒂𝒍  𝑬𝒏𝒓𝒊𝒄𝒉𝒎𝒆𝒏𝒕 =    𝜹𝒑𝒐𝒔𝒕 −   𝜹𝒑𝒓𝒆𝜹𝒅𝒐𝒔𝒆 −   𝜹𝒕𝒂𝒑   ×   𝟏𝟖.𝟎𝟐  ×  𝒂𝑾  ×  𝑨  
where W is the amount of water used to dilute the dose (in grams), A is the dose 
administered to the participant (grams) and a is the mass of the dose diluted for 
analysis (grams). 
For each isotope, a linear regression plot of the natural logarithm of fractional 
enrichment versus time was generated. The intercept and the slope of the regression 
line was calculated which was used to estimate the pool size and rate constant as 
below. 
𝟖     𝑷𝒐𝒐𝒍  𝑺𝒊𝒛𝒆   𝑵   𝒎𝒐𝒍𝒆𝒔 =    𝟏𝑰𝒏𝒕𝒆𝒓𝒄𝒆𝒑𝒕 𝟗     𝑹𝒂𝒕𝒆  𝒄𝒐𝒏𝒔𝒕𝒂𝒏𝒕   𝑲   𝒅𝒂𝒚𝒔!𝟏 = 𝒔𝒍𝒐𝒑𝒆 
where N denotes NO or ND and K denotes KO and KD for the respective isotopes. 
Both oxygen and hydrogen distribute to a varying extent in pools other than body 
water with hydrogen distributing more than oxygen in other pools. To adjust for this, 
a correction factor was applied to the calculated pool sizes as below. 
𝟏𝟎     𝑪𝒐𝒓𝒓𝒆𝒄𝒕𝒆𝒅  𝑵𝑫 =    𝑵𝑫𝟏.𝟎𝟒𝟐𝟕 
𝟏𝟏     𝑪𝒐𝒓𝒓𝒆𝒄𝒕𝒆𝒅  𝒑𝒐𝒐𝒍  𝒔𝒊𝒛𝒆   𝑵 =   𝑪𝒐𝒓𝒓𝒆𝒄𝒕𝒆𝒅  𝑵𝑫 +𝑵𝑶𝟐  
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Total body water was then calculated from the following equation. 𝟏𝟐     𝑻𝒐𝒕𝒂𝒍  𝑩𝒐𝒅𝒚  𝑾𝒂𝒕𝒆𝒓 = 𝑵  ×  𝟏𝟖.𝟎𝟏𝟓𝟐𝟖  (𝒈/𝒎𝒐𝒍) 
The corrected production rate of carbon dioxide is then calculated from the following 
equation published by Speakman(Speakman, Nair, & Goran, 1993). 
𝟏𝟑   𝒓′𝑪𝑶𝟐 =    𝑵𝟐.𝟏𝟗𝟔   ×   𝑲𝑶 −    𝟏.𝟎𝟒𝟐𝟕  ×  𝑲𝑫  
Total energy expenditure was calculated using the following Weir equation. 
𝟏𝟒     𝑻𝒐𝒕𝒂𝒍  𝑬𝒏𝒆𝒓𝒈𝒚  𝑬𝒙𝒑𝒆𝒏𝒅𝒊𝒕𝒖𝒓𝒆 =   𝒓′𝑪𝑶𝟐  ×  𝟐𝟐.𝟒  ×    𝟏.𝟏+    𝟑.𝟗𝑹𝑸  
where RQ is the respiratory quotient measured by indirect calorimetry 
3.9 Assessment of Whole Body Protein Turnover 
3.9.1 Leucine Isotope method 
There are broadly two different methods to measure whole body protein turnover - 
precursor method and the end-product method. Both methods involve administering 
a non-radioactive, stable isotope of an amino acid either intravenously or orally and 
sampling body fluids (plasma or urine) to measure isotopic enrichment which is then 
used to calculate protein turnover. The major difference between the methods is the 
site of sampling and the product of protein metabolism that is sampled. In the 
precursor method, the isotope is administered intravenously and timed plasma 
samples are obtained to measure the isotopic enrichment of the administered amino 
acid itself or its immediate transaminated product. The end-product method involves 
administering amino acid isotope intravenously or orally. However, what is measured 
is the isotopic enrichment of the ingested amino acid in the end-product of the 
protein metabolism – urea or ammonia – and not the amino acid itself as in the 
precursor method. Both these methods have different set of assumptions in their 
methodologies. 
In order to study whole body protein turnover (WBPT), the various methods and 
amino acid isotopes available were examined and the method that would be 
appropriate for subjects with advanced kidney disease was chosen. The 
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disadvantages of the other methods are explained in the protein turnover study 
chapter. In our study, WBPT was measured with the use of a carbon-labelled stable 
isotope of leucine (13C – leucine). There are a number of advantages in using leucine 
for WBPT study. Firstly, leucine is an essential amino acid and hence, is not 
synthesised de novo in the body. This means that apart from that produced as a 
result of protein breakdown, the only source of leucine would be that present in the 
sample administered the dose of which can be measured. Secondly, the fate of 
ingested leucine is well known and fairly straight-forward. Leucine in the precursor 
pool (plasma and intracellular stores) is either taken up for protein synthesis or 
oxidised resulting in the release of carbon dioxide. As the isotope is carbon labelled 
(13C), the amount of oxidation in steady state can be measured through the isotopic 
enrichment of carbon dioxide (13CO2) in the expired air. Thirdly, with an appropriate 
priming of the bicarbonate pool and a priming dose of leucine, the study can be 
completed in a relatively short time of 2-3 hours. The schema of leucine turnover is 
illustrated in Figure 3-2. 
 
 
Figure 3-2: Model of Leucine Turnover 
 
In the steady state, the rate of appearance of leucine (Ra) into plasma from protein 
breakdown and intake is equal to the rate of disappearance (Rd) of leucine from 
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plasma through protein synthesis and oxidation. This rate is denoted as the leucine 
flux (Q). Calculation of the flux is explained in a later section. 
3.9.1.1 Isotope administration and sampling 
The isotope samples – l-13C-leucine (99% atom excess) and 13C-sodium bicarbonate 
– were sourced from Sigma-Aldrich Company Limited (Dorset, UK). The providers 
conduct sterility and pyrogen testing of the samples. A copy of the test certificate is 
shown in Appendix F. The samples were provided in sterile, screw top ampoules in a 
powder form which is reconstituted with 0.9% sodium chloride to the desired volume. 
Subjects were given verbal and written instructions for the study. They were asked to 
avoid strenuous physical activity for the three days preceding the study day. They 
were also asked to maintain a food diary and were advised to avoid protein 
supplements and excessive protein intake for those three days. They were also 
asked to attend the research facility in empty stomach after overnight fasting on the 
study day. Participants’ body weight was measured to determine the dose to be 
administered. A cannula was inserted into the antecubital fossa for the isotope 
infusion. For haemodialysis patients, their existing vascular access (arteriovenous 
fistula or tunnelled dialysis catheter) was used for obtaining blood samples for 
analysis. For blood sampling in CKD patients, an intravenous cannula was inserted 
in the hand on the other side to that used for infusion as recommended by published 
literature (Waterlow, 2006). The required dose of the sodium bicarbonate isotope 
was reconstituted in 10ml of 0.9% sodium chloride solution and the leucine isotope in 
50ml of 0.9% sodium chloride solution. 0.5ml of the leucine isotope infusate was 
removed and stored for analysis of isotopic enrichment. A bolus dose of 0.11mg/kg 
body weight of 13C-sodium bicarbonate and 1mg/kg body weight of l-13C-leucine 
were administered. Following the bolus dose, leucine isotope infusion was started at 
a dose of 1mg/kg/hr and continued for 3 hours. At the end of the study period, the 
cannulae were taken out and subjects were given a meal to eat. 
A baseline blood sample (2.5ml) was collected before the injection of the bolus dose. 
A breath sample was also obtained at the same time by asking the subjects to blow 
into Exetainer® tube designed for expired air collection. Thereafter, both blood and 
breath samples were collected every 30 minutes for the first 2 hours of the infusion 
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and every 15 minutes between 2 and 3 hours. Subjects were not allowed to eat or 
drink during this period. 
Indirect calorimetry was also performed as explained in section 3.6.2 at the start of 
the study and around 2 hours after the start of the infusion. This was carried out to 
obtain direct measurements of REE and VCO2 (carbon dioxide consumption rate) 
which was used for calculation of protein turnover as explained below. 
3.9.1.2 Sample Analysis 
Breath samples obtained were stored in the airtight Exetainer® bottles at room 
temperature. Blood samples were collected in Lithium-Heparin coated (with gel 
separator) bottles. After collection, the blood samples were centrifuged at a speed of 
3000 revolutions per minute for 10 minutes. Plasma obtained from centrifugation was 
stored in Microtainer® bottles at -20°C. 
Plasma and breath samples were analysed at the Department of Metabolic and 
Molecular Physiology, University of Nottingham, Royal Derby Hospital Campus using 
isotope ratio mass spectrometry. The plasma samples were transported in the frozen 
state from Lister hospital. 
3.9.1.3 Calculation of Whole Body Protein Turnover 
WBPT was calculated as per previous published literature (Lim et al., 1998). Leucine 
taken up for oxidation intracellularly is transaminated into α-ketoisocaproate (α-KIC). 
Measurement of α-KIC enrichment in plasma has been shown to be a better marker 
of intracellular leucine enrichment compared to direct measurement of leucine in 
plasma (Matthews et al., 1982). Hence, plasma enrichment of α-KIC was measured 
in the samples. As explained in the earlier section 3.9.1, leucine and α-KIC flux (Q) 
was calculated using the following formula. 
𝟏𝟓     𝑸 =    𝑰𝒊  ×    𝜺𝒊𝜺𝒑 − 𝟏  
where Ii is the infusion rate of the isotope, εi is the isotopic enrichment of leucine in 
the infusate and εp is the enrichment of leucine or α-KIC in the plasma. 
 74 
The rate of carbon dioxide release (F13CO2) from tracer leucine oxidation will be 
calculated as follows: 
𝟏𝟔     𝑭𝟏𝟑𝑪𝑶𝟐 =    𝑽𝑪𝑶𝟐  ×  𝜺𝑪𝑶𝟐𝑩𝑾   ×    𝟔𝟎  ×  𝟒𝟏.𝟔𝟏𝟎𝟎  ×  𝟎.𝟕𝟕  
where VCO2 is CO2 production rate (ml/min, as measured by indirect calorimetry), * 
εCO2 is 13CO2 enrichment in the expired breath at isotopic steady-state and BW is 
body weight. The constants 60 (min/hr) and 41.6 (µmol/ml) convert VCO2 from 
ml/min to µmol/hr. The factor 100 changes moles% enrichment from a percent to a 
fraction and the factor 0.77 accounts for the fraction of 13CO2 produced by [l -13C] 
leucine oxidation released from the bicarbonate pool into the expired gas. 
The rate of leucine oxidation (O) is calculated as: 
𝟏𝟕     𝑶 =   𝑭𝟏𝟑𝑪𝑶𝟐  ×    𝟏𝜺𝒑 −    𝟏𝜺𝒊   ×  𝟏𝟎𝟎 
In a steady state condition, the rate of appearance of leucine in plasma should be 
the same that of leucine disappearance. This is expressed as the mass balance 
relationship below. 𝟏𝟖     𝑸 = 𝑺+ 𝑶 = 𝑩+ 𝑰 
where Q is the flux, S is the synthesis rate, O is the oxidation rate, B is the 
breakdown rate and I is the rate of intake. The whole body protein synthesis and 
breakdown rate can be calculated using the following formulae. 𝟏𝟗     𝑺 = 𝑸− 𝑶 𝟐𝟎     𝑩 = 𝑸− 𝑰  
3.10 Assessment of body composition and body water 
3.10.1 Watson formula 
Total body water (TBW) estimation was carried out using the below formula 
published by Watson et al(Watson et al., 1980). 
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For males: 𝑻𝑩𝑾   = 𝟐.𝟒𝟒𝟕− 𝟎.𝟎𝟗𝟓𝟏𝟔  ×  𝑨𝒈𝒆 +    𝟎.𝟏𝟎𝟕𝟒  ×  𝑯𝒆𝒊𝒈𝒉𝒕 +    𝟎.𝟑𝟑𝟔𝟐  ×  𝑾𝒆𝒊𝒈𝒉𝒕  
For females: 𝑻𝑩𝑾   = −𝟐.𝟎𝟗𝟕+ 𝟎.𝟏𝟎𝟔𝟗  ×  𝑯𝒆𝒊𝒈𝒉𝒕 +    𝟎.𝟐𝟒𝟔𝟔  ×  𝑾𝒆𝒊𝒈𝒉𝒕  
where TBW is expressed in Litres, age in years, height in cm and weight in kg 
3.10.2 Bio-impedance analysis 
Whole-body Bioimpedance analysis was carried out in many of the studies in this 
thesis using Inbody 720® (Biospace Company Limited, Seoul, Korea). Participants 
were asked to stand on the base platform of the analyser with a hand-held tactile 
electrode on each side for 2 minutes. The base platform also had tactile electrodes 
for heels and toes. The device measures body composition using multi-frequency 
currents. The outputs obtained from the device are intracellular-, extracellular- and 
total body water, skeletal muscle mass, fat-free and fat mass besides many other 
variables. 
3.11 Demographic and clinical data 
Demographic and clinical data were collected using respective renal electronic 
databases at the study sites. All data collected were anonymised using respective 
study ID numbers. The data collected included demographic and body size 
parameters (age, gender, ethnicity, height, weight) and clinical parameters (blood 
pressure, pulse rate). Height was measured using a wall-mounted stadiometer. 
Weight was measured using calibrated weighing scales used routinely in clinical 
practice. Besides these, parameters pertaining to dialysis adequacy were also 
obtained from the renal databases where appropriate. 
3.12 Assessment of extra-renal comorbidities 
Assessment of extra-renal comorbidity was carried out in two ways – information 
collected through a novel self-report comorbidity questionnaire and that from renal 
databases. Information obtained from medical records was used to calculate the 
Charlson Comorbidity Index as previously described (Charlson, Pompei, Ales, & 
MacKenzie, 1987). 
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3.12.1 Self-report Comorbidity Questionnaire 
In order to facilitate comorbidity data collection in a large scale prospective study, a 
self-report comorbidity questionnaire was designed. The development and reliability 
of this questionnaire in predicting short-term survival is discussed in detail in a 
subsequent chapter. Seven medical conditions that are commonly prevalent in 
patients with ESRD were chosen to be included in the questionnaire. The medical 
conditions were expressed in a plain language that could be understood by 
individuals without any prior medical knowledge. Also, participants had the option of 
adding 3 additional medical conditions other than the ones that were listed. For each 
of the seven listed conditions and the additional ones the participants could add, they 
were asked 3 questions – whether they had the disease and if they did, whether they 
were receiving any treatment and whether the disease was limiting their activities. 
Participants were asked to tick the respective box if the answer to the corresponding 
question was in the affirmative. The questionnaire took about 2-3 minutes for 
participants to complete. A Composite Self-report Comorbidity Score (CSCS) was 
calculated from the questionnaire (see chapter 5 for scoring methods) which was 
used in subsequent survival analysis. 
3.13 Analysis of the accelerometer data 
In the study involving direct measurement of physical activity, the accelerometer 
(GENEActiv) data was downloaded onto a computer for further analysis. Individual 
raw activity readings were aggregated to 1-minute epochs and provided in the form 
of the signal magnitude vector (SVM) as per previous published literature (Esliger et 
al., 2011). The resulting SI unit for the outcome variable was g-minutes (g-min). 
Validated algorithms were used to calculate time spent in different activity states 
(sedentary, light, moderate and vigorous - intensity PA). 
3.14 Blood analyses 
In the cross-sectional study of physical activity measurement, the following 
parameters were measured in the serum – urea and electrolytes, full blood count 
and C-reactive protein. 
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For the protein turnover study, plasma samples were analysed for isotopic 
enrichment of α-KIC. Blood samples were collected in Lithium-Heparin coated (with 
gel separator) bottles. After collection, the blood samples were centrifuged at a 
speed of 3000 revolutions per minute for 10 minutes. Plasma obtained from 
centrifugation was stored in Microtainer® bottles at -20°C. Plasma samples were 
analysed by Dr Ken Smith at the Department of Metabolic and Molecular Physiology, 
University of Nottingham, Royal Derby Hospital Campus using isotope ratio mass 
spectrometry. 
3.15 Statistical methods 
An explanation of specific statistical methods used is included in the relevant 
chapters. Statistical analysis was performed using SPSS v19. A general overview of 
the methods employed is mentioned below. A p-value of < 0.05 was considered 
significant in all the analyses. 
3.15.1 Regression techniques 
Linear, non-linear and logistic regressions were used when appropriate to examine 
the relationship between different variables as explained in relevant chapters. 
3.15.2 Univariate Survival Analyses 
Univariate survival analysis was carried out using Kaplan-Meier method in the 
prospective survival outcomes study and also in examining the predictive value of 
the self-report comorbidity questionnaire with regards to short-term survival. 
3.15.3 Multivariate Survival Analyses 
Multivariate survival analysis was carried out using Cox proportional hazard model 
for the two studies mentioned in the above section. Some variables such as age, 
residual renal function and comorbidity score were dichotomised in certain analyses 
and these are explained in relevant sections as are the other variables that were 
included in the models. 
 78 
 Chapter 4 
4. Body Composition, Energy Metabolism and Uraemic Toxin 
Generation 
 
4.1 Introduction 
Uraemic toxins accumulate in the blood and tissues in kidney failure and exert 
adverse effects on various organ systems (Au-Yeung et al., 2006; Glorieux, Helling, 
et al., 2004; D'Hooge et al., 2003). To maintain life in advanced kidney failure, these 
toxins need to be removed by dialysis. Patients with end-stage kidney disease have 
a wide range of clinical problems resulting from loss of kidney function and 
management of this need to focus on all the clinical manifestations of kidney failure. 
Hence, judging the minimum adequate dose of dialysis based on clearance of 
uraemic toxin alone is difficult. As the primary function of dialysis is to clear 
metabolic wastes, it might be expected that the minimum requirements for adequate 
dialysis would be related to the rate of metabolic waste production i.e. metabolic 
rate. But, this is not the basis of current clinical practice. 
Haemodialysis adequacy is currently measured by a dimensionless parameter Kt/V, 
where K is the dialyser urea clearance, t is the duration of a single dialysis session 
and V is the Urea distribution volume (or Watson Volume) which is equal to the total 
body water. As discussed in Chapter 2, this practice is based on the assumption that 
uraemic toxin production is a function of its distribution volume and hence, it is not 
normalised based on the generation rate of the toxin (urea in this instance). This may 
have a number of unintended consequences. 
The HEMO study showed survival benefit for women when given higher dialysis 
doses compared to men (Depner et al., 2004). A number of other studies have also 
shown an inverse relationship between body size and mortality in haemodialysis 
patients (Johansen et al., 2004; Port et al., 2002; Leavey et al., 2001; Leavey et al., 
1998). This phenomenon of “reverse epidemiology” is discussed in detail in section 
2.2.3. The underlying reason for the survival difference may be related to differences 
in body composition and metabolic activity (Huang et al., 2010; Spalding et al., 2008; 
Beddhu et al., 2003). As a result, some authors have suggested alternative 
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parameters that could be used for normalising the dialysis dose as discussed in 
chapter 2 (Daugirdas, Levin, et al., 2008; Spalding et al., 2008). 
Metabolic rate, expressed as resting energy expenditure (REE), is the sum total of all 
the metabolic activities at rest and as such, reflects the rate of metabolic waste 
production. In addition, any physical activity is expected to contribute to metabolic 
waste generation and for this reason, total energy expenditure (TEE) – comprised of 
REE, physical activity related energy expenditure and the thermic effect of food – 
may be a better indicator of total uraemic toxin generation. Body composition can be 
broadly grouped into two compartments – Fat-free mass (FFM) and adipose tissue 
(fat) mass. Adipose tissue contributes only a minor fraction to the metabolic activity 
at rest. An important component of FFM is the High Metabolic Rate Organ (HMRO) 
compartment. HMRO compartment comprises of liver, kidneys, spleen, heart and 
brain and has significantly higher metabolic rate compared with other compartments. 
The combined mass of these organs (HMRO mass) and FFM has been shown to 
correlate closely with REE (Gallagher et al., 1998). In order to replace the current 
dialysis scaling parameter (Watson Volume) with any of these parameters, it is 
important to understand how these parameters relate to metabolic waste production. 
No studies to date have examined the relationship between these parameters and a 
specific marker of uraemic toxin generation. 
There is considerable debate as to the choice of an ideal uraemic toxin marker. Urea 
was chosen as the marker for small solute toxin generation in this study for the 
following reasons. The current adequacy target for dialysis is based on urea 
clearance. Urea clearance by dialysis has been shown to correlate with patient 
survival in HD patients (Bloembergen et al., 1996; Owen et al., 1993). Urea 
generation rate (G) is an accepted surrogate marker of small solute uraemic toxin 
generation and can be calculated through formal urea kinetic modelling. 
The primary aim of the study was  
• To examine the relationship between body composition and energy 
expenditure and uraemic toxin generation 
• To identify predictors of G in haemodialysis patients 
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The experimental hypotheses for this study were that these metabolic parameters – 
REE, TEE, FFM and HMRO mass – have a closer relationship with uraemic toxin 
generation compared to Watson Volume and that one or more of these factors may 
determine uraemic toxin generation better than Watson Volume. 
This was a retrospective study conducted from an existing dataset. Patient 
recruitment and the study assessments were carried out for another study as part of 
Dr Vilar’s PhD (Dr Enric Vilar, PhD, University of Hertfordshire – degree awarded 
Feb 2012) at Lister Hospital. The modelling of urea generation rate and the study 
results shown here are carried out as part of this study and have not been reported 
in Dr Vilar’s PhD previously. 
4.2 Methods 
4.2.1 Ethical Review 
The study was approved by the Essex Research Ethics Committee (Ref: 
08/H0301/86). All study participants gave written informed consent at the start of the 
study. 
4.2.2 Study Design 
This was a cross sectional study of 166 haemodialysis patients. All study participants 
underwent a comprehensive metabolic analysis along with questionnaire-based 
assessment of physical activity. The data obtained was used to examine the 
relationship between energy expenditure variables and urea generation rate. 
4.2.3 Study Population 
A total of 166 chronic HD patients older than 18 years of age and have been 
established on HD programme for more than 3 months were recruited. Exclusion 
criteria included patients with active infection, untreated thyroid dysfunction, hospital 
admission in the previous month, recent respiratory infection, treated tuberculosis in 
the previous 12 months, a history of infection with hepatitis B, C or HIV, and those 
with amputated limbs. 
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4.2.4 Study Assessments 
The following data was collected on all patients. 
4.2.4.1 Anthropometric Measurements 
Demographic and anthropometric measurements were collected as explained in 
section 3.11. Height and weight were measured using calibrated scales. Body Mass 
Index (BMI), Body surface area (BSA) using Haycock formula (Haycock, Schwartz, & 
Wisotsky, 1978) and Watson volume (Watson et al., 1980) were calculated using this 
data. 
4.2.4.2 Dialysis Data 
Parameters required for Urea Kinetic Modelling to estimate Urea Generation (G) and 
eKt/V were collected. These included pre- and post-dialysis blood urea levels, 
interdialytic urine collection for estimation of urea clearance, dialyser characteristics, 
blood and dialysate flow rates, ultrafiltration volume and dialysis session length. 
4.2.4.3 Resting Energy Expenditure Measurement 
Measurement of REE was carried out as explained in the General Methodology 
section 3.6.2. All participants were given written and verbal instructions to be 
followed prior to the procedure. 
4.2.4.4 Physical Activity Assessment and estimation of Total Energy Expenditure 
All study participants completed the Stanford 7-day recall questionnaire. Total 
energy expenditure was calculated from the questionnaire data in conjunction with 
measured REE as explained in general methodology chapter (section 3.7.2.2) using 
equation (5). 
4.2.4.5 Body Composition Analysis 
Bioimpedance was performed using a Xitron Hydra 4200 in whole body continuous 
recording mode. Adhesive electrodes were placed on the hand and foot and the data 
was recorded over a period of five minutes at rest. Intracellular (ICW) and 
extracellular water (ECW) volume was obtained from the bioimpedance. Fat-free 
mass (FFM) was calculated as shown in the following section. 
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4.2.4.6 Urea Kinetic Modelling 
Solute Solver (Daugirdas, Depner, et al., 2009) is a formal urea kinetic modelling 
software. It models a dialysis session based on specific dialysis parameters that are 
input into the system. The dialysis data collected as mentioned above was used to 
model the dialysis session. The software was used to calculate 2-pool urea 
generation rate (G) and Standard Kt/V besides many other outcome variables. 
4.2.5 Calculation of Study-related Parameters 
4.2.5.1 Body Size Parameters 
The equations used for calculation of Body mass index (BMI) and BSA (Haycock 
equation) is shown below. 
𝑩𝒐𝒅𝒚  𝑴𝒂𝒔𝒔  𝑰𝒏𝒅𝒆𝒙   𝑩𝑴𝑰 =   𝑾𝒆𝒊𝒈𝒉𝒕   𝒌𝒈𝑯𝒆𝒊𝒈𝒉𝒕   𝒎 𝟐  
𝑩𝒐𝒅𝒚  𝑺𝒖𝒓𝒇𝒂𝒄𝒆  𝑨𝒓𝒆𝒂   𝑩𝑺𝑨 = 𝟎.𝟎𝟐𝟒𝟐𝟔𝟓  ×  𝑾𝒆𝒊𝒈𝒉𝒕   𝒌𝒈 𝟎.𝟓𝟑𝟕𝟖  ×  𝑯𝒆𝒊𝒈𝒉𝒕   𝒄𝒎 𝟎.𝟑𝟗𝟔𝟒 
Watson Volume was calculated using Watson equation explained in the general 
methodology chapter (section 3.10.1). 
4.2.5.2 HMRO mass 
HMRO mass is the combined mass of brain, heart, liver, kidneys and spleen. HMRO 
mass was estimated from a previously published model as mentioned below 
(Gallagher et al., 2006). 
𝑯𝑴𝑹𝑶  𝒎𝒂𝒔𝒔 = 𝟏.𝟐𝟐𝟑 − 𝟎.𝟎𝟎𝟖  ×  𝑨𝒈𝒆 + 𝟎.𝟖𝟎𝟏  ×  𝑯𝒆𝒊𝒈𝒉𝒕 + 𝟎.𝟎𝟏𝟔  ×  𝑾𝒆𝒊𝒈𝒉𝒕+ 𝟎.𝟑𝟎𝟓  ×  𝑺𝒆𝒙 − 𝟎.𝟐𝟓𝟏  ×  𝑹𝒂𝒄𝒆  
where Age is in years, Height in metres and Weight in kilograms; Sex is 0 if female 
and 1 if male; Race is 0 if White and 1 if Black 
This equation has been used reliably in a study of haemodialysis patients exploring 
the relationship between body composition and survival (Kotanko & Levin, 2007). 
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4.2.5.3 Fat-free mass 
Fat-free mass was calculated from the Intracellular (ICW) and Extracellular fluid 
volume (ECW) measured by bioimpedance as follows. 
𝑭𝒂𝒕 − 𝒇𝒓𝒆𝒆  𝒎𝒂𝒔𝒔   𝑭𝑭𝑴 =    𝒅𝑰𝑪𝑾  ×  𝑰𝑪𝑾 + 𝒅𝑬𝑪𝑾  ×  𝑬𝑪𝑾  
where dICW and dECW are the densities of ICW and ECW – 1.521 and 1.106 – 
respectively. 
4.2.6 Statistical Analysis 
Normally distributed data are presented as mean ± standard deviation and non-
normally distributed data as median (inter-quartile range). The differences between 
means were tested using Student’s t-test and of differences between medians by 
Mann-Whitney U-test. Analysis of variance with Bonferroni adjustment was carried 
out to test the differences among multiple group means. Linear regression was used 
to examine the relationship between variables. Multiple regression analysis was 
used to determine the predictors of G. A p-value of <0.05 was assumed to indicate 
statistical significance. 
4.3 Results 
4.3.1 Baseline Demographics 
A total of 166 patients were studied. The demographic, body size and dialysis-
related characteristics are given in Table 4-1. 
All body size parameters except BMI were significantly greater in men than women. 
There were no biochemical or haematological gender differences. eKt/V, but not 
Standard Kt/V, was slightly higher in women than men. 
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Table 4-1: Demographic, Body size and Dialysis characteristics of participants 
Values expressed as mean ± SD for normally distributed data and median (*interquartile 
range) for non-normally distributed data. Kt/V – Urea clearance normalised to total body 
water. 
 All patients 
(n = 166) 
Males 
(n = 97) 
Females 
(n = 69) p-value 
Age (years) 62.0 ± 15.5 60.8 ± 15.8 63.6 ± 15.1 NS 
Diabetes (%) 27 30 23 NS 
Ischaemic Heart Disease (%) 31 39 19 0.005 
Weight (kg) 74.0 ± 19.1 79.4 ± 18.2 66.4 ± 17.7 <0.001 
Height (m) 1.68 ± 0.10 1.74 ± 0.07 1.60 ± 0.08 <0.001 
Body mass index (kg/m2) 26.5 ± 6.0 26.7 ± 5.7 26.3 ± 6.5 NS 
Body surface area (m2) 1.84 ± 0.25 1.98 ± 0.26 1.74 ± 0.26 <0.001 
Watson V (L) 38.0 ± 8.0 42.5 ± 6.6 31.7 ± 4.8 <0.001 
Blood urea (mmol/L) 23.0 ± 6.3 22.4 ± 5.8 23.9 ± 6.9 NS 
Serum creatinine (µmol/L) 865 ± 258 895 ± 272 825 ± 232 NS 
Bicarbonate (mmol/L) 23.2 ± 2.8 23.3 ± 2.6 23.1 ± 3.0 NS 
Haemoglobin (g/dL) 11.4 ± 1.2 11.4 ± 1.1 11.4 ± 1.3 NS 
High CRP (>5 mg/L) (%) 50 51 48 NS 
Haemodiafiltration (%) 74 84 61 0.002 
Blood flow rate (Qb - ml/min) 330 ± 65 347 ± 62 307 ± 64 <0.001 
Duration of session (Td - ml/min) 191 ± 36 197 ± 38 182 ± 33 0.007 
Residual urea clearance* 
(ml/min) 0.6 (2.0) 0.8 (2.4) 0.5 (1.4) NS 
Equilibrated Kt/V (total) 1.41 ± 0.32 1.36 ± 0.28 1.48 ± 0.36 0.029 
Total Standard Kt/V 2.47 ± 0.36 2.44 ± 0.32 2.51 ± 0.39 NS 
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4.3.2 Energy expenditure and Urea Generation Rate 
Table 4-2 shows energy expenditure and urea generation rate data for the study 
participants. Both REE and TEE were low in women. Mean urea generation rate (G) 
was 4.3 ± 1.6 mg/min in women and 5.5 ± 2.2 mg/min in men (p < 0.001). TEE, but 
none of the other parameters, was lower in those with ischaemic heart disease (2135 
± 381 vs. 2304 ± 647 kcal/day; p = 0.039). REE (1651 ± 337 vs. 1523 ± 346 
kcal/day; p = 0.035) and HMRO mass (3.59 ± 0.51 vs. 3.38 ± 0.45 kg; p = 0.012) 
were higher in diabetic patients. This was likely related to the higher body weight in 
diabetic patients (81.1 ± 20.9 vs. 71.4 ± 17.7 kg; p = 0.003). 
Table 4-2: Energy Expenditure and Urea Generation Rate values 
 
All patients 
(n = 166) 
Males 
(n = 97) 
Females 
(n = 69) p-value 
Resting Energy 
Expenditure (kcal/day) 1588 ± 347 1679 ± 329 1387 ± 298 <0.001 
Mean daily MET 1.44 ± 0.12 1.45  ± 0.13 1.42 ± 0.11 0.237 
Exercise related Energy 
Expenditure (kcal/day) 689 ± 286 761 ± 315 588 ± 201 <0.001 
Total Energy 
Expenditure (kcal/day) 2247 ± 583 2440 ± 590 1976 ± 452 <0.001 
Fat-free mass (kg) 50.0 ± 17.2 56.4 ± 16.9 41.1 ± 13.2 <0.001 
High Metabolic Rate 
Organ mass (kg) 3.4 ± 0.5 3.7 ± 0.3 3.0 ± 0.3 <0.001 
Urea Generation Rate 
(mg/min) 5.03 ± 2.06 5.54 ± 2.19 4.32 ± 1.64 <0.001 
Urea Generation Rate/Kg 
(mg/min/kg) 0.069 ± 0.023 0.070 ± 0.021 0.068 ± 0.027 NS 
 
4.3.3 Factors related to Urea Generation Rate 
We examined the relationship between G and various study parameters which is 
shown in Table 4-3. All parameters except age were significantly correlated. The 
highest correlations were noted for REE (R2 = 0.303), TEE (R2 = 0.333) and fat-free 
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mass (FFM) (R2 = 0.366). The relationship between these three variables and G are 
shown in Figure 4-1 to Figure 4-3. 
 
Table 4-3: Univariate correlations with Urea Generation Rate 
 R2 p-value 
Age 0.012 NS 
Body Mass Index 0.153 <0.0001 
Weight 0.252 <0.0001 
BSA (Haycock formula) 0.257 <0.0001 
Watson Volume 0.286 <0.0001 
High Metabolic Rate Organ Mass 0.256 <0.0001 
Resting Energy Expenditure 0.303 <0.0001 
Exercise related Energy 
Expenditure  0.260 <0.0001 
Total Energy Expenditure 0.333 <0.0001 
Fat Free Mass 0.366 <0.0001 
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Figure 4-1: Relationship between REE and Urea generation rate 
 
 
 
Figure 4-2: Relationship between TEE and Urea generation rate 
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Figure 4-3: Relationship between FFM and Urea generation rate 
 
4.3.4 Gender and Body Size Differences in Urea Generation Rate 
Differences in urea generation rate based on gender and body size are shown in 
Figure 4-4 and Figure 4-5. The body size measure shown in the graph is Body mass 
index (BMI) with the cut-off being the median value. In both cases, the difference in 
G was significant (p < 0.001) with males and heavier individuals having higher levels. 
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Figure 4-4: Gender Differences in Urea Generation Rate 
 
 
Figure 4-5: Body Size Differences in Urea Generation Rate 
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4.3.5 Effect of normalising G to Energy Expenditure 
The effect of normalising G to energy expenditure measures, REE and TEE, was 
explored with regards to the gender and body size differences. Figure 4-6 and Figure 
4-7 shows the gender and body size difference respectively when G was normalised 
to REE. There was no significant difference between the groups in both cases. 
 
Figure 4-6: Differences in G normalised to REE based on Gender 
 
Figure 4-7: Differences in G normalised to REE based on Body Size 
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Similarly, the gender and body size difference when G was normalised to TEE is 
shown in Figure 4-8 and Figure 4-9. As with REE, there was no significant difference 
noted between the groups. 
 
Figure 4-8: Differences in G normalised to TEE based on Gender 
 
 
Figure 4-9: Differences in G normalised to TEE based on Body Size 
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4.3.6 Predictors of Urea Generation Rate 
A number of multivariate regression models to identify independent predictors of G 
were explored. The variables considered were age, sex, weight, BMI, Watson 
Volume (V), HMRO mass, BSA, REE, TEE and FFM. The best fit model is shown in 
Table 4-4. In this model, the only independent predictors of G were TEE and FFM 
and the model accounted for 42% of variance in G (adjusted R2 = 0.415). 
Table 4-4: Multivariate Linear regression model of independent predictors of 
Urea generation rate 
B is the unstandardised regression coefficient. 
 B Standard Error (B) Beta t p-value 
Constant 0.137 0.493  0.277 0.782 
Fat-free mass 
(kg) 0.048 0.009 0.397 5.014 <0.001 
Total energy 
expenditure 0.001 0.000 0.316 3.997 <0.001 
 
4.3.7 Relationship between Urea generation rate and Watson Volume 
The relationship between G normalised to body weight and Watson Volume was 
examined. Gender-specific V was calculated and was categorised with the mean as 
cut-off. There was a negative correlation between V and G/kg in women (R = -0.393; 
p = 0.001) but not in men. Gender differences in G/kg in relation to V are shown in 
Figure 4-10. Women of less than the mean gender-specific V had higher G/kg than 
those with higher V (p = 0.008). No such difference was noted in similarly grouped 
men. 
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Figure 4-10: Relationship between Watson Volume and Urea generation rate 
normalised to body weight 
 
The relationship between V and G normalised to FFM was also explored. G/FFM 
correlated with V in women (R = -0.268; p = 0.026) but not in men. Figure 4-11 
shows the gender differences in G/FFM in relation to V. Again, women of less than 
mean gender-specific V had higher G/FFM although the difference was statistically 
significant only in comparison to men with higher than mean gender-specific V (p = 
0026). 
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Figure 4-11: Relationship between Watson Volume and Urea Generation Rate 
normalised to Fat-free mass 
4.4 Discussion 
This study was designed to explore the relationship between various parameters 
related to energy metabolism and uraemic toxin generation as defined by the urea 
generation rate. The study results show that factors related to energy metabolism – 
REE, TEE and FFM – correlated better with G compared to Watson volume (V). In 
addition, the study explored the independent predictors of G and found that only TEE 
and FFM were significant variables in the model. Moreover, the study also showed 
that small women (with less than mean V) have significantly higher G relative to body 
weight compared to women with higher V. Similar results were obtained when G was 
normalised to FFM, although the statistical significance was only achieved in 
comparison to larger men. These findings are in favour of accepting the experimental 
hypothesis that these metabolic parameters have a closer relationship to uraemic 
toxin generation compared to Watson Volume. 
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Few studies have assessed the relationship between energy metabolism, body 
composition and urea generation rate. Sarkar et al (Sarkar et al., 2006) examined 
the relationship between FFM, HMRO mass and protein catabolic rate, a derivative 
of G. The study found that HMRO mass was the only independent predictor of G. It 
is worth noting that REE was estimated and not measured and the relationship 
between energy expenditure and PCR was not explored. This is the first study to 
date to have reported the relationship between measured REE and urea generation 
rate. The relationship between TEE, and thereby physical activity, and G had not 
been explored in any previous studies involving HD patients. Similarly, FFM has not 
been examined in relation to urea generation rate previously. This study has 
examined all these parameters in a single cohort which helps to identify the best 
parameter to predict uraemic toxin generation. 
The current study data also showed that TEE and G were closely correlated and that 
Exercise related Energy Expenditure correlated significantly with G. TEE was also an 
independent predictor of G in multivariate analysis. TEE comprises of REE, physical 
activity related energy expenditure and thermic effect of food. The finding that TEE 
correlates better than REE to G implies that physical activity may contribute to 
uraemic toxin generation. However, this has not been demonstrated in clinical 
studies to date. It could be argued that the relationship between physical activity and 
G relates to the dietary habits of physically active individuals. Physically active 
patients may have increased dietary protein intake resulting in increased net protein 
catabolism thereby having an impact on G. An alternative explanation is that physical 
activity contributes significantly to small solute uraemic toxin generation - patients 
with habitually high levels of physical activity tending to have increased production 
and mobilisation of metabolic waste products, and increased small solute uraemic 
toxin generation. These possibilities are not mutually exclusive – in either case 
dialysis requirements would be higher. 
As discussed in Chapter 2, there is an inverse relationship between body size and 
mortality risk in haemodialysis patients in that obese patients have better survival 
which is in contrast to the general population. It has been suggested that the likely 
reason for this phenomenon is that uremic toxin generation per unit of body mass is 
greater in patients with low body mass who also tend to have reduced body water 
volumes. As a result, the concentration of uremic toxins in body fluids is greater in 
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small subjects implying higher requirements for dialysis (Kotanko et al., 2007). This 
implies that a metabolic parameter which inherently corrects for gender and body 
size differences may provide equivalent dialysis doses to all patients. In this context, 
the study data shows that no gender and body size differences were apparent when 
G was normalised to REE or TEE. This implies that differences in energy metabolism 
may be implicated in the gender and body size differences in relation to G. 
The study also explored whether there is a need for higher dialysis doses to specific 
subgroups based on gender and body size. It demonstrates that small women have 
relatively higher urea generation rate irrespective of whether G is normalised to body 
weight or FFM. Though previous studies have shown that low-weight patients have 
relatively higher HMRO mass (Kotanko & Levin, 2007; Sarkar et al., 2006), this is the 
first study demonstrating the link between gender, body size and uraemic toxin 
generation. 
4.5 Limitations 
The study is limited by its cross-sectional nature and its relatively small sample size. 
In addition, the study only considers the factors influencing urea generation. The 
generation rate of other uraemic toxins may be influenced by a different set of 
variables. The study did not collect information regarding dietary protein intake of 
study subjects which would have enabled the investigation of the influence of 
physical activity on G independent of protein catabolism. Finally, the physical activity 
data was collected through a recall questionnaire, which enquires about physical 
activity in the preceding 7 days. Recall bias is therefore a potential confounder of the 
physical activity data. 
4.6 Conclusion 
In conclusion, the study data has demonstrated that REE, TEE and FFM are closely 
related to urea generation in HD patients and that FFM and TEE are independent 
predictors of urea generation rate. These associations may imply that smaller 
women have relatively higher small solute uraemic toxin production and hence may 
require relatively higher dialysis doses, as has been previously suggested (Ramirez 
et al., 2012; Spalding et al., 2008). Patients with high physical activity levels may 
also have higher requirements for dialysis. It is worth exploring the applicability of 
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these metabolic factors in deciding minimum dialysis adequacy targets. The 
relationship of physical activity to uraemic toxin generation also requires further 
exploration in prospective clinical studies. 
Elements of this chapter are reproduced with permission from International Society for 
Hemodialysis (Sridharan et al, Hemodial Int 2013; 17(4): 502-509). 
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 Chapter 5 
5. A Self-report Comorbidity Questionnaire for Haemodialysis 
Patients 
 
5.1 Introduction 
Comorbidity is an important outcome measure in patients with ESRD and has been 
shown to be a significant predictor of mortality in this patient population (van Manen 
et al., 2002; Chandna, Schulz, Lawrence, Greenwood, & Farrington, 1999; Khan, 
1998; Khan et al., 1993). A reliable means of obtaining comorbidity data is vital for 
clinical and research purposes. Charlson Comorbidity Index (CCI) was developed to 
predict patient survival using comorbidity data (Charlson et al., 1987) and has been 
traditionally used as a marker of comorbidity burden. CCI has been shown to be a 
significant predictor of clinical outcomes in ESRD patients (Rattanasompattikul et al., 
2012; Goodkin et al., 2003). As CCI is collected through medical records, it is time-
consuming and is limited by the availability of medical records and the accuracy of 
the documentation of specific medical conditions. 
A simple, self-report questionnaire would be a useful alternative tool for obtaining 
comorbidity data. After all, the patient is the source of the comorbidity data 
documented in the medical records. Moreover, patient-derived comorbidity data is 
reliable and valid compared to that from medical records (Katz, Chang, Sangha, 
Fossel, & Bates, 1996; Linet, Harlow, McLaughlin, & McCaffrey, 1989). Self-report 
questionnaires derived from general population may not be suitable for patient 
population with chronic illness such as end-stage renal disease. It is important to 
establish the role of self-report questionnaires in disease-specific patient population. 
In order to facilitate comorbidity data collection from patients with ESRD in one of the 
studies in this thesis and also for use in clinical practice, a self-report comorbidity 
questionnaire was developed. This study was conducted to examine the level of 
agreement between the questionnaire and medical records and also to explore the 
relationship between the questionnaire-derived comorbidity score and short-term 
survival in haemodialysis patient population. 
 99 
5.2 Materials and Methods 
5.2.1 Self-report Questionnaire Design 
The self-report questionnaire, shown in Appendix D, was based on that developed 
by Sangha et al (Sangha, Stucki, Liang, Fossel, & Katz, 2003). This questionnaire 
has been validated in a cohort of acute medical and surgical patients and correlates 
well with subsequent health status and resource utilisation. Eight comorbid 
conditions commonly prevalent in patients with ESRD were chosen to be included in 
the questionnaire. Participants also had the option of adding three additional 
comorbid conditions that were not listed. As can be seen from the questionnaire, the 
first 2 items enquire about cardiac disease, one relating to current and the other past 
history to enable more complete data capture about cardiovascular status. The 
conditions were expressed in plain language that could be understood by patients 
without prior medical knowledge. The questionnaire was translated into Bengali and 
Urdu to include patients from different ethnic backgrounds who did not have 
sufficient knowledge of English to complete the questionnaire. The translation was 
carried out by Straker Translations (London, UK) and was reviewed by two 
independent reviewers, who were native speakers of these languages, to confirm the 
accuracy of the translation. 
For each of the listed conditions and the ones the participants could add, subjects 
were asked 3 questions – whether they had the condition, and if they did, whether 
they were receiving any treatment and whether the condition was limiting their 
activities. If the answer to a particular question was in the affirmative, then they were 
asked to tick the respective box. All participants completed the questionnaire on their 
own without any help from healthcare staff. 
5.2.2 Scoring of the Questionnaire 
Each positive response had a score of 1. Hence, the maximum score was 3 for each 
medical condition – 1 for the presence of the disease, 1 for being on treatment and 1 
if the disease was limiting their activities. Of the listed conditions, the first 2 referred 
to cardiac disease and were considered as one item for purposes of scoring. A 
judgement was made on the admissibility of the optional items as significant 
comorbidities. In the event of the additional items listed by patients, only 
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cerebrovascular disease (“stroke”) was considered an additional significant 
comorbidity and included in the scoring. In addition since the level of agreement for 
depression between the questionnaire and the medical records was poorest of all 
listed conditions and since depression did not contribute to any of the models tested, 
this parameter was omitted from the scoring scheme. Hence the Composite Self-
report Comorbidity Score (CSCS) was derived from 7 conditions – giving a potential 
maximum of 21. Age was not included in this score. 
5.2.3 Ethical Review 
The study was approved by the North Wales Ethics Proportionate Review 
Committee (ref: 12/WA/0060 and UH Ethics ref: LMS/PG/NHS/00257). All 
participants provided informed written consent. 
5.2.4 Subjects 
Patients on maintenance, in-centre HD were recruited from the renal units of East 
and North Hertfordshire NHS Trust. The study included patients older than 18 years, 
dialysing thrice weekly and those able to understand English, Bengali or Urdu 
sufficiently to complete the questionnaire. Exclusion criteria included patients with no 
capacity to consent, those dialysing other than thrice weekly and those with limb 
amputations. 
5.2.5 Study Protocol 
The questionnaire was administered to each participant when they attended their 
regular HD session and were asked to complete it by the end of the session. The 
demographic information and their documented comorbidities were obtained from 
the local renal database. CCI was calculated as previously described (Charlson et 
al., 1987). All participants were followed up for 18 months to obtain survival data. 
5.2.6 Statistical Analysis 
Statistical analysis was carried out using SPSS ® version 19 (SPSS Software, IBM 
Corporation, Armonk, New York, USA). Normally distributed data are presented as 
mean ± SD, and non-normally distributed as median (interquartile range [IQR]).  
Correlations between scores were determined using the Spearman coefficient. 
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The agreement for individual items between the questionnaire and medical-record 
derived CCI was assessed using the inter-rater kappa (κ) statistic (Cohen, 1960). 
The overall agreement, defined as the number of cases in which both the patient 
responses and medical records agreed (both “yes” and “no” responses) divided by 
the total number of cases, was also calculated. 
Logistic regression models were used to identify independent predictors of survival in 
the study population. All models included age, sex, and ethnicity as variables. 
Individual patient-reported comorbid conditions that were significantly associated 
with survival were identified, as well as the contribution of the Composite Self-report 
Score (CSCS) and the CCI. 
Receiver Operator Curves (ROC) were constructed to compare the utility of the 
CSCS and the CCI in predicting mortality as well as defining the optimal cut-off 
points for this prediction for both these scales. The levels of agreement for the cut-off 
point in the scales were compared using the inter-rater κ statistic. In addition, the 
predictive power of these cut-off points in predicting mortality was compared in Cox 
Regression models. A p-value of < 0.05 was considered significant in all the 
analyses. 
5.3 Results 
A total of 282 patients were recruited out of 350 haemodialysis patients in our unit 
over a period of 1 month. There were 177 males (62.8%).  The mean age was 64.1 ± 
15.3 years. The ethnic make-up was 201 white (71.3%), 51 South Asian (18.1%) and 
30 black (10.6%). For the open-ended questions, 46 patients (16.3%) indicated 1 
additional disease, 10 patients (3.5%) indicated 2 diseases and 1 patient indicated 3 
diseases. Frequently mentioned additional diseases included hypertension (11), 
stroke (10), hypothyroidism (5), visual impairment (5), and peripheral vascular 
disease (2). Of these only stroke was considered as significant additional 
comorbidity as discussed earlier. Hypertension was not included since this is a 
feature of chronic kidney disease and present in a very high proportion of patients on 
haemodialysis and Peripheral vascular disease since it was listed only twice. The 
other conditions mentioned by patients were hearing loss, back pain, inguinal hernia, 
insomnia, lymphoedema, gout, glaucoma and diverticulitis. 
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5.3.1 Prevalence of Comorbid Conditions 
Table 5-1 shows the prevalence of each item as determined from the medical 
records and the comorbidity questionnaire. Prevalence of heart disease, diabetes 
mellitus and cancer was similar between the two instruments. The prevalence of 
both lung and liver disease as obtained from medical records was higher than the 
self-report. For the prevalence of arthritis, cerebrovascular disease and depression 
the opposite prevailed. 
Table 5-1: Prevalence of comorbid conditions according to Self-report 
comorbidity questionnaire and medical records 
 
Prevalence (%) 
Medical Records Comorbidity Questionnaire Limiting Disease 
Diabetes 84 (29.8) 82 (29.1) 22 (7.8) 
Heart disease 98 (34.8) 92 (32.6) 37 (13.1) 
Cancer 20 (7.1) 18 (6.4) 3 (1.1) 
Liver disease 12 (4.3) 7 (2.5) 3 (1.1) 
Lung disease 29 (10.3) 13 (4.6) 8 (2.8) 
Arthritis 22 (7.8) 72 (25.5) 47 (16.7) 
Cerebrovascular 
disease 10 (3.5) 22 (7.8) 2 (0.7) 
Depression 17 (6.0) 35 (12.4) 15 (5.3) 
 
5.3.2 Level of Agreement 
The level of agreement between the questionnaire data and medical records is 
shown in Table 5-2. Overall agreement exceeded 80% for all items with the highest 
agreement for diabetes mellitus (99%) and the lowest for arthritis (81%). Table 5-2 
also shows the κ statistic and the interpretation of the κ for each item. There was 
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almost perfect agreement between the two instruments for diabetes, substantial 
agreement for heart disease and cancer, and moderate agreement for liver disease.  
Table 5-2: Level of agreement between the questionnaire and medical records 
 Level of Agreement (%) 
Kappa 
(95% CI) 
Interpretation of 
Kappa 
Diabetes 99 0.97 (0.93, 1.00) Almost Perfect 
Heart disease 83 0.62 (0.52, 0.72) Substantial 
Cancer 96 0.72 (0.55, 0.89) Substantial 
Liver disease 97 0.51 (0.20, 0.83) Moderate 
Arthritis 81 0.35 (0.09, 0.50) Fair 
Lung disease 91 0.34 (0.10, 0.58) Fair 
Cerebrovascular 
disease 93 0.34 (0.09, 0.56) Fair 
Depression 88 0.29 (0.06, 0.51) Fair 
 
There was only fair agreement for lung disease, arthritis, depression and 
cerebrovascular disease. There was no association observed between gender and 
agreement of patient self-reports with medical records for any of the items listed. 
Using age as a dichotomous variable (age less than 65 vs. 65 or more) in this 
analysis, there were significant differences in level of agreement for arthritis and 
depression. κ was significantly higher in older patients for arthritis and in younger 
patients for depression (p = 0.03 for both). 
 
5.3.3 Composite Comorbidity Score 
The distributions of the CSCS and CCI are shown in Figure 5-1. The median CSCS 
was 2 (IQR3). The median CCI was 6 (IQR3). The CSCS correlated with the CCI 
(rho = 0.531: p<0.001). 
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Figure 5-1: Histogram showing distribution of CSCS and CCI 
 
5.3.4 Survival Prediction and Logistic Regression 
Of the 282 participants, 58 (20.6%) died in the 18 months following recruitment. 
Table 5-3 shows the best Logistic Regression Model for predictors of survival at 18 
months based on individual self-report comorbid conditions  (Hosmer and Lemeshow 
Chi-square 11.115; p = 0.195, Nagelkerke R-square value 0.197). Variables 
considered were age, sex, ethnicity, presence of self-report heart disease, 
cerebrovascular disease, cancer, diabetes, liver disease, lung disease, and arthritis. 
Heart disease, liver disease and arthritis were, along with age, the significant 
predictors of survival. 
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Table 5-3: The best Logistic Regression Model for predictors of survival at 18 
months based on individual self-report comorbid conditions 
 B S.E. Wald p-value Exp(B) 
Constant -4.169 .902 21.374 .000 .015 
Age .030 .013 5.287 .021 1.030 
Heart Disease 1.242 .319 15.124 .000 3.462 
Liver Disease 1.794 .856 4.392 .036 6.013 
Arthritis .858 .334 6.582 .010 2.358 
 
The logistic regression models for the CSCS and the CCI are shown in Table 5-4. 
The models including these individual parameters showed similar goodness of fit 
(Hosmer and Lemeshow Chi-square 4.151 [p = 0.843] and 1.878 [p = 0.985]) and 
predictive power (Nagelkerke R-square values 0.202 and 0.211 respectively). 	  Each 
parameter had a highly statistically significant relationship to survival within the 
models (p <0.001 in both cases). Interestingly the model was improved by inclusion 
of both parameters (Nagelkerke R-square 0.250) and in this model (Table 5-4 – 
lower panel) both parameters retained a high degree of statistical significance. 
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Table 5-4: Logistic regression models for survival at 18 months 
MODEL 1: Nagelkerke R2 = 0.202 B S.E. Wald p-value Exp(B) 
Age (Years) .030 .013 5.540 .019 1.031 
Sex (Male v Female) .440 .344 1.635 .201 1.553 
Ethnicity (Non-white v White) -.222 .381 .340 .560 .801 
CSCS .392 .081 23.386 .000 1.480 
Constant -4.616 .962 23.026 .000 .010 
MODEL 2: Nagelkerke R2 = 0.211      
Age (Years) -.015 .016 .894 .344 .985 
Sex (Male v Female) .211 .348 .367 .545 1.235 
Ethnicity (Non-white v White) -.213 .376 .322 .570 .808 
CCI .521 .105 24.445 .000 1.683 
Constant -3.641 .909 16.035 .000 .026 
MODEL 3: Nagelkerke R2 = 0.250      
Age (Years) -.002 .016 .021 .886 .998 
Sex (Male v Female) .298 .355 .702 .402 1.347 
Ethnicity (Non-white v White) -.315 .387 .663 .416 .730 
CCI .365 .117 9.715 .002 1.440 
CSCS .262 .092 8.180 .004 1.300 
Constant -4.251 .972 19.125 .000 .014 
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5.3.5 Receiver Operator Characteristics (ROC) Analysis 
ROC curves were constructed to compare the performance of CSCS and CCI in 
predicting death within the follow-up period, and to determine the best cut-off values 
of both these parameters for this prediction (Figure 5-2). The Area under the Curve 
in ROC analysis was similar for these parameters with overlapping 95% confidence 
intervals: 0.724 (0.651 – 0.797) and 0.754 (0.684 – 0.823) respectively. The best cut-
off points for predicting mortality during the follow-up period were determined as 
CSCS > 3 and CCI > 6. Patients with CSCS > 3 are subsequently referred to as 
having high CSCS. Likewise high CCI values refer to CCI > 6. 
 
Figure 5-2: Receiver Operator Characteristic curves comparing the 
performance of CSCS and CCI in predicting death 
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5.3.6 Comparison of cut-off points in mortality prediction 
Figure 5-3 compares the adjusted survival of patients with high CSCS (69 patients) 
and those with high CCI (94 patients). In both cases survival is adjusted for age, sex 
and ethnicity in Cox Regression models.  Both high CSCS and high CCI were highly 
predictive of mortality within their separate models (p < 0.001 in both cases). 
 
Figure 5-3: Adjusted Survival for patients with high comorbidity scores 
 
Hazard Ratios were over 4 for both parameters with overlapping 95% Confidence 
Intervals (4.050 [3.362 – 6.947] and 4.139 [2.202 – 7.774] respectively). In spite of 
this, when these parameters were included together in the same Cox model, both 
retained their significance, and Hazard Ratios of each were similar, approaching 3 
(Table 5-5). 
The level of agreement between patient with high CSCS and high CCI was only fair 
(κ = 0.325; p < 0.001). The main difference between these high comorbidity groups 
relates to mean age which, unsurprisingly, was significantly higher in the high CCI 
group than in the high CSCS group (73.6 ± 8.7 vs. 67.4 ± 11.7; p <0.001).  There 
were other differences. The best levels of agreement between CCI (high and low) 
and the presence or absence of individual components of the CCI, were for heart 
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disease (κ 0.447), diabetes (κ 0.443), cerebrovascular disease (κ 0.301) and cancer 
(κ 0.205). On the other hand, the best agreements between CSCS (high v low) and 
the presence or absence of individual components of the CSCS, were with heart 
disease (κ 0.491), arthritis (κ 0.442) and diabetes (κ 0.396). 
Table 5-5: Cox model of predictors of short-term survival in haemodialysis 
patients 
 
B S.E. Wald p-value Exp(B) 
Age (Years) .011 .012 .840 .359 1.011 
Sex (Male v Female) .405 .299 1.831 .176 1.500 
Ethnicity (Non-white 
v White) -.411 .315 1.700 .192 .663 
CCI > 6 1.020 .334 9.348 .002 2.773 
CSCS > 3 1.067 .292 13.309 .000 2.907 
 
5.4 Discussion 
Information on comorbid conditions is essential in routine clinical practice and also 
for research purposes. This study describes a simple, self-report questionnaire to 
obtain comorbidity data in patients with advanced kidney failure, receiving treatment 
by dialysis. The study data shows that the questionnaire has very good overall level 
of agreement with the medical records data. The questionnaire-derived comorbidity 
score – the CSCS – was significantly predictive of short-term survival in this patient 
group and may have clinical utility. 
There was almost perfect or substantial levels of agreement between the prevalence 
of self-reported diabetes, heart disease and cancer and the prevalence of these 
conditions derived from the detailed examination of the patients’ medical records. 
The level of agreement for liver disease was moderate. For arthritis, lung disease, 
cerebrovascular disease and depression the levels of agreement were only fair. 
Whilst lung disease and cerebrovascular disease were under-reported by patients, 
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arthritis and depression were reported more frequently compared to the medical 
records. 
There are a number of factors which may contribute to these discrepancies. Results 
from study data indicates that even though lung disease was under-reported in the 
questionnaire, a high proportion of those patients who did report having this 
condition indicated that their disease limited their activities. This suggests that 
patients with milder forms of lung disease may not attribute much significance to 
related symptoms (e.g. “smoker’s cough”) or may not be aware of the diagnosis at 
all. The under-reporting of cerebrovascular disease was almost certainly caused by 
the fact that this was not a condition specified on the questionnaire and patients 
wishing to report this condition had to write this in under “other medical conditions”.  
The conditions which were over-reported by patients, arthritis and depression, are 
predominantly diagnosed and treated in primary care. This may sometimes lead to 
their not being documented in hospital records unless they are receiving medication 
for that condition or if its severity warrants secondary care referral. The poorest level 
of agreement was found with depression and this, and its failure to contribute to any 
of the survival models that were considered, led to the exclusion of this parameter 
from contributing to the CSCS. 
The study data shows that CSCS was a significant predictor of survival in 
haemodialysis patients. The main individual comorbid conditions contributing to this 
predictive power in this patient group were the presence of heart disease, liver 
disease and arthritis. The power of the CSCS and the CCI in predicting mortality 
over the 18-month follow-up period was compared. In logistic regression models 
which allowed adjustment for age, sex and ethnicity, both these parameters were 
found to have similar predictive power (Table 5-4). Since the CCI includes a term for 
age, such a modelling approach is required to allow for this in the comparison. The 
ROC analysis also showed that the parameters performed similarly in predicting 
death within the follow-up period. The area under the ROC curve was greater for CCI 
than for CSCS (0.754 vs. 0.724). This difference was not significant and is probably 
accounted for by the fact that age is not controlled for in this method of comparison.  
ROC analysis was also used to help determine the best cut-off points for the CSCS 
and CCI for predicting mortality during follow-up. The high comorbidity groups were 
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determined as CSCS >3 and CCI >6.  The performances of these parameters in 
predicting death were similar in Cox Models, again controlling for age, sex and 
ethnicity. 
Interestingly the use of CSCS together with CCI in a logistic regression model 
improved the model with both terms retaining significant predictive power. The 
findings were similar with the use of both high CSCS and high CCI in a Cox Model. 
These findings, together with the only fair level of agreement between high CSCS 
and high CCI suggest that these parameters make different contributions to the 
assessment of comorbidity. The obvious difference relates to the inclusion of a 
contribution of patient age in the calculation of CCI. Indeed it was found that high 
CCI group was significantly older than the high CSCS group. There were other 
differences between these two groups. Both were similarly influenced by their 
components relating to heart disease, and diabetes but the high CCI group was 
more influenced by components relating to cerebrovascular disease and cancer, and 
the high CSCS group by the component related to arthritis.  
Instruments such as the CCI rely on availability and accuracy of medical records and 
as such, may be limited in its utility for clinical and research purposes. A self-report 
comorbidity questionnaire can help collect this information reliably and with relative 
ease. Various self-report health measures have been previously studied in patients 
with renal failure (Cavanaugh et al., 2008; Thong et al., 2008). This self-report 
questionnaire has the advantage of being brief, easily understandable by patients 
and at the same time being comprehensive enough to include commonly prevalent 
comorbid conditions in ESRD patient population. Also, the questionnaire enquires 
about the treatment and limitations imposed by specific diseases which can be used 
as a surrogate marker of the severity of the disease. The high level of agreement 
between the self-report and clinical records with respect to diabetes, heart disease 
and cancer suggests that the utility of the self-report approach could embrace the 
collection of such condition-specific data for inclusion in survival models. 
5.5 Limitations 
It has been shown previously that medical records may in themselves have 
substantial errors (Merkus et al., 2000; Peabody, Luck, Glassman, Dresselhaus, & 
Lee, 2000; Luck, Peabody, Dresselhaus, Lee, & Glassman, 2000) and hence, using 
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this method as a “gold standard” may be less than ideal. Also, with any 
questionnaire-based technique there is a potential for recall bias. Though patients 
had the option of adding any additional diseases that were not listed, it is possible 
that patients may not recall milder forms of existing comorbid diseases and this may 
exclude some important comorbid conditions such as cerebrovascular disease and 
peripheral vascular disease. Further development of this questionnaire should 
include specific enquiry about the presence and severity of these conditions. Finally 
this study only examined the predictive capacity of this self-report questionnaire with 
regards to short-term survival in haemodialysis patients and as such, the results 
should not be extrapolated to other groups of patients with kidney disease, or to the 
assessment of long-term survival. 
5.6 Conclusion 
In summary, this self-report comorbidity questionnaire is a simple and reliable tool for 
obtaining comorbidity data in clinical practice and research studies involving patients 
with end-stage renal disease on haemodialysis. There is strong agreement between 
this self-report instrument and data derived from medical records on important 
comorbid conditions that have an influence on patient outcome. The instrument also 
provides information on severity of the comorbid diseases. In addition, the 
comorbidity score generated (CSCS) has comparable predictive power for short-term 
survival in haemodialysis patients to the CCI. Further work is needed to adapt the 
questionnaire and to examine its applicability in studies assessing long-term survival 
and other clinical outcomes in patients with kidney disease. 
Elements of this chapter are reproduced from a published article - Sridharan et al, BMC 
Nephrol 2014; 15(1): 134. 
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 Chapter 6 
6. Impact of Renal Function on Energy Expenditure 
 
6.1 Introduction 
The relationship between metabolic rate and Glomerular filtration rate (GFR) is 
discussed in section 2.3.1. Singer (2001) showed, through studies on different 
animal species of varying body size, that metabolic rate and GFR scale to body 
weight by approximately the same exponent (Singer, 2001). He hypothesised that 
the reason behind this observation is that the metabolic rate is the driving process for 
renal blood flow. He also argued that the converse is not true i.e. a reduction in GFR 
as happens in Chronic Kidney Disease (CKD) should not result in a reduction of 
metabolic rate. There is circumstantial evidence to support this hypothesis. Studies 
carried out in patients with hypothyroidism have shown reduction of GFR (Davies et 
al., 1952; Mackay & Sherrill, 1943) and an increase in GFR in those with 
hyperthyroidism (Aizawa et al., 1986; Ford et al., 1961; Mackay & Sherrill, 1943). It 
was suggested that this effect on GFR was likely driven by corresponding changes in 
the metabolic rate in these thyroid disorders. However, there have been no clinical 
studies carried out in patients with different stages of CKD to explore the relationship 
between metabolic rate and CKD. 
Studies undertaken in this thesis have focused on basal metabolic rate (i.e. resting 
energy expenditure) and physical activity assessment methods in haemodialysis 
patients. It is vital to focus on these two elements together in the form of total 
metabolic rate i.e. Total Energy Expenditure (TEE) in the context of CKD. TEE 
consists of REE, physical activity-related energy expenditure (PAEE) and thermic 
effect of food, which comprises about 10% of TEE. 
Understanding TEE in CKD patients could be beneficial in many ways. As metabolic 
waste generation is dependant on total metabolic activity, it is plausible that TEE 
could be a better marker of uraemic toxin load compared to REE as it includes 
metabolic waste production from physical activity as well. A better knowledge of TEE 
will enable better dietary and nutritional management of patients with chronic kidney 
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disease. Moreover, studying TEE across the spectrum of CKD will help to 
understand the relationship between metabolic rate and GFR and test the hypothesis 
proposed by Singer. 
The gold standard technique of studying TEE in free-living conditions is by the 
doubly labelled water method (DLW). The alternative method is to obtain physical 
activity data through questionnaires and in conjunction with a measure of REE, TEE 
can be estimated. However, this is prone to measurement errors and will not provide 
accurate measurements of TEE as would be needed in studies examining the 
relationship with GFR. In addition, measuring TEE accurately will enable to explore 
its relationship with body size parameters such as total body water. As discussed in 
previous sections of this thesis, the practice of using total body water to normalise 
dialysis dose may lead to under-dialysis in some group of patients. Therefore, 
exploring the relationship between TEE and total body water may further our 
understanding of the gender differences in survival that have been reported in 
haemodialysis patients. 
Total body water calculation (Watson Volume) was derived from a cohort of normal 
individuals but is extensively used in dialysis patients for scaling dialysis dose. TEE 
measurement by the doubly labelled water technique will help to examine the validity 
of using Watson volume in patients with CKD. In addition, the accuracy of other tools 
of body water measurement such as bioimpedance can also be validated using this 
method. 
The doubly labelled water method of measuring TEE is associated with considerable 
costs and is time-consuming as measurements are typically carried out over a period 
of 10-14 days. These factors make this prohibitive for use in routine clinical practice. 
A useful alternative is to validate physical activity questionnaires using this technique 
which can then be employed in clinical practice for estimation of TEE. There have 
been no clinical studies published so far in CKD employing the doubly labelled water 
technique and therefore, no physical activity questionnaires validated for use in 
patients with CKD using this gold standard method. 
As little is known about total energy requirements specifically in renal disease, this 
study was designed to explore certain aspects of TEE in CKD with the following 
objectives: 
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1. To measure TEE in free-living conditions in patients with CKD 
2. To examine the influence, if any, of declining kidney function on TEE 
3. To examine the relationship between TEE and body water measured by 
bioimpedance and also that estimated from Watson equation 
4. To explore the relationship between measured TEE and urea generation rate 
which is a surrogate marker of uraemic toxin production 
5. To examine the validity of physical activity questionnaires for TEE estimation 
in patients with CKD 
The null hypothesis for this study was that a reduction in renal function will lead to 
reduction in metabolic rate and the experimental hypothesis was that declining renal 
function does not have a corresponding effect on metabolic rate. 
There are two separate aspects of this study – the first four objectives exploring the 
clinical aspects and the last one focusing on validating activity questionnaires. 
Hence, for clarity and ease of reading, the results are presented in two chapters. The 
methodology discussed below applies to both the chapters. This chapter discusses 
the effect of renal function of TEE and the relationship between TEE and body water. 
The next chapter discusses the validation of two physical activity questionnaires 
against the doubly labelled water method. 
The results presented in this chapter are from a total of 80 patients with CKD. 40 of 
these patients were recruited as part of this study. The other 40 patients were 
recruited for another similar study conducted as part of Dr Vilar’s PhD (Dr Enric Vilar, 
PhD, University of Hertfordshire – degree awarded Feb 2012) at Lister hospital 
where the current study was conducted too. The protocol for that study was 
essentially the same as the current one. There were two additional assessments 
carried out in the recent cohort of 40 patients. Firstly, the Recent Physical Activity 
Questionnaire (RPAQ) was used in addition to the Stanford questionnaire in the 
current study and secondly, subjects were asked to perform a 24-hour urine 
collection prior to the study day to enable estimation of urea generation rate. In 
addition, the bioimpedance device used for assessment in the current study is 
different to the one used in the previous cohort. However, the core methodology of 
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measuring REE and TEE were exactly the same for the two studies. In view of this, 
results from these two studies are presented as a single cohort in both these 
chapters. 
6.2 Considerations on use of doubly labelled water in kidney disease 
6.2.1 General Considerations 
The methodology of the doubly labelled water technique is explained in section 
3.8.1. A comprehensive discussion about the method and the theory behind its use 
can be seen in two seminal publications on this topic – a textbook by John 
Speakman(Speakman, 1997) and a document by the International Atomic Energy 
Agency which also provides guidance on the methodology and calculation of 
TEE(Prentice, 1990). This section discusses only the general considerations on the 
use of doubly labelled water in kidney disease. 
The technique involves use of a stable, non-radioactive isotope of oxygen (18O) and 
hydrogen (2H) to estimate the body water pool and production rate of carbon dioxide 
from which TEE is calculated. These isotopes are normally present in tap water but 
at a lower concentration. After ingestion of a measured dose, these isotopes will 
equilibrate in the body water pool within a few hours which will raise the enrichment 
level of these molecules in body water. The administered dose needs to enrich the 
concentration of these isotopes in the body water sufficiently to allow for the study to 
be conducted over a period of 7-14 days. During the study period, the excretion rates 
of these molecules are measured from urine samples. 2H (also known as deuterium) 
leaves the body primarily as water (2H2O) in urine and sweat. 18O, on the other hand, 
leaves the body as both water (H218O) and carbon dioxide (C18O2). By measuring the 
difference between the elimination rates of both these isotopes, production rate of 
carbon dioxide can be calculated which will enable calculation of TEE. If the 
respiratory quotient of the individual is known, then the oxygen consumption rate and 
REE can also be calculated. 
Doubly labelled water method has not been used in patients with end-stage renal 
disease previously due to a number of potential problems. Individuals receiving 
haemodialysis or peritoneal dialysis will have substantial short-term changes in the 
amount of body water pool which will lead to errors in isotope measurement. In 
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addition to the above mentioned routes of excretion, the isotopes are also likely to be 
excreted through dialysis which necessitates collection of dialysate effluent for 
isotope enrichment measurement and probably a much higher dose for 
administration, thereby increasing the costs of the study substantially. Moreover, the 
elimination rates of 2H and 18O may not be the same on dialysis which will introduce 
an error in the calculation of carbon dioxide production rate. However, the technique 
can be used reliably in patients with CKD who are not receiving any form of dialysis 
therapy. For this reason, we chose to conduct the study in patients with different 
stages of CKD.  
6.2.2 Safety of the isotope 
The technique is very safe and has been used reliably in many human studies over 
the last few decades. Both the isotopes are non-radioactive. Potability testing of the 
sample water was carried out to ensure that the sample was fit for ingestion by study 
participants. A copy of the test report is shown in Appendix E. 
6.2.3 Assumptions in the methodology 
As with any physiological study, the doubly labelled water method involves several 
assumptions(Prentice, 1990). It is assumed that the volume of the body water pool 
remains constant throughout the measurement period. Both 2H and 18O distribute to 
some extent in non-water body pools but this has been quantified and an appropriate 
correction factor is applied in the calculations as shown in section 3.8.1.3. 
There is an assumption that the isotopes leave the body only in the form of water 
and carbon dioxide. However, a small amount of urea is also excreted in faeces 
which produces an error of around 2% (Montoye, 1997). It is also assumed that the 
background levels of isotopes remain constant throughout the study period. Whilst 
theoretically, the background enrichment levels may change if the subject is to 
consume tap water from a different locality, in practical terms, this is unlikely to be a 
major problem during the 14-day study period. 
It is assumed that the concentration of the isotopes in water and carbon dioxide 
leaving the body are the same as those in body water at that time i.e. there is no 
isotopic fractionation. Fractionation can be minimised by storing the samples in air-
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tight containers and by freezing. Finally, it is also assumed that the water or carbon 
dioxide that has left the body does not re-enter the body. 
6.2.4 Sampling Methods 
As discussed in section 3.8.1, the samples can be collected using a ‘two-point’ or 
‘multi-point’ approach. The multi-point approach was chosen for this study as this 
would minimise potential problems because of sampling or analysis errors. Study 
participants were asked to collect a urine sample every day for a period of 14 days 
following the dose ingestion. However, only samples from days 1, 8 and 14 were 
used for analysis. 
6.3 Methods 
6.3.1 Ethical Review 
The study was reviewed and approved by Hatfield NHS Research Ethics Committee 
(ref: 13/EE/0388 and UH Ethics ref: LMS/PG/NHS/00255). All participants gave 
written informed consent. 
6.3.2 Overview of Study Design 
This was a prospective cross-sectional study of 80 CKD patients – 40 each in CKD 
stages 1-3 and CKD stages 4&5 group. Consenting subjects participated in a 14-day 
study. Subjects performed a 24-hour urine collection beginning the day prior to the 
study day. On day 0, a comprehensive metabolic analysis was performed and 
subjects were given a measured dose of doubly labelled water isotope. Participants 
were then asked to collect a urine sample each day, starting 24 hours after the 
isotope ingestion for a period of 14 days for measurement of isotopic enrichment and 
calculation of TEE. Subjects were asked to complete two physical activity 
questionnaires at the end of the study period for validation of these questionnaires. 
6.3.3 Study Population 
All subjects were recruited from the outpatient clinics of Lister Hospital. Potential 
participants were approached in person when they attended the renal clinic and were 
given the information sheet about the study. They were given the opportunity to ask 
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any questions about the study before consenting for the study. The inclusion and 
exclusion criteria are detailed below. 
6.3.3.1 Inclusion Criteria 
• Adult CKD patients older than 18 years of age in all stages of CKD 
6.3.3.2 Exclusion Criteria 
Patients with 
• untreated hypo- or hyperthyroidism 
• active malignancy 
• ongoing sepsis 
• active vasculitis or connective tissue disease 
• history of hospitalisation in the last month 
• current pregnancy 
• cardiac pacemakers or defibrillators 
• unexplained weight loss 
• HIV, Hepatitis B or Hepatitis C positive status 
• limb amputation 
• no capacity to consent for themselves 
• immobility due to any physical ailments 
6.3.4 Study Assessments 
6.3.4.1 Demographic and Clinical Data 
Data comprising of age, sex, ethnicity and comorbid conditions were collected for all 
study participants through direct measurements and individual medical records. 
Charlson Comorbidity Index was calculated according to previously published 
literature (Charlson et al., 1987). 
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6.3.4.2 Metabolic Analysis and Blood test 
All participants performed a 24-hour urine collection beginning the day prior to the 
study for estimation of urea generation rate. Subjects were asked to fast for at least 
3 hours prior to the study on the study day. On Day 0, participants attend the 
research facility. Accurate height and weight was measured. Bio-impedance analysis 
was carried out as described in section 3.10.2. Subjects were then asked to rest on a 
couch and indirect calorimetry was performed to measure REE as described in the 
General Methodology section 3.6.2. Following REE measurement, 5 ml of blood 
sample was taken for measurement of renal function and urea generation rate. The 
blood sample was analysed for measurement of serum urea, creatinine and full 
blood count. 
6.3.4.3 Doubly labelled water administration 
The doubly labelled water isotope administration along with calculation of the 
required doses and subsequent calculation of TEE are explained in detail in the 
General Methodology section 3.8.1. After ingestion of the measured dose of the 
sample on Day 0, subjects were asked to collect the first urine sample after 24 hours 
on Day 1. From then on, they were asked to collect a urine sample each day for a 
period of 14 days approximately around the same time every day. However, as 
explained above, only the samples on Day 1, 8 and 14 were used for analysis. If any 
of these samples were missing, the sample closest to the missing day (±1 day) was 
used. Samples were collected at the end of the study period and frozen at -20°C until 
analysis was performed. 
6.3.4.4 Physical Activity Questionnaires 
At the end of the 14-day period, participants completed two physical activity 
questionnaires – Recent Physical Activity Questionnaire (RPAQ) and Stanford 7-day 
recall questionnaire. The questionnaires are described in detail in section 3.7.2. 
6.3.5 Estimation of Renal Function and Urea Generation Rate 
Renal function was assessed using estimated GFR (eGFR) from the MDRD equation 
and by creatinine clearance estimation from Cockcroft-Gault (CrCl-CG) equation. 
The equations are given below. 
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𝒆𝑮𝑭𝑹   = 𝟏𝟖𝟔  ×    𝒄𝒓𝒆𝒂𝒕𝒊𝒏𝒊𝒏𝒆𝟖𝟖.𝟒 !𝟏.𝟏𝟓𝟒   ×   𝒂𝒈𝒆 !𝟎.𝟐𝟎𝟖  ×   𝟎.𝟕𝟒𝟐  𝒊𝒇  𝒇𝒆𝒎𝒂𝒍𝒆   ×  (𝟏.𝟐𝟏𝟎  𝒊𝒇  𝒃𝒍𝒂𝒄𝒌) 
 
𝑪𝒓𝑪𝒍 − 𝑪𝑮  (𝒎𝒍/𝒎𝒊𝒏)   =    𝟏𝟒𝟎 − 𝒂𝒈𝒆 ×  𝒘𝒆𝒊𝒈𝒉𝒕   𝒌𝒈 ×  (𝟏.𝟐𝟑  𝒊𝒇  𝒎𝒂𝒍𝒆,𝟏.𝟎𝟒  𝒊𝒇  𝒇𝒆𝒎𝒂𝒍𝒆)𝑺𝒆𝒓𝒖𝒎  𝒄𝒓𝒆𝒂𝒕𝒊𝒏𝒊𝒏𝒆  (𝝁𝒎𝒐𝒍/𝑳)  
 
Categorisation of the renal function into one of the five CKD stages was carried out 
as discussed in section 1.1.2 (Error! Reference source not found.). 
Urea generation rate (G) was calculated as follows. 
𝑮  (𝒎𝒎𝒐𝒍/𝒎𝒊𝒏)   =   𝑼𝒓𝒊𝒏𝒆  𝑽𝒐𝒍𝒖𝒎𝒆   𝑳   ×  𝑼𝒓𝒊𝒏𝒆  𝑼𝒓𝒆𝒂  𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏  (𝒎𝒎𝒐𝒍/𝑳)𝑫𝒖𝒓𝒂𝒕𝒊𝒐𝒏  𝒐𝒇  𝑼𝒓𝒊𝒏𝒆  𝒄𝒐𝒍𝒍𝒆𝒄𝒕𝒊𝒐𝒏  (𝒎𝒊𝒏𝒖𝒕𝒆𝒔)  
 
6.3.6 Estimation of Total Body Water 
Total body water was estimated in two ways – using whole-body bioimpedance 
(TBWBI) and Watson formula (TBWWF) which is given below. 
For males: 𝑻𝑩𝑾𝑾𝑭   = 𝟐.𝟒𝟒𝟕− 𝟎.𝟎𝟗𝟓𝟏𝟔  ×  𝑨𝒈𝒆 +    𝟎.𝟏𝟎𝟕𝟒  ×  𝑯𝒆𝒊𝒈𝒉𝒕 +    𝟎.𝟑𝟑𝟔𝟐  ×  𝑾𝒆𝒊𝒈𝒉𝒕  
For females: 𝑻𝑩𝑾𝑾𝑭   = −𝟐.𝟎𝟗𝟕+ 𝟎.𝟏𝟎𝟔𝟗  ×  𝑯𝒆𝒊𝒈𝒉𝒕 +    𝟎.𝟐𝟒𝟔𝟔  ×  𝑾𝒆𝒊𝒈𝒉𝒕  
 
where TBWWF is expressed in Litres, age in years, height in cm and weight in kg 
Total body water measurement from the doubly labelled water (TBWDLW) was 
calculated from equation 11 explained in section 3.8.1.3. 
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6.3.7 Estimation of Physical Activity Level from Questionnaires 
In RPAQ, participants were enquired about performance of various activities and the 
time spent doing each of them over the preceding 4 weeks. Each activity is then 
assigned a MET value as per the Compendium of Physical Activities (Ainsworth et 
al., 2011; Ainsworth et al., 2000; Ainsworth et al., 1993). Assuming the sleep time to 
be 6-8 hours per day and the unreported time to be spent in low intensity activity with 
a MET value of 1.3, the total daily MET was calculated by summation of the MET 
values for all the activities. Activity related MET was then calculated as shown below. 𝑨𝒄𝒕𝒊𝒗𝒊𝒕𝒚  𝒓𝒆𝒍𝒂𝒕𝒆𝒅  𝑴𝑬𝑻 = 𝑻𝒐𝒕𝒂𝒍  𝑴𝑬𝑻−    𝟐𝟒− 𝑺𝒍𝒆𝒆𝒑  𝒅𝒖𝒓𝒂𝒕𝒊𝒐𝒏   ×  𝟏  
Stanford 7-day recall questionnaire enquires about time spent on different intensities 
of activities over the preceding 7 days including average sleep duration per day. 
Total MET and activity related MET from Stanford questionnaire was calculated in a 
similar manner to RPAQ as explained above. 
6.3.8 Statistical Analysis 
Normally distributed data are presented as mean ± standard deviation and non-
normally distributed data as median (inter-quartile range). Differences in TEE 
between various subgroups were compared using unpaired t-test or one-way 
ANOVA as appropriate. Correlations between variables were analysed using 
Pearson correlation coefficient for normally distributed data and Spearman’s for non-
normally distributed data. Multiple regression models were constructed to examine 
the relationship between TEE and REE with renal function. The variables included in 
the model were age, weight, gender and eGFR. Collinearity testing was carried out 
for all the variables included in the regression model and variables with only low 
variance inflation factor (<10) were included. A p-value of <0.05 was assumed to 
indicate statistical significance. 
Total Body Water estimations from Watson formula (TBWWF) and whole-body 
bioimpedance (TBWBI) were compared with that measured using doubly labelled 
water (TBWDLW) using Bland-Altman technique (Bland & Altman, 1986). 
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6.4 Results 
6.4.1 Population Demographics 
The demographics and biochemical characteristics of study participants are shown in 
Table 6-1. 
Table 6-1: Demographic and Biochemical characteristics of Study Participants 
Significance in differences tested by: *unpaired t-test **Fisher’s Exact test; CCI: Charlson 
Comorbidity Index 
 All Patients CKD Stages 1-3 CKD Stages 4-5 p-value 
Number of 
patients 80 40 40  
Age (years) 56.7 ± 16.2 52.7 ± 17.0 60.7 ± 14.6 0.028* 
Male Gender 48 (60%) 21 (52.5%) 27 (67.5%) 0.254** 
Weight (kg) 77.0 ± 13.0 77.0 ± 13.8 77.0 ± 12.3 0.990* 
Height (cm) 169.0 ± 9.1 168.2 ± 8.0 169.8 ± 10.1 0.435* 
CCI 4.0 ± 2.5 2.9 ± 2.5 4.6 ± 2.1 0.001* 
eGFR 
(ml/min) 41.6 ± 32.1 66.6 ± 27.8 16.7 ± 6.1 < 0.001* 
CrCl-CG 
(ml/min) 50.7 ± 41.2 79.7 ± 40.3 21.7 ± 9.2 < 0.001* 
Haemoglobin 
(g/dL) 12.1 ± 1.7 12.8 ± 1.5 11.3 ± 1.5 < 0.001* 
 
There were 40 patients in each CKD group (stages 1-3 and stages 4-5). Subjects in 
the advanced CKD group were older and had higher comorbidity than those in the 
group with lesser degrees of CKD. There were no significant differences in the body 
size parameters such as weight and height between the groups. As would be 
expected, subjects in the advanced CKD group had significantly lower level of renal 
function (p < 0.001) and lower haemoglobin level (p < 0.001). 
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6.4.2 Half-life of Isotopes and Isotope Enrichment 
The mean baseline enrichment of 2H and 18O in the urine before administration of the 
isotopes was 151 (± 1.08) ppm and 1994 (± 1.82) ppm respectively. Following the 
ingestion of isotopes, the enrichment in the urine sample collected approximately 24 
hours later was 289 (± 19.87) ppm for 2H and 2242 (± 45.75) for 18O. Figure 6-1 
shows the relationship between half-life of 2H and that of 18O. As would be expected 
according to the principles of these isotope behaviours, the half-life of 18O was 
shorter with a mean of 6.6 days compared to the half-life of 2H with a mean of 8.5 
days. 
 
 
Figure 6-1: Half-lives of 2H and 18O 
 
6.4.3 Total Energy Expenditure Calculation 
Urine samples from day 1, 8 and 14 were analysed for isotopic enrichment of 2H and 
18O. Fractional enrichment of both the isotopes, calculated from equation 7 (section 
3.8.1.3), were plotted as a function of time. The exponential curve of each isotope 
was linearised using logarithmic transformation of the fractional enrichment. The 
 125 
intercept and slope of the line from this plot was used to calculate the pool size and 
carbon dioxide production rate as explained in section 3.8.1.3 (equations 8 – 15). 
The corrected pool size and carbon dioxide production rate was then used to 
calculate TEE. 
For all patients, there was a clear separation of isotope fractional enrichment levels 
of 2H and 18O by the end of the study observation period implying that the study 
duration was sufficiently long to ensure accurate calculation of carbon dioxide 
production rate. 
Figure 6-2 and Figure 6-3 shows the exponential and logarithmic plot of both 
isotopes from two patients. There was a close linear relationship between time and 
the logarithm of fractional enrichment. Pearson correlation coefficient between these 
two variables for both 2H and 18O were high. For 2H, the mean coefficient r was -0.99 
(± 0.0007) and for 18O, it was -0.99 (± 0.0006). 
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Patient 2 
 
Patient 2 
 
Figure 6-2: Exponential (top panel) and logarithmic (bottom panel) plots of 
isotope fractional enrichment over time. 
The intercept and slope from the logarithmic plot was used for TEE calculation. 
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Patient 16 
 
Patient 16 
 
Figure 6-3: Exponential (top panel) and logarithmic (bottom panel) plots of 
isotope fractional enrichment over time. 
The intercept and slope from the logarithmic plot was used for TEE calculation. 
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6.4.4 Energy Expenditure and Renal Function 
Mean measured REE (from indirect calorimetry) and TEE (from doubly labelled 
water) for the whole cohort and for CKD groups are shown in Table 6-2. Both REE 
and TEE did not differ significantly between the CKD groups. 
Table 6-2: Energy Expenditure of Study Participants 
 All patients (n = 80) 
CKD Stages 1-3 
(n=40) 
CKD Stages 4-
5 (n=40) p-value 
REE 
(kcal/day) 1560 ± 301 1580 ± 305 1540 ± 300 0.555 
TEE 
(kcal/day) 2481 ± 476 2501 ± 454 2460 ± 502 0.708 
REE/kg 
(kcal/kg/day) 20.4 ± 3.1 20.7 ± 3.1 20.1 ± 3.1 0.379 
TEE/kg 
(kcal/kg/day) 32.7 ± 6.3 33.0 ± 5.6 32.5 ± 7.0 0.724 
 
The plots of eGFR against REE and REE normalised to body weight are shown in 
Figure 6-4 and Figure 6-5. It can be seen that there is poor relationship between the 
estimated GFR and either of the variables. 
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Figure 6-4: Relationship between eGFR and REE 
 
 
Figure 6-5: Relationship between eGFR and REE/kg body weight 
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The plots of eGFR against TEE and TEE/kg are shown in Figure 6-6 and Figure 6-7. 
As with REE, there is a poor relationship between eGFR and either of these 
variables. 
 
Figure 6-6: Relationship between eGFR and TEE 
 
Figure 6-7: Relationship between eGFR and TEE/kg body weight 
 
 131 
Multivariate linear regression models with REE and REE normalised to body weight 
as dependent variable are shown from Table 6-3 and Table 6-6. The variables 
considered were age, sex, weight, height, fat-free mass (from bioimpedance 
measurement) and renal function expressed as eGFR from MDRD equation or 
Creatinine clearance from Cockcroft-Gault equation. Sex and weight were found to 
be significant predictors in all the models. In the models including eGFR, age was 
also found to be a significant predictor. Renal function was not significant in any of 
the models irrespective of the method of estimation of renal function (eGFR or CrCl-
CG). 
Table 6-3: Linear regression model of determinants of REE with eGFR 
Adjusted R2 = 0.505 
 Standardised coefficient (Beta) t p-value 
Constant  3.211 0.002 
Age -0.190 -2.040 0.045 
Sex 0.291 3.446 0.001 
Weight 0.591 7.115 < 0.001 
eGFR 0.100 1.073 0.287 
 
Table 6-4: Linear regression model of determinants of REE normalised to body 
weight with eGFR 
Adjusted R2 = 0.221 
 Standardised coefficient (Beta) t p-value 
Constant  12.088 < 0.001 
Age -0.246 -2.101 0.039 
Sex 0.370 3.488 0.001 
Weight -0.327 -3.134 0.002 
eGFR 0.145 1.237 0.220 
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Table 6-5: Linear regression model of determinants of REE with CrCl-CG 
CrCl-CG: Creatinine Clearance using Cockcroft-Gault equation; Adjusted R2 = 0.505 
 Standardised coefficient (Beta) t p-value 
Constant  3.557 0.002 
Age -0.173 -1.710 0.091 
Sex 0.296 3.474 0.001 
Weight 0.563 6.271 < 0.001 
CrCl-CG 0.115 1.097 0.276 
 
Table 6-6: Linear regression model of determinants of REE normalised to body 
weight with CrCl-CG 
CrCl-CG: Creatinine Clearance using Cockcroft-Gault equation; Adjusted R2 = 0.220 
 Standardised coefficient (Beta) t p-value 
Constant  12.966 < 0.001 
Age -0.225 -1.775 0.080 
Sex 0.375 3.510 0.001 
Weight -0.365 -3.240 0.002 
CrCl-CG 0.159 1.206 0.232 
 
Similar models were generated with TEE and TEE normalised to body weight as 
dependent variables which are shown from Table 6-7 and Table 6-10. Age, weight 
and height were found to be significant predictors in all these models. As with REE, 
renal function was not a significant predictor in any of the models. 
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Table 6-7: Linear regression model of determinants of TEE with eGFR 
Adjusted R2 = 0.392 
 Standardised coefficient (Beta) t p-value 
Constant  -0.419 0.676 
Age -0.327 -3.100 0.003 
Sex 0.217 1.924 0.058 
Height 0.276 2.467 0.016 
Weight 0.299 3.193 0.002 
eGFR 0.054 0.519 0.605 
 
Table 6-8: Linear regression model of determinants of TEE normalised to body 
weight with eGFR 
Adjusted R2 = 0.443 
 Standardised coefficient (Beta) t p-value 
Constant  2.336 0.022 
Age -0.305 -3.020 0.003 
Sex 0.248 2.297 0.024 
Height 0.238 2.226 0.029 
Weight -0.555 -6.191 < 0.001 
eGFR 0.083 0.833 0.408 
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Table 6-9: Linear regression model of determinants of TEE with CrCl-CG 
CrCl-CG: Creatinine Clearance using Cockcroft-Gault equation; Adjusted R2 = 0.392 
 Standardised coefficient (Beta) t p-value 
Constant  -0.415 0.679 
Age -0.319 -2.770 0.007 
Sex 0.217 1.926 0.058 
Height 0.279 2.473 0.016 
Weight 0.284 2.790 0.007 
CrCl-CG 0.058 0.494 0.623 
 
Table 6-10: Linear regression model of determinants of TEE normalised to 
body weight with CrCl-CG 
CrCl-CG: Creatinine Clearance using Cockcroft-Gault equation; Adjusted R2 = 0.444 
 Standardised coefficient (Beta) t p-value 
Constant  2.305 0.024 
Age -0.283 -2.568 0.012 
Sex 0.250 2.318 0.023 
Height 0.245 2.277 0.026 
Weight -0.583 -5.984 < 0.001 
CrCl-CG 0.107 0.949 0.346 
 
6.4.5 Physical Activity-related Energy Expenditure and Renal Function 
Table 6-11 shows the physical activity-related energy expenditure (PAEE) derived 
from doubly labelled water method and mean daily MET value estimated from the 
two activity questionnaires. Irrespective of the method of activity assessment, there 
was no difference noted between the two CKD groups. 
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Table 6-11: Physical Activity level of Study Participants 
DLW: Doubly labelled water method; RPAQ: Recent Physical Activity Questionnaire; 
*Median (inter-quartile range); † Mann-Whitney U test 
 All patients CKD Stages 1-3 CKD Stages 4-5 p-value 
DLW method 
(kcal/day) 672 ± 367 671 ± 325 674 ± 410 0.963 
Activity MET – 
RPAQ* 9.02 (8.5) 8.51 (7.3) 10.74 (9.3) 0.569
† 
Activity MET – 
Stanford* 18.59 (4.6) 18.50 (5.2) 18.63 (4.4) 0.552
† 
 
6.4.6 Comparison of body water measurement between Watson volume and 
DLW 
The total body water (TBW) as estimated by Watson formula (TBWWF) and that 
measured from doubly labelled water (TBWDLW) correlated significantly with a 
Pearson coefficient r = 0.831 (p < 0.001). The relationship between the two 
measurements is shown in Figure 6-8. 
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Figure 6-8: Relationship between TBWDLW and TBWWF 
 
A Bland-Altman plot comparing the two measurements is shown in Figure 6-9. The 
Watson formula overestimated the TBW with a mean bias of -2.17 Litres. The lower 
and upper 95% confidence interval limits for the bias were -9.6 and 5.27 Litres 
respectively. 
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Figure 6-9: Bland-Altman Plot of difference between TBWDLW and TBWWF 
Difference between total body water measured by DLW and Watson formula plotted against 
the mean of the two measurements. A negative sign indicates an overestimation and a 
positive sign indicates an underestimation by Watson formula. 
 
6.4.7 Comparison of body water measurement between Bioimpedance analysis 
and DLW 
The bioimpedance analysis for the 40 patients from the recent cohort was used for 
this analysis. TBW measured through bioimpedance (TBWBI) and TBWDLW correlated 
well with a Pearson coefficient (r) of 0.922 (p < 0.001). The relationship between the 
two measurements is shown in Figure 6-10.  
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Figure 6-10: Relationship between TBWDLW and TBWBI 
 
A Bland-Altman plot was constructed to compare the TBW measurements from the 
two methods which is shown in Figure 6-11. Bioimpedance analysis overestimated 
TBW with a mean bias of -4.8 Litres. The lower and upper limits of agreement were  
-11.7 and 2.1 Litres respectively. 
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Figure 6-11: Bland-Altman Plot of difference between TBWDLW and TBWBI 
Difference between total body water measured by DLW and Bioimpedance plotted against 
the mean of the two measurements. A negative sign indicates an overestimation and a 
positive sign indicates an underestimation by Bioimpedance. 
 
6.4.8 Relationship between TEE and Urea Generation rate 
Urea generation rate (G) was calculated for 37 patients in the recent cohort (3 
patients did not provide 24-hour urine collection sample). There was significant 
correlation between G and TEE with a Pearson coefficient (r) of 0.646 (p<0.001). 
The relationship between TEE and G are shown in Figure 6-12. There was a linear 
relationship between TEE and G with TEE alone explaining 42% of variance in G. 
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Figure 6-12: Relationship between TEE and Urea Generation Rate 
 
6.5 Discussion 
Due to the paucity of studies exploring total energy requirements in CKD, little is 
known about TEE in renal disease. One of the primary aims of this study was to 
explore the impact of varying kidney function on metabolic rate and total energy 
expenditure. The study data shows that there is no significant impact of worsening 
renal function on basal metabolic rate or TEE. Both Watson formula and 
Bioimpedance analysis perform reasonably well in measuring total body water when 
compared against that from doubly labelled water. There is also a strong relationship 
between TEE and urea generation rate implying that TEE may be closely related to 
uraemic toxin generation. The current study data is in favour of rejecting the null 
hypothesis and accepting the experimental hypothesis. 
The difficulties associated with measuring TEE using DLW method in dialysis 
patients are discussed in an earlier section of this chapter. Due to this, the criteria for 
study inclusion focused on patients with varying level of kidney function but not yet 
receiving dialysis. Total energy requirements were compared between subjects with 
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mild-moderate (CKD stages 1-3) and advanced renal disease (CKD stages 4-5). 
Study participants between the groups were well matched with regards to gender 
proportion and body size parameters. The mean age of the advanced CKD group 
was higher but this would be expected as renal failure is predominantly a disease of 
the elderly. Similarly, the mean haemoglobin was slightly but significantly lower in 
this group which, again, would be expected with progression of renal disease. 
The isotopes (2H and 18O) performed well and in a predictable manner in the study 
group. The mean half-life of 18O (6.6 days) was lower than that of 2H (8.5 days). This 
is because 18O is excreted as both carbon dioxide and water whereas 2H is excreted 
predominantly as water only. The log-transformed fractional enrichment of both the 
isotopes correlated strongly in all patients. This suggests that the limited multi-point 
technique used in the study is valid for the purpose of TEE measurement. 
The effect of varying level of renal function on REE and TEE was examined by 
comparing direct measurements of REE and TEE between the mild-moderate and 
advanced CKD groups. In order to permit comparison of energy expenditure 
measures across individuals of different body sizes, both REE and TEE were also 
examined after normalising them to body weight. There was no significant difference 
in TEE, TEE/kg, REE or REE/kg between these groups when compared using 
unpaired t-test. In addition, in multivariate linear regression analysis which takes into 
account the potential confounding variables such as age and body size measures, 
renal function was not a predictor of REE or TEE. Renal function explained between 
1-3% of variance with any of these parameters. This implies that GFR does not 
influence basal metabolic rate and renders support to the hypothesis proposed by 
Singer (Singer, 2001) that metabolic rate is the driving process for renal blood flow 
whilst the converse is not true. 
Previous studies examining the effect of renal function on REE have shown 
conflicting results. In a small study of 16 CKD patients, Panesar et al (2003) found 
that lower levels of GFR were associated with reduced REE (Panesar & Agarwal, 
2003). Monteon et al (1986) showed in 10 non-dialysed patients with CKD and 16 
haemodialysis patients that there was no difference in REE across the groups 
(Monteon et al., 1986). On the other hand, Kuhlmann (2001) measured REE 
sequentially in 22 patients as their renal function worsened and found that REE per 
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body cell mass increased with decreasing renal function (Kuhlmann et al., 2001). 
The authors suggested that this could be due to relative increase in lean body mass 
associated with weight reduction in chronic renal disease. The current study results 
show that there was no significant difference in REE with reducing renal function in 
80 patients. 
The level of renal function can be expressed using many ways. Two different 
measures of renal function – eGFR by MDRD equation and Creatinine clearance by 
Cockcroft-Gault equation – were used in this study to examine the relationship 
between renal function and energy expenditure. The most commonly used method at 
present in clinical practice is as estimated GFR (eGFR) by MDRD equation (Levey et 
al., 1999). This equation has been shown to underestimate GFR in those with higher 
levels of kidney function (GFR > 60 ml/min) (Poggio et al., 2005; Lin, Knight, Hogan, 
& Singh, 2003). Creatinine clearance estimated from Cockcroft-Gault equation 
performs better as a measure of renal function at higher levels of renal function 
compared to MDRD equation (Lin et al., 2003). For this reason, both these measures 
were used in this study. However, irrespective of the renal function measure, there 
was no significant impact of renal function noted on REE and this was also the case 
even after normalising REE to body weight. 
The impact of declining renal function on TEE was also explored in this study. As 
with REE, there was no significant impact of renal function on TEE irrespective of the 
renal function measure that was used or whether TEE was normalised to body 
weight. TEE encompasses both REE and physical activity related energy 
expenditure. As there has been no change in REE across CKD groups, the study 
data suggests there has been no significant change in physical activity level too with 
declining renal function. This is supported by the lack of significant difference 
between CKD groups in physical activity measures measured by DLW method and 
that estimated from two activity questionnaires. Studies assessing physical activity 
through direct measurements in patients with CKD are scarce. Two studies carried 
out in CKD patients with an eGFR > 30 ml/min where physical activity was measured 
using accelerometers showed low levels of physical activity in this patient group 
(Robinson-Cohen et al., 2013; Hawkins et al., 2011). However, another study by 
Wlodarek et al in 24 pre-dialysis CKD patients with a mean eGFR of 18 ml/min 
showed physical activity levels comparable to general population (Wlodarek, 
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Glabska, & Rojek-Trebicka, 2011). It may be expected that the physical activity level 
may decline with worsening renal function but there is no evidence published so far 
showing reduced total energy requirements with declining renal function. 
The study data supports the use of Watson formula for estimation of total body water 
in comparison to that obtained from bioimpedance analysis. Although the strength of 
association between TBWDLW and TBWBI was better than that between TBWDLW and 
TBWWF, Bland-Altman plot between TBWDLW and these two measures showed the 
Watson formula to have less bias compared to the bioimpedance analysis. Both the 
measurements overestimated TBW compared to the DLW method. There is no 
published literature on the accuracy of Watson formula for estimation of TBW in 
patients with CKD using the DLW method. This data strengthens the current clinical 
practice of using Watson formula for estimation of total body water in the prescription 
and monitoring of dialysis dose. 
Urea is categorised as a small molecule uraemic toxin and the extent of urea 
clearance is measured to define adequate dialysis dose. Urea generation rate can 
be considered a marker of small molecule uraemic toxin production. As shown in 
chapter 4, estimated TEE from physical activity questionnaires was a significant 
predictor of urea generation rate. This study is a direct measurement of TEE rather 
than an estimated one. The study data shows a strong relationship between 
measured TEE and Urea generation rate with TEE contributing to about 42% of 
variance in urea generation rate. This lends support to the notion that TEE and 
thereby, physical activity may play a significant role in uraemic toxin production and 
may impact on the minimum dialysis dose requirement. 
6.6 Limitations 
The limitations of the study are mostly related to the assumptions of the doubly 
labelled water technique as explained in an earlier section of this chapter. However, 
the methodology applied here is the standard technique and hence, results of any 
future studies can be compared to this study. This study is also limited by its sample 
size. Of course, a larger sample size may increase the power of the study but this is 
largely limited by the time-consuming nature of the study and the costs of the isotope 
and their analysis. Nevertheless, this study of 80 patients is the only study so far 
employing doubly labelled water to measure TEE in patients with renal disease. 
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6.7 Conclusion 
In summary, the study data have shown that declining renal function does not have a 
direct impact on basal and total metabolic rate. Any differences found between TEE 
levels in subjects with declining renal function are likely to be explained by 
differences in physical activity energy expenditure – though these were not apparent 
in this study sample. 
The study has also shown that the Watson formula provides a more accurate 
measure of total body water compared to that obtained from bioimpedance analysis. 
The study data also confirmed that TEE might exert a significant impact on uraemic 
toxin generation and hence influence the minimum dialysis dose requirements in 
patients with advanced renal disease. 
 145 
 Chapter 7 
7. Validity of Physical Activity Questionnaires in Chronic Kidney 
Disease 
 
7.1 Introduction 
Individuals with chronic kidney disease (CKD) often have poor appetite, especially in 
advanced stages, which could potentially contribute to low energy intake and protein-
energy wasting (Carrero et al., 2007; Kalantar-Zadeh, Block, McAllister, Humphreys, 
& Kopple, 2004; Burrowes et al., 2003). Assessing total energy requirements of 
individuals is vital for appropriate nutritional management of these patients. In routine 
clinical practice, total energy requirements are estimated by a combined measure of 
estimated basal metabolic rate (i.e. resting energy expenditure) and estimated 
physical activity level. There are predictive equations for estimation of resting energy 
expenditure (REE) such as Harris-Benedict, Mifflin-St Jeor and Schofield equations 
which are commonly used in clinical practice. Recently, a novel disease-specific 
predictive equation for REE has been published for use specifically in patients with 
renal disease (Vilar et al., 2014). This equation was derived and validated in a cohort 
of patients with renal disease and has been shown to be at least as accurate as the 
existing ones but with less bias compared to other equations. 
The estimation of physical activity is usually carried out by means of self-report 
physical activity questionnaire although prospectively completed activity diaries are 
an alternate option. There are many physical questionnaires that are available for 
use in clinical practice. Most of these questionnaires are derived from young healthy 
adults and as such, may not be applicable to specific groups of patients. CKD is 
predominantly a disease of the elderly and these activity questionnaires may not be 
valid in this patient population. A study by Bonnefoy et al (2001) examined the 
validity of ten physical activity questionnaires in elderly individuals in general 
population against doubly labelled water and found that only a few questionnaires 
were reliable for use in elderly (Bonnefoy et al., 2001). Moreover, the individual 
variability was high for all the questionnaires which limit their use in these individuals. 
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None of the physical activity questionnaires used in studies involving patients with 
kidney disease have been validated against doubly labelled water (DLW) method for 
estimation of physical activity-related energy expenditure (PAEE). Some of the 
available questionnaires have been tested against energy expenditure obtained from 
accelerometers. However, this is not ideal as accelerometer measurements 
themselves may also have a degree of associated measurement error. This error in 
itself has not been quantified using DLW method in patients with kidney disease. 
Whilst accelerometers serve as the next best tool to DLW method, it is important to 
validate physical activity questionnaires against DLW method in individuals with 
kidney disease. 
Recent Physical Activity Questionnaire (shown in Appendix B) enquires about the 
performance of various activities and the time spent on each of the reported activity 
over the preceding 4 weeks. The questionnaire is divided into three sections – 
activities at home and work and recreational activities. The questionnaire has been 
validated in healthy individuals against DLW method for categorising physical activity 
levels and estimation of PAEE (Besson et al., 2010). The calculations employed in 
the analysis of questionnaire data are discussed in the general methodology chapter 
(section 3.7.2.1). Two assumptions are made in estimating PAEE. Firstly, duration of 
sleep is assumed to be 6-8 hours depending on the total duration of the activity. 
Secondly, for the time not accounted for from the questionnaire, a MET (Metabolic 
Equivalent of Task) value of 1.3 is assumed if the individual’s common mode of 
travel is by walking or cycling and a value of 1 if any other mode of transport is 
specified. However, this may not be an appropriate method to calculate PAEE. 
Any activity other than sleep, even the energy cost of being just awake, is likely to 
have a MET value of more than 1. It is reasonable to assume that, in this 
unaccounted time, individuals are performing some activities at home which are not 
being specifically enquired by the questionnaire. Assigning an average MET value 
for this time is essential to have a better approximation of PAEE from the 
questionnaire. Hence, it is vital to explore the appropriate MET value that has the 
closest approximation to the measured PAEE and this can be carried out by 
employing the DLW method to measure PAEE directly. 
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Stanford 7-day recall questionnaire (shown in Appendix C) was developed for the 
Stanford Five City Project (Sallis et al., 1985). This questionnaire enquires about 
time spent on moderate, hard and very hard intensity activities and also sleep, over 
the preceding seven days. Any time not accounted for is considered to be spent 
performing light activities. 
Availability of a physical activity questionnaire that is validated specifically in patients 
with kidney disease will be beneficial in many ways. Firstly, it will be useful to 
estimate total energy requirements of the individuals which is the cornerstone of 
nutritional management in patients with kidney disease. Secondly, in haemodialysis 
patients, the estimated physical activity level from the questionnaire could potentially 
be used for adjusting dialysis dose according to metabolic needs of the individual 
patient. Finally, the activity data could be used to monitor the physical activity levels 
at regular intervals to encourage an active lifestyle for patients with kidney disease. 
Moreover, availability of a validated questionnaire may stimulate its consistent use in 
future research studies leading to comparable results across various studies. 
In view of the above potential benefits, this study was designed with the following 
objectives: 
1. To examine the validity of two physical activity questionnaires – Recent 
Physical Activity Questionnaire (RPAQ) and Stanford 7-day recall 
questionnaire – for estimation of TEE in subjects with kidney disease 
2. To identify appropriate Metabolic Equivalent of Task (MET) value for 
unaccounted time in RPAQ that, when applied, will better reflect the 
measured TEE 
As explained in the previous chapter, the DLW data presented here is from 80 
patients - 40 patients from the current study and 40 patients from another similar 
study conducted as part of Dr Vilar’s PhD (Dr Enric Vilar, PhD, University of 
Hertfordshire – degree awarded Feb 2012). However, the RPAQ was not used in the 
earlier study of Dr Vilar and hence, the validation cohort for RPAQ included only the 
40 patients from the current study whereas all 80 patients were included for 
examining the validity of Stanford questionnaire. 
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7.2 Methods 
7.2.1 Ethical Review 
The study was reviewed and approved by Hatfield NHS Research Ethics Committee 
(ref: 13/EE/0388 and UH Ethics ref: LMS/PG/NHS/00255). All participants provided 
written informed consent. 
7.2.2 Overview of Study Design 
This was a prospective cross-sectional study of 80 CKD patients – 40 each in CKD 
stages 1-3 and CKD stages 4&5 group. Consenting subjects participated in a 14-day 
study. Subjects performed a 24-hour urine collection beginning the day prior to the 
study day. On day 0, a comprehensive metabolic analysis was performed and 
subjects were given a measured dose of doubly labelled water isotope. Participants 
were then asked to collect a urine sample each day, starting 24 hours after the 
isotope ingestion for a period of 14 days for measurement of isotopic enrichment and 
calculation of TEE. Subjects were asked to complete two physical activity 
questionnaires at the end of the study period for validation of these questionnaires. 
7.2.3 Study Population 
All subjects were recruited from the outpatient clinics of Lister Hospital. The inclusion 
and exclusion criteria are as discussed in the previous chapter. Briefly, adult CKD 
patients older than 18 years of age were recruited. Individuals with any illness that 
may potentially cause abnormal metabolic rates were excluded from the study. 
7.2.4 Study Assessments 
7.2.4.1 Data collection and Metabolic Analysis 
Demographic, comorbidity and clinical data were obtained as discussed in the 
previous chapter. On the study day (Day 0), a thorough metabolic analysis was 
performed including anthropometric measurements, bioimpedance analysis and REE 
measurement by indirect calorimetry as previously explained. 
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7.2.4.2 Doubly labelled water administration 
The doubly labelled water isotope administration along with calculation of the 
required doses and subsequent calculation of TEE are explained in detail in the 
General Methodology section 3.8.1. After ingestion of the measured dose of the 
sample on Day 0, subjects were asked to collect the first urine sample after 24 hours 
on Day 1. From then on, they were asked to collect a urine sample each day for a 
period of 14 days approximately around the same time every day. However, as 
explained above, only the samples on Day 1, 8 and 14 were used for analysis. If any 
of these samples were missing, the sample closest to the missing day (±1 day) was 
used. Samples were collected at the end of the study period and frozen at -20°C until 
analysis was performed. 
7.2.4.3 Physical Activity Questionnaires 
At the end of the 14-day period, participants completed two physical activity 
questionnaires – Recent Physical Activity Questionnaire (RPAQ) and Stanford 7-day 
recall questionnaire. The questionnaires and the calculations for each of the 
questionnaire are described in detail in the general methodology chapter (section 
3.7.2). A brief description is provided below. 
7.2.5 Estimation of Physical Activity Level 
7.2.5.1 Recent Physical Activity Questionnaire (RPAQ) 
In RPAQ, participants were enquired about performance of various activities and the 
time spent doing each of them over the preceding 4 weeks. Each activity is then 
assigned a MET value as per the Compendium of Physical Activities (Ainsworth et 
al., 2011; Ainsworth et al., 2000; Ainsworth et al., 1993). If the total duration of 
reported activity exceeded 18 hours per day, then the total and individual activity 
duration was normalised to 18 hours. Sleep duration was assumed to be a maximum 
of 6-8 hours depending on the duration of the reported activity. For the time 
unaccounted for by the questionnaire, different MET values were assigned to explore 
the most accurate value that will achieve the best estimation of PAEE compared to 
that measured through DLW method. MET values for the unaccounted time were 
assigned in 0.05 increments from 1 through to 1.3. In addition, MET values for the 
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unreported time were also assigned as per the recommendation from MRC (MET 
(rec)). 
Two different methods of physical activity level estimation from RPAQ were 
explored. The first method involved calculating a mean daily MET value. This was 
carried out as follows. The MET value for each reported activity was multiplied by the 
duration of that activity. Similarly, assigned MET value for the unreported time and 
sleep was multiplied by the respective duration for the day. A total MET value, 
expressed as MET-hours/day, was calculated as explained in section 3.7.2.1. This 
was then divided by 24 (hours) to give a mean daily MET. TEERpaqMET was calculated 
by multiplying the daily MET by estimated REE derived from equation 1 (section 
3.6.1). In this method, the physical activity level is expressed as daily MET. The 
calculation steps are shown below. 
𝑴𝒆𝒂𝒏  𝑫𝒂𝒊𝒍𝒚  𝑴𝑬𝑻 =   𝑻𝒐𝒕𝒂𝒍  𝑫𝒂𝒊𝒍𝒚  𝑴𝑬𝑻𝟐𝟒  𝑻𝑬𝑬𝑹𝒑𝒂𝒒𝑴𝑬𝑻   𝒌𝒄𝒂𝒍/𝒅𝒂𝒚 = 𝑹𝑬𝑬   𝒌𝒄𝒂𝒍/𝒅𝒂𝒚   ×  𝑴𝒆𝒂𝒏  𝑫𝒂𝒊𝒍𝒚  𝑴𝑬𝑻 
The second method involves converting the total daily MET value to PAEE 
expressed as kcal/day. Energy expenditure from physical activity (MET-hours/day) 
was calculated by subtracting the basal metabolic rate from the total daily MET 
value. 𝑨𝒄𝒕𝒊𝒗𝒊𝒕𝒚  𝒓𝒆𝒍𝒂𝒕𝒆𝒅  𝑴𝑬𝑻 = 𝑻𝒐𝒕𝒂𝒍  𝑴𝑬𝑻−    𝟐𝟒− 𝑺𝒍𝒆𝒆𝒑  𝒅𝒖𝒓𝒂𝒕𝒊𝒐𝒏   ×  𝟏  
One MET is considered equal to 3.5 ml/kg/min of oxygen consumption. In order to 
convert the Activity related MET values (MET-hours/day) to PAEE expressed as 
kcal/day, a conversion factor is applied as shown below. The factor “3.5 x 60” 
converts the MET-hours/day into ml/kg/day. Multiplying this by “Weight / 1000” 
converts it to “L/day”. One Litre/min of oxygen consumption is considered equivalent 
to 5 kcal/min. Hence, this is multiplied by 5 to arrive at the final value in kcal/day. 
This is then added to REE to estimate TEERpaqPAEE as shown below. 
𝑷𝑨𝑬𝑬   𝒌𝒄𝒂𝒍/𝒅𝒂𝒚 =   𝑨𝒄𝒕𝒊𝒗𝒊𝒕𝒚  𝒓𝒆𝒍𝒂𝒕𝒆𝒅  𝑴𝑬𝑻  ×  𝟑.𝟓  ×  𝟔𝟎  ×  𝑾𝒆𝒊𝒈𝒉𝒕  ×  𝟓𝟏𝟎𝟎𝟎  
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𝑻𝑬𝑬𝑹𝒑𝒂𝒒𝑷𝑨𝑬𝑬   𝒌𝒄𝒂𝒍/𝒅𝒂𝒚 =    𝑹𝑬𝑬+ 𝑷𝑨𝑬𝑬𝟎.𝟗  
In addition, total activity duration spent in performing sedentary, moderate and 
vigorous intensity activity was also calculated. Sedentary time was estimated as the 
combined time spent watching television and that spent using a computer. Any 
activity with a MET value of 3 to 6 was considered moderate intensity and any 
activity having a MET value of more than 6 was considered vigorous intensity. 
Moderate and vigorous intensity activity duration was estimated by calculating the 
total reported time spent in the respective intensities. 
7.2.5.2 Stanford 7-day recall Questionnaire 
Stanford 7-day recall questionnaire enquires about time spent on different intensities 
of activities over the preceding 7 days. Any time not accounted for is considered to 
be spent performing light activities. Unlike RPAQ, this questionnaire enquires about 
the average duration of sleep over the preceding week and hence, no separate 
assumption is needed with regards to the sleep duration. Total daily MET was 
calculated similar to that carried out for RPAQ. TEEStMET and TEEStPAEE were 
calculated for this questionnaire in a similar fashion to that of RPAQ. 
7.2.6 Statistical Analysis 
Normally distributed data are presented as mean ± standard deviation and non-
normally distributed data as median (inter-quartile range). Comparison between 
questionnaire-derived TEE and PAEE and that from DLW method was carried out 
using Bland-Altman analysis. PAEE and TEE were calculated for each assigned 
MET value for the unaccounted time in RPAQ which were then compared with DLW 
measurements using Bland-Altman analysis (Bland & Altman, 1986). A p-value of < 
0.05 was considered significant. 
7.3 Results 
7.3.1 Population Demographics 
The demographic and biochemical characteristics of the study participants are 
discussed in the previous chapter (section 6.4.1) and reproduced here in Table 7-1 
below. 
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Table 7-1: Demographic and Biochemical characteristics of Study Participants 
Significance in differences tested by: *unpaired t-test **Fisher’s Exact test 
 All Patients CKD Stages 1-3 CKD Stages 4-5 p-value 
Number of 
patients 
80 40 40  
Age (years) 56.7 ± 16.2 52.7 ± 17.0 60.7 ± 14.6 0.028* 
Male Gender 48 (60%) 21 (52.5%) 27 (67.5%) 0.254** 
Weight (kg) 77.0 ± 13.0 77.0 ± 13.8 77.0 ± 12.3 0.990* 
Height (cm) 169.0 ± 9.1 168.2 ± 8.0 169.8 ± 10.1 0.435* 
CCI 4.0 ± 2.5 2.9 ± 2.5 4.6 ± 2.1 0.001* 
Haemoglobin 
(g/dL) 
12.1 ± 1.7 12.8 ± 1.5 11.3 ± 1.5 < 0.001* 
 
7.3.2 Reported activity duration from RPAQ 
The reported activity durations for different intensities of activities from RPAQ are 
shown in Table 7-2. The median reported activity duration per day was 9.2 hours 
with nearly half of that time spent in sedentary activities (median 4.6 hours). The 
median time spent in moderate intensity activity was approximately 30 minutes per 
day. The time spent in vigorous activity intensity was negligible. The median time 
that was not accounted for by the questionnaire was 6.8 hours. There were no 
significant differences between sexes in reported activity durations for any of the 
activity intensity groups. 
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Table 7-2: Reported daily activity durations from RPAQ 
Data presented are Median and inter-quartile range. 
 All Patients (n = 40) 
Males 
(n = 22) 
Females 
(n = 18) p-value 
Total reported activity time 
(hours) 9.2 (5.6) 9.2 (5.2) 8.6 (5.9) 0.63 
Sedentary time (hours) 4.6 (2.9) 4.8 (4.6) 4.6 (2.1) 0.91 
Moderate intensity activity time 
(hours) 0.29 (0.41) 0.28 (1.1) 0.33 (0.3) 0.52 
Unreported time (hours) 6.8 (5.5) 6.8 (5.2) 7.4 (5.9) 0.64 
 
7.3.3 Reported activity duration from Stanford Questionnaire 
The reported activity duration from Stanford questionnaire are shown in Table 7-3. 
The median daily MET was 1.49 (interquartile range: 0.2). The majority of the time is 
spent in light activity (median 15.3 hours). The median time spent in moderate 
activity intensity was 1 hour with negligible time spent in hard and very hard intensity 
activities. 
Table 7-3: Reported daily activity durations from Stanford Questionnaire 
Data presented are Median and inter-quartile range. 
 All Patients (n = 80) 
Males 
(n = 48) 
Females 
(n = 32) p-value 
Mean Daily MET 1.49 (0.2) 1.47 (0.2) 1.5 (0.2) 0.29 
Light Activity Time (hours) 15.3 (3.6) 15.3 (3.5) 15.4 (3.9) 0.84 
Moderate intensity activity 
time (hours) 1.0 (1.4) 0.9 (1.7) 1.1 (1.4) 0.34 
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7.3.4 Comparison of TEE from Stanford questionnaire and DLW 
As explained in the methods section, TEE was calculated in two ways from Stanford 
questionnaire – TEEStMET from the Daily MET and TEEStPAEE by converting MET into 
PAEE. The mean (± SD) for both these TEE values and that measured through DLW 
method are shown in Table 7-4. 
Table 7-4: TEE from Stanford Questionnaire and DLW method 
 Mean (±SD) 
TEEDLW (kcal/day) 2481 ± 476 
TEEStMET (kcal/day) 2541 ± 580 
TEEStPAEE (kcal/day) 3031 ± 754 
 
The estimated TEE from Stanford questionnaire was compared against TEEDLW by 
Bland-Altman technique. A Bland-Altman plot of TEEDLW and TEEStMET is shown in 
Figure 7-1. The X-axis represents the average TEE from these two measures and 
the Y-axis represents the difference between them. The mean difference between 
TEEDLW and TEEStMET was -61 kcal/day. The limits of agreement between the two 
measures were wide with the upper limit being 1003 kcal/day and the lower being -
1125 kcal/day.  
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Figure 7-1: Bland-Altman Plot of TEEDLW and TEEStMET 
Difference between TEE measured by DLW and Stanford questionnaire (as multiple of REE) 
plotted against the mean of the two measurements. A negative sign indicates an 
overestimation and a positive sign indicates an underestimation by the questionnaire. 
 
A Bland-Altman plot of TEEDLW and TEEStPAEE is shown in Figure 7-2. The mean 
difference between TEEDLW and TEEStPAEE was -551 kcal/day. The limits of 
agreement between the two measures were wider than that for TEEStMET with the 
upper limit being 788 kcal/day and the lower being -1889 kcal/day. 
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Figure 7-2: Bland-Altman Plot of TEEDLW and TEEStPAEE 
Difference between TEE measured by DLW and Stanford questionnaire (after conversion to 
PAEE) plotted against the mean of the two measurements. A negative sign indicates an 
overestimation and a positive sign indicates an underestimation by the questionnaire. 
 
7.3.5 Predicting the best approximation of MET for unreported time in RPAQ 
As discussed earlier in the chapter, different MET values ranging from 1-1.3 were 
assigned to the unreported time in RPAQ. TEE was calculated using each of these 
values in the two different methods described above and bias was calculated for 
each of these values compared to TEEDLW. The bias and the limits of agreement 
were examined separately using the measured REE and the estimated REE using 
the equation. Figure 7-3 shows the mean difference (bias) between TEEDLW and 
TEERpaqMET estimated with each of the assigned MET value from 1 to 1.3. MET (rec) 
is the recommended MET value assigned as described in the methodology section. 
Figure 7-4 shows the limits of agreement (upper and lower error bars) for these 
mean bias values. 
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Figure 7-3: Mean difference between TEEDLW and TEERpaqMET using different 
MET values for unreported time and estimated REE 
 
Figure 7-4: Error bars showing the limits of agreement for the bias between 
TEEDLW and TEERpaqMET using estimated REE 
Upper and lower error bars represent the upper and lower limits of agreement respectively. 
 158 
A MET value of 1.3 for the unreported time gave the least bias (108 kcal/day) and 
the best limits of agreement (upper limit: 822 kcal/day; lower limit: -607 kcal/day) 
compared to other MET values including the recommended MET value. 
Similarly, TEE was also calculated as above using the REE measured by indirect 
calorimetry instead of the estimated REE. Figure 7-5 and Figure 7-6 shows the mean 
bias and limits of agreement between the two TEE estimates using the measured 
REE. Again, the MET value of 1.3 had the least bias (171 kcal/day) and the best 
limits of agreement (upper limit: 1105 kcal/day; lower limit: -764 kcal/day) compared 
to other MET values. 
 
Figure 7-5: Mean difference between TEEDLW and TEERpaqMET using different 
MET values for unreported time and measured REE 
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Figure 7-6: Error bars showing the limits of agreement for the bias between 
TEEDLW and TEERpaqMET using measured REE 
Upper and lower error bars represent the upper and lower limits of agreement respectively. 
 
TEERpaqPAEE was also calculated as described above using the same assigned MET 
values. The mean difference between TEEDLW and TEERpaqPAEE using different MET 
values are shown in Figure 7-7 and the associated limits of agreement in Figure 7-8. 
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Figure 7-7: Mean difference between TEEDLW and TEERpaqPAEE using different 
MET values for unreported time and estimated REE 
 
Figure 7-8: Error bars showing the limits of agreement for the bias between 
TEEDLW and TEERpaqPAEE using estimated REE 
Upper and lower error bars represent the upper and lower limits of agreement respectively. 
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In contrast to the estimated TEERpaqMET, a MET value of 1 for the unreported time 
gave TEERpaqPAEE the least bias (-107 kcal/day) when compared to TEEDLW. 
However, the limits of agreement for this MET value (upper limit: 899 kcal/day; lower 
limit: -1113 kcal/day) were wider compared to that of TEERpaqMET. 
TEE calculation by this method using the measured REE instead of the estimated 
REE was also examined. Figure 7-9 and Figure 7-10 shows the mean bias and limits 
of agreement for TEE estimates using measured REE. Again, a MET value of 1 had 
the least bias (-42 kcal/day) but had wider limits of agreement (upper limit: 1102 
kcal/day; lower limit: -1186 kcal/day). 
 
Figure 7-9: Mean difference between TEEDLW and TEERpaqPAEE using different 
MET values for unreported time and measured REE 
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Figure 7-10: Error bars showing the limits of agreement for the bias between 
TEEDLW and TEERpaqPAEE using measured REE 
Upper and lower error bars represent the upper and lower limits of agreement respectively. 
 
7.3.6 Comparison of TEE from RPAQ questionnaire and DLW 
As a MET value of 1.3 for the unreported time was found to be the best 
approximation of activity intensity for the unreported time, this was employed to 
estimate TEERpaqMET and TEERpaqPAEE which were then compared with TEEDLW. The 
mean (± SD) for both these TEE values and that measured through DLW method are 
shown in Table 7-5. 
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Table 7-5: TEE from RPAQ Questionnaire and DLW method 
 Mean (±SD) 
TEEDLW (kcal/day) 2481 ± 476 
TEERpaqMET (kcal/day) 2324 ± 538 
TEERpaqPAEE (kcal/day) 2722 ± 667 
 
Both the estimated TEE values from RPAQ questionnaire were compared against 
TEEDLW by Bland-Altman technique. A Bland-Altman plot of TEEDLW and TEERpaqMET 
is shown in Figure 7-11. The mean bias was 108 kcal/day. The upper limit of 
agreement was 822 kcal/day and the lower limit was -607 kcal/day. 
 
Figure 7-11: Bland-Altman plot of TEEDLW and TEERpaqMET 
Difference between TEE measured by DLW and RPAQ (as multiple of REE) plotted against 
the mean of the two measurements. A negative sign indicates an overestimation and a 
positive sign indicates an underestimation by the questionnaire. 
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A Bland-Altman plot of TEEDLW and TEERpaqPAEE is shown in Figure 7-12. The mean 
bias was -290 kcal/day with the upper limit of agreement being 583 kcal/day and the 
lower limit being -1163 kcal/day. 
 
Figure 7-12: Bland-Altman plot of TEEDLW and TEERpaqPAEE 
Difference between TEE measured by DLW and RPAQ (after conversion to PAEE) plotted 
against the mean of the two measurements. A negative sign indicates an overestimation and 
a positive sign indicates an underestimation by the questionnaire. 
 
7.3.7 Relationship between TEE from the questionnaires and DLW method 
The relationship between TEE estimates derived from both the questionnaires and 
that measured using DLW method are shown in Figure 7-13 and Figure 7-14.  
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Figure 7-13: Relationship between TEEStMET and TEEDLW 
 
Figure 7-14: Relationship between TEERpaqMET and TEEDLW 
 
The estimated TEERpaqMET showed a closer relationship with TEEDLW (R2 linear – 
0.576) compared to that between TEEStMET and TEEDLW (R2 linear – 0.235). 
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7.4 Discussion 
The primary aim of this study was to examine the validity of the two physical activity 
questionnaires as tools to estimate TEE in clinical practice. The study showed the 
RPAQ questionnaire performs better for estimating energy requirements compared 
to Stanford 7-day recall questionnaire and has a higher correlation to TEE measured 
using the gold-standard doubly labelled water method. A MET value of 1.3 for the 
unreported time in RPAQ provides the best approximation of TEE from the 
questionnaire to the measured TEE. 
Assessing physical activity in patients with kidney disease will be beneficial in many 
ways. Firstly, it will help to characterise patients at risk of poor physical functioning. 
Secondly, it can be used to monitor the level of physical activity with disease 
progression and aid early detection of declining physical functioning. Finally, it can 
also be used to monitor the response to any clinical and psychological interventions 
related to physical activity levels. 
The DLW method does not offer a practical solution for measurement of TEE in 
clinical practice due to the time-consuming nature and the costs associated with it. 
Physical activity questionnaires are useful tools to assess activity levels on a routine 
basis. The commonly available physical activity questionnaires are not generally 
derived from elderly population or from specific subgroups of patients such as those 
with kidney disease. Questionnaires developed in younger people are inaccurate 
when used in elderly population (Washburn, Smith, Jette, & Janney, 1993; 
Washburn, Jette, & Janney, 1990). Patients with kidney disease are likely to be older 
adults and to have higher comorbidity and hence, the activity questionnaires need to 
be validated in this patient group. 
Two questionnaires – RPAQ and Stanford 7-day recall questionnaire – were 
examined for their validity in patients with kidney disease in this study. TEE derived 
from RPAQ correlated well with that measured from DLW method (R2 of 0.58). The 
strong correlation of RPAQ derived TEE with TEEDLW implies the questionnaire is an 
acceptable tool for use in patients with kidney disease. On the other hand, Stanford 
questionnaire had a weaker correlation with TEEDLW with the R2 being 0.24. This is 
comparable to other questionnaires that have been examined in patients with kidney 
disease (Johansen et al., 2001). Johansen et al (2001) compared 4 activity 
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questionnaires against accelerometer derived energy expenditure data and found 
wide variations in the validity of these questionnaires. Human Activity Profile was the 
best performing questionnaire in that study with a R2 of 0.53 for the Adjusted Activity 
Score from the questionnaire and the Stanford questionnaire had a R2 of 0.35. In a 
review by Neilson et al (2008), it was shown that the TEE derived from various 
questionnaires across many studies had only moderate correlation with TEE 
measured from DLW method (Neilson, Robson, Friedenreich, & Csizmadi, 2008). 
This highlights the limited capability of questionnaires for TEE estimation. However, 
the correlation between RPAQ-derived TEE and that from DLW is better than many 
of the other currently available questionnaires for energy expenditure estimation. 
There is a considerable amount of unreported time from RPAQ (median 6.8 hours 
per day) which does not include the sleep time. Excluding this time from TEE 
calculation will grossly underestimate the energy expenditure. The questionnaire 
captures higher intensity activities well with specific activities listed in detail. 
However, activities that are routinely carried out at home and low intensity activities 
are not specifically enquired for in the questionnaire. This may lead to these activities 
not being reported by patients. It is reasonable to assume that individuals are 
performing some activity – likely sedentary or low intensity activities – in this 
unreported time and hence, assigning an average MET value above 1 for this 
unreported time seems prudent. It is essential to identify an appropriate MET value 
to assign for this period which will enable better approximation of estimated TEE to 
the directly measured TEE from DLW method. 
A range of MET values (1 to 1.3) for the unreported time in RPAQ was explored. The 
study data shows that TEE estimated by assigning a MET value of 1.3 for the 
unreported time was the closest to the measured TEE compared to other MET 
values. Not only did the MET value of 1.3 showed the least bias but the limits of 
agreement with TEEDLW were also narrower when compared to other MET values. 
Intuitively, this would seem the appropriate MET for the unreported time. A MET 
value of 1.3 is generally considered the threshold between sedentary and light 
activities. Patients are more likely to under-report sedentary activities especially 
when not specifically enquired about it and hence, it is possible that patients with 
kidney disease are performing sedentary activities during this time. In another study 
measuring activity by accelerometer (chapter 8), it was found that the majority of the 
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day (>85%) was spent in sedentary activity by patients with kidney disease. 
Considering the activity data as measured by DLW method in this study and that 
measured by accelerometer (chapter 8) together, a MET value of 1.3 for the 
unreported time in RPAQ seems the best approximation to the true activity behaviour 
of patients with kidney disease. 
TEE estimation was also carried out using both measured REE and estimated REE 
from the specified equation. It was found that the bias and limits of agreement were 
higher with measured REE compared to that derived from predictive equation. This 
demonstrates that derivation of TEE from a questionnaire is only an approximation of 
the true total energy expenditure even when used in conjunction with measured REE 
values. Nevertheless, the better performance of predictive REE equation with MET 
value suggests that this is a reliable tool for TEE estimation in clinical practice. 
This study also explored two different methods of calculating TEE from the 
questionnaires. TEE can be expressed by a factorial approach as a multiple of REE 
using a physical activity factor which is the Mean Daily MET calculated from the 
questionnaires in this study. The total activity MET value per day can also be 
converted as energy expenditure related to physical activity (PAEE) in kcal/day. As 
there is no previous literature to suggest that one method is superior to other with 
regards to these two questionnaires, the study explored the reliability of both these 
methods against DLW technique. The study data showed that the factorial approach 
of estimating TEE was superior compared to that estimated by conversion to PAEE. 
This was true for both the questionnaires used in this study. Using the factorial 
approach for both the questionnaires and a MET value of 1.3 for the unreported time 
in RPAQ, it was seen that RPAQ performed better overall compared to the Stanford 
questionnaire in estimating TEE. Though the mean bias was slightly lower in 
Stanford questionnaire, the limits of agreement were much narrower with RPAQ than 
that with Stanford questionnaire. 
It has been suggested that the validity of activity questionnaires should not be 
assessed solely on correlations alone but be carried out in conjunction with other 
statistical methods (Schmidt & Steindorf, 2006; Bellach, 1993; Bland & Altman, 
1986). Bland-Altman plot is an appropriate way of exploring the validity of a new tool 
compared to a gold-standard method. This study has employed this method to 
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compare TEE measures from the questionnaire to DLW technique which strengthens 
the validity of the results reported here. If the questionnaire measures activity for a 
different time point than that measured by DLW, this may result in unreliable results 
from the questionnaire data (Neilson et al., 2008). The questionnaires in this study 
were administered at the end of the 14-day study period and hence the 
questionnaires reflect the activity behaviour in the same time frame as that 
measured by DLW. 
7.5 Limitations 
As explained in chapter 6, the main limitations of the study are related to the 
assumptions of the DLW method. As with any questionnaire method, recall bias may 
have been a confounding factor in the accuracy of the data. This has been negated 
to some extent by enquiring about specific activities in the preceding weeks which 
facilitates recall of the activities by the subjects. Moreover, the strength of 
relationship between questionnaire data and DLW method is also in line with 
previously published literature. Finally, the study is limited by its relatively small 
sample size but the costs associated with DLW method restrict the use of this 
technique in large-scale studies. 
7.6 Conclusion 
In conclusion, this is the first study to have validated activity questionnaires against 
doubly labelled water method in patients with kidney disease. This study has shown 
that RPAQ is a valid tool for assessment of activity level and TEE in CKD patients. 
Stanford questionnaire, though showing some relationship to the measured TEE, 
performs worse than RPAQ in estimating TEE in this patient group. A MET value of 
1.3 has been shown to be the best estimate of the activity level for the unreported 
time in RPAQ and use of this value is recommended when using RPAQ for patients 
with kidney disease. 
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 Chapter 8 
8. Influence of Physical Activity on Urea Generation Rate 
 
8.1 Introduction 
Individuals with Chronic Kidney Disease (CKD) have increased cardiovascular risk 
and high mortality from cardiovascular causes (Robinson-Cohen et al., 2009; 
Johansen, 2005). Physical activity levels are low in patients with CKD and ESRD 
(Robinson-Cohen et al., 2013; Johansen et al., 2000). Physical inactivity may play a 
significant role in CKD patients through its association with cardiovascular risk. 
Physically active lifestyle may reduce the progression of kidney disease(Kouidi, 
Grekas, Deligiannis, & Tourkantonis, 2004) and also reduce the malnutrition-
inflammation complex syndrome prevalent in this patient population (Castaneda et 
al., 2004). 
Exercise induces profound changes in renal haemodynamics and protein excretion. 
The renal fraction of the cardiac output decreases with increasing exercise intensity 
(Grimby, 1965) which may lead to a reduction in effective renal plasma flow. This 
produces a concomitant reduction in Glomerular Filtration Rate (GFR) although the 
reduction in GFR is proportionately less than that of renal plasma flow(Poortmans, 
1984) due to an increase in filtration fraction  which may reach up to 67% during 
heavy exercise (Castenfors, 1967). In addition, there is an increase in proteinuria 
during exercise and immediate post-exercise period which is also related to the 
intensity of exercise (Poortmans, Rampaer, & Wolfs, 1989; Poortmans & Labilloy, 
1988). This is due to an increased permeability of the glomerular capillaries and also 
to reduced reabsorption in the tubules. 
There is paucity of studies examining GFR levels at rest in physically active 
individuals. There are no comparative clinical studies comparing GFR in physically 
active and sedentary individuals. One might expect GFR to be higher in physically 
active individuals due to increased generation of metabolic waste products and there 
is circumstantial evidence to support this. 
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Lippi et al (2008) found that estimated GFR (by Modification of Diet in Renal Disease 
equation- eGFR-MDRD) was significantly higher in professional cyclists compared to 
sedentary controls(Lippi, Banfi, Luca Salvagno, et al., 2008), though  the  cyclists 
had lower body weight and BMI than sedentary controls, so no conclusions can be 
drawn about the direct influence of physical activity on GFR. In a similar study 
comparing renal function among amateur and professional cyclists and healthy 
sedentary controls, eGFR-MDRD was significantly higher in cyclists compared to 
sedentary controls (Lippi, Banfi, Salvagno, Franchini, & Guidi, 2008) but non-
significantly  higher in professional compared to amateur cyclists. A large 
prospective study in Norway showed that higher levels of physical activity were 
associated with increase in eGFR-MDRD over time in women but not men (Kronborg 
et al., 2008). Physical activity data was collected through questionnaires and not 
directly measured. 
There is however a definite and direct link between high body mass index (BMI) and 
GFR. In a cross-sectional study conducted by Kambham et al (2001) examining the 
relationship between obesity and glomerular changes, obese individuals were found 
to have glomerular hypertrophy compared to age- and sex-matched healthy controls 
(Kambham, Markowitz, Valeri, Lin, & D'Agati, 2001). They also found that creatinine 
clearance was significantly higher in obese individuals with 41.4% of study patients 
having a creatinine clearance of >130 ml/min. This effect of BMI on GFR is also seen 
in individuals with high BMI owing to increased muscle mass. Schwimmer et al 
(2003) reported findings from 3 male patients whose jobs involved strenuous 
physical activity (Schwimmer et al., 2003). BMI of these patients ranged from 30.4 – 
32.1 kg/m2 with body fat content of only 12.9-16.8%. All 3 patients had high 
measured creatinine clearance ranging from 113-208 ml/min and their renal biopsies 
showed glomerular hypertrophy. These studies provide some evidence to support 
the hypothesis that physical activity levels influence GFR. 
There are a limited number of studies that have measured habitual physical activity 
levels in haemodialysis patients. These studies have shown physical activity levels to 
be extremely low in HD patients (Baria et al., 2011; Cupisti, Capitanini, Betti, 
D'Alessandro, & Barsotti, 2011; Zamojska et al., 2006; Majchrzak et al., 2005; 
Johansen et al., 2000). A recent multi-centre study conducted by Avesani et al 
(2012) showed energy expenditure from physical activity in HD patients contributed 
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only 12-16% to total energy expenditure in comparison to the expected 15-30% in 
general population (Avesani et al., 2012). Similar results have also been reported in 
questionnaire-based studies of physical activity (Johansen et al., 2010; Stack & 
Murthy, 2008). 
Whether higher levels of physical activity result in increased metabolic waste 
generation and mobilisation from peripheral tissues in patients with end-stage renal 
disease (ESRD) has not yet been studied. The potential effect of physical activity on 
uraemic toxin generation may be important in this setting as it may influence 
minimum dialysis requirements. There is considerable debate as to the choice of an 
ideal uraemic toxin marker. The current adequacy target for dialysis is based on urea 
clearance. Urea generation rate (G) is an accepted surrogate marker of small solute 
uraemic toxin generation and can be calculated through formal urea kinetic 
modelling. However there are limitations to using urea for this purpose as discussed 
in section 2.2.1. 
This study was designed 
• To examine the impact of physical activity on urea generation rate and 
thereby, minimum dialysis requirement 
• To explore the relationship between measured physical activity and that 
estimated by the Recent Physical Activity Questionnaire (RPAQ). 
The experimental hypothesis for this study was that increasing physical activity 
levels contribute to higher uraemic toxin generation in haemodialysis patients. The 
null hypothesis was that there was no relationship between physical activity and 
uraemic toxin generation. 
8.2 Methods 
8.2.1 Ethical Review 
The study was approved by Essex Research Ethics Committee (ref: 13/EE/0053 and 
UH Ethics ref: LMS/PG/NHS/00254). All study participants gave written informed 
consent. 
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8.2.2 Study Design 
This was a cross sectional study of 120 haemodialysis patients. Physical activity was 
measured by a wrist-worn accelerometer over a period of 7 days. All study 
participants prospectively completed a food diary for three days during the study 
duration and also, the recent physical activity questionnaire (RPAQ) at the end of the 
study period. 
8.2.3 Study Population 
A total of 120 maintenance HD patients were recruited from the renal units of East 
and North Hertfordshire NHS Trust and Royal Free Hampstead NHS Trust. Inclusion 
criteria were patients older than 18 years of age, those who have been on 
maintenance haemodialysis for at least 3 months and those who were anuric. 
Exclusion criteria included patients with untreated hypo- or hyperthyroidism, active 
malignancy, ongoing sepsis, active vasculitis, history of hospitalisation in the last 
month, current pregnancy, cardiac pacemakers or defibrillators, unexplained weight 
loss, limb amputation, immobility due to major physical ailments and those with no 
capacity to consent. Only anuric patients were included to facilitate estimation of 
urea generation rate without the need for the inter-dialytic urine collection. 
8.2.4 Study Assessments 
The following assessments were carried out for the study. 
8.2.4.1 Demographic and Anthropometric data 
Data comprising of age, sex, ethnicity, weight, height and comorbid conditions were 
collected for all study participants through direct measurements and individual 
medical records. Charlson Comorbidity Index was calculated as previously described 
(Charlson et al., 1987). 
8.2.4.2 Dietary Assessment 
Participants were asked to prospectively complete a food diary for three days in the 
week when the activity was measured. They were asked to record all food and drinks 
consumed on a dialysis day, a non-dialysis day and a weekend day. The dietary 
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records were assessed by trained renal dieticians to estimate average total protein 
and energy intake during the study period. 
8.2.4.3 Measurement of Physical Activity 
Physical activity was measured using a validated wrist-worn tri-axial accelerometer, 
GENEActiv as explained in section 3.7.1. Study participants were asked to wear the 
accelerometer on the non-fistula hand for 7 consecutive days. They were asked to 
wear it for all 24 hours in the day. 
8.2.4.4 Recent Physical Activity Questionnaire 
The recent physical activity questionnaire (RPAQ) enquires about various physical 
activities at home, work and during leisure time in the preceding 4 weeks and is 
explained in detail in the general methodology chapter. Information on physical 
activity was also collected using the RPAQ questionnaire at the end of the 7-day 
period as explained in section 3.7.2.1. 
8.2.4.5 Metabolic analysis 
Resting energy expenditure (REE) was estimated using equation 1 described in 
section 3.6.1. Total body water was calculated using the Watson formula (section 
3.10.1). In addition, body water and composition was analysed using the Inbody 720 
bioimpedance device as explained in section 3.10.2. 
8.2.4.6 Urea Kinetic Modelling 
As explained in section 4.2.4.6, 2-pool Urea generation rate was calculated using 
Solute Solver. Normalised Protein Catabolic Rate (nPCR) can also be calculated 
using formal urea kinetic modelling. nPCR is a marker of protein degradation and 
when measured in-between dialysis sessions, is a marker of dietary protein intake in 
steady-state conditions. 
8.2.5 Measurement of Activity Time 
The data from GENEActiv accelerometer was downloaded onto a computer and was 
analysed as explained in the general methodology chapter (section 3.7.1). The raw 
data was analysed using a pre-defined algorithm and the outcome variables 
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obtained for each study day were total wear and non-wear time, time spent in 
sedentary, light, moderate and vigorous intensity activity. The algorithm does not 
define sleep time and hence, sleep time is included in the sedentary time. 
Analysis of the RPAQ data is explained in the general methodology chapter (section 
3.7.2.1). Moderate activity time from RPAQ was calculated by the summation of time 
spent in activities with a MET (Metabolic Equivalent of Task) value of 3-6. Vigorous 
activity time was calculated similarly by taking into account the activities with a MET 
value of higher than 6 as per the Compendium of Physical Activities (Ainsworth et 
al., 2011; Ainsworth et al., 2000; Ainsworth et al., 1993). 
8.2.6 Sample Size and Statistical Analyses 
Data from the questionnaire-based study of physical activity (chapter 4) was used to 
calculate the sample size for this study. A power analysis was performed to estimate 
the statistical power provided by a study of 120 haemodialysis patients. Assuming 
α=0.05, N=120 patients and the correlation coefficient from the previous study, the 
power to detect significant relationship between physical activity levels and G was 
estimated to be more than 0.8 with five to ten covariates in the model demonstrating 
sufficient power for the study. 
Normally distributed data are presented as mean ± standard deviation and non-
normally distributed data as median (inter-quartile range). Differences in activity time 
between groups were compared using unpaired t-test for normally distributed data 
and Mann-Whitney U test for non-normally distributed data and using ANOVA for 
multiple group comparisons. Correlations between variables were analysed using 
Pearson correlation coefficient for normally distributed data and Spearman’s for non-
normally distributed data. 
Specific criteria were applied to accelerometer wear time for inclusion in the study. 
The study day was considered ‘valid’ for analysis only when subjects have worn the 
accelerometer for at least 50% of the day. Patients who have worn the 
accelerometer for at least 3 ‘valid’ days during the 7-day period were included for 
analysis. Accelerometer-derived activity time was converted to logarithmic scale for 
normalisation and was used as such in linear regression models to predict urea 
generation rate. Collinearity testing was carried out for all the variables included in 
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the regression model and variables with only low variance inflation factor (<10) were 
included. A p-value of <0.05 was assumed to indicate statistical significance. 
8.3 Results 
8.3.1 Population Demographics 
A total of 120 patients were recruited for the study. Due to insufficient wear time of 
the accelerometer as described in statistical analysis section, 15 subjects were 
excluded and thereby, 105 patients were included in the analyses below. The 
demographic characteristics of the study population are given in Table 8-1. Body 
size parameters such as weight and height and REE were significantly higher in 
males. There were no differences between sexes with regards to age, ethnicity, 
comorbidity, haemoglobin, serum urea, dietary protein intake and presence of 
ischaemic heart disease and diabetes mellitus. The delivered dialysis dose 
(equilibrated Kt/V) was slightly higher in females even though the dialysis session 
time was less. 
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Table 8-1: Demographics of Study Participants 
Values expressed are mean ± SD. Categorical variables are expressed as percentages. 
Differences between sexes were analysed by unpaired t-test for continuous variables and by 
Fisher’s Exact test for categorical variables. CCI: Charlson Comorbidity Index; IHD: 
Ischaemic Heart Disease; REE: Resting Energy Expenditure 
 All patients (n = 105) 
Males 
(n = 66) 
Females 
(n = 39) p-value 
Age (years) 64.0 ± 14.3 62.5 ± 15.1 66.5 ± 12.5 0.173 
Weight (kg) 75.0 ± 20.8 80.4 ± 20.6 66.0 ± 17.9 < 0.001 
Height (cm) 166.9 ± 9.2 171.6 ± 6.3 159.0 ± 7.9 < 0.001 
White: Asian: 
Black Ethnicity (%) 61: 16.2: 22.9 
63.6: 18.2: 
18.2 
56.4: 12.8: 
30.8 0.310 
Urea (mmol/L) 20.1 ± 5.6 20.2 ± 5.3 19.8 ± 6.0 0.709 
Creatinine 
(µmol/L) 869 ± 236 924 ± 240 776 ± 198 0.001 
Haemoglobin 
(g/dL) 11.4 ± 1.4 11.6 ± 1.5 11.2 ± 1.1 0.175 
Dialysis Session 
Time (minutes) 222 ± 27 227 ± 27 213 ± 24 0.007 
Equilibrated Kt/V 1.43 ± 0.30 1.39 ± 0.26 1.51 ± 0.33 0.045 
CCI 3.3 ± 2.2 3.3 ± 2.3 3.2 ± 1.9 0.796 
IHD (%) 31.4 33.3 28.2 0.666 
Diabetes Mellitus 
(%) 21.9 25.8 15.4 0.235 
REE (kcal/day) 1542 ± 284 1655 ± 255 1351 ± 224 < 0.001 
Protein Intake 
(g/kg/day) 0.84 ± 0.31 0.81 ±0.31 0.89 ± 0.31 0.195 
nPCR (g/kg/day) 0.92 ± 0.20 0.93 ± 0.21 0.91 ± 0.18 0.666 
 
 178 
8.3.2 Accelerometer- and Questionnaire-derived Activity Time 
Table 8-2 shows the measured activity time in different intensities by the 
accelerometer. The measured vigorous intensity activity time was negligible with a 
median of zero minutes (interquartile range of 0.14 minutes). The estimated 
moderate and vigorous activity times from the reported data in RPAQ were also 
negligible with a median of zero minutes for both. 
Table 8-2: Measured Time Spent in Different Intensity Activities per day 
 Median (interquartile range) 
Sedentary Activity Time (minutes) 1149 (118) 
Light Activity Time (minutes) 122 (116) 
Moderate Activity Time (minutes) 11 (29) 
 
8.3.3 Differences in Activity Level on Dialysis and Non-dialysis Days 
The proportion of time spent in different intensity activities on dialysis and non-
dialysis days are shown in Table 8-3. As the total wear time might vary between 
days, the times are shown as proportion of total measured activity time. The 
sedentary time was significantly higher on dialysis days whereas subjects spent 
more time on light and moderate activity time on non-dialysis days. There was no 
significant difference in the vigorous activity time between dialysis and non-dialysis 
days. 
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Table 8-3: Comparison of Activity Time on Dialysis and Non-dialysis Days 
Values expressed are mean ± SD. Differences between dialysis and non-dialysis days were 
compared using paired Wilcoxon test. 
 Dialysis Days Non-dialysis Days p-value 
Sedentary Activity 
Time (%) 89.4 ± 7.4 87.8 ± 8.7 0.013 
Light Activity Time 
(%) 9.8 ± 5.7 10.6 ± 6.3 0.007 
Moderate Activity 
Time (%) 1.6 ± 2.1 1.9 ± 2.7 0.015 
Vigorous Activity 
Time (%) 0.02 ± 0.09 0.02 ± 0.07 0.387 
 
As subjects spent a considerable amount of time sedentarily while receiving dialysis, 
this time was deducted from the total sedentary time on dialysis days and compared 
with the sedentary time on non-dialysis days. The proportion of sedentary time was 
then significantly higher on non-dialysis days compared to dialysis days (69.4% vs. 
87.8%, p < 0.001 by paired Wilcoxon test) if the time spent on dialysis was not 
included. 
8.3.4 Correlates of Activity Time 
As vigorous intensity activity time was very small in the overall study population, the 
moderate and vigorous activity time was combined to reflect higher intensity activity 
time. Table 8-4 shows the correlates of M-V (moderate-vigorous) activity time. 
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Table 8-4: Correlates of Moderate-Vigorous Activity Time 
Correlation coefficient shown is Spearman’s (rho) correlation coefficient. CCI: Charlson 
Comorbidity Index; REE: Resting Energy Expenditure 
 Correlation coefficient (rho) p-value 
Age -0.484 < 0.001 
Ethnicity 0.168 0.086 
Weight 0.075 0.449 
CCI -0.505 < 0.001 
REE 0.253 0.009 
Fat-free mass (FFM) 0.222 0.028 
Muscle Mass 0.246 0.015 
Daily Protein Intake 0.370 < 0.001 
Protein Intake/kg body weight 0.310 0.002 
M-V Activity Time from RPAQ 0.330 0.001 
 
M-V activity time correlated negatively with age and Charlson comorbidity index and 
positively with REE, fat-free mass (FFM) and muscle mass. The correlation between 
body weight and M-V activity time was not significant. The measured M-V activity 
time also correlated significantly with daily protein intake and protein intake 
normalised to body weight. 
8.3.5 Correlates of Urea Generation Rate 
The mean urea generation rate (G) was 4.7 (± 1.6) mg/min. Univariate correlation of 
G with anthropometric, metabolic and activity measures are shown in Table 8-5. 
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Table 8-5: Correlates of Urea Generation Rate 
Correlation coefficient shown is Pearson’s (r) correlation coefficient; REE: Resting Energy 
Expenditure; FFM – Fat-free mass; M-V activity time: Combined moderate and vigorous 
activity time 
 Correlation coefficient (r) p-value 
Age -0.306 0.002 
Weight 0.598 < 0.001 
REE 0.641 < 0.001 
Watson Volume 0.657 < 0.001 
FFM 0.709 < 0.001 
M-V Activity time 0.204 0.037 
Daily moderate activity time 0.213 0.029 
Daily Protein Intake 0.108 0.298 
 
Urea generation rate correlated negatively with age with fat-free mass having the 
highest correlation coefficient. G also correlated significantly with resting energy 
expenditure and moderate-vigorous activity time. There was no significant correlation 
between G and daily protein intake. 
8.3.6 Relationship between G and REE and FFM 
The relationship between G and REE is shown in Figure 8-1. There was a significant 
positive relationship between these two variables with a R2 linear of 0.411. 
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Figure 8-1: Relationship between REE and Urea Generation Rate 
 
 
Figure 8-2: Relationship between FFM and Urea Generation Rate 
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Figure 8-2 shows the relationship between G and FFM which was better than that 
with REE with a R2 linear of 0.502. 
8.3.7 Relationship between Activity Time and G 
Figure 8-3 and Figure 8-4 shows the relationship between M-V activity time with G 
and G normalised to body weight. In both these cases, there was a trend towards 
higher urea generation rate between the lowest and the highest quartiles of activity 
time though it did not reach statistical significance (p = 0.08 for urea generation rate 
and 0.06 for urea generation rate/kg body weight). 
 
 
Figure 8-3: M-V Activity time and Urea Generation Rate 
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Figure 8-4: M-V Activity time and Urea Generation Rate normalised to body 
weight 
M-V activity time was dichotomised using a cut-off value of 10 minutes. The 
difference in G and G normalised to body weight between the two groups of M-V 
activity time is shown in Figure 8-5 and Figure 8-6. The urea generation rate was 
significantly higher in patients who spent at least 10 minutes in performing moderate-
vigorous activity time per day. 
 
Figure 8-5: Effect of M-V Activity time on Urea Generation Rate 
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Figure 8-6: Effect of M-V Activity time on Urea Generation Rate normalised to 
body weight 
 
8.3.8 Relationship between G and Ethnicity 
The relationship between G and ethnicity was explored. Urea generation rate was 
normalised to body weight to adjust for any body size differences among patients of 
different ethnic origins. Figure 8-7 shows the difference in G/kg body weight between 
Asians and Non-Asians. Non-Asians had a significantly higher urea generation 
rate/kg body weight compared to Asians (p = 0.019). 
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Figure 8-7: Urea Generation Rate normalised to body weight based on 
Ethnicity 
8.3.9 Relationship between G and Protein Intake 
Figure 8-8 shows a graph of G/kg body weight against dietary protein intake/kg body 
weight. There was a weak relationship between these variables with a R2 linear of 
0.068. 
 
Figure 8-8: Relationship between Protein intake and Urea Generation Rate 
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8.3.10 Predictors of Urea Generation Rate 
In order to explore the predictors of G, multivariate linear regression models were 
developed. M-V activity time was normalised using logarithmic transformation. The 
variables considered were age, sex, Asian ethnicity, weight, REE, Log of M-V activity 
time, dietary protein intake and Fat-free mass. Table 8-6 and Table 8-7 show two 
regression models of predictors of urea generation rate. Age and dietary protein 
intake did not contribute significantly to any of the models examined. The best model 
was the one that included Fat-free mass (adjusted R2 – 0.486). 
 
Table 8-6: Predictors of G with FFM excluded 
Adjusted R2 – 0.449 
 Standardised Coefficient (Beta) t p-value 
Constant  -0.902 0.369 
Male Gender 0.206 2.617 0.010 
Asian Ethnicity 0.208 2.837 0.006 
Weight 0.543 6.988 < 0.001 
Log M-V Activity 
Time 0.179 2.412 0.018 
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Table 8-7: Predictors of G with FFM included 
Adjusted R2 – 0.486 
 Standardised Coefficient (Beta) t p-value 
Constant  -0.997 0.321 
Male Gender -0.021 -0.222 0.825 
Asian Ethnicity 0.059 0.779 0.438 
Log M-V Activity 
Time 0.044 0.585 0.560 
Fat-free mass 0.706 7.293 < 0.001 
 
8.4 Discussion 
The experimental hypothesis for the study was that higher physical activity level 
contributes to increased uraemic toxin generation. The study data showed that 
higher level of moderate to vigorous intensity activity contributes to increased urea 
generation rate. Moderate-vigorous activity time was also a significant predictor of 
urea generation rate in multivariate regression models adjusted for other factors 
such as age, sex, ethnicity and body weight. These findings lend support in favour of 
rejecting the null hypothesis and accepting the experimental hypothesis. 
Habitual physical activity levels are low in haemodialysis (HD) patients. There are 
multiple physical and mental health benefits associated with higher activity levels in 
patients with kidney disease. Firstly, physically active HD patients have reduced 
mortality risk compared to sedentary patients (Matsuzawa et al., 2012; O'Hare et al., 
2003).  Secondly, exercise training in patients with kidney disease improves physical 
performance, skeletal muscle strength, exercise capacity and blood pressure control 
(Cheema et al., 2007; Cappy, Jablonka, & Schroeder, 1999; Boyce et al., 1997). 
Thirdly, exercise training is more likely to improve the quality of life and reduce 
symptoms of insomnia and depression (Anand et al., 2013; van Vilsteren, de Greef, 
& Huisman, 2005; Suh et al., 2002; Painter, Carlson, Carey, Paul, & Myll, 2000). 
Finally, increasing physical activity has also been shown to improve signs of 
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inflammation in patients with kidney disease (Viana et al., 2014; Castaneda et al., 
2004). In view of these potential benefits, there has been increasing efforts to 
encourage physical activity in haemodialysis patients. Besides considering factors 
such as patient characteristics and feasibility, a holistic exercise programme in HD 
patients should also consider the direct impact of physical activity on dialysis 
requirements. But, there is a knowledge gap here in that the influence of PA levels 
on dialysis requirements has not been explored so far. 
This study data showed that physical activity levels are extremely low in HD patients 
with the majority of the time being spent in sedentary activities. This is in keeping 
with previous published literature (Zamojska et al., 2006; Majchrzak et al., 2005). 
The time spent in moderate intensity activity was very low with no significant time 
spent at all in vigorous intensity activity. The sedentary activity time was higher on 
dialysis days compared to non-dialysis days. However, there was slight but 
significant increase in light and moderate activity time on non-dialysis days. The 
higher sedentary time on dialysis days may, in part, be due to the time spent 
receiving the dialysis treatment and possibly be secondary to the post-dialysis 
fatigue. Moderate-vigorous activity time correlated positively with metabolic 
parameters such as REE and FFM. There was also positive correlation with muscle 
mass. This suggests that even small increases, as seen in this cohort, in higher 
intensity activities can favourably impact on muscle mass. As would be expected, 
there was a negative correlation between activity time and age and comorbidity 
status. The activity time also correlated significantly with protein intake indicating that 
physically active individuals are likely to consume higher amounts of dietary protein. 
Urea generation rate (G) was used as a surrogate marker of uraemic toxin 
generation in this study. Urea generation rate correlated positively with parameters 
such as weight, total body water (Watson volume), REE and FFM. The best 
correlation was with fat-free mass. Fat-free mass encompasses the muscle mass 
and visceral organs where the bulk of uraemic toxin production occurs. Hence, it is 
not surprising that G, a marker of uraemic toxin generation, correlated significantly 
with FFM. The relationship between these two factors was also evident in regression 
models where FFM was the single most important determinant of urea generation 
rate with the model explaining nearly 49% of the variance in G. 
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Urea generation rate also correlated positively with moderate-vigorous (M-V) activity 
time. In multivariate regression model adjusted for sex, ethnicity and body size, M-V 
activity time was found to be a significant predictor of G. Urea generation rate was 
significantly higher in patients who performed at least 10 minutes of M-V intensity 
activity per day and the significance persisted even after adjusting the urea 
generation rate to body weight. This suggests that even small increases in M-V 
activity time may influence uraemic toxin generation. 
Though the cut-off of 10 minutes seems low, the significant contribution of log-
transformed activity time in regression model for predicting G suggests that the 
relationship between activity time and G is likely to be a true effect. In a study by 
Matsuzawa et al (2012) on 202 HD patients, there was 28% reduction in all-cause 
mortality with 10-minute increments in daily activity (Matsuzawa et al., 2012). The M-
V activity time cut-off of 10 minutes in this study is more likely a marker of overall 
levels of activity within the study cohort. The relationship between the M-V activity 
time of at least 10 minutes with G should be interpreted as a marker of the effect of 
activity on G rather than as an absolute value of time that may provide beneficial 
effects. 
The suggestion from the study data that increased activity contributes to higher 
metabolic waste generation has important implications on the prescription of dialysis 
dosing. The current practice does not take into consideration the activity level of 
patients when deciding the dialysis dose. If the above effect of activity on uraemic 
toxin generation is confirmed in future studies, then it is important that an adjustment 
of dialysis dose is carried out depending on activity level of individual patients such 
that a higher dose is delivered for more active patients. This practice will have the 
dual benefit of individualising the dialysis treatment for the patient and facilitating 
better clearance of uraemic toxins according to the metabolic needs of the individual. 
The average protein intake of the study participants was 0.84 g/kg/day which is 
much less than the recommended 1.1 g/kg/day of protein intake for HD patients 
(Naylor et al., 2013). However, there was no significant correlation found between 
urea generation rate and dietary protein intake. Although it is difficult to understand 
the lack of relationship between these variables, it is possible that the dietary records 
by the participants may not have been complete and did not reflect the entirety of 
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their diets. The dietary protein intake did not correlate significantly with normalised 
Protein Catabolic Rate (nPCR) as well. nPCR is estimated from inter-dialytic urea 
generation by urea kinetic modelling and is considered to be a marker of dietary 
protein intake. The poor correlation between nPCR and dietary protein intake, again, 
suggests possible incomplete dietary records and hence, it is difficult to derive any 
firm conclusions regarding the dietary protein intake of study participants. 
The moderate-vigorous activity time estimated from RPAQ correlated significantly 
with that measured by accelerometer. However, participants spent the bulk of their 
time in sedentary activities which is not captured adequately by the questionnaire. As 
discussed in chapter 7, questionnaires derived in general population need to be 
validated in patients with kidney disease as their activity behaviour is different to that 
of healthy individuals. It is important to design activity questionnaires specifically 
designed to capture low intensity and sedentary activity time which will facilitate 
physical activity data collection in physically inactive patient subgroups such as 
those with kidney disease. Nevertheless, RPAQ performs relatively well in estimating 
activity levels as shown by comparison with objectively measured physical activity by 
doubly labelled water (chapter 7) and by accelerometer in this study. 
8.5 Limitations 
The study is limited by its cross-sectional nature. Physical activity is measured only 
at a single time-point. However, the measurements were carried out over a period of 
7 days which might adjust for any short bursts of increased activity by individual 
subjects. Moreover, the activity level of participants is in line with published literature 
suggesting activity level in this study is representative of the haemodialysis patient 
population. There are some limitations associated with using urea generation rate as 
a marker of uraemic toxin generation. It has been suggested that urea kinetics is 
different to other uraemic toxins in the same class and hence, urea removal on 
dialysis may not be representative of overall uraemic toxin removal (Eloot et al., 
2007; Eloot et al., 2005). No other molecule has been identified as the ideal marker 
of uraemic toxin till date. Urea clearance on dialysis has been shown to be 
associated with mortality risk (Bloembergen et al., 1996; Owen et al., 1993) and 
current dialysis adequacy guidelines are based only on urea clearance. Moreover, 
many of the uraemic toxins are end products of protein metabolism as is urea. 
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Hence, at present, urea generation rate is possibly the closest marker of overall 
uraemic toxin generation. 
8.6 Conclusion 
In conclusion, the study data supports the hypothesis that increasing physical activity 
level contributes to higher uraemic toxin generation as measured by urea generation 
rate. Fat-free mass was found to be the single most important determinant of 
uraemic toxin generation. Estimated activity time from RPAQ significantly correlated 
with measured activity time by the accelerometer. Further research is needed to 
develop physical activity questionnaires that would capture sedentary and low 
intensity activities. 
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 Chapter 9 
9. Relationship of Whole Body Protein Turnover and Resting 
Energy Expenditure in Chronic Kidney Disease 
 
9.1 Introduction 
Kidneys play a major role in protein and amino acid metabolism through involvement 
in all aspects of whole body protein turnover such as synthesis, degradation and 
excretion of amino acids. Approximately 50-70 g/day of amino acids is filtered and 
reabsorbed by the kidneys. As explained in section 2.3.1.2, malnutrition is common 
in patients with CKD. The mechanisms underlying the specific form of malnutrition 
that happens in renal failure, termed ‘Protein energy wasting’, are being increasingly 
explored in clinical studies. Whatever the underlying mechanisms are, it is clear that 
there is derangement of protein metabolism in renal failure. 
Given the important role of kidneys in protein metabolism, deranged protein 
metabolism is expected. However, the magnitude of derangement and the specific 
abnormalities in various components of the protein turnover have not been clearly 
studied. A detailed review of whole body protein turnover studies carried out in 
patients with CKD and in those on HD is discussed in section 2.3.1.2 and is not 
discussed here for reasons of brevity. It can be seen from these studies there has 
not been a definitive conclusion about the alterations in protein turnover in HD 
patients. 
Protein turnover is an important component of basal metabolic rate and constitutes 
about 20% of resting energy expenditure in healthy adults (Boirie et al., 2001; Welle 
& Nair, 1990). However, this relationship has not been explored in the setting of 
renal failure. Although it is not expected that the energetic cost of protein turnover 
will be any lower than healthy adults but, given the derangement in protein 
metabolism, it may be higher in patients with advanced renal disease. The energetic 
cost of protein turnover in CKD has not been studied previously. 
Dietary protein intake has a significant impact on whole body protein turnover but 
whether this is an important determinant of resting energy expenditure (REE) is not 
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known. Moreover, many of the uraemic toxins are the product of tissue protein 
turnover and hence, protein turnover is likely to influence uraemic toxin generation in 
patients with renal failure. 
This pilot study was therefore conducted with the following objectives: 
1. To measure whole body protein turnover (WBPT) in maintenance 
haemodialysis patients and in those with advanced CKD not receiving any 
form of dialysis therapy 
2. To estimate the energetic cost of protein turnover in the above patient 
population 
9.2 Considerations on isotope selection and methodological issues in kidney 
disease 
9.2.1 Measurement Methods for Whole Body Protein Turnover 
Measurement methods for whole body protein turnover can be broadly categorised 
into two categories – precursor method and end product method. Both these 
methods involve administering a stable isotope of an amino acid orally or 
intravenously and measuring isotopic enrichment of the amino acid or its immediate 
transaminated product in various body pools. However, the difference lies in the site 
of sampling and the molecule that is sampled as discussed below. 
In the end-product method, a nitrogen-labelled stable isotope of an amino acid 
(typically 15N-glycine) is administered orally or intravenously. The nitrogen in the 
amino acid consumed is then absorbed and is metabolised in a similar way to other 
proteins and finally incorporated into urea and ammonia which are then excreted in 
urine and faeces. The amount excreted in faeces is considered to be negligible and 
hence, the isotopic enrichment of 15N in urea and ammonia in urine is measured to 
enable calculation of WBPT. The urine samples are collected at regular intervals 
throughout the 10-hour study period. The advantage of this method is that it is non-
invasive (when the isotope is given orally) as the only samples needed are the urine 
samples. However, this method assumes normal excretion of urea and ammonia 
within the study duration which may not hold true in patients with kidney disease. 
Moreover, many of the HD patients are anuric which poses a practical problem in 
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this population. Even though, this method has been used in a study of WBPT in 
peritoneal dialysis patients, it has not been validated for use in renal failure or anuric 
patients (Tjiong et al., 2008). 
The other method is the precursor method. Here, the stable isotope of an amino acid 
is given intravenously, typically as a priming bolus dose followed by an infusion 
either in the fed or post-absorptive state. Once the steady state is reached, a series 
of blood (and breath samples in certain studies) samples are taken to measure the 
isotopic enrichment of the amino acid or a related metabolite of the infused amino 
acid which will enable calculation of the WBPT. The steady state is the period when 
the isotopic enrichment has reached plateau level with minimal variation between the 
readings. The choice of the amino acid used for the study becomes important in 
patients with kidney disease due to the derangement of amino acid handling in this 
condition. 
Two stable isotopes were considered as potential candidates for our study – 2H5-
phenylalanine and 13C-leucine. The former isotope, when infused, is rapidly 
converted to tyrosine and measuring the isotopic enrichment of phenylalanine and 
tyrosine at steady state will enable calculation of WBPT (Thompson et al., 1989). 
This method is based on the assumption that in-vivo conversion of phenylalanine to 
tyrosine is not impaired in study subjects. In steady-state conditions, conversion of 
phenylalanine to tyrosine occurs predominantly in liver and kidneys. It has been 
shown that this pathway is impaired significantly in patients with renal failure as the 
contribution of kidneys to the phenylalanine metabolism is very little (Kopple, 2007). 
Hence, phenylalanine isotope may not be suitable for WBPT studies in renal failure 
and as such, has not been validated for use in this patient population. 
This means that 13C-leucine is the ideal isotope to use for WBPT in patients with 
kidney disease. The advantages of using leucine isotope for WBPT measurement 
and the model of leucine turnover are discussed in section 3.9.1. 
9.2.2 Safety of the Isotope 
13C-leucine is a stable isotope and is non-radioactive. The isotope has been used for 
WBPT studies in normal healthy adults and in various disease conditions. Sterility 
and pyrogen testing was carried out by the isotope providers and a certificate of 
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analysis (shown in Appendix F) was provided for each batch of the isotope 
purchased. The isotope infusions were prepared in a strict sterile manner as per the 
local hospital guidelines. 
9.2.3 Assumptions in the methodology 
There are several assumptions made in the protein turnover study model. The first is 
that the body pools are homogenous. Although this may not be correct at all times, 
this assumption is necessary for analysis of any protein turnover studies. The 
second assumption is that the amino acid exchanges between compartments occur 
at constant fractional rates. Although this assumption is essential in certain models 
of protein turnover studies especially those involving compartmental analysis, it is 
irrelevant in stochastic analysis such as that used in this study where steady state of 
tracer is achieved. 
The third assumption is that the amount of tracee amino acid in each pool remains 
constant throughout the study period i.e. the tracee is in a steady state. This 
assumption is reasonable and accurate enough in studies conducted over a period 
of few hours. Finally, the whole body protein pool is considered to be turning over at 
a slow enough rate to ensure that there is no recycling of the tracer within the study 
period. This is dependant on the rate of turnover of the tracer amino acid in a given 
pool and the duration of the study period. Although the tracer recycling is not to be 
ignored, it is unlikely that this will cause significant errors in studies conducted over a 
few hours compared to those carried out over days. 
9.2.4 Timing of the samples 
It is vital to obtain a series of blood and breath samples after the steady state is 
reached for measurement of isotopic enrichment. Previous published studies 
showed the steady state would be reached around 2 hours from the start of the 
infusion. Samples were collected every 30 minutes for the first 2 hours to establish 
that the steady state has been reached and every 15 minutes between 2 and 3 hours 
for measurement of isotopic enrichment. 
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9.3 Methods 
9.3.1 Ethical Review 
The study was reviewed and approved by Cambridge East Research Ethics 
Committee (ref: 13/EE/0158 and UH Ethics ref: LMS/PG/NHS/00256). All study 
participants provided written informed consent. 
9.3.2 Overview of Study Design 
A cross-sectional study of 12 patients – 6 of them receiving maintenance 
haemodialysis and 6 of them with advanced renal disease (eGFR < 20 ml/min/1.73 
m2) – was carried out to measure WBPT. All subjects maintained a prospective food 
diary for three days prior to the study day. Subjects who were not anuric also 
performed a 24-hour urine collection starting the day before the study. On the study 
day, metabolic analysis was performed including indirect calorimetry for REE 
measurement. Leucine isotope infusion was carried out for 3 hours. Blood and 
breath samples were collected at specified time points from the start of the infusion. 
There were no further follow-up visits for the study. 
9.3.3 Study Population 
Subjects were recruited from the renal unit and the outpatient clinics at Lister 
Hospital. Potential patients were initially approached in person when attending their 
regular HD session or the outpatient clinic. A written information sheet about the 
study was given to them. They were given a minimum of 24 hours to consider 
participation in the study and were given an opportunity to clarify any queries about 
the study before they consented. The inclusion and exclusion criteria are given 
below. 
9.3.3.1 Inclusion Criteria 
• Adult haemodialysis patients older than 18 years of age and have been on 
maintenance HD for at least 3 months 
• CKD patients with an eGFR of <20 ml/min/1.73 m2 and not receiving any form 
of renal replacement therapy 
 198 
9.3.3.2 Exclusion Criteria 
Patients with 
• untreated hypo or hyperthyroidism 
• active malignancy or receiving chemotherapy/radiotherapy 
• ongoing sepsis 
• active vasculitis or lupus 
• history of hospitalisation in the last month 
• current pregnancy 
• unexplained weight loss 
• metabolic acidosis 
• limb amputations 
• no capacity to consent for themselves 
9.3.4 Study Assessments 
9.3.4.1 Study Preparation 
All subjects were given verbal and written instructions about the study. They were 
advised to restrain from strenuous physical activity for 3 days preceding the study 
day. They were also asked to maintain a food diary and were advised to avoid 
protein supplements and excessive protein intake for those three days. Participants 
who were not anuric also performed a 24-hour urine collection beginning the day 
prior to the study. 
9.3.4.2 Demographic and Anthropometric data 
Data comprising of age, sex, ethnicity, weight, height and comorbid conditions were 
collected for all study participants through direct measurements and individual 
medical records. 
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9.3.4.3 Study Procedure 
Participants were advised to attend the research facility in an empty stomach after 
overnight fasting. Body composition analysis was performed using bioimpedance as 
described previously. Isotope administration and sampling was carried out as 
described in section 3.9.1.1. Indirect calorimetry was performed at baseline and at 
steady state to obtain direct measurements of REE and VCO2. All participants were 
also asked to complete the RPAQ questionnaire to obtain information regarding 
habitual physical activity data. 
9.3.5 Calculation of Protein Turnover and Energetic Cost of WBPT 
The individual components of WBPT – synthesis, breakdown and oxidation rates and 
the total flux – were calculated as explained in the general methodology chapter 
(section 3.9.1.3). 
The best-fit regression line equation was identified using a plot of leucine flux and 
REE which was of the form 𝑹𝑬𝑬 = 𝒂  ×  𝑳𝒆𝒖𝒄𝒊𝒏𝒆  𝑭𝒍𝒖𝒙+ 𝑪𝒐𝒏𝒔𝒕𝒂𝒏𝒕 
Using this equation energy expenditure of protein turnover for each patient was 
estimated using the leucine flux. Energetic cost of protein turnover is then the 
proportion of REE that has been contributed by the protein turnover.  
9.3.6 Statistical Analysis 
Leucine flux at steady state and the rate of whole body protein synthesis, oxidation 
and breakdown calculations are described in detail in section 3.9.1.3. Continuous 
variables are expressed as mean ± SD. Differences between CKD groups were 
compared using unpaired t-test. Correlations between variables were examined 
using Pearson’s correlation coefficient. 
9.4 Results 
9.4.1 Demographics of Study Participants 
A total of 12 patients with kidney disease were recruited – 6 patients with advanced 
CKD (eGFR < 20ml/min/1.73 m2) not receiving dialysis therapy (CKD group) and 6 
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patients on chronic maintenance haemodialysis (HD group). However, one of the 
CKD patients was found to have abnormally high CRP on the day of the study and 
hence, has been excluded from analyses. 
The demographic and clinical data of the study participants are shown in Table 9-1. 
The mean eGFR in the CKD group was 15.4 (±2.8) ml/min/1.73m2.There were no 
differences between CKD and HD groups in age, body size measures and 
haemoglobin. There were also no differences in REE, daily protein and energy intake 
between the groups. Serum albumin was significantly lower in HD group (p = 0.015). 
Physical activity, expressed as Daily MET from RPAQ, was significantly lower in HD 
group. 
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Table 9-1: Demographic and clinical data of Study participants 
Values expressed are mean ± SD. Differences between the groups were examined by 
unpaired t-test; nPCR: Normalised Protein Catabolic Rate; REE: Resting Energy 
Expenditure 
 All patients (n = 11) 
CKD group 
(n = 5) 
HD group 
(n = 6) p-value 
Age (years) 65.3 ± 8.2 65.7 ± 9.7 65.0 ± 7.6 0.891 
Males: Females 5:6 2:3 3:3  
Height (cm) 166.8 ± 9.3 168.0 ± 9.9 165.8 ± 9.6 0.721 
Weight (kg) 73.8 ± 8.9 75.0 ± 8.1 72.8 ± 10.2 0.706 
Haemoglobin 
(g/dL) 11.2 ± 1.7 10.5 ± 1.5 11.9 ± 1.7 0.194 
Albumin (g/L) 38.9 ± 2.7 40.8 ± 2.3 37.2 ± 1.7 0.015 
Urea generation 
rate (mmol/min) 0.18 ± 0.06 0.19 ± 0.09 0.18 ± 0.04 0.785 
nPCR (g/kg/day) 0.92 ±0.25 0.96 ± 0.34 0.90 ± 0.18 0.707 
Protein Intake 
(g/kg/day) 0.94 ± 0.21 1.03 ± 0.27 0.87 ± 0.15 0.249 
Energy Intake 
(kcal/day) 1743 ± 338 1853 ± 336 1651 ± 341 0.351 
Daily MET 1.27 ± 0.11 1.34 ± 0.09 1.21 ± 0.10 0.038 
REE (kcal/day) 1317 ± 225 1237 ± 217 1383 ± 228 0.309 
 
9.4.2 Measures of Whole Body Protein Turnover 
Table 9-2 shows the mean (± SD) values of different components of whole body 
protein turnover for 11 patients included in the analysis. The breakdown rate was 
higher than the protein synthesis rate and as a result, there was negative balance 
(Synthesis rate minus Breakdown rate) in terms of whole body protein turnover. 
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Table 9-2: Components of Whole Body Protein Turnover 
 Mean ± SD 
Leucine Flux (µmol/kg/hr) 92.3 ± 11.1 
Synthesis rate (µmol/kg/hr) 83.3 ± 11.0 
Oxidation rate (µmol/kg/hr) 9.0 ± 3.7 
Breakdown rate (µmol/kg/hr) 92.3 ± 11.1 
Net balance (µmol/kg/hr) -9.0 ± 3.7 
 
9.4.3 Clinical Correlates of WBPT 
Univariate correlation between clinical parameters and the net balance of WBPT are 
shown in Table 9-3. 
Table 9-3: Clinical Correlates of WBPT Net Balance 
The coefficient shown is Pearson’s correlation coefficient; nPCR: Normalised Protein 
Catabolic Rate 
 Correlation Coefficient p-value 
Age 0.048 0.889 
Serum Albumin -0.461 0.154 
Urea Generation Rate -0.663 0.026 
nPCR -0.624 0.040 
Daily Protein Intake per 
kg body weight 0.373 0.259 
Daily Energy Intake -0.641 0.033 
Fat-free mass -0.216 0.523 
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Urea generation rate, nPCR and daily energy intake were the only parameters which 
correlated significantly with WBPT net balance. Both synthesis and breakdown rates 
did not correlate significantly with any of these parameters. 
9.4.4 Correlation between WBPT and Physical Activity Measures 
Table 9-4 shows the correlation between net turnover balance and physical activity 
measures derived from activity questionnaire RPAQ. Mean Daily MET estimated 
from RPAQ correlated highly with net turnover balance. As with the clinical 
parameters, neither the breakdown rate nor the synthesis rate correlated significantly 
with any of these activity measures. 
Table 9-4: Correlation between Net Turnover Balance and Activity Measures 
The coefficient shown is Pearson’s correlation coefficient; MET: Metabolic Equivalent of 
Task 
 Correlation Coefficient p-value 
Daily MET -0.839 0.001 
Moderate Activity 
Time -0.403 0.220 
Vigorous Activity 
Time 0.150 0.660 
 
9.4.5 Comparison of WBPT between CKD and HD Groups 
The differences in various components of whole body protein turnover between the 
CKD and HD groups are shown from Figure 9-1 to Figure 9-3. The protein 
breakdown and synthesis rates were significantly higher in HD group compared to 
that of CKD group. However, there was no significant difference in the net balance of 
protein turnover between the groups. 
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Figure 9-1: Protein Breakdown rate in the CKD and HD groups 
 
 
Figure 9-2: Protein Synthesis rate in CKD and HD groups 
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Figure 9-3: Net Balance of Protein Turnover in CKD and HD groups 
9.4.6 Energetic Cost of Protein Turnover 
The relationship between leucine flux and REE is shown in Figure 9-4. There was a 
moderate relationship between the two variables with a R2 value of 0.143. The 
equation of the best-fit regression line is as shown in the figure. The energy 
expenditure associated with WBPT was calculated from the regression equation. 
Energy cost of WBPT was then calculated as a percentage of measured REE. The 
mean energy expenditure associated with WBPT was 705 (± 85) kcal/day. This 
equates to a mean energetic cost of 55% of the resting energy expenditure per day 
for Whole Body Protein Turnover. 
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Figure 9-4: Relationship between Leucine flux and REE 
 
9.4.7 Relationship between Protein Turnover and Urea Generation Rate 
The relationship between urea generation rate and protein breakdown rate is shown 
in Figure 9-5. There was a moderate positive relationship between these two 
variables with a R2 value of 0.263. 
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Figure 9-5: Relationship between Protein Breakdown and Urea Generation 
Rate 
 
Figure 9-6: Relationship between Net Turnover Balance and Urea Generation 
Rate 
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Figure 9-6 shows a graph of urea generation rate against net turnover balance. The 
variables correlated negatively with more negative net balance of protein turnover 
contributing to higher urea generation rate. 
9.5 Discussion 
The primary aim of this study was to measure whole body protein turnover in pre-
dialysis CKD patients and in chronic haemodialysis patients. The study showed that 
both pre-dialysis and HD patients are in negative protein balance. The study also 
showed that dialysis patients have a significantly higher protein turnover compared 
to pre-dialysis CKD patients i.e. a higher rate of breakdown and synthesis. But, the 
balance between the synthesis and breakdown is of similar magnitude between the 
groups. The energetic cost of WBPT per day in this cohort of patients was around 
55% of the daily resting energy expenditure. 
It is widely believed that uraemia is a catabolic state. In animal models, an increase 
in protein degradation and reduction in protein synthesis has been demonstrated in 
the presence of uraemia (Arnold & Holliday, 1979; Harter, Karl, Klahr, & Kipnis, 
1979; Holliday, Chantler, MacDonnell, & Keitges, 1977). This has not been replicated 
universally in human studies. A few studies have compared protein turnover in CKD 
patients and healthy controls and have come to contrasting conclusions. A study by 
Adey et al (2000) on 12 CKD patients and 10 healthy controls showed that there was 
no difference between different components of WBPT between CKD patients and 
healthy controls (Adey et al., 2000). Similarly, Goodship et al (1990) showed no 
differences in WBPT in non-dialysis CKD patients compared to healthy controls 
irrespective of whether they were on a high or low protein diet (Goodship et al., 
1990). However, some other studies have shown reduced turnover, oxidation and 
synthesis in CKD patients compared to healthy controls (Lim & Kopple, 2000; 
Castellino et al., 1992). 
Comparative studies examining whole body protein turnover in pre-dialysis CKD and 
HD are scarce. The only such study was published by Lim et al (1998) in which 
WBPT was measured in a same cohort of patients before initiation of dialysis therapy 
and 8-10 weeks after initiation of haemodialysis (Lim et al., 1998). In this study, 
though there was an increase in protein breakdown rate, there was a relatively 
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higher increase in protein synthesis rate after HD initiation compared to pre-dialysis 
period. 
The study data compares WBPT between pre-dialysis CKD patients and HD 
patients. The protein breakdown rate was significantly higher in HD patients 
compared to CKD patients which was also matched by the increase in synthesis rate 
in HD group. This implies that the turnover rate is much higher after initiation of 
haemodialysis therapy. Studies have shown that the dialysis treatment itself induces 
increased protein catabolism and higher protein loss and this effect might even last 
for many hours after the completion of a dialysis session (Raj et al., 2004; Ikizler et 
al., 2002). Though there was a net negative balance of protein turnover in HD 
patients, there was no difference in the magnitude of the protein loss compared to 
pre-dialysis patients. There was a 19% increase in synthesis rate and 15% increase 
in breakdown rate in HD patients compared to CKD group. This is comparable to the 
previously published data showing approximately a 19% increase in synthesis and 
breakdown rates after initiation of haemodialysis therapy (Lim & Kopple, 2000). 
The study also aimed to explore the energetic cost of protein turnover in patients 
with kidney disease. It was found that protein turnover contributes to about 55% of 
the basal metabolic rate (i.e. REE). This is in line with previously published literature 
in normal individuals which showed the energetic cost of protein turnover to be 
approximately 50% of the metabolic rate (Nair & Halliday, 1985). However, if the 
metabolic rate was adjusted for active cell mass, the energetic cost reduces 
significantly to around 20% of metabolic rate (Welle & Nair, 1990). It is worth noting 
that these previous data are derived from young healthy individuals. Though there is 
a suggestion that the energetic cost of protein turnover is similar between young and 
elderly individuals (Boirie et al., 2001), no previous data are available for comparison 
in patients with kidney disease. The small numbers of patients did not permit 
calculation of energetic cost in each group in this study and hence, any potential 
difference in energetic cost between CKD and HD groups was not explored. 
The study also showed a significant negative correlation between urea generation 
rate and the net turnover balance. As discussed in previous chapters, urea 
generation rate can be considered a surrogate marker of uraemic toxin generation. 
Given that many of the uraemic toxins are products of protein metabolism, it is not 
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surprising that protein turnover contributes significantly to uraemic toxin generation. 
However, this relationship between whole body protein turnover and uraemic toxin 
generation has not been demonstrated before. This implies that individuals with 
higher protein turnover rates may generate higher amounts of uraemic toxins thereby 
necessitating dialysis dose adjustments based on metabolic needs. 
The study has several strengths. All studies published on this topic to date have 
been carried out on younger individuals, typically in their mid-40s. The mean age of 
patients in this study was 65 years which makes it the first study to examine protein 
turnover in patients with kidney disease above the age of 65. Apart from one 
published study on this topic, there have been no studies comparing WBPT between 
pre-dialysis CKD and HD patients.  The patients in the two groups were well 
matched in terms of age, body size and dietary parameters which allowed better 
comparison of the groups with regards to protein turnover. By comparing these two 
groups, this study has contributed to a better understanding of protein turnover 
changes that occur after initiation of haemodialysis therapy. This is also the first 
study that had explored the energetic cost of protein turnover in patients with kidney 
disease. And finally, this study has also demonstrated a significant positive 
relationship between whole body protein turnover and uraemic toxin generation in 
patients with advanced kidney disease which has not been shown in any studies to 
date. 
9.6 Limitations 
The study is limited by its small sample size. The intensive nature of the whole body 
protein turnover study combined with patient factors such as older age and 
comorbidity that are prevalent in patients with advanced kidney disease restricts the 
sample size of such studies to small numbers. This is evident in majority of protein 
turnover studies in patients with kidney disease where the sample size is restricted 
to around 6-12 patients. Whilst these studies, including the current study, provide 
valuable information on whole body protein turnover in renal failure, any definitive 
conclusions based on these study data need to be made cautiously. The small 
sample size had also restricted the comparison on energetic cost of protein turnover 
between the CKD and HD groups. 
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9.7 Conclusion 
In summary, the rate of protein turnover was significantly higher in chronic 
haemodialysis patients compared to pre-dialysis patients with advanced kidney 
disease. The net turnover balance was negative, albeit to a similar magnitude, in 
both the pre-dialysis and haemodialysis patient groups. The energetic cost of protein 
turnover in these patients was around 55% of resting energy expenditure. There was 
also a direct relationship between protein turnover rate and uraemic toxin generation. 
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Chapter 10 
10. Determinants of Habitual Physical Activity in Haemodialysis 
Patients 
 
10.1 Introduction 
One of the primary functions of dialysis is to remove metabolic waste products. 
Judging minimal requirements for dialysis is difficult. The metabolic waste removal is 
not the only function of dialysis. Other aspects of renal replacement therapy such as 
excess fluid removal, nutrition, anaemia management and calcium and phosphate 
management do need to be taken into account when defining adequate dialysis. 
However, in practice, the dialysis dose is quantitatively measured based on the 
effectiveness of urea clearance during a dialysis session. 
The urea-centric model of dialysis adequacy has some disadvantages to it as 
discussed in section 2.2.1. Although urea removal has been shown to correlate with 
better survival (Owen et al., 1993), urea in itself is not toxic even at high 
concentrations. A study by Johnson et al (1972) in patients with end-stage renal 
disease showed that patients did not have any adverse symptoms until the urea 
concentration was as high as 107 mmol/L (normal range: 2.5 – 7.8 mmol/L) 
(Johnson, Hagge, Wagoner, Dinapoli, & Rosevear, 1972). Moreover, even uraemic 
toxins that are similar in size to urea do not share the same kinetics in vivo and 
hence, may not be cleared to the same extent as urea. In addition, larger sized 
toxins and the protein bound uraemic solutes also have dissimilar kinetics to urea. 
In current practise, dialysis dose is prescribed by a dimensionless parameter termed 
Kt/V where K is the dialyser clearance of urea in a single dialysis session, t is the 
duration of the session and V is the urea distribution volume which is equal to total 
body water. This dose prescription is not based on the rate of metabolic waste 
production but on the presumed volume in which the toxins are distributed. This 
practise of normalising dialysis dose to total body water may disadvantage some 
groups of dialysis patients as explained below. 
Total body water (V), sometimes referred to as Watson volume, is routinely 
estimated using Watson formula (Watson et al., 1980). This formula was derived by 
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pooling total body water data from multiple studies in healthy adults. For any given 
age, height and weight, women will have lower estimated V compared to men. 
Similarly, men with small body size will have lower V compared to their larger 
counterparts. This implies that for a given Kt/V target, women and small men will 
receive less dialysis dose compared to larger men. This may be the reason behind 
the survival advantage noticed in women when given higher dialysis doses (Depner 
et al., 2004; Port et al., 2004). Moreover, it has been shown that for a given Kt/V, 
patients with low V have as much as two-fold higher relative risk of mortality (Wolfe 
et al., 2000). Whilst it can be argued that individuals with low V also are prone to 
malnutrition, it is likely that the current dialysis practice of using V as a normalising 
factor also contributes to this effect. This may be due to the differences in body 
composition and potentially a higher toxin load per unit of body weight in small 
individuals as discussed in sections 2.2.3 and 2.3.1.1.  
As a result of this, a number of parameters have been suggested as potential 
alternatives for scaling the dialysis dose. A review by Daugirdas et al (2008) 
examining the theoretical aspects of these parameters concluded that Body Surface 
Area (BSA) is likely to be the best alternative parameter. However, as explained in 
section 2.3.1, metabolic rate (i.e. resting energy expenditure) could be a more 
physiological parameter to use for scaling dialysis dose. This may be due to the fact 
that metabolic rate and GFR scale to body weight by approximately the same 
exponent. Singer and Morton also hypothesised that the metabolic rate drives the 
GFR in those with normal renal function. It has been shown that GFR is reduced in 
patients with untreated hypothyroidism and the opposite effect prevails in those with 
hyperthyroidism. These changes could be due to corresponding changes in 
metabolic rate in these conditions (Ford et al., 1961; Davies et al., 1952; Mackay & 
Sherrill, 1943). Moreover, as resting energy expenditure (REE) represents the sum 
total of all metabolic activity at rest, it may be a better marker of metabolic waste 
generation. 
Total energy expenditure (TEE) is a combination of REE, energy expenditure from 
physical activity and the thermic effect of food. TEE encompasses more potential 
sources of metabolic waste production and hence, may potentially be a better 
marker of total metabolic activity. In the study described in chapter 4, it has been 
shown that TEE influences urea generation rate which is a marker of uraemic toxin 
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generation. Moreover, as physical activity is the most variable component of TEE 
between individuals, scaling dialysis dose to TEE may also have the benefit of 
individualising the dialysis dose as per the metabolic needs. 
There have been no published studies exploring the applicability of these three 
parameters to clinical practice for scaling dialysis dose. The benefits of these three 
parameters in relation to patient outcomes are also not known. Ramirez et al (2012) 
showed that BSA-normalised dialysis dosing will deliver higher dose to women and 
may have a favourable impact on survival of women receiving haemodialysis 
(Ramirez et al., 2012). However, REE and TEE has not been examined in a similar 
way nor has there been a comparative study to explore all three parameters 
together. 
In order to address this issue, a large-scale, multi-centre prospective study was 
designed with a primary aim of exploring the applicability of these parameters to 
clinical practice and to examine the impact on patient survival with potential use of 
these parameters for scaling dialysis dose. As there are multiple elements to this 
study, the study results are presented in three separate chapters for clarity and ease 
of reading. The self-report comorbidity questionnaire, described in chapter 5, was 
developed as a part of this study and was used in this study for comorbidity data 
collection. This chapter discusses the physical activity profile of the study 
participants and determinants of physical activity in this cohort of haemodialysis 
patients. The next chapter discusses the potential benefit of scaling dialysis dose 
using BSA, REE and TEE. The following chapter discusses the potential impact of 
using these parameters on patient survival and derivation of dialysis dose 
adjustments to the current clinical practice based on these parameters. The 
methodology explained in this chapter applies to all the three chapters related to this 
study. 
The aim in this section is to examine the physical activity profile of haemodialysis 
patients and to explore the independent predictors of physical activity-related energy 
expenditure in this patient population. 
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10.2 Methods 
10.2.1 Overview of the Study Design 
This was a prospective, multi-centre study of 1500 chronic haemodialysis patients. 
Anthropometric data was collected through direct measurements. Information on 
comorbidity and physical activity was collected through self-report questionnaires. 
Dialysis-related data was collected from medical records at baseline and at various 
follow-up time points. The study cohort was followed up for a period up to 24 months 
from recruitment. Besides the dialysis-related data, survival data was also collected 
at regular time points during the follow-up. 
10.2.2 Ethical Review 
The study was approved by the North Wales Research Ethics Committee (ref: 
12/WA/0060 and UH Ethics ref: LMS/PG/NHS/00257). All subjects provided written 
informed consent to take part. 
10.2.3 Study Participants 
Chronic adult HD patients older than 18 years and with dialysis vintage greater than 
3 months were recruited from different centres. Renal units of five hospitals – Lister, 
Southend, Wirral, Royal Free and Royal London hospitals – participated in the study. 
Exclusion criteria included patients dialysing for other than thrice weekly frequency, 
those with amputated limbs and those with no capacity to consent. Study information 
sheet, consent forms and questionnaires were translated into Bengali and Urdu to 
facilitate data collection from non-English speaking patients in the participating units. 
10.2.4 Study Protocol 
The following data were collected from each patient. 
1. Demographic data including age, sex, dialysis vintage, employment status 
2. Anthropometric data including height and weight were collected by direct 
measurement as mentioned in the general methodology. 
3. Routine pre- and post-dialysis biochemistry and haematology results were 
obtained from the local pathology system of each participating unit. The 
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results collected were serum urea, creatinine, haemoglobin and haematocrit 
values. Single-pool Kt/V (spKt/V) was calculated using the Daugirdas formula 
(Daugirdas, 1993). 
4. Physical activity data was obtained through Recent Physical Activity 
Questionnaire (RPAQ) which codes data on activity performed at home, work 
and leisure in the preceding 4 weeks. It has been validated against doubly 
labelled water technique in general population (Besson et al., 2010). Detailed 
explanations about the questionnaire and energy expenditure calculation from 
it are discussed in General Methodology chapter (section 3.7.2.1). 
5. Comorbidity data was collected using the self-report questionnaire explained 
in chapter 5. This scale is based on self-reporting of the presence and 
severity of 7 potential comorbidities - arthritis, cancer, diabetes, heart disease, 
lung disease, liver disease, and stroke. The questionnaire enquired whether 
participants had any of these conditions and if they did, whether they were 
receiving treatment and whether it limited their daily activities. Each positive 
response was given a score of 1 and hence, the maximum score for the 
questionnaire could range from 0–21. High comorbidity is designated as a 
composite self-report comorbidity score (CSCS) > 3. 
10.2.5 Estimation of Alternative Scaling Parameters 
Body surface area (BSA, Haycock equation) and Watson Volume (V) were derived 
from the following equations (Watson et al., 1980; Haycock et al., 1978). Height is 
expressed in cm and weight is expressed in kg in both these equations. 
𝑩𝑺𝑨 = 𝟎.𝟎𝟐𝟒𝟐𝟔𝟓  ×  𝑾𝒆𝒊𝒈𝒉𝒕𝟎.𝟓𝟑𝟕𝟖  ×  𝑯𝒆𝒊𝒈𝒉𝒕𝟎.𝟑𝟗𝟔𝟒 𝑽 = 𝟐.𝟒𝟒𝟕 − 𝟎.𝟎𝟗𝟓𝟏𝟔  ×  𝑨𝒈𝒆 + 𝟎.𝟏𝟎𝟕𝟒  ×  𝑯𝒆𝒊𝒈𝒉𝒕 + 𝟎.𝟑𝟑𝟔𝟐  ×  𝑾𝒆𝒊𝒈𝒉𝒕  (males) 
𝑽 = −  𝟐.𝟎𝟗𝟕 + 𝟎.𝟏𝟎𝟔𝟗  ×  𝑯𝒆𝒊𝒈𝒉𝒕 + 𝟎.𝟐𝟒𝟔𝟔  ×  𝑾𝒆𝒊𝒈𝒉𝒕  (females) 
Resting Energy Expenditure (REE) was estimated from a validated predictive 
equation which was derived in a cohort of HD patients (Vilar et al., 2014). This 
disease-specific equation was found to be at least as accurate as the existing 
general equations and was associated with less bias. The equation is given below. 
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𝑹𝑬𝑬 = −𝟐.𝟒𝟗𝟕  ×  𝑨𝒈𝒆 𝒚𝒆𝒂𝒓𝒔   ×  𝑭𝒂𝒄𝒕𝒐𝒓𝒂𝒈𝒆   +    𝟎.𝟎𝟏𝟏  ×  𝑯𝒆𝒊𝒈𝒉𝒕𝟐.𝟎𝟐𝟑 𝒄𝒎   +    𝟖𝟑.𝟓𝟕𝟑  ×  𝑾𝒆𝒊𝒈𝒉𝒕𝟎.𝟔𝟐𝟗𝟏 𝒌𝒈   +    𝟔𝟖.𝟏𝟕𝟏  ×  𝑭𝒂𝒄𝒕𝒐𝒓𝒔𝒆𝒙  
where Factorage is 0 if age <65 and 1 if ≥65 and Factorsex is 0 if female and 1 if male. 
Physical activity data - Each reported activity was assigned a Metabolic Equivalent of 
Task (MET) value as per the Compendium of Physical Activities (Ainsworth et al., 
2011). For subjects reporting more than 18 hours of total activity duration per day, 
duration of each activity was proportionately adjusted so that the maximum reported 
total activity duration was 18 hours per day. Sleep duration per day was assumed to 
be 6-8 hours. Any remaining time not accounted for by the questionnaire was 
assumed to be spent in performing light activity and was assigned a MET value of 
1.3. Mean daily MET value was calculated as explained in section 3.7.2.1. 
Total Energy Expenditure (TEE) was estimated from the following equation. 𝑻𝑬𝑬 = 𝑹𝑬𝑬  ×  𝑴𝒆𝒂𝒏  𝑫𝒂𝒊𝒍𝒚  𝑴𝑬𝑻 
Physical Activity-related Energy Expenditure (PAEE) was calculated by subtracting 
the total energy expenditure from resting energy expenditure. 
10.2.6 Statistical Analysis 
Statistical analysis was carried out using SPSS ® version 19 (SPSS Software, IBM 
Corporation, New York, USA). Normally distributed data are presented as mean ± 
SD, and non-normally distributed as median [± interquartile range]. The significance 
of differences between means was determined by Student’s t-test and of differences 
between medians by the Mann-Whitney U test. The significance of difference in 
PAEE between multiple group means was assessed by Kruskal-Wallis test. 
Multivariate regression models to examine predictors of PAEE were developed using 
linear regression. The variables used in the model were age, sex, ethnicity, 
comorbidity, employment status, dialysis adequacy (Kt/V), body weight and 
haemoglobin. Collinearity testing was carried out for all the variables included in the 
regression model and variables with only low variance inflation factor (<10) were 
included. A p-value of <0.05 was assumed to indicate statistical significance. 
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10.3 Results 
10.3.1 Demographics 
A total of 1500 patients (910 men and 590 women) were recruited. Demographic, 
anthropometric and biochemical characteristics are shown in Table 10-1. Females 
were significantly younger, a higher proportion of them classifying themselves as 
black, and fewer self-classifying as employed. All body size parameters except BMI 
were significantly greater in men than women. Men had slightly higher serum urea, 
creatinine and haemoglobin levels compared to women. 
Table 10-1: Demographic, anthropometric and biochemical characteristics of 
Study patients 
Values expressed are mean ± SD. Proportions of categorical variables are 
expressed as percentages. 
 All patients 
(n = 1500) 
Males 
(n = 910) 
Females 
(n = 590) 
p-value 
Age (years) 62.9 ± 15.5 63.8 ± 15.6 61.6 ± 15.1 0.007 
Weight (kg) 75.2 ± 18.3 78.4 ± 17.3 70.4 ± 18.6 <0.001 
Height (cm) 165.9 ± 10.0 170.6 ± 8.2 158.7 ± 8.2 <0.001 
Ethnicity (% South 
Asian: Black: White) 
27.9: 26.7: 
45.5 
27.3: 24.0: 
48.7 
28.6: 30.9: 
40.5 
0.003 
Body Mass Index 
(kg/m2) 
27.3 ± 6.0 26.9 ± 5.3 27.9 ± 7.0 0.002 
High Comorbidity (%) 29.5 28.7 30.7 NS 
Employed (%) 11.5 13.1 9.2 0.021 
Serum Urea (mmol/L) 19.3 ± 5.7 19.6 ± 5.6 18.7 ± 5.8 0.004 
Serum Creatinine 
(µmol/L) 
802 ± 239 839 ± 252 744 ± 203 <0.001 
Haemoglobin (g/dL) 10.9 ± 1.2 11.0 ± 1.3 10.8 ± 1.2 0.002 
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Energy expenditure and physical activity levels expressed as Mean Daily MET are 
given in Table 10-2. The reported total activity time, sedentary time and activity time 
are shown in Figure 10-1. 
 
Table 10-2: Energy expenditure and Physical Activity Level of study patients 
Values expressed are Mean ± SD (* Median and inter-quartile range). REE: resting energy 
expenditure, MET: metabolic equivalent of task, PAEE: Physical activity-related energy 
expenditure, TEE: total energy expenditure 
 All patients 
(n = 1500) 
Males 
(n = 910) 
Females 
(n = 590) 
p-value 
REE (kcal/day) 1545 ± 250 1621 ± 230 1429 ± 236 <0.001 
Daily MET 1.19 ± 0.13 1.20 ± 0.14 1.17 ± 0.10 <0.001 
PAEE (kcal/day) * 243 (159) 262 (185) 221 (132) <0.001 
TEE (kcal/day) 1841 ± 388 1948 ± 390 1676 ± 322 <0.001 
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Figure 10-1: Reported Activity Time in Study Participants 
 
Both REE and TEE were significantly lower in females and the physical activity 
levels were very low with a mean daily MET for the overall study population of only 
1.19. The mean total reported activity time was 6.2 hours per day with females 
reporting slightly lesser time compared to males (5.7 vs. 6.4 hours). However, the 
majority of this time was spent in sedentary activity (mean - 5.3 hours) with only a 
small proportion being spent in other intensities of activities (mean - 0.8 hours). 
10.3.2 Gender and Physical Activity 
Figure 10-2 shows the gender differences in PAEE which was significantly higher in 
males compared to females (327 vs. 247 kcal/day; p < 0.001). 
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Figure 10-2: Gender differences in Physical Activity Level 
 
10.3.3 Age and Physical Activity 
Figure 10-3 shows the difference in PAEE between younger (age < 65) and older 
(age ≥ 65) subjects. Younger patients had higher activity-related energy expenditure 
compared to their older counterparts (367 vs. 226 kcal/day; p < 0.001). 
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Figure 10-3: Influence of Age on Physical Activity Level 
10.3.4 Ethnicity and Physical Activity 
PAEE in patients of different ethnic origins is shown in Figure 10-4. There was no 
significant difference in physical activity between patients of different ethnic origins. 
 
Figure 10-4: Influence of Ethnicity on Physical Activity 
 
 223 
10.3.5 Comorbidity and Physical Activity 
As shown in Figure 10-5, physical activity-related energy expenditure was 
significantly higher in patients with low comorbidity (comorbidity score ≤ 3) compared 
to those with high comorbidity (317 vs. 244 kcal/day; p < 0.001). 
 
Figure 10-5: Physical Activity level differences based on Comorbidity 
 
10.3.6 Employment and Physical Activity 
Figure 10-6 shows PAEE between employed (n = 173) and unemployed subjects. As 
expected, working patients had higher total activity-related energy expenditure 
compared to those who were not working (707 vs. 242 kcal/day; p < 0.001). A 
majority of the employed patients (91%) were working in a sedentary or a light 
activity occupation with only a handful of them doing a manual job. 
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Figure 10-6: Effect of Employment Status on Physical Activity level 
 
10.3.7 Body size and Physical Activity 
The relationship between PAEE and body weight is shown in Figure 10-7. PAEE 
progressively increased with the heavier patients having higher PAEE compared to 
their smaller counterparts. There were significant differences across the group (p < 
0.001, Kruskal-Wallis test). 
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Figure 10-7: Relationship between Physical Activity and Body Size 
 
10.3.8 Relationship of Physical activity to comorbid illnesses and biochemical 
parameters 
Univariate correlations of PAEE with specific comorbid conditions and biochemical 
parameters are shown in Table 10-3. PAEE correlated positively with body weight, 
serum urea and creatinine. Presence of cardiac disease, diabetes mellitus and 
arthritis were negatively correlated with PAEE. Other comorbid conditions specified 
in the questionnaire did not have significant correlations with PAEE. 
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Table 10-3: Univariate Correlations of Physical Activity-related Energy 
Expenditure 
Spearman’s correlation coefficients are stated in the table. Comorbid conditions 
mentioned refer to the presence of these diseases. 
Variable Correlation Coefficient p-value 
Watson Volume 0.326 < 0.001 
Body Weight 0.254 < 0.001 
Serum Urea 0.142 < 0.001 
Serum Creatinine 0.232 < 0.001 
Haemoglobin 0.047 NS 
Cardiac disease - 0.075 0.004 
Diabetes Mellitus - 0.064 0.012 
Arthritis - 0.149 < 0.001 
 
 
10.3.9 Predictors of Physical Activity 
Table 10-4 shows a linear regression model with PAEE as dependent variable. The 
variables considered were age, sex, ethnicity, comorbidity, employment status, 
dialysis adequacy (Kt/V), body weight and haemoglobin. Ethnicity, dialysis adequacy 
and haemoglobin were not significant in the model. 
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Table 10-4: Linear regression model of Physical Activity-related Energy 
Expenditure 
Adjusted R2 for the model: 0.513 
 Standardised coefficient (Beta) t p-value 
Age - 0.152 - 7.544 < 0.001 
Sex 0.123 6.475 < 0.001 
Comorbidity Score - 0.045 - 2.294 0.022 
Employment Status - 0.602 - 31.452 < 0.001 
Weight 0.145 7.189 < 0.001 
 
10.4 Discussion 
The main aim of this study was to examine the physical activity profile of the study 
participants and to explore the determinants of their physical activity-related energy 
expenditure in this section. It was found that physical activity levels were very low 
across the whole of the study population. Gender, age, comorbidity and employment 
status have significant impact on physical activity-related energy expenditure. Given 
their effect on physical activity, these variables along with weight were found to be 
significant predictors of PAEE in linear regression model. 
Physical activity levels have been reported to be low in haemodialysis patients even 
when compared to sedentary individuals (Avesani et al., 2012; Zamojska et al., 
2006; Johansen et al., 2000). Dialysis patients are exposed to a number of factors 
that may predispose to low physical activity. Firstly, these patients are likely to have 
significant comorbidities which may restrict their activities. Uraemia per se may lead 
to sarcopenia thereby reducing the ability to perform regular exercise. Indeed, a 
study carried out on dialysis patients showed 30% of incident and 39% of prevalent 
dialysis patients to have signs of muscle atrophy (Carrero et al., 2008). Moreover, 
renal failure is predominantly a disease of the elderly and factors related to aging 
may also contribute to reduced physical activity (Brown et al., 2005; Johansen et al., 
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2000). Finally, studies have shown markedly diminished physical functioning 
capacity in CKD patients even in earlier stages of kidney disease (Leikis et al., 2006; 
Castaneda et al., 2001; Boyce et al., 1997). 
The study findings showing reduced physical activity is in line with previously 
reported studies mentioned above in the haemodialysis patient population. There 
were also a number of factors associated with reduced physical activity. Females, 
elderly and those with high comorbidity have even lower physical activity levels 
compared to the rest of the cohort. This is in line with the potential causes underlying 
physical inactivity as explained above. Perhaps, it is not surprising that patients who 
are employed have higher activity-related energy expenditure compared to their 
unemployed counterparts. However, it is worth noting that the time reportedly spent 
on sedentary activities at home is only marginally less in employed compared to 
those unemployed (4.7 vs. 5.4 hours). 
Physical activity-related energy expenditure correlated positively with body weight, 
Watson Volume and Serum urea and creatinine. Urea and creatinine are classified 
as small molecule uraemic retention solutes. This association between physical 
activity and these molecules indicates that there may be a relationship between 
physical activity and uraemic toxin generation. This is merely an association and by 
no means, implies causality. Physical activity also correlated inversely with three 
specific comorbid conditions – cardiac disease, diabetes mellitus and arthritis. 
Individuals with cardiac disease and diabetes derive health benefits from increased 
activity level (Jonker et al., 2013; Koivula, Tornberg, & Franks, 2013; Myers, 2003). 
The study results show that these are the very individuals who have higher risk of 
reduced physical activity. The reduced physical activity in this high-risk group might 
predispose them to increased cardiovascular mortality risk. 
Physical activity levels showed a significant impact on body weight with more active 
individuals being heavier compared to the relatively inactive patients. Whilst this 
finding in itself is expected, it does highlight an interesting relationship with regards 
to dialysis dosing. As referred to at various points in this thesis, the relative effect of 
metabolic wastes in heavier individuals is likely to be less compared to the smaller 
patients implying that heavier patients need relatively less dialysis dose. However, it 
is likely, as shown in chapter 4, that increased physical activity may contribute to 
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higher uraemic toxin generation and thereby, necessitating higher dialysis doses in 
these heavier active individuals. Hence, it is essential to individualise the dialysis 
dose based on body size and activity level to deliver appropriate dialysis dose rather 
than based on body weight alone as is the current practice. 
Given the well-documented poor physical activity levels of dialysis patients, 
significant efforts are being made by many dialysis units to encourage patients to 
perform intra-dialysis exercise and also to improve habitual physical activity levels 
between dialysis sessions. Whilst every effort should be made to improve activity 
levels across the haemodialysis patient population, it is worthwhile focusing more on 
groups of patient at risk of reduced activity such as females, elderly and those with 
high comorbidity. However, the effect of increased physical activity on uraemic toxin 
generation has not been studied so far. In order to move forward with holistic 
exercise programs for haemodialysis patients, the relationship of physical activity to 
uraemic toxin generation needs to be explored in future studies. 
10.5 Limitations 
This study has some limitations. The physical activity data was collected through an 
activity questionnaire. The gold standard method of calculating total energy 
expenditure (and thereby, physical activity-related energy expenditure) – the Doubly 
Labelled Water method – is expensive, time-consuming and is not feasible to be 
carried out in large scale studies. The assessment of physical activity using 
accelerometers, though easier than the doubly labelled water method, is still difficult 
to perform in large cohort of patients such as this. Hence, questionnaire-based 
methods were deemed a useful alternative. As with any questionnaire method, there 
is a risk of recall bias from the participants. The questionnaire enquires regarding 
activities carried out in the preceding 4 weeks which is assumed to represent the 
overall activity levels which may not be true in all patients. Nevertheless, the overall 
activity levels found in this study are in line with previously published literature in this 
field (Avesani et al., 2012; Zamojska et al., 2006; Johansen et al., 2000). 
10.6 Conclusion 
In conclusion, physical activity level is very low in haemodialysis patients with some 
groups of patients performing even lower levels of activity compared to the 
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population as a whole. Further studies are needed to examine the impact of 
increased physical activity on uraemic toxin generation. In addition, the relationship 
between body size and physical activity should be explored with regards to the 
dosing of dialysis. The potential benefits of scaling dialysis dose based on body size 
and activity levels and the impact of such a practice on patient survival will be 
discussed in subsequent chapters. 
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 Chapter 11 
11. Scaling Haemodialysis Dose to Reflect Metabolic Activity: 
Potential Benefits 
 
11.1 Introduction 
The current recommended minimum Kt/V target is 1.2 per dialysis session for both 
men and women ("Clinical Practice Guidelines for Hemodialysis Adequacy, Update 
2006," 2006). As discussed in the previous chapter, parameters such as body 
surface area (BSA), resting energy expenditure (REE) and total energy expenditure 
(TEE) could be considered as potential scaling factors for normalising dialysis dose. 
Apart from BSA, the other two parameters have not been explored as a scaling 
factor for dialysis dosing in clinical studies to date. As REE and TEE are likely to be 
better markers of metabolic activity, using these parameters may deliver appropriate 
dialysis doses with respect to individual metabolic needs. In order to examine the 
reliability and explore the practical application of these parameters for dialysis dose 
scaling, it is essential to identify the equivalent dialysis dose using these parameters 
corresponding to current minimum Kt/V target. Although previous studies have 
explored the impact of using BSA for scaling dialysis dose (Ramirez et al., 2012; 
Daugirdas, Depner, et al., 2008), no study to date has suggested an equivalent 
dialysis dose using any of the alternate scaling parameters. 
The primary aim of this study was 
• To explore the equivalent dialysis dose that would be delivered using the 
above parameters for scaling corresponding to the current recommended 
minimum dose target 
• To identify patient characteristics that would be associated with risk of sub-
optimal delivered dialysis doses with current dosing practice. 
The experimental hypothesis of this study was that current minimum Kt/V target 
would deliver sub-optimal dialysis dose compared to that estimated using one of the 
alternate scaling parameters and the null hypothesis was that there would be no 
difference in dialysis dose delivered with any of these scaling parameters. 
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11.2 Methods 
11.2.1 Ethical Review 
The study was approved by the North Wales Research Ethics Committee (ref: 
12/WA/0060 and UH Ethics ref: LMS/PG/NHS/00257). All subjects provided written 
informed consent to take part. 
11.2.2 Study Protocol 
1. The study population consisted of 1500 chronic haemodialysis patients. The 
inclusion and exclusion criteria are explained in chapter 10. 
2. Demographic, anthropometric and biochemical data was collected for each 
study participant as detailed in chapter 10. 
3. Physical activity data was collected using Recent Physical Activity 
Questionnaire (RPAQ) and comorbidity data from a self-report comorbidity 
questionnaire. Both the questionnaires were administered once only at the 
time of recruitment. 
11.2.3 Estimation of Alternative Scaling Parameters 
Estimation of all relevant parameters – Watson volume, body surface area, resting 
energy expenditure, physical activity-related energy expenditure and total energy 
expenditure – are explained in the methodology section in chapter 10. 
11.2.4 Scaling of Dialysis Dose 
KDOQI guidelines recommend a minimum target dose of single-pool Kt/V (spKt/V) of 
1.2 per dialysis session for a thrice-weekly schedule. Hence, in order to compare 
minimum dialysis targets using alternative scaling parameters, Kt was calculated for 
each patient as below. 𝑲𝒕 = 𝟏.𝟐  ×  𝑽 
where V is Watson Volume. Corresponding target values of Kt/BSA, Kt/REE and 
Kt/TEE were calculated by dividing Kt by the respective parameters for each 
individual patient. 
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11.2.5 Sample Size and Statistical Analysis 
A power analysis was performed to estimate the statistical power provided by a 
study of 1500 patients on haemodialysis, assuming a study drop-out (attrition) rate of 
15% per annum due to loss from follow-up or transplantation. Assuming α=0.05, and 
N=1500 patients, and the estimated Hazard ratios in a previous study in our unit, the 
power to detect group differences (between the middle and lower tertiles) for the 
different methods of estimating dialysis dose are as follows: 1-β=0.91 Kt/V dose; 1-
β=0.98 for Kt/REE; and 1-β>0.99 for Kt/BSA. This provides strong evidence that the 
study is likely to have sufficient power to demonstrate differences between the 
relevant groups for each parameter. 
Statistical analysis was carried out using SPSS ® version 19 (SPSS Software, IBM 
Corporation, New York, USA). Normally distributed data are presented as mean ± 
SD, and non-normally distributed as median [± interquartile range]. The significance 
of differences between means was determined by Student’s t-test and of differences 
between medians by the Mann-Whitney U test. The significance of differences 
between multiple group means was assessed by ANOVA with differences between 
individual groups being assessed using the Bonferroni test. Multivariate regression 
models to examine predictors of Kt/TEE were developed using stepwise linear 
regression. The variables used in the model were age, sex, employment status, 
ethnicity, body weight and comorbidity score. Ethnicity was used as a categorical 
variable as belonging to White ethnic origin or not. Collinearity testing was carried 
out for all the variables included in the regression model and variables with only low 
variance inflation factor (<10) were included. A p-value of <0.05 was assumed to 
indicate statistical significance. 
11.3 Results 
11.3.1 Demographics 
A total of 1500 patients (910 men and 590 women) were recruited. Some selected 
anthropometric details are shown in Table 11-1. For other variables, please refer to 
the demographic section in chapter 10. All body size parameters were significantly 
greater in men than women. 
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Table 11-1: Demographic, anthropometric and biochemical characteristics of 
Study patients 
Values expressed are mean ± SD. Proportions of categorical variables are 
expressed as percentages. 
 All patients (n = 1500) 
Males 
(n = 910) 
Females 
(n = 590) p-value 
Age (years) 62.9 ± 15.5 63.8 ± 15.6 61.6 ± 15.1 0.007 
Weight (kg) 75.2 ± 18.3 78.4 ± 17.3 70.4 ± 18.6 <0.001 
Height (cm) 165.9 ± 10.0 170.6 ± 8.2 158.7 ± 8.2 <0.001 
Ethnicity (% South 
Asian: Black: White) 
27.9: 26.7: 
45.5 
27.3: 24.0: 
48.7 
28.6: 30.9: 
40.5 0.003 
High Comorbidity (%) 29.5 28.7 30.7 NS 
Employed (%) 11.5 13.1 9.2 0.021 
 
Body size and energy expenditure measures are shown in Table 11-2. Watson 
Volume, BSA, REE, Mean daily METs and TEE were all significantly lower in women 
than men. 
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Table 11-2: Body size and energy expenditure characteristics of Study patients 
Values expressed are Mean ± SD. REE: resting energy expenditure, MET: metabolic 
equivalent of task, TEE: total energy expenditure 
 All patients (n = 1500) 
Males 
(n = 910) 
Females 
(n = 590) p-value 
Watson Volume (L) 37.5 ± 7.4 41.0 ± 6.6 32.2 ± 4.9 <0.001 
Body Surface Area 
(m2) 1.87 ± 0.26 1.93 ± 0.24 1.77 ± 0.26 <0.001 
REE (kcal/day) 1545 ± 250 1621 ± 230 1429 ± 236 <0.001 
Mean Daily MET 1.19 ± 0.13 1.20 ± 0.14 1.17 ± 0.10 <0.001 
TEE (kcal/day) 1841 ± 388 1948 ± 390 1676 ± 322 <0.001 
 
 
11.3.2 Relationship between Watson Volume and Body Surface Area 
The relationship between Watson volume (V) and BSA is shown in Figure 11-1. As 
can be seen, for any given V, females had higher BSA compared to males. 
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Figure 11-1: Relationship between Watson Volume and BSA 
 
11.3.3 Relationship between Watson Volume and Energy Expenditure 
The relationship between Watson volume and REE and TEE are shown in Figure 
11-2 and Figure 11-3. Similar to that with BSA, females had higher REE and TEE for 
a given V although the magnitude of difference is smaller than that seen in 
comparison with BSA. 
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Figure 11-2: Relationship between Watson Volume and REE 
 
Figure 11-3: Relationship between Watson Volume and TEE 
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11.3.4 Gender differences in Metabolically Normalised Doses 
The mean values of metabolically normalised dialysis doses (Kt/BSA, Kt/REE, 
Kt/TEE) equivalent to a Kt/V of 1.2 are shown in Table 11-3. The equivalent dose 
expressed as Kt was markedly less in females than males (38,662 ± 5,940 v 49,251 
± 7,937: p < 0.001). There were also marked gender differences in the metabolically 
normalised parameters. Kt/BSA was 21,851 ± 246 ml/m2 for women and 25,392 ± 
1,208 ml/m2 for men (p < 0.001). For Kt/REE these were 27.18 ± 1.87 ml/kcal for 
women and 30.34 ± 1.25 ml/kcal for men (p < 0.001) and for Kt/TEE, 23.37 ± 2.60 
ml/kcal for women and 25.60 ± 2.73 ml/kcal for men (p < 0.001). 
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Table 11-3: Dialysis dose equivalent to a Kt/V of 1.2 expressed as Kt/BSA, 
Kt/REE and Kt/TEE 
BSA: body surface area, REE: resting energy expenditure, TEE: total energy expenditure; 
*significant difference by unpaired t-test (p<0.001), **significant difference by unpaired t-test 
(p<0.01), † significant differences across group by one-way ANOVA 
 NUMBER Kt(ml) Kt/BSA (ml/m2) Kt/REE 
(ml/kcal) 
Kt/TEE 
(ml/kcal) 
All Patients 1500 45,086 ± 8,879 29,999 ± 1,976 29.10 ± 2.17 24.72 ± 2.89 
GENDER 
Male 910 49,251 ± 7,937* 25,392 ± 1,208* 30.34 ± 1.25* 25.60 ± 2.73* 
Female 590 38,662 ± 5,940 21,851 ± 246 27.18 ± 1.87 23.36 ± 2.60 
WEIGHT QUARTILES (kg) 
≤ 62.3 375 35,616 ± 3850† 22,833 ± 1,526† 28.08 ± 2.11† 24.08 ± 2.65† 
62.4 to 72.7 375 42,244 ± 3,876 23,823 ± 1,787 28.90 ± 1.86 24.50 ± 2.65 
72.8 to 84.5 375 46,906 ± 4,377 24,258 ± 1,786 29.31 ± 1.96 24.80 ± 2.91 
>84.5 375 55,578 ± 7,433 25,082 ± 2,072 30.11 ± 2.24 25.48 ± 3.17 
AGE QUARTILES (years) 
≤ 52 375 46,932 ± 10,185† 24,734 ± 2,507† 28.15 ± 2.45† 22.98 ± 3.13† 
52.1 to 65.3 375 45,980 ± 9,222 24,133 ± 2,024 27.60 ± 1.99 23.28 ± 2.60 
65.4 to 75.5 375 45,218 ± 8,451 23,780 ± 1,673 30.36 ± 1.43 26.22 ± 2.06 
>75.5 375 42,215 ± 6,579 23,351 ± 1,198 30.29 ± 0.86 26.38 ± 1.62 
ETHNICITY 
Asian 418 42,692 ± 8,099† 23,861 ± 1,975 28.60 ± 2.26† 24.16 ± 2.70† 
Black 400 46,456 ± 8,617 24,047 ± 2.124 28.87 ± 2.18 24.57 ± 2.93 
White 682 45,750 ± 9,209 24,055 ± 1,882 29.54 ± 2.02 25.14 ± 2.93 
COMORBIDITY 
Low 1058 44,964 ± 8,911 24,091 ± 2,033** 28.98 ± 2.19* 24.40 ± 3.00* 
High 442 45,377 ± 8,804 23,780 ± 1,815 29.38 ± 2.11 25.47 ± 2.47 
EMPLOYMENT 
Working 173 48,597 ± 9,132* 24,922 ± 2,181* 28.83 ± 2.18 20.61 ± 2.68* 
Not working 1337 44,628 ± 8,745 23,879 ± 1,916 29.13 ± 2.17 25.25 ± 2.17 
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11.3.5 Body-size and Age-related Differences in Metabolically Normalised 
Doses 
There were also marked differences in these parameters with respect to body size. 
Table 11-3 shows the influence of the body weight (expressed in quartiles).  For 
each parameter there was a significant difference between the means across the 
quartiles as judged by one-way ANOVA. Smaller patients received a much lower 
overall dose irrespective of whatever the metabolically normalised parameter that 
was used. The mean dose of Kt/BSA ranged from 22,876 (±1,549) ml/m2 in the 
lowest weight quartile group to 25,101 (±2,047) ml/m2 in those in the highest quartile. 
For Kt/REE, this ranged from 28.14 (±2.08) ml/kcal to 30.15 (±2.23) ml/kcal and for 
Kt/TEE, 24.15 (±2.60) ml/kcal to 25.47 (±3.17) ml/kcal. 
Patient age also influenced these parameters (Table 11-3).  For Kt there was a 
significant reduction across age quartiles by ANOVA. The magnitude of the reduction 
was smaller for Kt/BSA, but still significant, reducing from a mean of 24,734 (± 
2,507) ml/m2 in the youngest group to 23,351 (± 1,198) ml/m2 to the oldest group. 
However both Kt/REE and Kt/TEE increased with increasing age. The mean Kt/REE 
in the youngest age quartile was 28.15 (± 2.45) ml/kcal which progressively 
increased to 30.29 (± 0.86) ml/kcal in the oldest age quartile. For Kt/TEE, the 
corresponding values were 22.98 (± 3.13) ml/kcal and 26.38 (± 1.62) ml/kcal. 
11.3.6 Effect of Ethnicity, Comorbidity and Employment on Dialysis Dosing 
Table 11-3 also shows the differences between these parameters with respect to 
ethnicity.  In general the equivalent dose for Asians was lower than that for Blacks 
which was lower than that for Whites. For Kt, Kt/REE, Kt/TEE there was a significant 
difference in means between ethnic groups by one-way ANOVA. For Kt/BSA the 
differences were not significantly different. 
Patients with high comorbidity (CSCS >3) had slightly but significantly higher Kt/REE 
and Kt/TEE levels than their counterparts with lower comorbidity, though values of 
Kt/BSA were slightly lower. The corresponding values are shown in Table 11-3. 
Values of Kt/REE and Kt/TEE were consistently higher in those with arthritis, cancer, 
diabetes and heart disease than in those without these conditions. 
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Patients in employment had lower levels of Kt/TEE than those not employed, though 
levels of both Kt and Kt/BSA were higher (Table 11-3). This reflects the significantly 
higher weight (79.4 ± 18.4 vs. 74.7 ± 18.2; p = 0.001) and physical activity expressed 
as Mean Daily MET (1.42 ± 0.19 vs. 1.16 ± 0.07; p < 0.001) of employed individuals.  
11.3.7 Impact of Gender-specific Body Size Differences on Dialysis Dosing 
Given the major influence of gender on these parameters, the within gender 
differences in relation to body weight, age, ethnicity, comorbidity and employment 
status were examined. Figure 11-4 to Figure 11-7 depicts the effect of weight on 
these parameters. For women, there was no significant difference in the dose that 
would be delivered across the weight quartiles irrespective of what the scaling 
parameter was. However, in males, the delivered dose would be significantly lower in 
smaller men compared to their larger counterparts with any of the three parameters 
(p < 0.001 for all). 
 
 
Figure 11-4: Predicted delivered minimum dialysis dose in relation to gender-
specific weight quartiles using Kt 
FQ1 to FQ4 – Weight quartiles lowest to highest for women; MQ1 to MQ4 – Weight quartiles 
lowest to highest for men; Males (open circles) and Females (filled circles) (for Figure 11-4 
to Figure 11-7) 
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Figure 11-5: Predicted delivered minimum dialysis dose in relation to gender-
specific weight quartiles using Kt/BSA 
 
 
Figure 11-6: Predicted delivered minimum dialysis dose in relation to gender-
specific weight quartiles using Kt/REE 
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Figure 11-7: Predicted delivered minimum dialysis dose in relation to gender-
specific weight quartiles using Kt/TEE 
 
11.3.8 Gender-specific Dosing with Kt/TEE in Patient Subgroups 
As shown in Table 11-3, the differences between the groups were most consistent 
with Kt/TEE. Hence, this parameter was chosen to study the effect of age, ethnicity, 
comorbidity, and employment status on dialysis dosing. This is shown in Figure 11-8 
to Figure 11-11. In both males and females Kt/TEE was lower for younger patients, 
for those with low comorbidity, and for those in employment.  In males, there seemed 
little influence of ethnic group on Kt/TEE, whereas in Asian females Kt/TEE was 
slightly but significantly lower than in other females  (22.45 ± 2.42 v 23.72 ± 2.59; p < 
0.001). 
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Figure 11-8: Effect of age on predicted delivered minimum Kt/TEE 
 
 
Figure 11-9: Effect of ethnicity on predicted delivered minimum Kt/TEE 
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Figure 11-10: Effect of comorbidity on predicted delivered minimum Kt/TEE 
 
Figure 11-11: Effect of employment on predicted delivered minimum Kt/TEE 
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The best linear regression model (adjusted R square 0.573) of independent 
predictors of Kt/TEE is shown in Table 11-4. Age, gender, weight, Asian ethnicity, 
and employment status were the variables found to predict Kt/TEE. 
Table 11-4: Independent Predictors of Kt/TEE 
Model 
Standardised 
Coefficients 
(Beta) 
t p-value 
Constant  23.789 < 0.001 
Age 0.340 19.109 < 0.001 
Sex 0.340 19.552 < 0.001 
Weight 0.187 10.571 < 0.001 
Asian Ethnicity -0.056 -3.251 0.001 
Employment 0.458 25.954 < 0.001 
 
11.4 Discussion 
This study aimed to explore the minimum dialysis dose, corresponding to current 
recommended Kt/V target of 1.2, that would be delivered using some of the alternate 
scaling parameters and also to identify the characteristics of patients who are at risk 
of under-dialysis with current dosing practice. The study results demonstrated that 
the predicted minimum delivered dialysis dose would be significantly lower in women 
compared to men if any of the three parameters – BSA, REE or TEE – are used 
though they all would have had identical Kt/V values. The study findings are in favour 
of rejecting the null hypothesis and accepting the experimental hypothesis that 
current dialysis practice delivers sub-optimal dose to some subgroups of patients. 
Small women would have received lower doses compared to larger women if Kt/BSA 
was used. However, small men would have received significantly lower doses 
compared to their larger men irrespective of whatever the scaling parameter was. 
Besides sex, younger age, employment, Asian ethnicity and comorbidity status also 
have an impact on dosing based on these metabolic factors. 
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There has been an ongoing debate on what is the best parameter for dialysis dosing. 
Some authors have argued that Kt/V is the best parameter while others have refuted 
it (Gotch, 2000; Lowrie, 2000). Daugirdas et al (2008) have shown that BSA-based 
dialysis dosing will result in higher dialysis doses to women and small men 
(Daugirdas, Depner, et al., 2008). A recent study has also shown a better 
relationship with survival for the BSA-based dosing compared to current practice 
(Ramirez et al., 2012). Morton and Singer (2007) have argued that the dialysis dose 
should be based on metabolic rate because of the non-linear correlation between 
body mass and metabolic rate (Morton & Singer, 2007). Previous findings have also 
shown that women have relatively higher urea generation rate and TEE is an 
independent predictor of urea generation rate (Sridharan, Vilar, Berdeprado, & 
Farrington, 2013). This would mean that TEE could also be considered a potential 
scaling parameter for dialysis dosing. 
As shown in Figure 11-1 to Figure 11-3, for any given Watson volume, women have 
higher level of any of the metabolic parameters examined here. This would mean 
that using these parameters would meet the higher requirements for dialysis dose in 
females compared to males. 
There were gender, body size and age related differences in metabolically 
normalised dialysed doses based on these parameters. The current study 
demonstrates that with V-based dosing, women of all body sizes are at risk of under-
dialysis compared to similar-sized men if equivalent doses are estimated using 
metabolic parameters such as BSA, REE or TEE as denominators. As shown in 
Figure 11-4 to Figure 11-7, females have a requirement for a greater dialysis dose 
and this overrides any effect of weight. This shows that V-based dosing targets need 
to be gender-specific, unlike current recommendations. Not only was there 
significant gender difference, but there were also dialysis dose differences based on 
body weight. Smaller males require a greater relative dose than larger males. The 
study also found that women and small men would receive significantly lower dialysis 
dose with BSA-based dosing compared to their larger counterparts as per the 
current minimum dialysis dose target. This implies that V-based dosing targets also 
need to be body-size specific. Alternately, using parameters such as BSA, REE or 
TEE may inherently adjust for these gender and body size differences thus negating 
the problem of having multiple dose targets. 
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Dialysis dose expressed as Kt/REE or Kt/TEE was significantly lower in patients with 
low comorbidity compared to those with higher levels of comorbidity. This would 
mean that individuals with low comorbidity are at risk of under-dialysis and may have 
a requirement for higher dose. However, it is worth noting that these findings are 
based mainly on body size and estimated physical activity and do not take into 
account the potential differences in energy metabolism which may be associated 
with specific comorbidities. 
The current study also identified other possible patient characteristics that may be 
associated with risk of under-dialysis. Both Kt/REE and Kt/TEE increased with 
increasing age, suggesting a need for higher dialysis doses in younger age groups. 
Kt/TEE was also significantly lower in those who are in employment compared to 
those who are not, thereby, implying a greater dialysis dose requirement in 
employed individuals. Patients of Asian ethnicity were also found to be at risk of 
under-dialysis if REE or TEE were considered as scaling parameters. However, it 
has to be emphasised that these subgroup differences are likely to be secondary to 
differences in body weight and physical activity levels rather than a direct effect of 
these characteristics on metabolic needs. Given this relationship between the above 
characteristics and energy metabolism, these factors were shown to be significant in 
predicting Kt/TEE in a linear regression model. 
There is dearth of comparative studies using these 3 parameters in clinical studies 
and hence, it is difficult to ascertain if one of these parameters is superior to others in 
providing dialysis dose based on metabolic needs of the individual. Daugirdas et al 
(2008) have argued that theoretically using REE, unlike BSA, will not result in 
substantial increase in dialysis dose to women (Daugirdas, Levin, et al., 2008). 
However, there is suggestion from a previous study that metabolic rate drives the 
glomerular filtration rate (GFR) (Singer, 2001). Also, GFR and metabolic rate scale to 
body mass with virtually the same exponent (Singer & Morton, 2000). Hence, 
metabolic rate i.e., REE could be a potential scaling parameter. Physical activity 
contributes to increased metabolism and thereby, higher metabolic waste production. 
It could be argued that TEE, incorporating both REE and physical activity, could be a 
better parameter reflecting the metabolic activity. However, these are theoretical 
arguments and there is need for comparative outcome-based studies employing 
standardised forms of these parameters to examine this issue. 
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11.5 Conclusion 
In conclusion, the current study has demonstrated that metabolic parameters such 
as BSA, REE and TEE could be used to scale dialysis dose and that current V-
based dosing risk under-dialysing women and small men. Our study findings suggest 
a gender-, body size- and physical activity-specific V-based dosing or dosing based 
on these alternate metabolic parameters. Scaling dialysis dose based on these 
metabolic parameters may benefit some subgroups of patients by providing more 
dialysis and may in turn impact on their survival outcome. The potential impact on 
survival of using these metabolic parameters for dialysis dosing will be examined in 
the next chapter. 
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 Chapter 12 
12. Metabolic Activity-Based Haemodialysis Dosing: Impact on 
Survival 
 
12.1 Introduction 
As discussed in previous chapters, parameters reflecting metabolic activity such as 
body surface area (BSA), resting energy expenditure (REE) and total energy 
expenditure (TEE) have a potential role as scaling factors for haemodialysis dosing. 
The arguments put forward in support of these energy expenditure parameters have 
been theoretical ones and there has not been any published study examining REE or 
TEE in relation to patient outcomes. As explained in chapter 10, this prospective 
multi-centre study was designed with a primary aim of examining the impact of using 
these metabolic parameters for scaling dialysis dose on patient survival. The 
previous chapters have shown some subgroups of patients to be at risk of under-
dialysis with current dosing practice and may benefit from use of one of these 
metabolic parameters. 
The main aim of the study was to compare dialysis doses prescribed using each of 
these parameters in relation to survival outcomes. The study also aimed to develop 
possible adjustments to the current recommended minimum dialysis dose that would 
be needed to better reflect the metabolic needs of various subgroups of patients. 
The experimental hypothesis for this study was that one or more of these 
parameters, when used to scale dialysis dose, might predict survival better than the 
current practice of using Kt/V. The null hypothesis was that there would be no 
difference in predictive power with regards to survival between these scaling 
parameters. 
12.2 Methods 
12.2.1 Ethical Review 
The study was approved by the North Wales Research Ethics Committee (ref: 
12/WA/0060 and UH Ethics ref: LMS/PG/NHS/00257). All subjects gave written 
informed consent to take part. 
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12.2.2 Study Protocol 
1. The study population consisted of 1500 maintenance haemodialysis patients. 
The inclusion and exclusion criteria are explained in chapter 10. 
2. Demographic, anthropometric and biochemical data was collected for each 
study participant as detailed in chapter 10. 
3. Physical activity data was collected using Recent Physical Activity 
Questionnaire (RPAQ) and comorbidity data from a self-report comorbidity 
questionnaire. Both the questionnaires were administered once only at the 
time of recruitment. 
4. Study participants were followed up at pre-specified time points – at 3 months 
from recruitment, and then, at 6, 12 and 18 months. Patients from the renal 
units of Lister hospital were followed up till 24 months from recruitment. 
5. The following data were collected at follow-up – patient survival; change in 
renal replacement therapy modality such as transplantation, home 
haemodialysis or peritoneal dialysis or transfer to a different dialysis unit not 
included in the study; data pertaining to haemodialysis session to enable 
calculation of delivered dialysis doses at each time point. 
6. Study subjects were censored for transplantation, change of renal 
replacement therapy from in-centre haemodialysis (i.e. home haemodialysis 
or peritoneal dialysis) and recovery of renal function or if their care was 
transferred to another centre. 
12.2.3 Scaling Dialysis Dose 
The alternate scaling parameters – Body Surface Area (BSA), Resting Energy 
Expenditure (REE) and Total Energy Expenditure (TEE) – were calculated as 
explained in chapter 10. 
Delivered dialysis dose based on current practice (Delivered Kt/V) was calculated for 
study subjects at each time point and a mean delivered Kt/V for the entire study 
duration was calculated. Delivered Kt was calculated for each patient as below. 
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𝑫𝒆𝒍𝒊𝒗𝒆𝒓𝒆𝒅  𝑲𝒕   =   𝑫𝒆𝒍𝒊𝒗𝒆𝒓𝒆𝒅  𝑲𝒕𝑽   ×  𝑽 
where V is Watson volume. Corresponding values of delivered Kt/BSA, Kt/REE and 
Kt/TEE were calculated by dividing Delivered Kt by the respective parameters for 
each patient at each time point. Similar to the delivered Kt/V, corresponding mean 
delivered doses for the entire duration of the study was calculated. 
12.2.4 Standardising the Dialysis Dose 
In order to allow comparison between Kt/V, Kt/BSA, Kt/REE and Kt/TEE, it is 
essential to standardise these parameters. All the parameters were standardised to 
within one standard deviation of each parameter by the following method. 
For each parameter, mean and standard deviation of the study population was 
calculated. Then, the individual value for each patient was subtracted from the mean 
and divided by the standard deviation. For example, the Standardised Kt/TEE was 
calculated as below. 
𝑺𝒕𝒂𝒏𝒅𝒂𝒓𝒅𝒊𝒔𝒆𝒅   𝑲𝒕𝑻𝑬𝑬   =    𝑲𝒕𝑻𝑬𝑬−   𝝁𝝈  
where Kt/TEE is the parameter value for each patient, µ is the population mean of 
Kt/TEE and σ is the standard deviation of the population. Standardised Kt/V, Kt/BSA 
and Kt/REE were calculated similarly using respective parameter means and 
standard deviations. 
12.2.5 Statistical Analysis 
Statistical analysis was carried out using SPSS ® version 19 (SPSS Software, IBM 
Corporation, New York, USA). Normally distributed data are presented as mean ± 
SD, and non-normally distributed as median [± interquartile range]. The significance 
of differences between means was determined by Student’s t-test and of differences 
between medians by the Mann-Whitney U test. The significance of differences 
between multiple group means was assessed by ANOVA with differences between 
individual groups being assessed using the Bonferroni test. Survival differences 
between groups were analysed using Kaplan-Meier plot with Log-rank test. 
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Independent predictors of survival were assessed using Cox regression models. A p-
value of <0.05 was assumed to indicate statistical significance. 
12.3 Results 
12.3.1 Demographics 
The demographic and anthropometric details of patients at baseline were discussed 
in chapter 10. Some selected anthropometric information and energy expenditure 
details are shown in Table 12-1. For other variables, please refer to the demographic 
section in chapter 10. For weight, Watson volume and the three metabolic 
parameters, a mean value was calculated by taking an average of the respective 
measurements at each time point during the follow-up. These mean values are 
shown in Table 12-1. All measures of body size and energy expenditure were 
generally lower in females compared to males. 
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Table 12-1: Anthropometric and Energy Expenditure Characteristics of Study 
Patients 
 All patients 
(n = 1500) 
Males 
(n = 910) 
Females 
(n = 590) 
p-value 
Age at Baseline (years) 62.9 ± 15.5 63.8 ± 15.6 61.6 ± 15.1 0.007 
Mean Weight (kg) 74.9 ± 18.3 78.0 ± 17.0 70.2 ± 19.0 <0.001 
Height (cm) 165.9 ± 10.0 170.6 ± 8.2 158.7 ± 8.2 <0.001 
Ethnicity (% South 
Asian: Black: White) 
27.9: 26.7: 
45.5 
27.3: 24.0: 
48.7 
28.6: 30.9: 
40.5 
0.003 
High Comorbidity (%) 29.5 28.7 30.7 NS 
Employed (%) 11.5 13.1 9.2 0.021 
Mean Watson Volume 
(Litres) 
37.5 ± 7.4 40.9 ± 6.5 32.2 ± 5.0 <0.001 
Mean BSA (m2) 1.86 ± 0.26 1.93 ± 0.24 1.77 ± 0.26 <0.001 
Mean REE (kcal/day) 1542 ± 250 1617 ± 229 1426 ± 236 <0.001 
Mean TEE (kcal/day) 1837 ± 388 1944 ± 391 1673 ± 321 <0.001 
 
The mean delivered dose of Kt/V and estimated mean delivered doses using the 
alternate metabolic parameters are shown in Table 12-2. The delivered Kt/V dose 
was significantly higher in females compared to males (p < 0.001). The delivered 
dose expressed as Kt or Kt/BSA was significantly lower in females (p < 0.001 for 
both). However, there is no statistically significant gender difference in the delivered 
dose expressed as Kt/REE or Kt/TEE. 
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Table 12-2: Gender Differences in the Delivered Dialysis Dose 
 All patients 
(n = 1500) 
Males 
(n = 910) 
Females 
(n = 590) 
p-value 
Mean Kt/V 1.37 ± 0.22 1.32 ± 0.20 1.44 ± 0.22 <0.001 
Mean Kt (ml) 47,046 ± 8,494 49,698 ± 8,404 42,954 ± 6,854 <0.001 
Mean Kt/BSA (ml/m2) 27,161 ± 4,120 27,732 ± 4,101 26,280 ± 3,993 <0.001 
Mean Kt/REE (ml/kcal) 32.97 ± 5.11 33.14 ± 4.81 32.71 ± 5.54 NS 
Mean Kt/TEE (ml/kcal) 28.0 ± 5.0 27.93 ± 4.84 28.1 ± 5.23 NS 
 
The median follow-up time was 18.5 months (range: 18 – 25 months). There were a 
total of 263 deaths during the study period. 192 patients were censored for various 
reasons of which 143 were due to renal transplantation. 
12.3.2 Survival Based on Gender 
Kaplan-Meier analysis showed significantly higher survival rates in women compared 
to men (p = 0.003, Log-rank test) as shown in Figure 12-1. 
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Figure 12-1: Kaplan-Meier plot of Gender difference in Survival 
 
12.3.3 Survival based on Ethnicity 
Using a Kaplan-Meier analysis, it can be seen that there was significantly higher 
survival rate in Non-Whites compared to those of White ethnic origin (p < 0.001, Log-
rank test; Figure 12-2). 
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Figure 12-2: Kaplan-Meier plot of Ethnic difference in Survival 
 
 
12.3.4 Survival based on Comorbidity 
Kaplan-Meier analysis showed significantly higher survival rate in patients with low 
comorbidity (comorbidity score ≤ 3) compared to those with higher scores (p < 0.001, 
Log-rank test, see Figure 12-3). 
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Figure 12-3: Kaplan-Meier plot of Survival based on Comorbidity 
 
12.3.5 Determining the parameter that best predicts survival 
Given the significant survival differences with regards to gender, ethnicity and 
comorbidity as shown above, these variables were included in the Cox regression 
models to explore the parameter that best predicts survival in this group of 
haemodialysis patients. 
In order to allow comparison between these parameters, standardised measures of 
these variables – Kt/V, Kt/BSA, Kt/REE and Kt/TEE – were used in the Cox models 
which are shown in Table 12-3 through to Table 12-6. 
 
 
 259 
Table 12-3: Cox Model of Survival using Standardised Kt/V 
 p-value Hazard Ratio 
95% confidence interval for 
Hazard Ratio 
Lower Upper 
Age < 0.001 1.032 1.021 1.043 
Male Gender 0.441 1.113 0.848 1.461 
Non-White Ethnicity 0.004 0.684 0.528 0.884 
Comorbidity Score < 0.001 1.156 1.097 1.219 
BMI < 0.001 0.937 0.914 0.961 
Mean Daily MET 0.022 0.157 0.032 0.761 
Standardised Kt/V < 0.001 0.721 0.626 0.831 
 
Table 12-4: Cox Model of Survival using Standardised Kt/BSA 
 
p-value Hazard Ratio 
95% confidence interval for 
Hazard Ratio 
Lower Upper 
Age < 0.001 1.028 1.017 1.039 
Male Gender 0.006 1.448 1.110 1.888 
Non-White Ethnicity 0.003 0.675 0.522 0.874 
Comorbidity Score < 0.001 1.156 1.097 1.218 
BMI < 0.001 0.940 0.917 0.964 
Mean Daily MET 0.025 0.163 0.034 0.797 
Standardised Kt/BSA < 0.001 0.708 0.617 0.812 
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Table 12-5: Cox Model of Survival using Standardised Kt/REE 
 
p-value Hazard Ratio 
95% confidence interval for 
Hazard Ratio 
Lower Upper 
Age < 0.001 1.037 1.026 1.048 
Male Gender 0.062 1.286 0.988 1.674 
Non-White Ethnicity 0.003 0.674 0.521 0.873 
Comorbidity Score < 0.001 1.156 1.097 1.218 
BMI < 0.001 0.942 0.919 0.965 
Mean Daily MET 0.024 0.161 0.033 0.786 
Standardised Kt/REE < 0.001 0.717 0.627 0.820 
 
Table 12-6: Cox Model of Survival using Standardised Kt/TEE 
 
p-value Hazard Ratio 
95% confidence interval for 
Hazard Ratio 
Lower Upper 
Age < 0.001 1.037 1.025 1.048 
Male Gender 0.062 1.285 0.987 1.673 
Non-White Ethnicity 0.003 0.673 0.520 0.871 
Comorbidity Score < 0.001 1.156 1.097 1.218 
BMI < 0.001 0.942 0.919 0.966 
Mean Daily MET < 0.001 0.032 0.006 0.174 
Standardised Kt/TEE < 0.001 0.697 0.600 0.810 
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In all the above models, Body Mass Index (BMI) was included as adjustment for 
body size and Mean Daily MET for level of physical activity. Age, ethnic origin, 
comorbidity, BMI and Mean Daily MET significantly predicted survival in all the 
models. Gender was a significant predictor in the model using Kt/BSA but was not so 
in other models. The hazard ratios for the standardised measures of dialysis doses 
represent the risk of death associated with a unitary increase in one standard 
deviation of the corresponding parameter. Standardised Kt/TEE had the lowest 
hazard ratio of death (0.697) in these models with Standardised Kt/V having the 
highest hazard ratio (0.721). 
12.3.6 Determining the “optimum cut-off” point for the alternate parameters 
The study data was analysed to identify the optimum cut-off point for dialysis doses 
expressed using the alternate parameters that would better predict the survival in the 
study cohort. A Cox regression model using quartiles of delivered Kt/BSA is shown in 
Table 12-7 along with the survival plot based on Kt/BSA quartiles (Figure 12-4). 
 
Figure 12-4: Survival Differences based on Kt/BSA Quartiles 
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Table 12-7: Survival model using Kt/BSA Quartiles 
 
p-value Hazard Ratio 
95% confidence interval for 
Hazard Ratio 
Lower Upper 
Age < 0.001 1.028 1.017 1.040 
Male Gender 0.013 1.398 1.072 1.823 
Asian Ethnicity 0.452 0.893 0.665 1.199 
Black Ethnicity < 0.001 0.444 0.302 0.651 
Comorbidity Score < 0.001 1.145 1.086 1.207 
BMI < 0.001 0.944 0.921 0.968 
Mean Daily MET 0.010 0.120 0.024 0.605 
Kt/BSA – Quartile 1 < 0.001 2.210 1.522 3.210 
Kt/BSA – Quartile 2 0.002 1.805 1.239 2.628 
Kt/BSA – Quartile 3 0.995 1.001 0.667 1.503 
 
In this model, White ethnicity and the highest quartile of Kt/BSA (Quartile 4) were 
used as reference groups to compare with their respective counterparts in the other 
groups. Compared with the highest Kt/BSA quartile, the bottom 2 quartile groups had 
significantly higher risk of death but there was no difference in survival when 
compared to the quartile 3. This suggests that the median dose of delivered Kt/BSA 
would be the cut-off point where a significant impact on patient survival is seen. This 
is also clearly evident in the survival plot shown (Figure 12-4). 
As Kt/TEE had the lowest hazard ratio for death in the overall Cox models discussed 
above, a similar model was constructed using Kt/TEE instead of Kt/BSA which is 
shown below (Table 12-8). 
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Table 12-8: Survival model using Kt/TEE Quartiles 
 
p-value Hazard Ratio 
95% confidence interval for 
Hazard Ratio 
Lower Upper 
Age < 0.001 1.036 1.025 1.048 
Male Gender 0.054 1.298 0.995 1.692 
Asian Ethnicity 0.489 0.901 0.670 1.212 
Black Ethnicity < 0.001 0.457 0.312 0.670 
Comorbidity Score < 0.001 1.143 1.084 1.206 
BMI < 0.001 0.945 0.922 0.969 
Mean Daily MET < 0.001 0.028 0.005 0.154 
Kt/TEE – Quartile 1 < 0.001 2.408 1.659 3.493 
Kt/TEE – Quartile 2 0.044 1.421 1.009 2.002 
Kt/TEE – Quartile 3 0.503 1.125 0.798 1.585 
 
Similar to the previous model, White ethnicity and highest quartile of Kt/TEE were 
used as reference groups. As with Kt/BSA, there was significantly higher risk of 
death pertaining to those in the lowest 2 quartiles of delivered Kt/TEE dose with no 
difference in survival between Kt/TEE quartiles 3 and 4. Again, this suggests the 
median delivered Kt/TEE dose to be the optimum cut-off point where survival 
differences are evident. A survival plot showing the differences in survival across 
these groups is shown in Figure 12-5. A model using Kt/REE also showed similar 
findings with the median value being the optimum cut-off point. 
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Figure 12-5: Survival Differences based on Kt/TEE Quartiles 
12.3.7 Determining the Equivalent cut-off dose of Kt/V based on Kt/BSA 
In order to provide equivalent dialysis doses across genders and patients of different 
body size, the minimum target Kt/V needs to be adjusted based on these factors. 
The study data was analysed to determine the equivalent cut-off dose of minimum 
target Kt/V based on Kt/BSA which will incorporate gender and body-size 
differences. 
A plot of delivered Kt/BSA against delivered Kt/V based on gender-specific weight 
cut-offs is shown in Figure 12-6. Gender-specific median weight was used as the 
cut-off value for categorising into four groups (males and females, above and below 
median weight). The best fit line for each group was then populated. The relationship 
between Kt/BSA and Kt/V had a similar fit in females irrespective of their weight but 
some separation could be seen in males depending on weight. The horizontal 
reference line in the graph corresponds to median Kt/BSA as this was found to be 
the optimum threshold value for survival benefit. Equivalent Kt/V values for each of 
these groups were then interpreted from the graph as shown. 
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Figure 12-6: Equivalent Kt/V dose based on Kt/BSA 
From the graph, the equivalent dose of Kt/V corresponding to the median Kt/BSA 
was 1.49 for females (irrespective of weight), 1.31 for smaller males (less than 
median body weight) and 1.26 for larger males (more than median weight). This 
equivalent dose of Kt/V incorporates gender- and body size-specific adjustments. 
12.3.8 Activity-related adjustment of Kt/V dose 
In order to find the magnitude of dose adjustment needed for different levels of 
physical activity, study participants were categorised into 4 activity categories based 
on the Mean Daily MET estimated from RPAQ. Those with daily MET of ≤ 1.2 were 
categorised as sedentary, 1.21 to 1.5 as Light Active, 1.51 to 2 as Active and > 2 as 
Highly Active. 
Table 12-9 shows the mean delivered Kt/TEE doses for each of the activity 
categories. There were significant differences in the mean delivered doses across 
the groups as assessed by ANOVA (p < 0.001). 
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Table 12-9: Activity Categories and Delivered Kt/TEE doses 
 
Number of Patients Mean Std. Deviation 
Sedentary (MET ≤ 1.2) 1100 29.13 4.68 
Light Active (1.21 – 1.5) 346 25.65 4.11 
Active (1.51 – 2) 52 20.06 3.42 
Highly Active (> 2) 2 15.75 3.28 
 
The relationship between the mean delivered Kt/V and delivered Kt/TEE is shown in 
Figure 12-7. The equivalent dose of Kt/V corresponding to median Kt/TEE, 
interpreted from the graph, was 1.37. The vertical broken lines in the graph represent 
the mean delivered Kt/TEE doses for each activity group discussed above. For each 
of these lines, the corresponding equivalent Kt/V dose was interpreted. The mean 
delivered Kt/V progressively decreased with increasing activity – 1.28 for Light 
Active, 1.09 for Active and 0.96 for Highly Active groups. 
As median Kt/TEE was found to be the optimum threshold value to ensure better 
survival, the equivalent Kt/V dose of 1.37 is considered to be the target dose for all 
these groups. In order to achieve target Kt/TEE above median (28.0), the equivalent 
dose increment in Kt/V needed for each of these groups is as follows: 
• Sedentary patients (median Kt/TEE – 28.6) = Nil 
• Light Active patients (median Kt/TEE – 25.7) = 0.1 
• Active patients (median Kt/TEE – 20.1) = 0.3 
• Highly Active patients (median Kt/TEE – 15.8) = 0.4 
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Figure 12-7: Equivalent Kt/V dose based on Activity Level 
 
12.3.9 Comparison of Delivered and Recommended Kt/V doses 
A recommended minimum target Kt/V dose was calculated for each individual patient 
based on the above gender, body-size and activity-related increments to the current 
minimum target Kt/V of 1.2. The frequency distribution of the recommended 
minimum target Kt/V is shown in Table 12-10. The minimum recommended Kt/V 
ranged from 1.26 to 1.89 based on gender, body-size and activity level with nearly 
50% of them requiring a minimum dose of 1.41 or higher. 
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Table 12-10: Distribution of Recommended Minimum Target Kt/V 
Recommended Minimum 
Kt/V Number of Patients % of cohort 
1.26 311 20.7 
1.31 317 21.1 
1.36 119 7.9 
1.41 117 7.8 
1.49 472 31.5 
1.56 25 1.7 
1.59 110 7.3 
1.61 20 1.3 
1.71 1 0.1 
1.79 7 0.5 
1.89 1 0.1 
 
The mean recommended and delivered Kt/V doses are shown in Table 12-11. The 
mean delivered Kt/V dose, both at baseline and throughout study period, was lower 
than the above recommended minimum target Kt/V. 
 
Table 12-11: Recommended and Delivered Kt/V doses 
 Mean Std. Deviation 
Recommended Minimum Kt/V 1.44 0.11 
Delivered Kt/V at Baseline 1.34 0.26 
Delivered Kt/V during the study 1.37 0.22 
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The mean delivered Kt/V for the entire study period was compared with the above 
recommended Kt/V for exploring the characteristics of patients who were under-
dialysed. The proportion of patients who were under-dialysed based on gender alone 
and considering gender and body-size together are shown in Table 12-12 and Table 
12-13. A higher proportion of females were under-dialysed compared to males 
(63.2% vs. 52.6%). The problem of under-dialysis was particularly high in women of 
greater than median weight with 79.7% of them being under-dialysed. This was 
significantly higher in comparison to smaller women (46.8%), smaller men (46.6%) 
and larger men (58.7%). 
 
Table 12-12: Proportion of Patients Under-dialysed based on Gender 
 
Proportion of Patients Under-dialysed 
Females 63.2% 
Males 52.6% 
 
 
Table 12-13: Proportion of Patients Under-dialysed based on Gender and Body 
Size 
 Proportion of Patients Under-
dialysed 
Females > Median Weight 79.7% 
Females < Median Weight 46.8% 
Males > Median Weight 58.7% 
Males < Median Weight 46.6% 
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12.3.10 Impact of Under-dialysis on Survival 
The mortality risk associated with under-dialysis in comparison with the above 
recommended Kt/V was examined. Using Cox regression model, it was noted that 
patients who failed to achieve the average recommended minimum target Kt/V had 
around 76% increase in adjusted mortality risk (Table 12-14 and Figure 12-8). 
 
Table 12-14: Adjusted Mortality Risk in Under-dialysed Patients 
 
p-value Hazard Ratio 
95% confidence interval for 
Hazard Ratio 
Lower Upper 
Age < 0.001 1.032 1.021 1.043 
Male Gender 0.012 1.403 1.076 1.830 
Asian Ethnicity 0.388 0.878 0.654 1.179 
Black Ethnicity < 0.001 0.451 0.308 0.662 
Comorbidity Score < 0.001 1.148 1.088 1.211 
BMI < 0.001 0.946 0.923 0.970 
Mean Daily MET 0.001 0.069 0.014 0.351 
Under-Dialysis < 0.001 1.761 1.362 2.276 
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Figure 12-8: Adjusted Mortality Risk based on Dialysis Adequacy 
 
12.4 Discussion 
The primary hypothesis of this study was that one or more of the metabolic 
parameters predict survival better than Kt/V. Result from the study showed that body 
size and activity related adjustments to the dialysis dosing favourably impact on 
patient survival. The metabolic activity related parameters, especially BSA and TEE, 
might potentially be a better scaling parameter compared to Watson volume. The 
study results also showed that the mean recommended dose derived based on body 
size and physical activity level was significantly higher compared to the delivered 
dialysis dose and those under-dialysed as per this criteria has had unfavourable 
survival outcomes. These findings are in favour of rejecting the null hypothesis and 
accepting the experimental hypothesis that one or more of these parameters, when 
used for scaling dialysis dose, predict survival better than total body water. 
 272 
In the current practice of using Kt/V for prescribing dialysis dose, the effect of using 
V as a denominator is to scale dialysis dose to body water volume which is linearly 
related to body weight. However Resting Energy Expenditure (REE) – and related 
parameters e.g. body surface area (BSA) - are related to body weight (W) by power 
functions of the form REE = CWb, in which b < 1.  Hence if such parameters, 
reflecting energy expenditure, were more appropriate dose scaling factors than V, 
then to achieve the same target dose expressed in these terms, smaller compared to 
larger individuals would require relatively larger dialysis doses expressed as Kt/V. 
Expressed another way, the relative concentration of metabolic wastes per unit of 
body weight may be higher in small individuals (Kotanko & Levin, 2007) and hence, 
the dialysis requirement per unit weight may be greater in these individuals. 
The current guidelines for dialysis dose prescription recommend a minimum target 
single-pool Kt/V of 1.2 per session for both males and females ("Clinical Practice 
Guidelines for Hemodialysis Adequacy, Update 2006," 2006). Although, the 
guidelines suggest that the target may have to be higher in women than men, it falls 
short of stating gender-specific minimum targets for dialysis dosing. This study 
findings show that women are receiving generally higher dialysis doses than men in 
current clinical practice. The study results also show that women have better survival 
compared to men after adjustment for age, ethnicity and comorbidity. This is in line 
with the survival pattern seen in general population where women have reduced 
mortality risk compared to men. Previous reports have shown the loss of survival 
benefit in women receiving haemodialysis and as a result, have similar mortality risk 
as men ("UK Renal Registry - The Sixteenth Annual Report," 2013). It is plausible 
that the survival benefit for women shown in this study is due to higher delivered 
dialysis doses as this survival difference cease to exist when adjusted for delivered 
Kt/V. This argues for a case for gender-specific minimum haemodialysis dose with 
relatively higher doses for women compared to men. 
Results from the study demonstrate that using BSA, REE or TEE for scaling dialysis 
dose will deliver higher dialysis doses to some patient groups who are at risk of 
under-dialysis with current practice. The standardised measures of dialysis dose 
using these parameters were compared and it was found that Kt/TEE had the lowest 
hazard ratio for death whilst Kt/V had the highest. Physiologically, using TEE for 
scaling dialysis would make sense as it encompasses the basal metabolic activity 
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and the physical activity component, thereby, serving as a good marker of total 
metabolic waste production. This is the first comparative study to date of these three 
metabolic parameters for dialysis dosing and the study data showed that TEE is the 
best parameter of them all with regards to predicting patient survival in 
haemodialysis population. 
The major pitfall in using total body water (V) for scaling dialysis dose is that it does 
not adjust for the relative uraemic toxin concentration in individuals with different 
body sizes. This is the reasoning behind suggesting BSA as the scaling parameter 
instead of V. It is also important to account for the activity-related metabolic waste 
generation which is better captured by a parameter such as TEE. So, any novel 
alternative parameter to V for scaling dialysis dose should inherently adjust for body 
size and activity-related changes in the uraemic milieu. 
Given the well-established practice of using Kt/V for dialysis dosing and the practical 
difficulties of converting to a novel scaling parameter, it is prudent to make specific 
adjustments to Kt/V itself depending on body size and activity level of the individual 
patient rather than adopting a completely different scaling parameter. With this in 
mind, an algorithm was developed to decide the minimum target Kt/V for an 
individual based on body size and activity level. Using Kt/BSA, the minimum target 
Kt/V values for women, smaller and larger men were identified. As shown in the 
previous chapter, female gender overrides any effect of weight in dosing based on 
these alternate scaling parameters and hence, women have a single minimum target 
irrespective of body size whereas in men, smaller men have higher minimum target 
level compared to larger men. To this minimum target values, an additional 
adjustment is made based on activity level to arrive at a recommended minimum 
target Kt/V value. 
The study results showed that those under-dialysed based on the derived 
recommended minimum Kt/V had 76% higher risk of mortality compared to those 
who were adequately dialysed. This implies that adjusting dialysis dose for metabolic 
activity has a favourable impact on patient survival. This is the first study to have 
explored and suggested an algorithm to decide minimum target Kt/V based on 
metabolic activity. 
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12.5 Limitations 
There are some limitations to this study. This is only a cross-sectional study with 
estimations of metabolic parameters carried out from a single anthropometric 
reading. However, anthropometric values from each subject were obtained through 
direct measurements and not derived from historic medical records. TEE was 
calculated from physical activity data collected through a recall questionnaire and 
hence, recall bias is a potential confounder in the accuracy of the data. Any 
questionnaire-based activity energy expenditure will only provide an estimate of TEE 
rather than an accurate value and the method employed here is no exception to this. 
It is worth noting that the algorithm for Kt/V adjustments for activity level is derived 
from the specific questionnaire that has been used in this study. Given the variable 
accuracy and precision of different activity questionnaires, it is likely that the results 
may vary if another physical activity questionnaire is employed and as such, this 
algorithm is only valid for use with RPAQ. Finally, the findings discussed are in 
relation to short term survival and hence, these cannot be extrapolated to long-term 
survival benefits. 
12.6 Conclusion 
In conclusion, the study results demonstrate that metabolic activity related 
parameters could potentially be used for scaling dialysis dose and one or more of 
these parameters may be better than the total body water currently used in clinical 
practice. The study has also shown that adjusting dialysis dose based on body size 
and habitual physical activity will have a positive impact on survival in haemodialysis 
patients. An algorithm has also been developed to make dialysis dose adjustments 
based on body size and reported physical activity. Further studies are needed to 
examine the validity and applicability of this algorithm for routine clinical practice. 
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 Chapter 13 
13. General Discussion 
 
13.1 Overview 
Kidneys perform a multitude of metabolic functions to maintain the internal milieu. 
Although the primary function is to excrete metabolic wastes from the body, kidneys 
play a very important role in maintaining body fluid volume, blood pressure 
regulation, acid-base and electrolyte balance, bone mineral metabolism and 
maintaining serum haemoglobin level. In end-stage renal disease, therefore, a wide 
range of metabolic abnormalities is seen relating to the native functions of the 
kidney. The spectrum of metabolic abnormalities and the associated clinical 
manifestations stretch beyond the effects of just uraemic solute accumulation. 
Anaemia and acidosis in advanced kidney disease is one such example. Similarly, 
derangement of bone mineral metabolism lead to higher serum phosphate levels 
resulting in increased vascular calcification and cardiovascular mortality risk. 
The major adverse consequences of renal failure, though, are thought to be 
secondary to the effects of accumulated uraemic toxins in blood and tissues. 
Uraemic toxins are categorised according to their molecular size and protein-binding 
capacity. Many of these toxins have been shown to exert pathological effects on 
organ systems. For example, protein-bound toxins such as p-cresylsulphate and 
indoxyl sulphate have been shown to be associated with higher mortality risk in 
patients with kidney disease (Liabeuf et al., 2010; Barreto et al., 2009). Increased 
serum level of small molecules such as phosphate could lead to increased 
cardiovascular mortality through vascular calcification (Shanahan, Crouthamel, 
Kapustin, & Giachelli, 2011). 
The synthesis and metabolic pathways of many of these uraemic toxins have not 
been mapped completely. However, many of these uraemic toxins are by-products of 
cellular metabolism and protein turnover in the body that have accumulated to toxic 
levels due to reduced metabolism and/or reduced excretion by the kidneys in renal 
failure. The goal of renal replacement therapy in end-stage renal disease is to 
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substitute for lost renal function. Although, some adverse consequences of renal 
failure such as fluid imbalance and acid-base and electrolyte disturbances could be 
managed with varying success through renal replacement therapy, the primary goal 
is removal of accumulated metabolic waste products. It is worth noting that achieving 
adequate solute removal through dialysis alone should not be considered as the 
optimal therapy. The definition of adequate dialysis should encompass the 
appropriate management of all the different pathological and clinical manifestations 
associated with kidney failure. As a result, judging minimal dialysis requirement is 
difficult. The current practice of deciding adequate dialysis based on urea clearance 
normalised to total body water may lead to some unintended consequences. 
13.2 Dialysis Dosing and Patient Survival 
Specific subgroups of haemodialysis patients seem to be at risk of reduced survival. 
For example, the survival benefit of women compared to men in the general 
population is attenuated in patients on renal replacement therapy i.e. there is no 
survival difference between women and men receiving renal replacement therapy 
("UK Renal Registry - The Sixteenth Annual Report," 2013). There are also body 
size differences in survival – obese haemodialysis patients tend to have better 
survival compared to those with even ideal body weight (Port et al., 2002). 
As discussed in chapter 2, some of these differences could be due, at least in part, 
to the practice of normalising dialysis dose based on total body water. A number of 
studies, discussed in detail in chapter 2, have been published suggesting that 
women and possibly small men are under-dialysed with current dosing practices. 
This has led to investigators suggesting alternate parameters such as body surface 
area, resting energy expenditure, high metabolic organ mass etc. to be considered 
as a factor for scaling dialysis dose instead of total body water. All these factors have 
been suggested to closely reflect metabolic waste production. However, the direct 
relationship of these parameters to a measure of uraemic toxin generation has not 
been studied to date. Though theoretical arguments have been presented in favour 
and against each of these alternate parameters for scaling dialysis dose (Daugirdas, 
Levin, et al., 2008), with the exception of body surface area, none of these factors 
have been examined in clinical studies with regards to their applicability and patient 
outcomes. 
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It is important to understand the factors that influence generation of these uraemic 
solutes and to identify ways to incorporate suitable measures of these factors in 
deciding minimum dialysis requirements. As uraemic toxins are metabolic waste 
products, it is plausible that measures of metabolic activity such as basal metabolic 
rate or total energy expenditure could be a suitable marker of uraemic toxin 
generation. One would presume that the dialysis dose be normalised based on these 
markers of uraemic toxin generation. The current practice, however, normalises 
dialysis dose based on total body water which is the volume in which the uraemic 
solutes are distributed. This is a ‘one size fits all’ method of treatment delivery and 
does not take into account individual variations in metabolic activity. There is also a 
knowledge gap here in that the impact of metabolic activity on uraemic solutes has 
not been studied in patients with advanced kidney disease. 
The overarching aim of this thesis is of the form “optimal management of advanced 
kidney failure should take into account metabolic factors that influence the rate of 
uraemic toxin generation”. In order to achieve this aim, a better understanding of the 
relationships between different measures of metabolic activity and uraemic toxin 
generation is needed. Studies in this thesis focus on two different aspects – firstly to 
examine the relationship between metabolic factors such as resting energy 
expenditure and total energy expenditure on metabolic waste production and 
secondly, to explore the impact of these factors on survival outcome in patients with 
advanced kidney disease. An important point of focus in many studies in this thesis 
is the physical activity level of patients with kidney disease. Physical activity is the 
most variable component of total energy expenditure and developing tools to 
quantify activity may facilitate better measurement of total metabolic needs on an 
individual basis. 
13.3 Metabolic Factors Influencing Uraemic Toxin Generation 
13.3.1 Basal Metabolic Rate 
Basal metabolic rate is expressed as resting energy expenditure and is the sum total 
of the metabolic activities at rest. As mentioned above, it would be expected that 
resting energy expenditure is a good marker of uraemic toxin generation. The 
relationship between metabolic rate and urea generation rate was explored in this 
thesis. As shown in chapter 4, there was a significant positive correlation between 
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these two variables which was better than that observed between total body water 
and urea generation rate. This implies that higher levels of resting energy 
expenditure contribute to increased uraemic toxin generation and thereby, higher 
dialysis dose requirement. A study by Vilar et al (2014) showed that REE adjusted to 
body weight was higher in individuals with low body mass index compared to obese 
individuals (Vilar et al., 2014) suggesting that smaller individuals may require 
relatively higher dialysis dose compared to the larger individuals. This phenomenon 
might explain the poorer survival in women and small individuals as they would have 
received relatively lower dialysis doses in relation to their metabolic needs with 
current dialysis dosing. 
The relationship between resting energy expenditure and whole body protein 
turnover was also explored. As shown in chapter 9, there is a significant relationship 
between whole body protein turnover and resting energy expenditure with the former 
contributing to about 55% of the basal metabolic rate. As many of the uraemic toxins 
are considered to be products of protein metabolism, the results from chapters 4 and 
9 suggest a close relationship between resting energy expenditure and uraemic toxin 
production. And finally, the impact of declining renal function on resting energy 
expenditure was explored in chapter 6. The study data showed that there is no 
significant change in resting energy expenditure with decline in renal function from 
CKD stages 1 through to 5. This supports the previously proposed argument that 
metabolic rate is the driving force for GFR and not vice-versa. 
The significant relationship between resting energy expenditure and uraemic toxin 
generation across these studies has been consistent. Combined with the lack of 
impact of renal function on metabolic rate, this strengthens the arguments in favour 
of resting energy expenditure being a better scaling parameter for dialysis dosing 
compared to total body water. The main strengths of these studies lie in the fact that 
resting energy expenditure was measured directly and was not estimated from 
predictive equations and that objective measures of uraemic toxin generation have 
been used. The studies carried out in this thesis have provided novel insights into 
the influence of metabolic rate on uraemic toxin generation. 
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13.3.2 Physical Activity 
Physical activity is the most variable component of total energy expenditure and can 
be measured. Physical activity is being studied increasingly in patients with kidney 
disease. As a result, a multitude of physical and mental health benefits has been 
shown to be associated with active lifestyle in CKD patients. Many studies have also 
demonstrated benefits from intra-dialytic exercise programmes (Cheema, 2008). 
However, some questions regarding physical activity in this patient group are still not 
answered – are there any specific subgroups of patients who are at high risk of 
inactivity? What is the effect of increasing activity on metabolic waste generation? 
Should the dialysis dose be adjusted according to activity level? 
Studies in this thesis have sought to answer these questions. A study of large cohort 
of haemodialysis patients in this thesis (chapter 10) has shown that physical activity 
is low in the overall dialysis population. But, there are specific subgroups of patients 
– females, elderly and those with high comorbidity – who are at increased risk of 
even lower activity than the rest of the group. This implies that exercise programmes 
in haemodialysis patients should make additional efforts to identify these subgroups 
of patients at higher risk and motivate them to lead a more active lifestyle. 
A logical question that follows these efforts is whether higher physical activity 
contributes to increased metabolic waste generation. As shown in chapter 8, 
measured physical activity correlates with urea generation rate. Even after 
adjustment of demographic variables, increased levels of high-intensity activity 
remained a significant predictor of urea generation rate in regression models. This 
implies that higher physical activity levels may contribute to increased uraemic toxin 
generation. It would seem physiological to assume that physical activity will lead to 
increased metabolic waste production due to a number of potential changes 
associated with higher activity level. For example, increased activity may lead to 
changes in muscle protein turnover, increase in lean body mass and reduction in 
body fat (Park et al., 2014, 2011; Scott, Blizzard, Fell, & Jones, 2011). There may 
possibly be other associated changes such as increase in dietary protein intake and 
alterations in substrate metabolism secondary to changes in body composition. This 
aspect of physical activity has not been shown in clinical studies to date and this 
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thesis (chapter 8) has demonstrated the relationship between activity and uraemic 
toxin generation using objective measures. 
Does this mean that physically active individuals need higher dialysis dose due to 
increased uraemic toxin generation? The answer to this has been explored in 
chapters 10 to 12. There is an interaction between physical activity and body size of 
individuals. The study data in Chapter 10 showed highly active individuals were 
heavier in body size compared to their sedentary counterparts. As has been the 
common theme in this thesis, it is likely that heavier individuals need relatively less 
dialysis dose with regards to their body size. However, they are likely to need a 
higher dose based on the activity level. These two effects would cancel out each 
other to certain extent. The direction in which the balance of dialysis dosing would tip 
in this patient subgroup depends on individual body size and activity level measures. 
The interaction between body size and physical activity means that dialysis dosing 
practice needs to focus on providing individualised doses based on metabolic needs 
and move away from a generalised approach. The combined results of these studies 
in this thesis have provided better understanding of physical activity behaviour and 
its impact on clinical practice in patients with kidney disease. 
In addition to examining the above aspects of physical activity, two physical activity 
questionnaires have also been examined for their validity in CKD patients. Most of 
the existing physical activity questionnaires were derived from young, healthy active 
individuals. As a result, these questionnaires may not be suitable for elderly 
population and may not be useful in studying sedentary or low-intensity activity. 
Patients with kidney disease are likely to be older and perform only low levels of 
activity (Johansen et al., 2000). Hence, it is important to validate activity 
questionnaires in patients with kidney disease. The study results from chapter 7 
showed the Recent Physical Activity Questionnaire (RPAQ) to perform better than 
the Stanford questionnaire. The activity-related energy expenditure derivation from 
the questionnaire was examined in detail and the best estimated measure had 
acceptable correlation with energy expenditure measured from doubly labelled 
water. This is the first study to date that has validated activity questionnaires in 
patients with kidney disease using doubly labelled water method. This validation 
study has thus demonstrated that RPAQ is a valid tool for estimating activity-related 
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energy expenditure in CKD patients which will facilitate easier activity data collection 
in routine clinical practice. 
13.3.3 Total Energy Expenditure 
If resting energy expenditure (REE) and physical activity impact on uraemic toxin 
generation on their own, does a combined measure of these – total energy 
expenditure (TEE) – have an even greater influence on metabolic waste generation? 
This question has been explored in two studies in this thesis (chapters 4 and 7). In 
one of these studies (chapter 4), TEE was estimated from measured REE and 
estimated physical activity from a questionnaire in haemodialysis patients. The study 
data showed a significant relationship between TEE and urea generation rate. The 
strength of the correlation between TEE and urea generation rate was stronger than 
that between REE or physical activity and urea generation rate. This suggests that 
TEE may be a better marker of uraemic toxin generation compared to the other two 
parameters. 
In the study presented in chapter 6, TEE was measured by the gold standard 
method using doubly labelled water in patients with different levels of kidney 
function. The results of this study also showed a significant positive relationship 
between TEE and urea generation rate and the strength of the correlation was even 
stronger than that demonstrated in the previous study (chapter 4). Moreover, TEE 
along with fat-free mass was a significant determinant of urea generation rate in 
multivariate regression models as shown in chapter 4. 
The gold-standard doubly labelled water technique has never been employed in 
CKD patients for TEE measurement and the reported study in this thesis is the first 
study to have directly measured TEE in this patient group using this method. These 
two studies have demonstrated a consistent relationship between total energy 
expenditure and urea generation rate suggesting that TEE has a significant impact 
on uraemic toxin generation in patients with kidney disease. Given the stronger 
correlation between these two variables, Total Energy Expenditure may possibly be 
a better marker of uraemic toxin generation compared to resting energy expenditure 
or physical activity-related energy expenditure alone. 
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13.3.4 Whole body protein turnover 
The relationship between whole body protein turnover, REE and urea generation 
rate was explored in the study reported in chapter 9. The study showed that overall 
there was a negative protein balance both in pre-dialysis patients with advanced 
kidney disease and in chronic haemodialysis patients. The study also showed a 
significant correlation between protein breakdown and urea generation rate. In 
addition, urea generation rate increased with more negative net turnover balance. 
Haemodialysis patients in this study had higher protein turnover rate compared to 
pre-dialysis CKD patients. Although, there was no difference in net turnover balance 
between these groups in this study, the dietary protein intake was lower than 
recommended in haemodialysis patients which puts them at risk of worsening 
negative protein balance in the long-term. Increased negative balance may 
contribute to higher uraemic toxin generation. However, there is a close interaction 
between protein turnover and REE. It is unlikely that the contribution of whole body 
protein turnover to uraemic toxin generation is independent of REE as protein 
turnover is a subset of resting energy expenditure. The sample size of this study did 
not allow for such analysis to be performed in this thesis and whether protein 
turnover contributes to uraemic toxin generation independent of REE remains to be 
seen. 
13.4 Practical Implications on Dialysis Dosing 
Studies presented in this thesis have consistently suggested that measures of 
metabolic activity – resting energy expenditure (REE) and total energy expenditure 
(TEE) – impact on uraemic toxin generation. This argues in favour of these 
parameters to be used as a scaling factor for normalising dialysis dose instead of 
total body water. Body surface area (BSA) normalised dialysis dose has been shown 
to deliver higher dialysis doses to women and favourably impact on survival as well 
(Ramirez et al., 2012). However, REE and TEE have not been studied in this context 
till date. 
The applicability of these parameters and the associated potential benefits of using 
these parameters for scaling dialysis dose have been explored in chapters 11 and 
12. The study results showed that there is risk of under-dialysis to specific subgroups 
of patients with current practice of using total body water for scaling dialysis dose 
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and using the metabolic parameters, namely BSA, REE or TEE, will deliver relatively 
higher dialysis doses to these groups at risk. The study also showed that for any 
given Watson volume, women had higher level of any of these three metabolic 
parameters implying that use of these scaling parameters would deliver higher 
dialysis dose to women. 
There has been no comparative study exploring the impact of all three parameters 
with regards to patient survival. This was examined in the study presented in chapter 
12. The study data showed that all three parameters – BSA, REE and TEE – 
influence patient survival when used for normalising dialysis dose. TEE was found to 
be the best scaling parameter with the lowest hazard ratio for death compared to 
others including Watson volume (V). The study showed that women had significantly 
better survival compared to men even after adjustment for age, ethnicity and 
comorbidity which reflects the survival pattern in general population. The study also 
showed that women are receiving higher dialysis dose compared to men in current 
clinical practice and this may have contributed to the improved survival in this group. 
This is the only study that has explored the applicability of REE and TEE as dialysis 
scaling parameters with respect to patient survival and is the only comparative study 
of all three parameters for dialysis dosing till date. 
What are the practical implications of this finding for dialysis dosing? The practice of 
prescribing and monitoring dialysis dose using Kt/V is ingrained in clinical practice 
worldwide. The best way forward to provide adequate dialysis based on individual’s 
metabolic needs would be to define algorithms that can be used to make dose 
adjustments based on body size and physical activity. Is there any way of 
incorporating dose adjustments for body size and activity level to the current 
practice? To answer this, the equivalent doses of Kt/BSA and Kt/TEE that would 
provide survival benefit were explored. The study data was then used to develop 
algorithms to make adjustments to the current minimum Kt/V target. Recommended 
minimum target Kt/V for women, small and large men were derived and it was found 
that those who were under-dialysed based on this recommended target Kt/V had 
poorer survival outcomes. 
These study results (chapters 11 and 12) have the potential to modify clinical 
practice to achieve better patient outcomes. These studies have strengthened the 
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notion that scaling dialysis dose should take into consideration individual differences 
in body size and metabolic activity. With further research to validate and refine, these 
algorithms developed for adjustment of Kt/V dose can potentially be applied to 
routine clinical practice. Dialysis dosing practice should move away from a ‘one size 
fits all’ therapy to a more practical and individualised form of therapy that would 
deliver the appropriate dose based on the individual’s metabolic needs. The studies 
reported in this thesis are a step in that direction and with further research, this goal 
of individualising dialysis therapy can be a reality in the near future. 
13.5 General Limitations of the Studies 
The studies reported in this thesis have certain general limitations. Urea generation 
rate was used as a surrogate marker of uraemic toxin generation in these studies. 
There is no consensus on the ideal marker for uraemic toxin generation. The most 
recent publication of the European Uremic Toxin Work Group (EUTox) lists 88 
uraemic retention solutes that have been identified in patients with end-stage renal 
disease (Duranton et al., 2012). Given the variations in the physiological properties, 
kinetics and metabolic pathways of these toxins, it is unlikely that a single molecule 
will be identified as an ‘ideal’ uraemic toxin to be studied. In addition, the kinetics of 
many of these toxins has not been clearly mapped at present. Since the current 
dialysis practice is based largely on urea clearance and that urea clearance has 
been shown to be associated with survival, using urea generation rate as a marker of 
uraemic toxin generation seems the best pragmatic solution to this problem. As 
such, results presented here relate to the factors influencing urea generation. The 
generation rate of other uraemic toxins may be influenced by a different set of 
variables. 
The studies here have focused largely on haemodialysis and not on peritoneal 
dialysis. Patients receiving peritoneal dialysis (PD) may have different demographic 
and clinical characteristics compared to haemodialysis patient cohort. In addition, the 
activity level of PD patients may be different too. Measurement of dialysis dose in PD 
patients is also different to that for HD patients as many of these patients have 
significant residual renal function. As such, the results of the studies presented here 
should not be extrapolated directly to PD patients. It is likely that the general 
underlying principles of the relationship between metabolic rate and uraemic toxin 
 285 
generation still holds true for PD patients although this needs to be tested in future 
clinical studies. 
13.6 Future Directions 
There are a number of topics that are discussed in this thesis where further research 
needs to be carried out. These potential areas for future studies are discussed 
below. 
13.6.1 Developing a disease-specific physical activity questionnaire 
Although the RPAQ has been shown to be a valid tool for activity data collection in 
patients with kidney disease, the sedentary and low intensity activities are not 
adequately captured in this questionnaire. As patients with end-stage kidney disease 
predominantly perform sedentary and light activity, a physical activity questionnaire 
that captures this level of activity will enable better estimation of total energy 
expenditure in routine clinical practice. In addition, activity questionnaires generally 
do not enquire about sleep disturbances. Sleep disturbances are common in patients 
with kidney disease and may lead to increased muscle activity contributing to total 
energy expenditure. Development of a new physical activity questionnaire should 
seek to integrate questions to capture sleep disturbances. Of course, the new 
questionnaire has to be validated against objective physical activity measures or 
against other validated activity questionnaires. 
13.6.2 Validating the dialysis dosing algorithm in other dialysis cohorts 
The dialysis dosing adjustment to Kt/V based on body size and activity level 
algorithm was developed from a single large cohort of patients in the study reported 
in chapter 12. This algorithm needs to be tested and validated in other cohorts of 
dialysis patients using survival outcomes based on this recommended dialysis dose. 
It is worth noting that the activity level adjustment for dialysis dose is specifically 
based on the data collected from RPAQ and has not been validated for use in 
conjunction with similar activity measures derived from other physical activity 
questionnaires. If this algorithm performs consistently across different dialysis 
cohorts, future research should focus on integrating this into routine clinical practice. 
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13.6.3 Monitoring of physical activity in haemodialysis patients 
The dialysis dosing algorithm discussed in chapter 12 relies on obtaining the 
physical activity data from a questionnaire. Physical activity level is dependant on 
various factors and may vary time to time based on factors such as acute illness, 
personal circumstances etc. Increase in activity levels may necessitate an increase 
in dialysis dose. This implies that the physical activity level needs to be monitored 
regularly so that appropriate dialysis dose adjustments can be carried out. However, 
the frequency of monitoring needed cannot be decided based on current evidence. It 
is recommended that future studies measure physical activity longitudinally to 
examine the intra-individual variation in activity over a longer period. Such studies 
will enable decision-making on the appropriate frequency of activity monitoring for 
dialysis dose adjustments. 
13.6.4 Impact of dialysis dosing alterations on protein turnover and nutrition 
The study of whole body protein turnover (chapter 9) has demonstrated negative 
protein balance in haemodialysis patients which may lead to muscle wasting in the 
long term. Though there have been many molecular level disturbances that have 
been attributed as a cause for muscle wasting in renal failure, it is not known 
whether delivery of adequate dialysis dose will counteract the negative protein 
balance. The dialysis dosing algorithm (chapter 12) seeks to provide appropriate 
dialysis dose based on individual’s metabolic needs. Future studies in this field could 
be designed to explore the impact of delivering dialysis dose based on this algorithm 
on whole body and muscle protein turnover. 
13.7 Summary 
In summary, the studies presented in this work have demonstrated the important 
influence of resting and total energy expenditure on uraemic toxin generation and the 
beneficial effect of using these parameters for scaling dialysis dose on patient 
survival. Moreover, it has been shown that physical activity levels impact on dialysis 
dose requirements. It is important to design further studies to explore appropriate 
methods to incorporate measures of energy expenditure in management of patients 
with kidney disease. 
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